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Key Success Factors for Sales Force Readiness 
during New Product Launch 
A Study of Product Launches in the Swedish Pharmaceutical Industry 
 
Doctoral Thesis 
 
Abstract 
This research identifies a set of key success factors for sales force readiness, for driving 
the success of a new product launch within the pharmaceutical industry. Drawing from 
the analysis of fifty product launches in the Swedish pharmaceutical market, the study 
has succeeded in discriminating between four types of key success factors: the key 
factors that are important and crucial for a successful launch; the key factors that are 
important yet not necessarily crucial for a successful launch; the market conditions that 
are most ideal for a successful launch, and finally the type of newness of the product that 
is most suitable for successful launch. The overall aim of the research project was to 
provide guidance in optimizing the sales force readiness during the launch of a new 
pharmaceutical product. The research question is driven by the great importance and high 
cost of the sales force, together with the need for the pharmaceutical companies to 
continuously launch new products in a marketplace with increased challenges for all parts 
of the business. The research approach divides the research into two main parts. The first 
part reviews earlier studies/findings in the literature, collects empirical data in the form of 
six case studies and conducts six expert interviews with the purpose of formulating a 
Research Model. In the second part, the Research Model and its variables are 
quantitatively tested against fifty launched pharmaceutical products in Sweden. The study 
employs a bottom-up analysis method with Partial Least Squares Analysis, being 
predictive in nature, rather than the more conventional top-down and hypothesis-testing 
approach that typically employs regression analysis methods. In order to provide both 
practitioners and researchers with guidance on the results, its interpretation is presented 
in terms of its managerial implications as well as proposals for further research.  
 
Key Words: Sales Force, Sales Force Management, Product Launch, Product 
Introduction, New Product Launch, Pharmaceutical Industry 
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1. INTRODUCTION 
 
This study aims to provide guidance in how to successfully launch a pharmaceutical 
product with the use of a sales force. The launch of a pharmaceutical product is its 
commercial entry into the market and represents an important phase in a product’s life 
cycle. The study sets out to identify the key success factors for sales force readiness 
during this stage of the life cycle. The research topic crosses three broad areas of the 
literature: Sales Force Management (including Selling), Product Launch, and the 
Pharmaceutical Industry. However, the definitions and terms found to be used within 
each area only partially or too broadly cover the specific kind of empirical situation 
addressed in the present research. Therefore, the label “Sales Force Readiness during 
New Product Launch” has been chosen to denote the kind of empirical situation 
addressed here. In the research conducted here, “Sales force Readiness during New 
Product Launch” is broadly understood to be the degree to which a sales force is 
prepared, able or willing to support a new product in order to generate a successful 
launch. The term will later be further defined and linked to the literature, but in short, 
“sales force readiness during new product launch” refers to a set of properties of the 
product to be introduced into a market place, properties of such a market, properties of 
the sales force conducting such an introduction, and the outcome of such a product 
launch.  
 
The following introductory text is structured with the aim of giving an overview of the 
research topic. First, a brief broader background is given and the two main issues, the 
high sales force cost and the need to effectively launch new products, are introduced as 
core drivers for the research question. Secondly, these two issues are explored in more 
detail under the sections, the cost issue of sales forces and sales force and the launch of 
new products. Thirdly, the research aim is presented and described in terms of the target 
groups of the research findings as well as the objectives, purpose and process of the 
research. Fourthly, the justification of the research is given. Fifthly, the research focus 
and scope are defined followed by the definition of sales force readiness during new 
product launch. The introduction ends with an overview of the pharmaceutical sales force 
operations and the pharmaceutical product’s life cycle challenges in order to give a more 
complete background as well as to further define and describe the context and challenges 
that the pharmaceutical companies and their sales forces are facing.  
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1.1. Background  
 
As the sales force is suggested to be a major contributing factor or maybe the most 
important contributing factor to new product success (Cooper 1998; Cooper 1980; di 
Benedetto 1999; Hultink and Atuahene-Gima 2000; Moriarty and Kosnik 1989; Song et 
al. 1997; Song and Parry 1997), managers needs to pay attention to the sales force’s 
preparation and execution of the launch. In broad terms, the new product launch of a 
pharmaceutical product includes many strategic elements that need to be considered. 
Examples of these elements are the way in which the sales representatives and managers 
adapt themselves, their working processes and behavior to fit the new conditions. Further 
examples are the effort and commitment the new product gains from the sales force, how 
outcome control or behavior control are enforced in the sales force together with how 
management succeeds with internal marketing, training, selection of the right salespeople 
in terms of their characteristics and competence as well as organizational set-up and 
incentive systems. There are also many other aspects in the environment that may 
influence the launch and/or the sales force in their effort to achieve a successful launch. 
The majority of these elements aim to prepare the sales representatives to successfully 
conduct sales calls, also referred to as detailing, which is one of the most important 
communication tools for the sales force (Lilien et al. 1981; Hahn et al. 1994) as it is the 
sales call that is the primary interaction point between the sales representative and its 
main customer, the physician. Literature has proven that the sales call (detailing) is 
effective in increasing the mean prescription rate (Elling et al. 2002; Gonul et al. 2001; 
Manchanda and Chintagijnta 2004; Mizik and Jacobson 2004; Rhee 2009). 
 
The pharmaceutical industry is currently exposed to significant changes and 
unprecedented market dynamics, challenging the conventional Big Pharma research-
oriented business model, where all functions of the value chain are integrated (Dutton and 
Reece 1996; Elling et al. 2002; Gilbert et al. 2003; Rod et al. 2007; Smith 1991; Smith et 
al. 2002; Tengilimoglu et al. 2004). The challenges for the executives of these Big 
Pharma companies are many in this new environment. The pharmaceutical industry is a 
truly global industry, in the sense that a developed product is typically launched across all 
the major markets, including North America, Europe, Asia, and South America (EIU 
2005; Popper and Nason 1994). A driving force of the industry has been the sales of the 
so-called blockbuster products that are sold across the world. A blockbuster product is 
usually defined as a single product generating total revenue of more than one billion 
dollars. The phrase “Big Pharma” is often used to refer to companies with revenue in 
excess of $3 billion, and/or R&D expenditure in excess of $500 million, and represents 
around 30 or so companies (Gilbert et al. 2003). The United States is the largest 
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pharmaceutical market, followed by Europe, where the largest markets include the UK, 
Germany, France, Italy, and Spain (MIDAS-Database 2007a). Based on the most recent 
years’ growth, rates are declining in both the United States and the European big five 
markets (MIDAS-Database 2007a). A brief overview of the pharmaceutical industry size 
and value is presented in Appendix 7. One key issue for Big Pharma is how to effectively 
launch new products in order to maximize return on investments and in turn support the 
development and clinical research for these firms. Another key issue being dealt with by 
these firms is how to optimize sales forces utilization in order to control the extensive 
operating costs of sales forces in times when efficiency and effectiveness are required. 
These two issues combined create the topic of sales force readiness during new product 
launch, where this research aims to provide additional scientific learning.  
 
To better contextualize the empirical situation investigated it can be formulated as; the 
challenge met by the managers responsible for the configuration and management of a 
sales force, with the aim of contributing to a successful launch of a pharmaceutical 
product.  
 
In order to better handle the two above mentioned key issues the high sales force cost and 
to effectively launch new product with a sales force, managers need guidance as to where 
to focus their efforts to optimize the prediction of a successful launch. It is, as stated 
above, in a combination of these areas that this research aims to generate knowledge, 
defined as a set of key success factors. In addition, there are other broader issues for the 
pharmaceutical companies, their sales forces and their products that highlight and 
reinforce the need for a successful launch, and these will be discussed later in this 
Chapter.  
 
The text above provides a brief introduction to the pharmaceutical industry and the 
context of the research. It also introduces two key issues, the cost issue of sales forces 
and the need to effectively launch new product, which are the core drivers for the research 
question. These two issues will be explored in more detail in the next two sections under 
the topics of the cost issue of sales forces and sales force and the launch of new products.  
 
1.1.1. The Cost Issue of Sales Forces 
 
Kotler (2000) reinforces the cost element with the statements, “No one debates the 
importance of the sales force in the marketing mix. However, companies are sensitive to 
the high and rising costs (salaries, commissions, bonuses, travel expenses, and benefits) 
of maintaining a sales force”. Companies sometimes see the sales force as a cost item 
instead of an investment (Rangaswamy et al. 1990). In general, the expenditure of 
utilizing a sales force in the form of a field sales force is a substantial investment and the 
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maintenance and deployment of a field sales force is, according to Piercy et al. (1999), at 
least equal to marketing expenditure on advertising and sales promotions (Piercy et al. 
1999). Moreover, Piercy et al. (1997) and Baldauf and Cravens (1999) concluded that for 
the business-to-business marketplace, the field sales force is also one of the main 
marketing expenditures, and estimates of total cost suggest that personal selling may 
account for as much corporate resources as higher profile media advertising. They 
continue to suggest that for many organizations in industrial markets, direct selling costs 
far exceed expenditure on media advertising or other forms of sales promotion (Baldauf 
and Cravens 1999; Piercy et al. 1999). Baldauf and Cravens (1999) also suggest that as 
the selling cost accounts for a major portion of sales and marketing expenditure in 
business-to-business sales organizations, companies are consequently recognizing the 
importance of improving the effectiveness of sales organizations as a high priority on the 
agenda. Lilien et al. (1981) argue that sales efforts in the sales force are the major portion 
of expenditure in the pharmaceutical marketing mix.   
 
Responding to the challenges of the rapidly changing global business environment, sales 
executives need to take actions to improve sales organizational effectiveness (Baldauf 
and Cravens 1999; Corcoran et al. 1995; Cravens 1995; Elling et al. 2002; Rangaswamy 
et al. 1990). Also, the increased pressure on competitiveness from global sourcing, 
reductions by major customers in supplier bases, and additional problems imposed by 
low economic growth add a sense of urgency to the need to seek greater effectiveness and 
superior performance in selling operations (Piercy et al. 1999). 
 
The costs of pharmaceutical sales forces, as for most other industries’ sales forces, as 
described above, are significant (Dannacher and Stahl 2005; Elling et al. 2002; 
Manchanda and Chintagijnta 2004; Mizik and Jacobson 2004) and are becoming a burden 
for Big Pharma (Dannacher and Stahl 2005; Elling et al. 2002). Actions to reduce and 
identify less burdensome cost structures and alternatives are ongoing. As an example, 
there has been a significant increase in the cost of personal selling activities, which 
makes managers seek more knowledge of the various factors which can be influenced, 
e.g. productivity and improved recruitment (Blackshear and Plank 1994). Manchanda and 
Chintagunta (2004) give an example within the pharmaceuticals industry of a typical 
product and how the sales force cost accounts for 80% of all promotional expenditure, or 
represents 20% of sales. Also, in the case of companies that utilize multi-product sales 
forces, which is often the case in pharmaceutical companies, there is research that argues 
considerable “duplications” of sales force efforts (Rangaswamy et al. 1990). There is 
evidence in literature that suggests that the pharmaceutical industry spends around one 
quarter of its revenue on sales and marketing, almost twice as much as it spends on 
research and development (Froud et al. 1998; Lloyd and Newell 2001). Furthermore, 
there is a concern among pharmaceutical companies that expenditures are “wasted” due 
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to “over-detailing”, which has not led to more sales and in some cases may have a 
negative impact on sales (Elling et al. 2002; Manchanda and Chintagijnta 2004). 
   
The section has provided an overview of the key issue, the cost issue of sales forces, 
which together with the second key issue, the need to effectively launch new product, is 
the driver for the research question. An overview of the challenges when launching a new 
product with a sales force is explored in the next section.  
1.1.2. Sales Force and the Launch of New Products  
 
Several studies have suggested that the sales force is a major contributing factor to new 
product success (Cooper 1998; Cooper 1980; di Benedetto 1999; Hultink and Atuahene-
Gima 2000; Moriarty and Kosnik 1989; Song et al. 1997; Song and Parry 1997); however 
company management has no guarantee of sales force commitment to a new product 
(Atuahene-Gima 1997). A new product can create excitement; however, many companies 
are reluctant to add additional sales representatives in support of both the new and older 
products, even though they usually recognize that this is required (Rangaswamy et al. 
1990). Atuahene-Gima (1997) suggest that successfully launching a new product to the 
company’s sales force requires the same high levels of creativity, energy, and managerial 
insights as does the product’s launch into the marketplace. Also, it is argued that to 
ensure sales force adoption of a new product, careful consideration of the characteristics 
of the product, the competitive environment, the firm, and the sales force itself is 
required. Managers should view the salespeople as the first line of customers to ensure 
that they have full support of the sales teams (Atuahene-Gima 1997). Consequently, 
managers and researchers need to examine more closely the factors underlying the 
successful launch of a new product to a firm’s sales force (Atuahene-Gima 1997).  
 
While the literature on the full discipline of selling and sales force management has 
increased in the last decade and a substantial amount of literature continues to become 
available (Baldauf et al. 2005; McBane et al. 2003; Moncrief et al. 2000), there is not 
nearly as much activity in the research community around the product launch phase 
(excluding new product development process), especially on the sales force impact on the 
successful launch of a product. In a way, this may be odd, as a successful commercial 
product-launch process may bring a product to its sales peak faster, which in turn, may 
contribute to its overall market success; while a badly performed product-launch process 
may actually contribute to a product never reaching its projected sales peak (Cooper 
1998; Rao 2002). The literature supports the notion that a significant determinant of a 
successful launch is the motivation of the sales force selling the product (Cooper 1998; di 
Benedetto 1999; Micheal et al. 2003). Also, the literature around new product 
development has repeatedly shown that a major cause of failure of a new product is 
inadequate marketing, including sales (Calantone and Cooper 1981; Cooper 1998; 
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Cooper 2000; Song and Parry 1994). For example, Smith et al. (2002) concludes that the 
product launching phase is found to be typically decisive for the success of a new product 
and requires significant investments. In addition, some literature suggests that successful 
commercialization of new products is a core factor for a firm’s survival (Calantone et al. 
1996; Cooper 1998; Cooper 1979; Cooper 1980; Cooper 2000; Cooper and Kleinschmidt 
2000; Smith et al. 2002). In addition to these general launch challenges; the 
pharmaceutical sales forces are meeting new challenges. These challenges will be 
described in more detail later in this chapter, however, the issue of limited access to 
physicians (Dannacher and Stahl 2005; Elling et al. 2002) is an example of a key issue 
for Sweden, the country being investigated in this research.   
 
This section provided an overview of the challenges when launching a new product with 
a sales force, the actual core of this research. This topic will be further discussed in later 
sections.  
 
1.2. Research Aims  
 
The overall aim of conducting this research project is to provide guidance in how to 
successfully launch a pharmaceutical product with the use of a sales force. More 
specifically, this guidance is aimed to be formulated as a set of key success factors for 
sales force readiness during new product launch.  
 
This research and its model aim to answer the research question:  
What are the Key Success Factors for Sales Force Readiness during the Launch of a 
New Pharmaceutical Product on the Swedish Market? 
 
These key success factors will provide insights into which factors matter the most and 
should receive maximal attention by management when launching a product if the 
product launch is to be a success. 
 
The assumption is that by studying earlier launches, it is possible to conduct new 
launches with a higher probability of success. A second assumption underlying this 
research is that there are systematic differences in successful launches compared to those 
that are unsuccessful in terms of sales force readiness.   
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1.2.1 Target Groups for the Research Findings  
 
The results of research findings presented in this text aim at two types of professionals: 
researchers and practitioners.  
 
The first major target group addressed here is the scholars studying and researching the 
area of product launch and sales force.  
 
Continuing with the second target group, practitioners may be divided into two 
subgroups: the staff members of companies formulating and implementing sales force 
strategies, as well as management consultants and advisors. The staff members include 
any role that conducts activities related to the launch of products. Examples of this are 
market directors and managers, market and business analysts, business developers, 
product managers, and business unit managers. This refers also to management 
consultants, advertising and communication advisors who specialize in product launch or 
sales force consultancy.  
 
In addition, even if the research presented here has been adapted for the Swedish 
pharmaceutical industry, the findings could very likely provide guidance to other 
countries. The Swedish local industry has probably experienced one of the most radical 
transformations in the pharmaceutical industry in many areas, yet this is foremost in 
terms of sales force-imposed-regulations and guidelines and may, therefore, be used for 
forward-seeing purposes for other markets. This is argued to be highly likely because of 
the global trends showing that most markets will eventually face very similar conditions 
(Dannacher and Stahl 2005; Dutton and Reece 1996). This will be further explored later 
in this Chapter.    
 
1.2.2. Research Objectives 
 
Within the defined research scope, the research objective is:  
To have identified the Key Success Factors for Sales Force Readiness during New 
Product Launch, within the Swedish Pharmaceutical Industry.  
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1.2.3. Research Purpose  
 
The focus will be defined below and given this focus, the defined target groups and 
objective for this research; two purposes have guided this research.  
 
Research Purpose 1: To contribute to the knowledge constitution process that 
accumulates scholarly knowledge about successful strategies and management of sales 
forces, during the product launch phase, thereby increasing the understanding of this 
process. This advanced understanding, in turn, aims to facilitate design of further 
research investigations within the addressed domain. 
 
Research Purpose 2: To guide managers and management advisors in the process of 
design and execution of successful strategies and execution for sales force readiness 
during the product launch phase, thereby facilitating achievement of higher return on 
investment from the product development. 
 
1.2.4. Research Process 
 
The research is conducted in two parts; the first with a qualitative focus and the second 
with a quantitative focus. In the first part of the research, the research question is defined 
and the literature review conducted followed by the formulation of a Preliminary Model. 
The Preliminary Model was derived from six models drawn from literature and the 
models belong to the two scholarly areas of new product adoption and sales force 
efficiency. The nature of the Preliminary Model is highly generic and is intended to guide 
the next research step where six case studies and six expert interviews are conducted. The 
findings of these case studies and interviews, together with other findings in literature, 
provide knowledge for developing the Preliminary Model into a Research Model as 
defined for the scope of this research. See Figure 1 for an overview of the formulation 
process. The Research Model includes a set of variables to be tested quantitatively with 
empirical data. The second research part includes the formulation of the data collection 
instrument, identification of subjects for investigation, data collection, statistical analysis 
and interpretation of the results. The research utilizes a bottom-up pattern identifying 
research approach, employing the Partial Least Squares Analysis (PLS) guided by e.g. 
Thomson (2004), Chin (1998) and Haenlein and Kaplan (2004). The test has predictive 
aspiration, where PLS is considered more powerful than its current alternatives (Ryan et 
al. 1999). The research process and methodology are described in more detail in Chapter 
2, Research Approach.  
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Figure 1: Formulation process of the Preliminary Model and the Research Model 
 
 
 
 
 
1.3. Research Justification and Motivation  
 
The justification and motivation for this research is built on the many areas described in 
the full introduction chapter, with the key motivational factors being; 1) the importance, 
challenges and cost issue of sales force operations, and 2) the need for pharmaceutical 
companies to successfully launch new products, in order to receive returns on 
investments on their research efforts, within the increased challenging environment.  
These two key motivational factors are summarized below.  
 
1.3.1. The Importance of the Sales Force 
 
Strategy development, in the phase of a new product’s introduction, has always been a 
key marketing process, where sales force management and sales force readiness belong 
(Cooper 1998; Cooper 1979; Cooper 1980; Cooper 2000; Cooper and Kleinschmidt 
2000; Rao 2000b). Sales force management plays an important role in the 
implementation of a business strategy and is a key functional activity driving success 
(Slater and Olson 2000). According to Kotler (2000), “No one debates the importance of 
the sales force in the marketing mix”. Furthermore, the importance of sales organizations 
is emphasized by companies’ continuous modifications to sales management strategies 
and sales organization variables in an attempt to enhance or retain competitiveness, and 
the urgency of such changes appears greater in the current business environment 
(Babakus et al. 1996; Hise and Reid 1994; Lloyd and Newell 2001; Piercy et al. 1999). 
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Sales personnel serve as the company’s personal link to the customers and the sales 
representative is often regarded as the company for many of its customers while at the 
same time bringing back much-needed information from the customer (Kotler 2000).  
 
Corcoran et al. (1995), defines the rationale for sales force investments: “Ultimately a 
sales organization’s role is to translate the company’s strategy from a board-room vision 
to an everyday reality, add value for customers beyond that provided by the products and 
services, create competitive differentiation, and contribute to the company’s profitability” 
(Corcoran et al. 1995). Moreover, the sales representative plays a central role in many 
companies, linking the production of product or service to the customer (Lloyd and 
Newell 2001). Lilien et al. (1981) and Hahn et al. (1994) argue that detailing (sales calls) 
from sales representatives to physicians is one of the most important components in the 
marketing mix for a pharmaceutical company. If the Big Pharma is to maximize revenue, 
it must invest in extensive sales and marketing operations, with large sales teams 
spanning a broad range of countries (Datamonitor 2007b). Streamlining marketing and 
sales processes can fundamentally alter a new pharmaceutical product sales profile with 
incremental revenue of $500 million to $1 billion within five years of sales (Rao 2002). 
 
The literature regarding the full discipline of selling and sales force management has 
increased substantially in the last decade and has started to mature as a field (Baldauf et 
al. 2005; McBane et al. 2003; Moncrief et al. 2000). Having said that, it is also concluded 
that even if there is a rapid increase in the number of publications, most of the research 
areas within selling and sales management as well as sales performance are still in their 
infancy (Giacobbe et al. 2006; Ingram 2004). This is especially true for the literature 
around sales force management during the new-product-launch phase. 
 
The importance of the sales force has gained strong support in literature, as well as the 
acknowledgement of the costs associated with its operations, which drives researchers to 
conclude the rising need for managers to find efficiency and effectiveness. The sales 
force operations for the pharmaceutical companies will be further explored and described 
later in this chapter in order to give a more holistic view of the change drivers and 
empirical situation being investigated.  
 
1.3.2 The Importance of a Successful Launch 
 
The risks encountered by a pharmaceutical product during its life cycle are many. The 
rising cost of research and development (Gilbert et al. 2003; Pharmaceutical-Executive-
Europe 2006; Popper and Nason 1994; Yeoh 1994), the struggle for high cost R&D 
organizations to bring new innovative entities through the pipeline (Gilbert et al. 2003; 
IMS 2007; Yeoh 1994) and the increased challenges of getting the few products that 
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come through the pipeline approved by the regulatory authorities around the world 
(Datamonitor 2007b; IMS 2007; Pathak et al. 1992; Popper and Nason 1994; Yeoh 
1994), are a few examples. This means that the so-called blockbusters together with all 
the new products are harder to introduce and have a lower return on investments (Gilbert 
et al. 2003). To make matters even more challenging, recent market trends show that the 
overall global pharmaceutical industry growth rate is declining (IMS 2007). Some 
suggest that for a pharmaceutical company to maintain double-digit growth, the company 
would need to launch four new products every year (Rao 2002). The time when the 
products are in the market is also challenged on the other end of the life cycle, where 
generic companies very aggressively challenge patents earlier and more frequently 
(Datamonitor 2007b; Elling et al. 2002; Gilbert et al. 2003; IMS 2006; Yeoh 1994). Other 
issues are the price pressure and the stricter reimbursement guidelines that 
pharmaceutical products meet around the world (Datamonitor 2007b; Elling et al. 2002). 
The consequence is a significant loss of revenue over time (Pharmaceutical-Executive-
Europe 2006). As all these broader issues contribute to the importance for companies to 
launch new products successfully, these will be explored in more detail later in this 
chapter.  
 
With the high risk of medical and commercial failure of a product as well as loss of time 
in the market, it is becoming crucial that these products reach peak sales as early as 
possible to optimize the time on the market and generate maximized revenue (Elling et al. 
2002; PhRMA 2003; PhRMA 1995; Rao 2002). The risk research-based companies are 
facing as they commercialize pharmaceutical products is very uncertain (Cooper 1998; 
Cooper 1979; Cooper 1980; Cooper 2000; Cooper and Kleinschmidt 2000; Gilbert et al. 
2003; Popper and Nason 1994; Rao 2000b) and the launch phase is becoming 
increasingly critical, as there is less time and money available allowing less room, if any, 
for a second chance to recoup a failed launch, i.e. a re-launch. 
 
This could also be further supported by Guiltinan’s (1999) more general analysis of the 
whole new product development process. A conclusion made is that the phase labeled 
“the product launching”; here called “new product launch”, is found to be typically 
decisive for the success of a new product and requires significant investments; despite 
that, there are few empirical studies on the subject (Guiltinan 1999). 
 
Almost all of the above broad-range challenges and issues remain unanswered. The 
research presented here, which investigates and focuses on the key success factors for 
sales force readiness during the new product launch phase of pharmaceutical products on 
the Swedish market, aims to bring directions and guidance in this topic, both to practicing 
managers and as a contribution of new information for scholars.  
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1.4. Research Focus and Scope  
 
The key message in this section is the defined focus and scope, hence the boundaries, of 
the domain researched in this study.  
 
Overall, the scope of the investigation is identifying the key success factors for sales 
force readiness during the new product launch phase for pharmaceutical products on the 
Swedish market. In broad terms, a “Key Success Factor” refers here to any quality, 
characteristics, or condition, present in the sales force readiness during a product launch 
phase, which positively influences its outcome in such a way that without it, the outcome 
would not be as favorable.  
 
The scope is further laid out and presented in detail according to the areas; Industry 
(pharmaceutical) & Geographical (Sweden), Life Cycle Stage (new product launch), 
Pharmaceutical Products (ethical prescription drugs) & Customers (physicians). These 
areas are further described and justified below. 
 
Industry and Geographical (Market) Scope 
 
The research presented here has been adapted for the Swedish pharmaceutical industry. 
The general arguments for focusing on a particular industry type and its market have been 
provided by various contributions to industry analyses (McGahan 2004; Porter 1995; 
Porter 1987), which basically argue that different industries and markets are governed by 
different conditions, for example, regulatory, economic, cultural and social etc. 
(McGahan 2004; Porter 1995; Porter 1987). Furthermore, every industry imposes various 
determinants upon its actors, here the pharmaceutical companies, where these 
determinants condition the performance of these companies, and by derivation, the set-up 
of the capabilities of these companies (Churchill Jr et al. 1985; Porter 1995). Indeed, 
various investigations have argued that the pharmaceutical industry manifests a particular 
uniqueness, driven by tight and heterogeneous regulatory conditions. This postulate is 
clearly manifested by the new regulations within the industry with regard to physician-
access (Dutton and Reece 1996). In literature with empirical data collected around new-
product launches, it is found that the role of the behavior of the team leader and 
marketing skills are affected by national culture (Calantone et al. 1996; Shane 1994a; 
Shane 1994b; Song et al. 1997). Also, this research area has proven that there are 
differences as to which launch decisions are of importance when introducing a new 
product between industrial and consumer products (Hultink and Robben 1999). 
Furthermore, research in the area of sales organization effectiveness suggests that cultural 
differences may be determinative (Baldauf et al. 2001a; Piercy et al. 1999; Piercy et al. 
2004; Rouzies and Macquin 2003). 
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The conclusions from the literature of selling and sales force management, mostly pooled 
information from a number of unrelated industries is investigated together in an attempt 
to provide generalization of results (Blackshear and Plank 1994; Ingram 2004), which 
might not then provide a sufficiently specific result for practical guidance for managers in 
a particular industry.  
 
The research is focused on the discipline of sales force management and selling in a field- 
based environment. As discussed earlier, even though the whole global pharmaceutical 
industry is experiencing transformation, the Swedish local pharmaceutical industry has 
probably experienced one of the most radical transformations. This is true in many areas, 
but primarily in terms of sales force-imposed regulations and guidelines, and it may 
therefore, not be representative of the pharmaceutical industry in other countries. 
However, based on the global emerging environment for pharmaceutical sales forces 
around the world (Dutton and Reece 1996), this market might be used for forward-seeing 
purposes in other markets, where the same trends are emerging (Dannacher and Stahl 
2005). Moreover, some evidence has been found that differences occur between sales 
forces in different nations: e.g. Engle and Barnes (2000) found, when investigating 
beliefs about the various uses and value of the sales force automation systems in three 
countries within a pharmaceutical company, that the individual country means were 
significantly different for almost all questions (Engle and Barnes 2000). It is also 
concluded in literature that the role of a sales representative varies according to type of 
industry, product, market structure, and customers (Tengilimoglu et al. 2004). This 
suggests differences in market dynamics over nations, industries and within the same 
industry, which might have implications on sales force readiness.    
 
Product Life Cycle Phase 
 
Building on Kotler’s (2000) definition of the stages of a general product’s lifecycle, the 
definition of the full lifecycle for an ethical research-based pharmaceutical product is 
defined and described in five main phases, Research & Development, Introduction 
(Launch), Growth, Maturity and Decline. The full definition and description are 
presented in Appendix 8. The Research and Development stage could also be further 
divided in the sub-stages Discovery, Clinical Development and Registration. The 
development of pharmaceutical products is to a great degree done by pharmaceutical 
companies, with academia and government contributing less than 10% (Dimasi and 
Grabowski 1995). In the pharmaceutical industry, the Launch phase or Introduction 
accounts for two sub-stages: firstly, market inductor activities, such as delivering the 
product to the pharmacies and informing the physicians of its existence and basic 
characteristics, while the second stage is the initial marketing and sales operations that 
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follow immediately after the market introduction. The first stage, the physical market 
introduction of the product, is typically short and definitive. It is during the second stage, 
the initial marketing and sales operations, that the actual communicative and other 
tactical launch activities may be executed. The Growth and Maturity stage of the 
lifecycle is constituted by regular marketing and sales operations, representing the typical 
activities conducted by the various marketing, sales, medical, regulatory, and other types 
of resources of the company, in order to reach sales goals. The Decline phase is defined 
as a period when sales show downward drift and profits are eroded (Kotler 2000). This 
phase could also be referred to here as Patent Expiry.  
 
This research is investigating the Introduction phase, which will be mainly referred to as 
new product launch or launch. There are suggestions from research conducted around 
sales call effectiveness in the pharmaceutical industry, that selling a new product differs 
from selling an old or mature product, based on its relative importance for the physician 
(Parsons and Abeele 1981). 
 
Pharmaceutical Products & Customers 
 
There are different “categories” of pharmaceutical products, their target customers and 
the way marketing literature has defined marketing and selling efforts or strategies 
towards these customers. Here, the scope of the research in the area of the products and 
their customers will be described in accordance with “research-based, ethical and 
prescription drug” (product category), “physicians” (target customers) and “mass 
market” (marketing strategy). These concepts and the way in which they are applied here 
will be defined below. Further, the products investigated were launched during the time 
period between 1995 and 2005. The key motivation for this was to keep the product 
launches current in order to best reflect ongoing changes, while still representing a 
sufficiently large base of research subjects. 
 
Research-based, ethical and prescription drugs 
 
The pharmaceutical industry provides so-called ethical drugs or ethical pharmaceuticals, 
also referred to as prescription drugs, which are defined as a patented drug, marketed 
under a brand name which cannot be bought without the written permission, or 
prescription, of a doctor or dentist (Froud et al. 1998). This denotes those pharmaceutical 
products that are sold for the deliberate treatment of an individual’s health as opposed to 
illegal drugs on the market (note that the same drug substance – e.g. morphine – may be 
regarded as ethical or as illegal, depending on the manner and context of its use). 
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A second distinction to be introduced here is that between research-based drugs and 
generic drugs. A new drug is typically the outcome of an intensive and costly R&D 
process, conducted by one or more pharmaceutical companies, sometimes in 
collaboration with universities and institutes. Typically, one or more patents protect a 
drug for 20 years, which means that the patent holder has exclusive rights to produce and 
sell the patented drug. A new product that is the result of an R&D process and is 
protected by patents, is categorized here as a research-based drug. On the other hand, 
there are companies that copy products which have been successful in the marketplace, 
and produce and sell them after the patent protections have expired; these products are 
understood as generic drugs (Froud et al. 1998).   
 
The third distinction here is the difference between drugs under prescription, i.e. 
pharmaceutical products that require a physician or other eligible health care professional 
to prescribe the drug, and Over-The-Counter (OTC) drugs, i.e. pharmaceutical products 
which can be bought by anyone at the pharmacy or department store (Froud et al. 1998). 
The rules and regulations concerning marketing and sales differ greatly between 
prescription and OTC drugs, based on both how they are bought and how they are 
allowed to be marketed. The rules and regulations also differ from country to country, for 
example European regulations do not allow direct marketing of prescription drugs to 
consumers, but in New Zealand and the USA, promotion is allowed via general media 
(Lloyd and Newell 2001).  
 
Physicians  
 
A further factor limiting the scope of this research is the target customer group towards 
which the products are marketed. This refers to the specific group that a pharmaceutical 
sales force can target, namely a certain type of physicians or other stakeholders. There are 
three core customer types for the pharmaceutical company (Rao 2000a). Physicians – in 
which the value propositions are primarily treatment results and options but could also be 
process support and issue handling. Patients – depending on therapy and treatment goal, 
the value propositions are the increased possibility of being cured, relief of symptoms or 
prevention of disease. Payers – the value propositions are increased efficiency in 
healthcare and its related costs. Depending on the system, usually defined by the nation, 
the payers could be governments, insurance companies, patients or a combination of the 
above. In this research, the physicians in their role as prescribers will be the subject of 
investigation.  
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Mass Market  
 
To further clarify and limit the scope of this research, the concept of mass market is 
introduced. This factor is introduced so that sales management practitioners can better 
relate to the results in a real world environment and to more accurately use any 
recommendation in practice. Also, some literature argues that measures and scope should 
be related to an explicit situation, thus rendering the patterns in the results more reliable 
and making them more valuable for managers (Blackshear and Plank 1994). This is 
further supported by Wotruba (1991) who suggests that to be able to better compare the 
outcome of research, the studied subjects should be homogenous in terms of the sales 
forces’ need for internal capabilities and know-how as well as to which extent their 
customers’ operations are conducted (Wotruba 1991). Lilien et al. (1981) in their 
investigation of detailing effort effect in the pharmaceutical industry, have also selected a 
certain physician specialty in order to gain better accuracy in results.   
 
Under Kotler’s concept of a product’s life cycle he discusses the stages of market 
evolution and how a market can be divided or how it can emerge in terms of optimizing 
the launch of a product (Kotler 2000). He refers to three options of introduction for a 
product: 1) a single-niche strategy, where the new product meets the preference of one of 
the corners of the market; 2) a multiple-niche strategy, where the new product can be 
simultaneously launched towards two or more parts of the market; or, 3) a mass-market 
strategy, where the product meets preference to the middle or majority of the market.    
 
In the pharmaceutical industry, all of the above options could apply depending on how 
the company or product management choose to approach the market (Rangaswamy et al. 
1990). The most common way of segmenting the market is by physicians’ therapeutic or 
medical specialty (Rangaswamy et al. 1990). Depending on the market, physicians can be 
divided up into many specialties (Manchanda and Chintagijnta 2004), such as 
cardiologists, psychologists or transplant surgeons. The physicians classified as General 
Practitioners (GP), also referred to as Primary Care Physicians (PCP), represent the 
largest group of physicians in most markets. Literature has empirically proven that 
pharmaceutical sales representatives’ detailing (sales calls) has different effects according 
to physician specialty just as the physicians’ prescription behavior and their prescription 
rates significantly differ within types of physician specialty groups (Manchanda and 
Chintagijnta 2004). Also, anecdotally, there are several differences between drivers in the 
market and practical sales force implementation when launching a product aimed at 
General Practitioners and specialists (e.g. psychologists or transplant surgeons). 
 
Following the above line of argument, physicians working as General Practitioners are 
defined as the mass market in the pharmaceutical industry. It is also in this mass market 
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segment that sales forces are the largest and drive the most costs. The population of 
General Practitioners is usually seen as a homogenous group with similar requirements, 
purchasing power, buying attributes or buying habits. Relating to the pharmaceutical 
sales forces, Rangaswamy et al. (1990) argues that a large segment with specialized 
needs can often be reached by a sales force selling only the relevant products for that one 
segment, which often increases profitability and sales force effectiveness thus 
compensating for any increases in the cost of selling (Rangaswamy et al. 1990).   
 
Therefore, it is argued that sales force activities towards General Practitioners can be 
considered to be a mass marketing strategy, while sales force activities aimed at a group 
of specialty physicians could be a single-niche or a multiple-niche strategy.  
 
This research has defined and assumed a market introduction matrix for the 
pharmaceutical industry, based on the core customer groups defined above (Rao 2000a), 
and the introduction strategies defined by Kotler (2000) - see Figure 2. This narrowing of 
the scope and definition for the sales force context will further increase the relevance of 
the results, in the form of the identified key success factors, for the intended target groups 
of this research.   
 
 
Figure 2: Market introduction matrix for the pharmaceutical industry 
    
 
 
 
 
 
 
 
 
 
 
Summary of Scope  
 
In sales management literature, it is argued that depending on the practice of selling, this 
may not be the same at a given time in all industries, or in all companies in the same 
industry or even in all components of the total sales organization within one company 
(Wotruba 1991). Even if this does apply to reality, this research argues that in the case of 
scoping by geographical borders (giving similar regulatory, legal and governmental 
conditions),  industry (adopting similar entry and exit barriers, risks and dynamics) and a 
homogenous group of research subjects (here manifested by pharmaceutical products 
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aimed at the same homogenous customer group – defined as General Practitioners), the 
right level of limitations to the scope has been applied in order to identify interesting and 
relevant results applicable both to the academic community and to the practicing sales 
management and company executives. This more explicit situation will make the patterns 
in the results more reliable as well as more valuable for managers (Blackshear and Plank 
1994). 
 
In summary, the defined focus, hence boundaries, of the researched domain in this 
research project could be stated as the identified key success factors for sales force 
readiness for field sales forces during new product launch for research-based ethical 
pharmaceutical products launched between the years 1995 – 2005, aimed at physicians 
working as general practitioners in the Swedish pharmaceutical industry. See Table 1 for 
an overview of the research focus. 
 
 
Table 1: Summary of the research focus assumed in the present study 
 
Research Focus Attribute Scope 
Industry Pharmaceutical 
Geographical Market Sweden 
Product Life Cycle phase Product Launch 
Product Pharmaceutical, Research-based, Ethical  
Selling mechanism Prescription (Rx) 
Operations Management of Field Sales Force  
Sales Force Target Group Physicians as Prescribers 
Type of Prescribers General practitioners (Mass Market)  
Time Frame Launched products 1995-2005 
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1.5. Definition of Sales Force Readiness during New Product 
Launch 
 
Given the previously characterized empirical situation covered here, as described in the 
Background, the Research Justification and Motivation, together with the defined 
Research Focus and Scope, which challenge managers responsible for the configuration 
and management of a sales force, which in turn are aimed at contributing to a successful 
launch of a pharmaceutical product; a number of terms and their definitions are utilized to 
characterize these kinds of situations, or parts thereof. Examples of such terminology 
include; “New Product Adoptions” (Atuahene-Gima 1997), “Sales Force Effectiveness” 
(Piercy et al. 1997), and “Sales Force Management Control” (Baldauf et al. 2005). 
However, as understood here, all these definitions only partially or too broadly cover the 
specific kind of empirical situation addressed in the present research. Therefore, the label 
“Sales Force Readiness during New Product Launch” has been chosen here to denote the 
empirical situations addressed in this research. In this research, the label “Sales force 
Readiness during New Product Launch” is broadly understood as the degree to which a 
sales force is prepared, able or willing to support a new product in order to generate a 
successful launch. More specifically, this label refers to situations when the context is 
constituted by a product of a certain kind (Micheal et al. 2003) that is to be introduced 
(Kotler 2000) into a certain market-place, with its specific characteristics (Hultink and 
Atuahene-Gima 2000). In such contexts, Sales Force Readiness accounts for one of 
several sales representatives conducting actual sales behavior, which is commanded and 
controlled by one or more supervisors in relation to defined sales and other kinds of 
targets, all of which are aimed to contribute to the overall sales performance of the 
product (Hultink and Atuahene-Gima 2000). In this case, the sales representatives have a  
certain kind of characteristics as individuals (Atuahene-Gima 1997), are organized into a 
certain kind of organizational set-up (Micheal et al. 2003) and have received a certain 
kind of preparation for their product introduction sales work (Hultink and Atuahene-
Gima 2000). The above description is what is meant here by “Sales Force Readiness 
during New Product Launch” and more detailed definitions of each part are further 
explained when presenting the Preliminary Model in section 4.1. 
 
In short, “Sales Force Readiness during New Product Launch” refers to a set of properties 
of the product to be introduced into a market place, the properties of such a market, the 
properties of the sales force that conducts such an introduction, and then the outcome of 
such a product launch. 
 
Given this notion of the real-life concerns of managers occupied with reflections about 
and actions to configure a sales force for a successful product launch, the sales force 
readiness during new product launch is here understood to be one central managerial 
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domain of any Sales Force Strategy. However, clearly there are other managerial domains 
that may also be regarded to be part of a Sales Force Strategy, such as the coordination of 
the sales force operations with marketing or after-sales operations, as well as sales force 
configuration to address post-product launch phases, such as growth or decline.  
 
1.6. Pharmaceutical Sales Force Operations and Life Cycle 
Challenges 
 
Pharmaceutical companies are subject to an increased number of challenges in today’s 
market, making it harder to achieve their projected return on investments (ROI) for their 
products. In addition to sales force issues and launch issues, the broad spectra of 
challenges faced by pharmaceutical companies all reinforce the importance of a 
successful new product launch.  
 
To give a more complete background and to further define and describe the context and 
challenges that the pharmaceutical companies are facing, a description of the sales force 
operations and its challenges together with the challenges being met by the 
pharmaceutical product during its life cycle are presented here.  
 
1.6.1. Pharmaceutical Sales Force Operations and its Challenges 
 
The success of a pharmaceutical product and its market presence, in terms of sales 
volume, is primarily managed within the marketing and sales operations of a 
pharmaceutical company. For pharmaceutical companies, the sales force activity is the 
primary source of promotion (Lilien et al. 1981; Manchanda and Chintagijnta 2004; 
Mizik and Jacobson 2004; Tengilimoglu et al. 2004). In the industry , several different 
drugs or treatment choices are available for a given medical condition and therefore 
pharmaceutical companies must invest heavily in marketing and sales (Datamonitor 
2007b). In this respect, successful management of the sales force has been and still is a 
crucial component while also remaining a dominating cost component (Dannacher and 
Stahl 2005; Dutton and Reece 1996; Kotler 2000; Lloyd and Newell 2001; Mizik and 
Jacobson 2004; Tengilimoglu et al. 2004; Zoltners et al. 2001). Sales operations are 
typically executed by a group of sales representatives and their managers, such as field 
sales managers and area sales managers (Kotler 2000). The description of the role of the 
sales force as the face of the company is also applicable to the pharmaceutical industry 
(Parsons and Abeele 1981). However, the actual sales moment in the pharmaceutical 
business differs somewhat from sales in most other industries, as the sales representatives 
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do not actually close the product sales. The sales moment is typically a pharmacy selling 
the pharmaceutical products to the patients. Rather, the sales representative’s key role is 
to deliver messages and provide information to their primary customers (the physicians) 
and to educate them about the product’s therapeutic value, side effects, dosage (based on 
clinical studies) and deliver samples to promote the company’s products (Dong-Gil and 
Dennis 2004; Lloyd and Newell 2001; Mizik and Jacobson 2004; Parsons and Abeele 
1981; Rangaswamy et al. 1990). The sales connection is only made when a physician 
meets a suitable patient and writes a prescription, which the patient takes to the pharmacy 
to be dispensed (Datamonitor 2007b; Dong-Gil and Dennis 2004; Lloyd and Newell 
2001). The sales representative and physician interaction is considered the primary source 
of information for the physicians and literature has proven that detailing (sales calls) is 
effective in increasing the mean prescription rate (Elling et al. 2002; Manchanda and 
Chintagijnta 2004). 
 
There are several types of stakeholders influencing the sales performance of a product; 
these include physicians, nurses, patients and their relatives, pharmacists, local and 
central authorities, insurance companies, and press and media. The stakeholders vary 
depending on the market and the product; however, it is the physician in her or his role as 
drug prescriber that the sales representatives typically target with their promotional 
messages (Elling et al. 2002).  To clarify this, a particular physician may also assume 
various other roles than that of prescriber. He/she may be a member of various local, 
national and international professional organizations and committees, may be a member 
or advisor to various expert committees making recommendations regarding the medical 
preferences of a drug; and may be a so-called key opinion leader (Meffert 2009), in terms 
of clinical research, thus influencing the professional community, the authorities, or the 
public opinion. However, in the context of this study, the focus is on the physicians in 
their role as a prescriber of drugs to patients.  
 
It is important to note that a drug may be prescribed by professions other than physicians. 
For example, contraceptive products are often also prescribed by nurses in some 
countries. These exceptions will not be considered in this research.  
 
Another point around the sales channel for a pharmaceutical drug is the distinction 
between prescription-based drugs and those sold over-the-counter (OTC). A patient does 
not need a prescription to buy the latter, which is typical for ordinary “headache” pills. 
However, the major volume and the overwhelming value of drugs are sold via 
prescriptions, which thus control the sales volume and consequently, the revenue streams.  
The sales forces of pharmaceutical companies attempt to influence this control 
mechanism by informing the prescribers in order to steer the prescription habits (Elling et 
al. 2002; Manchanda and Chintagijnta 2004). This is typically accomplished by means of 
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sales representatives’ face-to-face visits with the physicians, in which they are informed 
of the existence of the product, its medical and therapeutic functions, and when needed, 
of the product’s advantages compared with other competing drugs as well as its health 
economic benefits (Elling et al. 2002; Mizik and Jacobson 2004). These sales operations 
are typically coordinated in some manner with the marketing operations that may, for 
example, deliver a similar message to the physicians by means of advertisements in 
medical magazines and other channels. 
 
Pharmaceutical sales force operations are meeting new challenges  
 
The pharmaceutical sales force operations described above are increasingly encountering 
challenges in the market place in the form of stricter regulations and restrictions, a trend 
which is taking place in most countries around the world (Dutton and Reece 1996; Smith 
et al. 2002). Over the years, pharmaceutical sales forces have undergone significant 
changes in both the total number of representatives in the field, and the necessary skills 
required for representatives to excel in their position. As in many other industries, the 
pharmaceutical industry has lately seen a decrease in sales force sizes together with a 
reassessment by the firms of the overall effectiveness of their sales forces in the light of 
the changing environment (Datamonitor 2007a; Dutton and Reece 1996; Rangaswamy et 
al. 1990). Rangaswamy et al. (1990), has put the selling of pharmaceutical products in the 
category of a repetitive buying environment, which is usually defined as having short 
purchase cycles and competitive interchangeable products available. The consequence of 
this is that the sales representatives must attempt to maintain a constant presence at the 
doctors’ offices (Rangaswamy et al. 1990). More recently, the issue of limited access to 
physicians (Dannacher and Stahl 2005; Elling et al. 2002) or decision makers has 
escalated, driven by regulations as well as by the fact that the physicians themselves are 
beginning to view the presence of the sales representatives as an inconvenience, feeling 
that the sales representative is not helping them in high-stake decisions (Lloyd and 
Newell 2001; Rangaswamy et al. 1990). Furthermore, it is argued that calling on 
customers is vital for maintaining sales of the product and in many situations the 
relationship between the sales representative and the physician has a positive impact on 
sales (Rangaswamy et al. 1990).   
 
In the case of the Swedish pharmaceutical industry, which is the scope of this research, 
ongoing developments have transformed the conditions of the sales forces operations of 
the pharmaceutical companies, with regard to the sales representatives’ access to the 
physicians (Dannacher and Stahl 2005). While in most markets, and indeed previously 
within the Swedish market, sales representatives were granted free access to the 
physicians, conditioned only by the decisions of the physicians themselves; recently 
formulated and implemented regulations have restricted this free access (Dannacher and 
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Stahl 2005). These restrictions have developed over time, resulting only in tighter 
regulations. Furthermore, the typical access method was that a sales representative could 
meet a physician on a face-to-face, one-to-one basis at any pre-determined time period, at 
the discretion of the physician. However, the newly emerged conditions restrict this 
format and the majority of meetings are set up as a meeting for a group of physicians, at a 
pre-determined time period, for example over a lunch.  
  
The pharmaceutical companies are making all attempts to adjust to these new conditions 
(Dannacher and Stahl 2005; Elling et al. 2002; Lloyd and Newell 2001; Tengilimoglu et 
al. 2004). Currently, there is limited scientific analysis of these situations for potential 
strategies to overcome these hurdles. Many companies have been experimenting with 
novel approaches in order to adapt to the changed environment. An example is the 
introduction of call centres whereby the physicians are invited to learn about new 
products at their convenience. Another example is the introduction of so-called Medical 
Science Liaisons positions, which are more scientifically and medically-oriented 
personnel, and are thereby less influenced by all the new access regulations. In addition 
to these examples, some companies have approached this issue by having more sales 
representatives selling a narrower range of products and by introducing multiple sales 
forces instead of single sales forces (Rangaswamy et al. 1990).  
 
1.6.2. Challenges during a Pharmaceutical Product’s Life Cycle 
 
The challenges encountered by pharmaceutical companies exist and are increasing during 
all the phases of the life cycle in terms of substantial costs and risks attached to 
undertaken investments. A more detailed definition and description of a pharmaceutical 
product’s life cycle can be found in Appendix 8.   
 
The identified macro challenges highlight the need to successfully introduce a new 
product in order to maximize return on investments. The following section summarizes 
these issues, divided in three areas: cost and risk in research and development; market 
risks; and risks at the end of the life cycle. This order also follows the phases of product’s 
life cycle.   
 
Cost and Risk in Research & Development 
   
The pharmaceutical industry has the highest research and development investment of all 
industries (PhRMA 2001). Pharmaceutical research and development expenditures in 
2004 were around $38 billion (PhARMA 2005). Of the total research and development 
investments being made, the pharmaceutical industry accounts for around 17%. The 
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industry in second place in terms of the highest investments was Computer Software & 
Services, accounting for around 10-11% of the total, followed by Electrical & Electronics 
with around 8% and then Office Equipment & Services with around 7-8%. The 
pharmaceutical development process is exceptionally hazardous and the development 
cost of a novel prescription drug, from discovery to marketing authorization, typically 
exceeds $800 million (Datamonitor 2007b; Gilbert et al. 2003). All of this suggests 
enormous capital investments for a major pharmaceutical company developing a large 
portfolio of products which must always be balanced against the risks.  
 
High and increasing cost of development 
 
The cost of research and development is rising (Gilbert et al. 2003; Popper and Nason 
1994; Yeoh 1994). There are measurements that suggest that the average cost of 
discovering and developing a new pharmaceutical product has increased from around 
$1.1 billion during the years 1995-2000, to around $1.7 billion during the years 2000-
2002 (Gilbert et al. 2003). Cost in all phases of research and development has increased; 
however, the largest increase can be seen in the clinical development phase, where costs 
have more than doubled. Split by development phase, the average cost of development 
through 1995-2000 compared to the years 2000-2002 has increased significantly. 
Spending in the discovery phase has increased from $0.6 to $0.65 billion, pre-clinical 
from $0.05 to $0.1 billion, Phase I from $0.05 to $0.15 billion, Phase 2 from $0.15 to 
$0.3 billion, Phase III/file (registration) from $0.2 to $0.4 billion (Gilbert et al. 2003). 
The fact that development is becoming more costly and implies greater risk is further 
supported in literature (Ballance et al. 1992; Lloyd and Newell 2001; Popper and Nason 
1994; Rao 2000a; Rao 2000b; Rao 2002).   
 
Low success rate of new compounds 
 
Data from the Centre for the Study of Drug Development, Tuffs University, shows that the 
calculated success rate for moving compounds through the different research and 
development stages imposes a high risk for the pharmaceutical companies. During the 
discovery phase more than 10,000 compounds are screened. Out of the 10,000 only about 
250 enter Pre-clinical testing and out of those 250 only 10 enter the Clinical testing 
phases. Of the 10 compounds making it to the expensive clinical testing phases only 1 
(one) receives regulatory approval (PhRMA 1995; Rao 2002) 
 
Proportion of increased R&D investments versus new products approved 
 
The increased research and development spending has not led to a greater number of 
approvals over the years (Gilbert et al. 2003; IMS 2007; Yeoh 1994). In fact, while the 
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cost of research and development spending has risen dramatically, the numbers of NME 
(New Molecule Entity) approvals have not increased to nearly the same extent (PhRMA 
2003). According to PhRMA (2005), in 1975 there were 15 new drug approvals, while 
the research and development expenditures were about $5-6 billion. For 1993, the 
numbers of new drug approvals were around 20, while research and development 
expenditures where about $16-17 billion. By 2004, the number of new drug approvals 
had increased to 25, while the research and development expenditures had ballooned to 
about $38 billion. All expenditure has been adjusted to reflect inflation (PhRMA 2005).  
 
Increased regulatory burden 
 
The increased challenges of getting the few products that come through the pipeline 
approved by the regulatory authorities around the world is a major concern for the 
research-based pharmaceutical companies (Datamonitor 2007b; IMS 2008; IMS 2007; 
Pathak et al. 1992; Popper and Nason 1994; Yeoh 1994). The regulatory burden on the 
pharmaceutical industry is increasing in many aspects: for example, “over –regulation”, 
lack of harmonization of regulatory guidelines among nations and regions, different 
geographical standards of medicine and the requirement for large-scale post-approval 
commitments (Rod et al. 2007). Also, the trend is moving towards a growing regulatory 
conservatism, with the shift in risk/benefit ratio, increasing safety requirements as well as 
increasing efficacy requirements (Mizik and Jacobson 2004; Popper and Nason 1994; 
Rod et al. 2007). Furthermore, the government is becoming more restrictive about 
marketing activities during the launch of new drugs (Mizik and Jacobson 2004; Popper 
and Nason 1994; Rod et al. 2007).  
  
Increased time in the Research & Development process 
 
Another factor influencing the return on investment is the increased time the drug stays in 
the research and development stage after the patent has been filed (CMR 2005). Data 
from the Centre of Medicine Research, CMR, shows that the duration in years from when 
the patent application is filed to when it is approved has increased from 6.1 years in 1997 
to 10.1 years in 2003 (CMR 2005). This is of great importance as pharmaceutical 
products in most markets are only of substantial value for researched-based 
pharmaceutical companies during the time the product has exclusivity, in other words, 
under patent protection.  
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Market Risks  
 
Risk in clinical learning 
 
The risk of product failure continues even after launch. Once the product is in the market 
and while still covered by its patent exclusivity, referred to as the stages “Introduction” 
(Launch), “Growth” and “Maturity” in the lifecycle, the clinical learning around the 
product imposes a risk. This is because any pharmaceutical product on the market, 
successful or not, can be withdrawn due to emerging adverse events and negative safety 
profile. An example is the case of the product Vioxx (trade name), rofecoxib (generic 
name), from Merck & Co (MSD), which was withdrawn in 2004 based on confirmed 
cardiovascular events (Stockholm-TT 2008; www.merck.com 2004). 
   
Competitors 
 
As in any industry, competitive forces are in full force in the pharmaceutical industry. 
Usually a new drug, - innovative or not - is often followed by intense competition from 
other companies developing compounds for the same medical condition or symptom but 
with another solution or mechanism of action. This is reinforced by Srivasava et al. 
(1995) in the quotation “Pharmaceutical companies traditionally made investments in the 
marketing support for new drugs via communications and branding when patents were 
about to expire in order to extend the life of drugs by sustaining higher margins and 
revenue beyond patent expiration. However, in these days of substantially shorter life 
cycles (competitors might develop drugs with equal or better performance characteristics 
before the patent expired), it is becoming important to invest in marketing and branding 
activities at the launch stage for two reasons – first, to accelerate time to market in order 
to recoup cash flow at higher margins as soon as possible and second, to provide 
protection against ever-faster competitive entries” (Srivastava et al. 1999).  
 
Pricing and reimbursement issues 
 
There are increasing challenges and obstacles to receiving a good price and 
reimbursement all around the world (Gilbert et al. 2003). As suggested by Kolassa 
(1997), current trends that, if left unchallenged, are likely to continue include: narrowing 
of the range of prices charged in different nations; further consolidation of buyers into 
more powerful groups; more non-physician decision makers; continued growth of generic 
drugs; continued increase in healthcare spending and scrutiny of drug budgets; more 
attempts by pharmaceutical manufacturers to use price as a selling point; and, continued 
demand for discounts by many customers (Kolassa 1997; Yeoh 1994). In many regions, 
 36 
 
especially in Europe, there has been an increase of parallel imports among nations, which 
leads to a further erosion of prices (IMS 2007).  
 
Certain nations are actively working on lowering the price of pharmaceutical products 
and are utilizing different mechanisms to secure that spending does not increase or that it 
remains within the expected range (Elling et al. 2002; Kolassa 1997). 
 
All these factors have implications on the price and reimbursement status a 
pharmaceutical product can achieve at launch as well as how it develops over time.  
 
Risks at the end of the life cycle 
 
Generic patent attacks 
 
A product is generally protected for a period of twenty years (Rhee 2009). A product’s 
patent protection usually starts after discovery of the substance; thus, it is typically 
several years before the product has been developed and is ready for market introduction, 
giving the product a shorter period of patent protection when on the market. As soon as a 
successful drug loses its patent protection, generics are introduced thus eliminating the 
basis for generation of any significant revenues in most markets (Elling et al. 2002; 
Popper and Nason 1994). 
  
Traditionally, in the pharmaceutical industry, when the patent of a pioneering brand 
expired, the loss of sales to less expensive drugs occurred only very gradually. However, 
since the 1990s, the competitive environment and government pressure has intensified 
(Yeoh 1994), leading to a rapid loss of revenues for products losing their patent. As a 
generalization, in the 1990’s, after losing patent protection, a branded ethical drug lost 
about 50 per cent of sales within two years, but recent examples have shown a drop in 
sales of 50 per cent after only a few months (Froud et al. 1998). Generic companies are 
also becoming more aggressive at an earlier stage in questioning the patents or part of the 
patents protecting a drug, sometimes even entering the market “on chance” before the 
questionings of original patents are proven right (Thomaselli 2005). Once a product has 
been targeted by a generic, the odds are not in a branded company’s favor. Historical data 
on patent litigation with court decisions in the USA, shows that a generic applicant wins 
72,5% (n=29 of 40), while a brand-name company wins 27,5% (n=11 of 40). In the cases 
appeals are done by  brand-name companies, the generic wins 93% (n=13 of 14) of those 
cases (FTC 2002). 
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1.7. Structure of this Thesis 
 
Given the defined justification, focus and aims of this research, the structure of the 
remaining text will be as follows. 
 
The next chapter presents the Research Approach that accounts for the methodological 
aspects of this study, in other words, its how. This includes the chosen methods of 
research; both for the review of existing literature on the topic being addressed here, the 
formulation of the Preliminary Model and the Research Model, and for the collection and 
analysis of empirical data. 
 
The following chapter presents the Literature Review, identifying the models, theories 
and frameworks received, or utilized, here in order to proceed with the study and to guide 
the design of the empirical investigation.  
 
The chapter after that presents the Development of the Research Model, in which a 
Preliminary Model for sales force readiness during new product launch is first derived 
from the literature and subsequently tested with six case studies and six expert interviews 
in order to formulate the Research Model for the assumed research scope. The Research 
Model is then tested empirically with 50 new product launches. The Research Model, its 
variables and data collection instrument are also described in this chapter.  
 
The next chapter presents the Results, comprising a brief description of the data set 
followed by the key success factors for sales force readiness during new product launch 
in the Swedish pharmaceutical industry. Also included in this chapter are the discussions 
and managerial recommendations derived from the results.   
 
The full text ends with a Summary and Conclusion chapter, where the whole research 
project is summarized and concluded together with proposal for further research.  . 
References and the Appendices are provided after the final chapter.  
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2. RESEARCH APPROACH  
 
This chapter presents the Research Approach employed here, as a means for answering 
the defined research question. It opens with a presentation of an overview in which the 
research approach employed is presented as a chain of subsequent activities conducted in 
order to answer the defined research question. Each of these parts will thereafter be 
presented in detail. 
 
2.1. Overview 
 
This section provides a brief overview of the Research Approach. The aim here is to 
provide an understanding of the whole research approach as such prior to characterizing 
each of the constituting parts in detail. 
 
The research approach is divided into two main research parts. The first research part 
reviews and utilizes the findings in the literature, a set of case studies, and a set of expert 
interviews to formulate the Research Model. This Research Model includes a set of 
variables that represent the proposed key success factors to be tested within the defined 
research scope. In the second part of the research, the model and its variables are 
quantitatively tested after which the test results are analyzed and an interpretation is done. 
The study conducted here employs a bottom-up analysis method with Partial Least 
Squares Analysis, rather than the more conventional top-down and hypothesis-testing 
approach that typically employs regression analysis methods. The results and their 
interpretation are presented as key success factors with their respective importance. A 
conclusion is drawn and the second part concludes with a discussion on the results with 
managerial implications and topics for possible further research.  
 
The whole research process presented here may be understood from the above-mentioned 
two research parts and in terms of eight key phases of research. The first part includes the 
following phases: Formulation of the Research Question; Literature Review; Formulation 
of the Preliminary Model; and Formulation of the Research Model. The second part 
includes the following phases: Design of the Empirical Survey; Collection of the 
Empirical Data; Analysis of the Empirical Data; and Derivation of Implications and 
Conclusions. Each phase is briefly presented below and this research process in terms of 
its key phases and their outcomes is summarized in Table 2. 
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Table 2: Summary of the research process 
The research process in terms of its key phases and each phase’s activities, outcomes, 
and purpose 
 
Phase 
# 
Research Part 1 Key Phase Activities Phase Outcome Phase Purpose 
 
1 
 
Formulation of the 
Research Question 
 
- Personal professional 
experience 
- Professional dialogues 
- Preliminary literature studies 
 
Research Question 
Defined 
 
To guide the 
Research Process 
aiming at developing 
new and relevant 
knowledge 
 
 
2 
 
Literature Review 
 
- Literature search & retrieval 
- Literature analysis 
 
Patterns of current 
knowledge 
identified and 
literature reviewed.  
 
 
To enable the 
formulation of a 
Preliminary Model 
with relevant 
scientific models  
 
To find specific 
scientific results in 
order to ground the 
Research Model’s 
variables in the 
literature  
 
3 
 
Formulation of 
Preliminary Model 
 
- Comparison of identified 
models 
- Synthesis of the relevant parts 
of the models into a Preliminary 
Model 
 
 
Preliminary Model 
defined 
 
 
To enable 
formulation of an 
adapted  Research 
Model 
 
4 
 
Formulation of Research 
Model 
 
- Design & execution of 
relevant case studies 
- Design & execution of expert 
interviews 
- Analysis of collected 
information  
- Adaptation of the Preliminary 
Model (using results from case 
studies, expert interviews and 
literature review) into the 
Research Model 
 
 
Formulated 
Research Model 
with a set of 
variables (proposed 
key success factors) 
to be quantitatively 
tested  
 
To guide the 
quantitative data 
collection process 
# Research Part 2 Key Phase Activities Phase Outcome Phase Purpose 
 
5 
 
Design of the Empirical 
Survey 
 
- Identification of the inquired 
population  
- Selection of data analysis 
approach 
- Design of data collection 
instruments 
 
 
Execution of 
Empirical Data 
Collection Defined 
 
To enable the actual 
data collection & 
analysis 
 
6 
 
Collection of the 
Empirical Data 
 
-Initiating contacts with the 
inquired subjects 
- Execution of the data 
 
Empirical Data 
collected 
 
To enable data 
analysis  
 40 
 
collection 
 
 
7 
 
Analysis of the Empirical 
Data 
 
Execution of statistical analysis 
of collected data 
 
Data patterns 
identified 
 
To enable the 
possibility to answer 
the Defined Research 
Question  
 
 
8 
 
Derivation of 
Implications and 
Conclusions 
 
- Interpretation of the results 
obtained in the context of the 
literature reviewed 
 
 
-Scientific 
Conclusions 
Defined 
 
-Managerial 
conclusions defined 
 
 
Contribute to the 
knowledge and 
success of the field 
 
 
The first research phase defined is the Formulation of the Research Question. This was 
motivated and driven by the researcher’s professional experience in the addressed field, 
together with a set of professional dialogues with colleagues and professors as well as 
preliminary literature research. All this leads to the general conclusion that 
pharmaceutical companies are highly dependent on successful product launches and that 
they spend significant resources on the sales force during these launches, yet there are 
very limited scientific guidelines for how to conduct this in a successful manner. A 
further focus of this research was set as the Swedish pharmaceutical industry. The 
purpose of this definition was to guide the rest of the Research Process to generate the 
necessary knowledge and answer the defined research questions properly. Given the 
inductive and intuitive nature of this research phase, no further characterization is 
provided here; however, the actual definition and justification of the defined Research 
Question is detailed in Chapter 1, Introduction. 
 
The second research phase defined is the Literature Review, which is a classical literature 
review, aiming to identify current knowledge about the addressed research area. The 
main purpose of this is to enable the formulation of a Preliminary Model and ground any 
variables to be tested in earlier literature results. 
 
The third research phase is the Formulation of the Preliminary Model, which includes a 
reformulation and synthesis of the relevant findings from the previous research phase. 
This Preliminary Model assumed a generic character and aimed at becoming customized 
for the purpose of the Research Questions and Scope defined here. 
 
The fourth research phase is the Formulation of Research Model, which includes two of 
the three empirical data collection activities in the full research process. A set of case 
studies and a set of expert interviews are conducted. The outcome of this qualitative-
oriented data collection is a formulated Research Model with a set of variables, defined 
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as proposed key success factors to the research scope and focus addressed here, all 
aiming at providing guidance for the successive collection of a larger set of empirical 
data.  
 
The fifth research phase is the Design of the Empirical Survey that produces a detailed 
and operational definition of how data is to be collected. This include the definition of the 
population of concern, design of data collection instruments but also selection of data 
analysis methods. The purpose is to enable a successful data collection process. 
 
The sixth research phase is the Collection of the Empirical Data which resulted in data 
being collected. This aims at enabling the data analysis work. 
 
The seventh research phase here is the actual data analysis work. This resulted in an 
identification of the identified patterns in the data and aimed at a forthcoming derivation 
of answers to the Research Question. The present study employed a so-called bottom-up 
analysis approach with Partial Least Squares Analysis, rather than the more conventional 
top-down and hypothesis-testing approach that typically employs regression analysis 
methods. 
 
The final research phase conceived is the Derivation of Implication and Conclusions, 
which include an interpretation of the identified data patterns and thereby derivation of 
scientific and managerial conclusions that became the answer to the initially posted 
Research Question; this ultimately aiming at a contribution to the knowledge and success 
within the field of concern. 
 
Confidentiality 
 
The majority of people involved in this research have asked for confidentiality with 
regard to their respective names, products and company. In honoring this request, the 
traceability to a specific person, product or companies has been minimized. The 
implication on this presented text in relation to procedures, analysis and results is seen as 
relatively insignificant.  
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2.2. Literature Review 
 
This section describes the second key research phase, the Literature Review. As the 
intriguing and important Research Question was identified and defined in broader terms, 
this research phase conducted a careful literature review aiming at identifying the current 
knowledge within the defined research area. This literature review resulted in the precise 
formulation of the research question and the identification of available knowledge in the 
area of concern.  
 
Given the aim of this research, the review of the literature was focused on three main 
areas and their overlaps. The main areas targeted within the literature search were Sales 
Force Management (including Selling), Product Launch, and the Pharmaceutical 
Industry. The overlaps identified were Sales Force Management during Product Launch, 
Sales Force Management within the Pharmaceutical Industry and Product Launch within 
the Pharmaceutical Industry. See Figure 3 for a graphical representation.  
 
The first main area was Sales Force Management, beginning with a limited focus on 
“sales force management during the launch of pharmaceutical products”, expanding the 
focus to include “sales force management during product launch” and “sales force 
management within the pharmaceutical industry” and ending with the broader scope 
within the full discipline of “Selling and Sales Force Management”. The second main 
area was Product Launch, adding search and review in the area of “Product launches 
within the pharmaceutical industry” and in the broader scope of “Product Launch”. The 
third main area was the pharmaceutical industry. This was reviewed more briefly as the 
overlaps of importance were covered within the other topics. However, some literature 
and sources were advised in order to gain full support for the motivation and justification 
of the research as well as for an industry overview with related definitions.  
 
Besides literature in academic search engines, the reference list of each retrieved text was 
also scanned for additional relevant sources. In addition, other sources were utilized, such 
as industry and sales management reports and magazines covering the defined topics.   
 
The next key activity within this research phase was the analysis of the identified 
literature. This included a careful perusal of these texts followed by an analysis of their 
content. The central aspects of this analysis are presented in Table 3. The results and 
knowledge obtained from this analysis were implemented to a different extent in the 
further research phases. The literature review revealed that there is still much to learn in 
the area of the chosen research topic and that no literature has covered this subject in the 
past. However, in addition to the justification and motivation of the research question, the 
literature provided two main areas of important knowledge – relevant academic models 
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and specific scientific results within the research field and supporting the identified 
model variables, as described in the next two paragraphs.  
 
 
Figure 3: A graphical representation of the scope of the literature review.  
This research may be understood to be an intersection of three professional and 
intellectual domains: Sales Force Management, Product Launch, and the 
Pharmaceutical Industry; the area of this research is the intersection of these three 
domains. 
 
 
 
 
 
 
 
Product  
Launch Pharmaceutical  
Industry 
Sales Force  
Management 
Sales Force  
Management during  
Product Launch  
Sales Force Management  
within the  
Pharma Industry 
Product Launch  
within the  
Pharma Industry 
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Table 3: The central aspects of the analysis of the identified literature 
 
Central Aspect of Literature Analysis 
The actual research area? 
 
• type of industry, e.g. pharmaceutical, chemical, etc. 
• markets addressed, e.g. Europe, Australia, Austria, 
etc. 
• phase of lifecycle: product launch, product on-
market, product withdrawal, etc. 
• function: marketing, sales, after-sales, etc. 
The research questions defined? 
 
• sales force 
• product launch 
• pharmaceutical industry 
The type of constructs employed? 
 
• outcome control 
• behavioral control 
• sales representative characteristics 
• etc 
The type of research conducted? 
 
• conceptual, empirical, empirical cases, empirical 
survey 
Type of data analysis utilized 
 
• content analysis, statistical hypothesis-testing 
The results obtained 
 
• patterns identified positively or dismissed 
The validity claim of the results obtained • explorative and suggestive, conclusive 
 
The limitations of the research and its results • constructs and variables utilized, number of 
respondents 
And then the relevance of the results for the 
present research process 
 
• not-relevant = no constructs and patterns to be 
absorbed here 
• partly relevant = some constructs and/or patterns to 
be absorbed here 
• fully relevant = all constructs and/or patterns to be 
absorbed here. 
 
 
Results in terms of relevant academic models 
 
Six highly relevant models and constructs, key scientific contributions, were found and 
subsequently compared to each other which revealed a pattern where some, in terms of 
their conceptualization and constructs, overlapped and some did not. This, in turn, 
constituted the foundation for the next key step of the research phase: the Formulation of 
the Preliminary Model. 
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Results in terms of specific scientific results  
 
The literature review also provided important information and specific results related to 
both the broader research topic and to the various variables in the identified models. The 
information obtained from the literature was mainly used to finalize the Research Model 
and its variables. This secured utilization of earlier scientific contributions, but most 
importantly, it led to a final Research Model, with variables (proposed key success 
factors), well-grounded in the literature.  
 
Presentation of the literature review 
 
The reviewed literature, which investigated the three academic fields of Sales Force 
Management (and Selling), Product Launch and Pharmaceutical Industry, included a 
group of heterogeneous publications. Based on this, the literature review is presented in 
Chapter 3, Literature Review, according to four main sales force management themes 
together with the identified six key scientific contributions. The main sales force 
management themes are; Sales Force Management Control; Internal and External Sales 
Force Collaboration; Sales Force Accountability and Decision Making; and Complexity 
of the Sales Environment. The choice to present the review according to these themes is 
based on the fact that they follow, and match well, the areas defined in the Preliminary 
Model and the Research Model. The six key scientific contributions are presented in 
greater detail than any other publication, based on their importance for this research’s 
model formulation process. These six publications (see Table 4) also include the different 
constructs and definitions which are the main foundation for the definition of Sales Force 
Readiness during New Product Launch. In addition to the review of these publications in 
Chapter 3, Literature Review, their models are further described and presented in 
Appendix 1. 
 
Furthermore, many of the literature findings describing the sales environment and new 
product launch for the pharmaceutical sales forces are presented in Chapter 1, 
Introduction.  
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2.3. Formulating the Preliminary Model   
 
The third research phase covered the Formulation of a Preliminary Model. This model 
was constructed from one of the key outcomes of the preceding research phase where 
current knowledge of the area addressed was identified and six relevant key models were 
identified. The formulation of this preliminary model was a conceptual endeavor, and 
was guided by the following central question: 
 
? Which of the identified models, from the literature review, manifest relevance to 
the research question addressed here?  
 
This was assessed in terms of each of the model’s dependent and independent variables, 
and the underlying constructs for each of these variables. The constructs (that gave a 
positive response to the question defined here) were included into the newly formulated 
Preliminary Model.   
 
The purpose of the Preliminary Model was to act as a foundation, well-grounded in the 
literature, to guide the identification of the most important variables (proposed key 
success factors), for this research scope, with a set of six case studies, a set of six expert 
interviews and the specific scientific results found in the literature, in the next phase of 
the research; Formulation of the Research Model. The formulation process of the 
Preliminary Model included synthesis and merger of the models and their constructs. A 
graphic representation of the formulation process can be found in Figure 4. 
 
The models identified in the literature were derived from rather different areas in the 
literature. Based on the respective area in which they were found, they were divided into 
two groups. All models are based on the selling and sales management area of the 
literature, but different focuses and research streams have taken the concepts and 
constructs in somewhat different directions. However, similarities and overlaps of 
constructs could be identified.  
 
The first group included constructs from the literature in the sales force management 
discipline in terms of sales force adoption, sales force performance and the new product 
launch discipline. This group was named, “Models for Sales Force Strategy for New-
Product-Launch”. The second group included models found in the literature in the 
discipline of sales force management in terms of sales force effectiveness, in where no 
regards to product life-cycle stage were considered. This group was named, “Models for 
Sales Force Strategy disregarding the product-lifecycle”. The source models from the 
literature are listed in Table 4 and are described in detail in Appendix 1. 
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Within each group, the models were compared and were synthesized into one model. The 
two synthesized models were unified into one model, which resulted in the Preliminary 
Model. This model could also be referred to as a “Generic Model for Sales Force 
Readiness during New Product Launch”. The Preliminary Model or generic model for 
sales force readiness during new product launch is described in three stages: 1) 
Circumstance; 2) Sales Force Factors; and, 3) Effect. Each stage comprises one category 
or a set of categories and these categories are themselves made up of a different number 
of variables and items, all of which are well-grounded in the literature. As the concern 
here is on new product launch, the interrelations between the mediating variables are 
ignored in this model synthesis as they may be assumed to be general. 
 
The process of synthesizing the models and their constructs within each group together 
with the merger into one Preliminary Model is described in detail in Appendix 2.   
 
 
Figure 4: Illustration of the process for Preliminary Model formulation  
On the left hand, a set of research models has been identified in the literature, and 
analyzed and assessed for their relevance for the present research initiative. Relevant 
constructs were selected from each of the selected research models and introduced into 
the Preliminary Model formulated here. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Model 1 
A 
B 
C 
D 
Model 2 
B 
C 
D 
E 
Model n 
A 
E 
F 
G 
Preliminary 
Model 
A 
B 
C 
D 
E 
F 
G
 
Formulation 
Process 
 48 
 
Table 4: Source models for the development of the Preliminary Model 
The Preliminary Model is also referred to as the generic model for sales force readiness 
during new product launch. 
 
 
 
2.3.1. Limitation of the Preliminary Model 
 
The limitation of the research activities presented here, and therefore of the formulated 
Preliminary Model, may at least have two kinds of characteristics. The first is related to 
the literature review and may include at least two limitations: (i) that the literature review 
has not been successful in identifying all currently available and relevant research 
models; and, (ii) that the analysis of the identified models made a mis-assessment by 
either not including relevant constructs or vice versa, by including constructs that lack 
relevance. The second kind of limitation could be (iii) faulty design of the Preliminary 
Model, such as a misalignment of the included constructs. 
 
The limitation concerning unsuccessful literature review was addressed by a particular 
activity at the very end of the research process, as a new, shorter, literature review was 
conducted to search for any new or missed publications. Nothing critical was found. 
Furthermore, this limitation may be easily diagnosed by any reader conducting a brief 
literature review, which would typically show if any key publication and thus substantial 
knowledge relevant for this research has been omitted. 
  
The second limitation of mis-assessment of the models identified may also be easily 
assessed by the reader, as the content of the models is presented openly in Appendix 1.  
 
Model  Source  
Models for Sales force Strategy for New-Product-Launch 
“Model #1: The Adoption of New Products by the Sales Force” (Atuahene-Gima 1997) 
 
“Model #2: Effect of Sales force Adoption on New Product Selling” (Hultink and Atuahene-Gima 2000) 
“Model #3: Product Newness and Sales Management Strategy” (Micheal et al. 2003)  
 
Models for Sales force Strategy disregarding the product-lifecycle 
“Model #4: Model for Sales Force Effectiveness in B2B 
organizations” 
(Piercy et al. 1997)  
 
“Model # 5: Model for Sales Organization Effectiveness - A” (Baldauf and Cravens 1999) 
 
“Model # 6: Model for Sales Organization Effectiveness - B” (Piercy et al. 1999)  
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Finally, the third potential limitation of faulty alignment of constructs in the formulation 
process could also be diagnosed by the reader as the process and content are presented in 
Appendix 2. However, the Preliminary Model does not necessarily aim to cover all 
aspects, but only the ones found to be most relevant, in part or in full. This research phase 
with the Preliminary Model aims to secure that concept and conceptualizations are valid 
and relevant. Therefore, as the Preliminary Model has more of a guiding purpose within 
this research, all of the above limitations are carefully considered and covered by the 
addition of the next research phase. In the next phase, a set of case studies and expert 
interviews together with specific literature findings will guide the adaptation of the 
Preliminary Model into a final model, the Research Model, which is optimized and 
relevant for the industry, the phase of product lifecycle and the market of concern.  
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2.4. Formulating the Research Model 
 
The fourth research phase concerns the formulation of the Research Model. This is 
achieved by adapting the Preliminary Model. The process is qualitative and empirical 
data is collected from six case studies and six expert interviews. These interviews were 
conducted during end of 2007 and beginning of 2008. In addition, the second key 
outcome from the literature review, specific scientific results, is used in the formulation 
process to further ground the Research Model in the literature. As the Preliminary Model 
is of generic nature in terms of relevance for the industry and the market of concern, this 
generic nature reduced the efficiency of the Research Question addressed here. 
Therefore, the research strategy makes a deliberate adaptation of this Preliminary Model 
into the scope and focus addressed by the Research Question. As defined in Chapter 1, 
the latter implied the focus on the successful sales force readiness, during product launch 
phase, in the Swedish pharmaceutical industry.  
  
This adaptation process initiates the start of the first systematic empirical experience in 
this research process. The selected approach here is to conduct a set of case studies and a 
set of interviews with local industry experts so as to obtain the specific characteristics of 
the addressed research. These specific characteristics are, in turn, utilized to inform the 
adaptation and thus re-shape the Preliminary Model thereby transforming it into the 
adapted Research Model. The case study process follows methodology described by Yin 
(1984). For example, well-received theoretical propositions should be acquired before 
going into “the field” and the same theoretical propositions should be followed, i.e. those 
leading to the case study (Yin 1984), here defined as the Preliminary Model.  
  
This adaptation and reshaping process starts with the identification of a set of cases from 
actual product launches within the Swedish pharmaceutical industry – see Table 5 for a 
summary. Once these cases have been identified, the next step is to identify interview 
subjects to represent these cases and thereby provide necessary case information. This 
identification further includes booking interviews with the selected informers. Two to 
four people involved in each product launch as either sales management or sales 
representative are interviewed.  
 
The case study selection criteria include product launches that match the scope of the 
research. This match is made based on the author’s experience and dialog with managers 
in the pharmaceutical industry. All investigated products are launched by marketing and 
sales subsidiaries belonging to a company defined as a “Big Pharma”. To recall, the term 
Big Pharma is usually referred to pharmaceutical companies with revenue in excess of $3 
billion, and/or R&D expenditure in excess of $500 million (Gilbert et al. 2003). These 
global companies have marketing and sales affiliates that execute the product launches. 
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All companies being investigated are marketing and sales affiliates of Big Pharma in 
Sweden, and the country of origin should not be of significance based on the received 
notion that these companies are seen to be very homogeneous in terms of processes and 
culture. However, the choice is to include in the case studies some products launched by 
the same company so as to deliberately be able to reflect upon, for example, the impact 
on company processes and culture. This reflection is discussed in section 4.2.3. 
Conclusions and Results from the Case Studies. Further, as the author is a native of 
Sweden and has practical experience of some of these companies, a greater understanding 
of discussions and interpretation of the case studies’ result and expert interviews might be 
assumed.  
 
The interviews are steered by an interview-guide that specifies the type of information to 
be obtained, in terms of defined questions. This interview-guide is reproduced in 
Appendix 3. Moreover, this interview-guide has been formulated to reflect the content of 
the defined Preliminary Model. 
 
Finally, the interviews have either been conducted face-to-face or via the telephone, to 
secure the quality of the information obtained, when compared with the traditional 
written survey. The final set of case studies comprises six products launched by three 
different companies. The case studies are presented in Section 4.2, Case Studies and 
Appendix 4. The reporting of the case studies follows a multiple-case study report 
method, with the individual cases being described separately and with a cross-case 
analysis and results report (Yin 1984), see Section 4.2 and Appendix 4. Further, the case 
study does examine, as described as an important methodological aspect by Yin (1984), 
the conditions of time-series analysis, i.e. the how and what questions about the 
relationship of events over time. In addition to the subsequent expert interviews, the case 
study reports and their results have also been validated by some of the participants being 
allowed to read the reports, also in accordance with the case study methodology guidance 
from Yin (1984).  
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Table 5: Overview of the case studies 
Conducted case studies of product launches in the Swedish Pharmaceutical Industry.  
 
Company Disease Area  # of sales 
management 
interviewees 
# of sales 
representatives 
interviewees 
Case # 
Company A Infection  1 1 1 
Company A Pain 1 1 5 
Company B Depression  2 2 4 
Company B Gastro 2 1 2 
Company B Birth Control 1 1 3 
Company C Migraine 1 1 6 
 
 
The interviews with selected local industry experts represent the second empirical 
information collection phase in this research. See Table 6 for a summary of the experts’ 
profiles. The actual procedure and content of these interviews are similar to those of the 
cases studies presented above, with a structured interview approach, following the Yin 
(1984) guidelines; however, some of the case studies’ results are also presented during 
the interviews together with some literature findings which are briefly discussed to enrich 
the discussion. The main purpose of the interviews is to validate the results and narrow 
down the identified variables for the final model including the recommendation for data 
collection procedure. To secure this, this process is also iterative with the expert in terms 
of clarifying their opinion on data collection measures once the variables of the Research 
Model’s have been finalized. The experts are selected both from the academic world or 
are individuals considered to be experts in the industry with experience of formulating 
and implementing sales force strategy. Two experts have marketing expertise from the 
academic world, while two experts are strategy consultants working with pharmaceutical 
companies formulating and implementing marketing and sales strategies. One is a senior 
executive within a company providing outsourcing of sales forces and sales personnel to 
pharmaceutical companies and one is a senior executive within the Swedish 
pharmaceutical industry association (LIF) with broad industry experience.   
 
The interviews, both of the actual launch cases and the local industry experts, build on 
the assumption that they may provide information as to the actual local conditions that 
could not be supplied by the Preliminary Model. In practical terms, each attribute of the 
model is critically reviewed, and where evidence from the cases and the experts induces 
this, current attributes are eliminated alternatively additional new attributes are added – 
an example of the former is “organizational design” and of the latter “number of sales 
representatives” - see section 4.4 Construction of the Research Model, for further details. 
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Table 6: Summary of the key characteristics of the interviewed experts 
 
Expert # Expert: Line of 
Profession 
Background / Expertise 
1 Academic University Professor in Sweden with and extensive background in both the 
academic world and commercial industry. This expert has seven years of 
sales and marketing experience in the pharmaceutical industry and an 
additional eight years in other industries, prior to assuming a Professor 
position at a Business School in Sweden.  
2 Academic Professor at Business School in Sweden. This expert has a background 
within academic institutions and a research focus on customer value and 
CRM. Has consultancy and research experience with mainly consumer 
product companies but also with a few pharmaceutical companies. Has taken 
part in launching new pharmaceutical products in the Swedish market in an 
advisory role.    
3 Consultant  CEO of a Business Consultancy Company. This expert has a background of 
senior management consulting in a number of high profile consultancy 
firms. Extensive experience of the pharmaceutical industry and many other 
industries. Main competence and experience in formulation of company, 
marketing and sales force strategies. Has actively taken part in launching 
new pharmaceutical products in the Swedish market. Academic record: 
MBA and PhD. 
4 Consultant Senior Management Consultant. This expert has a background in 
management consulting with focus on sales strategies, sales force efficiency 
and sales force training. Focus on pharmaceutical industry, but has 
experience of other industries. A working history as Product Manager, Sales 
Manager and Sales Representative within a pharmaceutical company. Has 
actively taken part in launching new pharmaceutical products in the Swedish 
market. Academic record: MBA 
5 Pharmaceutical 
Sales Force 
Outsourcing  
Partner in a company outsourcing pharmaceutical sales forces and providing 
consultancy services to this industry. This expert has a background in 
several pharmaceutical companies in positions such as Sales Manager, Sales 
Representative, Product Manager and Business Unit Manager. Has actively 
taken part in launching new pharmaceutical products in the Swedish market. 
Academic record: M.Sc. 
6 Pharmaceutical 
Association 
Executive 
Leading Executive within the Swedish Pharmaceutical Industry Association 
(LIF). Extensive experience of the pharmaceutical industry and within the 
public healthcare sector.  Has actively taken part in launching new 
pharmaceutical products in the Swedish market. Academic record: M.Sc. 
 
 
Although the Preliminary Model is well-grounded in the literature, the specific scientific 
results found in the literature review are also used in the analysis and formulation in order 
to ground and validate the Research Model’s variables (proposed key success factors) 
even more with existing literature.  
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As a result of this process of local knowledge collection and the reshaping of the 
Preliminary Model, a new and adapted Research Model has been produced, including a 
set of proposed Key Success Factors (the Research Model’s variables) related to the 
scope of the assumed research presented here. This model reflects the addressed area of 
concern as closely and as practically as possible. The purpose of this model is to guide 
the forthcoming quantitative collection of empirical data, so as to secure the relevance of 
the data to be collected. The Research Model’s variables are directly linked to the 
Preliminary Model categories, as the variables in the Research Model are derived 
variables or items. The variables are listed in the Research Model in the order they are 
derived from the categories in the Preliminary Model.  
 
By adding interviews and earlier scientific results to the case studies when adapting the 
model, the Research Model and its more limited number of variables are validated from 
several angles; i.e. internal, external and academically. This also helps recognize any bias 
that might arise from the interviews in the case studies, as the personnel interviewed had 
experienced the launch, but the fact remained that the launch had taken place in their 
history. Also, the process validated the use of consistent interpretation of taxonomy.  
 
2.4.1. Potential Limitation of the Formulation of the Research Model 
 
There may be several potential limitations of the above described adaptation process and 
thus its outcome: the Research Model. 
 
One fundamental limitation originates in the quality of the Preliminary Model Process, as 
the conducted data collection and consequent adaptation were guided by the content of 
the Preliminary Model, their limitations will limit the adaptation. For example, if the 
preliminary model did not include some of the key attributes (as a consequence of the 
limitations inherent in its formulation process, as discussed above) then the interview 
process and the interviewed subjects could not actively reflect upon these non-existent 
attributes and therefore assess their relevance or otherwise for the research area addressed 
here. In such a case, the quality was left to the assumption that the interviewed person 
could spontaneously add such a crucial and missing attribute, of which he or she was 
aware. 
 
This fundamental limitation of the Preliminary Model opens itself to some potential 
limitations which are specific to the adaptation work. One limitation may emerge if the 
wrong case studies were selected and a similar limitation may emerge if the wrong 
experts were selected. The term “wrong” is used here to mean not representative of the 
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addressed research area. As these selections were guided both by knowledge of and the 
availability of the people to be interviewed, it is possible to reflect briefly upon this here. 
 
The selection of the cases was partly based on the researcher’s more than five years of 
practical knowledge of the Swedish pharmaceutical industry, and after having met 
representatives of most of the key companies within that industry. The knowledge was 
also based upon having actively worked with business development and product launch 
activities within the industry, during the last five years. Secondly, the availability of the 
selected representatives for interview is assumed to be positive as none of the approached 
persons declined the opportunity to provide this research process with their information. 
 
The case studies and expert interviews suggest a continued development of the 
pharmaceutical industry, especially in terms of customer access issues, and governmental 
and economic pressure. This is also highlighted in the literature, where it is concluded 
that physicians are starting to ask questions about what patients think of the drug, how 
much they pay, whether they comply with treatment regime and recommendation lists, 
etc. (Elling et al. 2002; Tengilimoglu et al. 2004). This will probably have some impact 
on the Research Model in the long-term, however, the results in this study are considered 
stable over the foreseeable future since, as discussed earlier: the industry over most 
markets show a great amount of homogeneity, the Swedish pharmaceutical industry is 
considered to be ahead of other markets in terms of its evolution (Dannacher and Stahl 
2005) and the global emerging environment for pharmaceutical sales forces around the 
world follows this trend (Dutton and Reece 1996). This evolution seems to have 
stagnated in Sweden, but is still ongoing in the Northern European markets, as well as 
other parts of the world. However, the likely long-term impact of the Research Model and 
results are primarily identified to be two things. Training, which was excluded in the 
Research Model, might arise as one of the Key Sales Force Factor, in the form of the 
need to provide sales representatives with further surrounding knowledge of important 
influencers of prescribing behaviors, such as health economy, hospital budget processes, 
etc. The second identified possible modification is the problem-solving approach, 
because of the increased complexity to the sales situation (as discussed above). The trend 
might shift from systematic problem-solving towards a more flexible and intuitive 
problem-solving approach as it may be necessary to have a more flexible and innovative 
sales force to penetrate with the message or convince the prescribers of the full product 
benefits. For the future, it might be of interest to build-in the relationship management 
concept around the sales role (Davies et al. 2010). This suggests a changing role of the 
sales person in business-to-business, which may require a different attitude among many 
sales representatives. Also of interest is the debate introduced by Dinu and Tachiciu 
(2009) concerning “the Sales-Entrepreneur”, in which the sales person is looking at sales 
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as his own business. Overall it can be concluded that further research is needed to find 
out which market trends would drive changes over time.  
 
This study does, to a great extent use single-item measures. This is because the variables 
(key sales force factors) selected from the Preliminary Model are, to a majority, an item 
from another defined variable within the Preliminary Model. Since specific item was 
chosen as a key success factor, it was decided that instead of developing new items 
relating to the Research Model’s identified variables, these could remain single-item and 
dichotomous in the majority of cases. It is acknowledged that multiple-item measures are 
usually preferred over single-item measures. However, based on the process of 
formulation, it is believed that they provide validity and are reliably captured for the 
domain of the construct. This was also confirmed with the interviewed experts.  Also, the 
analysis method chosen, Partial Least Square analysis (as further described below) puts 
minimal demands on measurement scales. Further, the Research Model formulated is 
constituted by a fairly large set of variables, which opens up the possibility for a large 
amount of interrelations or multi-collinearity amongst them. This issue is also handled by 
the Partial Least Square analysis (Ryan et al. 1999). In addition, this study offered 
independent variables with different weights, which can be handled successfully by PLS 
(e.g. Ryan et al, 1991). Also the fact that these variables were different (icl. dichotomic 
variables) is again something that PLS handles better than the more conventional 
approaches (Hernandez-Maestro et al. 2009). 
 
2.5. Designing and Executing the Data Collection 
 
Design and Execution of the Data Collection are the fifth and sixth phases of this 
research. These phases included three distinct areas of research work: the definition of the 
subject to be inquired, the design and method of the data collection instruments, and the 
selection of data analysis approach. While the two first-mentioned are detailed in this 
section, the data analysis approach is presented with the seventh phase, Analysis of the 
Empirical Data, below. 
 
2.5.1. Definition of Subjects of Inquiry and Response Rate 
 
A central research task was to determine the subjects of the research. This was achieved 
with regard to the following aspects. First, as derived from the defined Research 
Question, the matter in hand here was the product launches within the Swedish 
pharmaceutical industry where General Practitioner physicians were targeted. The second 
limitation was set to these product launches (registration date) during the time period 
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between 1995 and 2005. The key motivation for this was to keep the product launches 
current in order to best reflect ongoing changes, while still representing a sufficiently 
large base of research subjects. Furthermore, the product should be a prescription-based 
ethical drug from a research-based company, which is under patent, i.e. not a generic 
drug.  
 
A list of products was received from a database of all registered pharmaceutical products 
during in Sweden 1995-2005 (MIDAS-Database 2007b). The list included over 3500 
registered products. In the database, it was possible to filter out the original brands thus 
eliminating the registered generic products and the products registered for parallel import. 
Also, even with a filtered list, inconsistencies were identified in for example 
manufacturer versus the company actually selling the product, based on licensing 
agreements. This was identified by using the Internet and questioning companies by 
phone, to search for the product and validate which company it belonged to for sales and 
marketing in Sweden. Products that were registered but not sold by a sales force or had 
no sales were eliminated. Molecules that were launched under different brand names 
were retained. The rationale is that the product might have used a different sales force, 
had a different launch timing, etc.  
 
The list now included 247 original brands that were identified to have been launched in 
Sweden with an active sales force during 1995-2005. To find the products that had been 
launched aimed at general practitioners, three industry experts were consulted. Two of 
the experts had a commercial background in the pharmaceutical industry and one had a 
medical director background in the pharmaceutical industry. All products identified by 
the experts as having a potential history of being launched towards general practitioners 
were included.  
 
A final population of 79 subjects was identified for investigation in this research. These 
subjects were clearly-identified pharmaceutical products that had been launched in 
Sweden and were highly likely to have been launched with a sales force aimed at general 
practitioners.  
 
To secure that the right subjects were included in the data set, a control question initiated 
all data collection interviews, confirming a launch towards General Practitioners with a 
sales force. This process further limited the population to 68 subjects. 
 
Given that the number of product launches in the total population was not enormous, the 
approach selected was to make an attempt to investigate all subjects, i.e. product launches 
within the scope. Typically for research data collection efforts, some subjects did not 
respond for various reasons. Out of the total population number of 68 subjects, the 
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response number was 50, giving a response rate of 74%; which is considered to be very 
good. The respondent representing each product launch was, at the time of launch, in a 
Sales Manager or equal position. There were two principal reasons for the non-responses, 
as understood here. Firstly, in some cases it was not possible to identify any trustworthy 
informants who could represent the particular product launch. In the second case, some of 
the identified potential informants did not want to participate. In some such instances, 
alternative informants were identified and inquired; however, it was not possible to do 
this in all of these cases.  
 
2.5.2. Design of the Data Collection 
 
Given the definition and identification of the population of subjects to be investigated and 
then that the Research Model was elaborated and defined, the foundations for the design 
of the data collection instruments were established. This consisted of the following 
stages: the design of the data collection questions, the selection of the data collection 
channel, and the design of the data collection procedure. Starting with the second stage, 
the choice of data collection channel was direct telephone interviews with the person 
representing the subjects, i.e. product launch. This was driven by two aspects: firstly, the 
aspiration to collect high quality data, limiting the cases of no full responses; secondly, as 
the total number of the subjects was not very great this allowed the utilization of this 
channel. Moving over to the third mentioned component, the data collection procedure, 
the following procedure was designed and utilized:  
 
1. Establishing contact with the representative of the subject to be 
interviewed, via telephone 
2. Establishment of an agreement regarding the representative’s 
participation in the inquiry and consequently the date and time for an 
interview 
3. Execution of the interview, in which the defined data was collected, in 
accordance with the defined data collection questions 
4. Entrance of collected data directly into a predefined Excel-file 
 
Finally, the first-mentioned component, i.e. the data collection questions, was formulated 
in accordance with the Research Model, defined and based on recommendation from the 
interviewed experts. The model provided a set of constructs that were also validated by 
previous research initiatives. These constructs were transformed into questions. Section 
4.4, The Research Model, lists and explores the model’s constructs and questions. The 
full data collection instrument can be found in Appendix 6. The questions were asked in 
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English and further explained in Swedish if necessary, as the chosen data collection 
channel admitted this approach.    
 
2.6. Analyzing the Empirical Data 
 
In this seventh phase, the selection of approach to the data analysis was conducted. This 
is summarized in two steps: first, the motivation of the selected type of data analysis 
method, and secondly, the character of the selected data analysis method. Starting with 
the former, the motivation of the method selected, the current research circumstances 
were determinative. Firstly, the formulated Research Model is constituted by a fairly 
large set of variables, which opens up the possibility for a large amount of interrelations 
or multi-collinearity among these. Secondly, no related empirical research has previously 
been conducted within the selected focus: sales force readiness during the launch of new 
products in the Swedish pharmaceutical industry. Rather, the Research Model defined 
here is the result of a synthesis process, where various models were developed in other 
contexts and circumstances, which made the Preliminary Model highly generic. To 
reduce some parts of this generic quality and thus to adapt the Preliminary Model to the 
research domain addressed here, an adaptation of that model was conducted resulting in 
the current Research Model, which also defined the proposed key success factors as 
identified from the case studies, expert interviews and literature. Yet, as mentioned, this 
model has a fairly large amount of variables and no qualified interpretations between 
these were obtained during the adaptation process.  
  
2.6.1. Partial Least Squares Analysis 
 
Instead of utilizing the traditional top-down, hypothesis-testing research approach with 
regression analysis techniques and Structural Equation Modeling, the approach selected 
here was to utilize a so-called bottom-up pattern identifying research approach, 
employing Partial Least Squares Analysis (PLS). A number of modern statistical methods 
are used “to develop theory regarding the nature of constructs” and “to summarize 
relationships in the form of a more parsimonious set of factor scores that can then be used 
in subsequent analyses” (Thompson 2004). Indeed, supported by Chin (1998, 295-296) 
Haenlein and Kaplan (2004, p.283) summaries that PLS “…can be used to either identify 
or confirm theoretical hypothesis based on the analysis of empirical data” (Chin 1998; 
Haenlein and Kaplan 2004).  
 
Partial Least Squares (PLS) analysis is a more recent statistical technique that generalizes 
and combines aspects from principal component analysis and multiple regressions 
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(Haenlein and Kaplan 2004). Its aim is to analyze and predict a set of dependent variables 
from a set of independent variables or predictors. This in turn is achieved by extracting 
from the predictors a set of latent variables (i.e. the largest sources of systematical 
variance) that have the best predictive strength. 
 
In this study, the Research Model (see Figure 6, the Research Model, in Chapter 4) can 
be regarded as the grand hypothetical model proposed for the empirical test. In this 
Research Model, all independent variables may receive a specific type of relation with 
the dependent variable and the question is then: What is the pattern of these relations in 
the proposed Research Model?  
 
Justification of PLS analysis in this research 
 
Beside this bottom-up approach to the empirical investigation, and thus its justification of 
the PLS-method selection here, several other peculiar characteristics of the present study 
have motivated the employment of PLS for data analysis.  
 
1) This grand-model test has predictive aspiration, where PLS is clearly more 
powerful than the current alternatives mentioned (Ryan et al. 1999).  
2) PLS is more suitable for use when the data set to be analyzed is relatively small 
(Brown and Mazzarol 2009) and simultaneously the number of independent 
variables is relatively large (Garthwaite 1994) – both are features of the present 
study.  
3) As described in brief above, the ability of PLS to handle positively multi-
collinearity (Ryan et al. 1999) is also a characteristic of the present data set. F 
4) This study offered independent variables with different weights, which can be 
handled successfully by PLS (e.g. Ryan et al, 1991), and also the fact that these 
variables were different (icl. dichotomic variables) is again something that PLS 
handles better than the more conventional approaches (Hernandez-Maestro et al. 
2009).  
5) The PLS approach which are relevant for the present study, are that it puts 
minimal demands on measurement scales (Brown and Mazzarol 2009) and also 
that it handles random error variance well (Garthwaite 1994).  
6) A more general supportive fact, for using PLS here, is that while PLS is still not 
widely used within the various social science disciplines, despite its being 
advocated by prominent authors (Cassel and Hackl 2000; Ryan et al. 1999), it 
seems that it has been successfully adopted in marketing science (Graber et al. 
2002).  
7) Finally, a somewhat tautological yet powerful motive for utilizing PLS in this 
study is the fact that the conducted analysis generated a clear and undistorted data 
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pattern within the proposed Research Model. This outcome, as described and 
discussed in the Result Chapter, is regarded as very feasible, thus receiving a 
positive face-validation. 
 
Given this, the judgment in the present selection of analytical method was that a PLS 
analysis was well suited to the conditions at hand: the fairly large set of independent 
variables and the lack of full knowledge for the formulation of hypotheses regarding the 
potential relation between the independent and the dependent variable. The analysis 
included the preparation phase, the analysis phase and the validation phase. 
 
 
Preparation Phase 
 
Starting with the preparation phase, three means were assumed: handling the possibility 
of missing data; handling variable expansion; and, conducting auto-scaling. Even though 
there is no perfect way to fully compensate for the lack of information, there are ways of 
handling it so as to improve the case compared with no data. In the present case, the 
assumption was that there would be sufficient redundancy between variables and the 
object in the data, so that a few random or evenly distributed elements with missing data 
will not affect the modeling in a significant way, if properly handled in the estimation 
algorithms. It is important to substitute the missing values with other values by using a 
method that does not create systematic patterns in the data which could be interpreted as 
actual phenomena. In this case mainly two different methods would be used. In the case 
of missing values in variables with continuous values (1-10) mean average would be 
used. Other methods such as approximation of the missing value can be hazardous since 
no underlying truth exists to guide the relation between the variables as in natural 
science. Discrete variables of the nature Yes/No will be expanded into two variables, 
numerically described with 1/0 for yes respective no. Missing values will be replaced 
with 0. Secondly, the approach for handling all non-linear or bilinear variables was to 
expand them into several variables, described by alternative 1 / 0. For example, in the 
present case one of the independent variables, the character of sales representatives in 
problem solving situation, could assume two positions: Systematic Approach or Intuitive 
Approach. In such a case this bilinear variable was expanded so that one variable 
Systematic Problem Solving Approach could be described by the alternative 1 / 0, and 
likewise the a second variable, Intuitive Problem Solving Approach could be described 
by the alternative 1/ 0. Thirdly, the units of measurements can be very different for the 
variables (descriptors) and their measured values can vary in magnitude, i.e. 1-10 or 1/0 
etc. For this reason it is necessary to scale the values of the descriptors so that their 
variations can be compared to each other. One common way to scale values of 
descriptors is to subtract their mean and divide them by their standard deviation over the 
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set of variables. This will give each variable a standard deviation of one. Scaling to unit 
variance will give each variable an equal chance to influence the model. With this 
procedure, no prior assumptions as to the relevance of the different variables are made. 
This procedure is particularly important in a data set with a large spread in the numerical 
values of the variables. 
 
Analysis  
 
The choice made was to define “Successful Launch” as the dependent variable and open 
up for the possibility that any of the remaining variables may cause or drive this success 
to a greater or lesser degree. A successful launch was defined in the data set as a having 
given a positive answer to the two questions (items), defined as “subjective data”, under 
the variable “Performance in selling a new product”. Also, for validation purposes, data 
was collected from two sources. In addition to the more subjective data collected, being 
the two items in the collection instrument, data available from a third party sales and 
market share database (MIDAS-Database 2007b) was also used and defined as “objective 
data”. For more detailed information see Chapter 4, Development of the Research Model 
and Appendix 6, Collection Instrument for the Research Model. As the investigated 
launches were products within different therapy areas, where the size of the market 
differed, the effort to normalize this was made thorough a comparison of the mean 
increase for years one and two and the mean increase for years three and four. The results 
from the two data sources, “subjective data” and “objective data” were put in to a PLS 
score plot for comparison and the results are presented in Chapter 5, Results.   
 
The PLS regression analysis, as conducted here for the variables in the Research Model, 
produces a model that transforms a set of correlated explanatory variables into a new set 
of uncorrelated variables (Graber et al. 2002). The set of uncorrelated explanatory 
variables is the predictors (i.e. the biggest sources of systematical variance) that have the 
best predictive strength towards a “successful launch”. Several PLS-algorithms can be 
used, where each has its advantages according to the situation (Geladi and Kowalski 
1986). The algorithm utilized here is described in detail in the publication by Geladi and 
Kowalski (1986) and is, according to the authors, the most complete PLS-algorithm when 
prediction is important.  
 
The interpretation of success for each variable, or key success factor for sales force 
readiness during new product launch, is set within a range, what is here called the 
success-range. This means that in order to contribute to a successful product launch the 
given variable must assume a value within the defined success-range. Further, within this 
success-range, an ideal-value has been defined, which is the mean-value for each variable 
within the success-range. 
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Validation  
 
The third phase included the question of internal validity of this modeling. The PLS 
modeling was performed with a leave-one-out cross-validation technique (jack-knifing) 
in all cases. The jack-knifing validation technique is used here because of the limited 
numbers of objects. The ideal situation to test robustness would have been to possess a 
larger data set in order to be able to split up the data and use one set for building the 
model and one set for validation of the model. In this research, as discussed, the data set 
was not sufficiently large for this approach. The number of valid principal components is 
determined by leave one out cross-validation. The leave-one-out prediction results are 
also used as validation data, i.e. the predicted object is never included in the model while 
it is predicted. This is an internal validation method which, like an external validation 
method, seeks to validate the calibration on independent test data. But contrary to 
external validation it does not waste data for testing only. If there are 100 objects, one 
object will be removed and a model is created with the remaining 99 objects; the object 
left out is predicted with several numbers of principal components by the obtained model. 
The object is put back into the data-set and the next object is removed and the technique 
is repeated. When all objects are tested, the number of significant principal components 
can be determined. With this technique, over-estimation can be avoided and an accurate 
model be obtained. Jack-knifing technique determines the numbers of Principal 
Components (PC) to be used in the model. If the prediction errors over the objects are 
added together, the minimum error which can be reached in the modeling is obtained 
with three PCs. If more than three PCs are included, more “noise” will be included in the 
model, which is comparable with a less accurate model. Hence, three PCs have been used 
in this model. The results of the validation are presented in Figure 12.  
 
2.7. Derivation of the Implication and Conclusions 
 
Finally, after the collected data was analyzed and a pattern emerged as presented in 
Chapter 5, Results; the eighth and final research phase was the interpretation of the 
identified pattern, and derivation of conclusions, both scientific and managerial. This 
work is not merely analytical as it also includes associations and synthesizing, and can 
thus not be accounted fully. However, the guidelines assumed here were to relate the 
identified data pattern first to the Research Model utilized, thereafter to the Research 
Question defined, and finally to the its context: the challenge of sales force readiness to 
achieve a successful launch of products in the Swedish pharmaceutical industry. In this 
step-by-step reflection and contextualization process attempt, the scientific and 
managerial implications will be presented in Chapter 5, Results. 
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2.8. Overview of Validity, Reliability, Relevance and 
Generalizability 
  
In addition to the research process described above, an overview of Validity, Reliability, 
Relevance and Generalizability is presented here.  
 
The question of how valid the findings of this study may be considered in various ways, 
of which two are assessed here: construct validity and the representational validity. 
The first question concerns the validity of constructs utilized here to collect the empirical 
data. The invariable meaning of these constructs is important to assure that the correct 
data was collected. Three approaches were considered as an attempt to secure this 
construct validity. The first is the fact that the utilized constructs were derived from 
literature that presented previous studies where the constructs were validated (see 
Chapter 3, Literature Review and Chapter 4, Formulation of Research Model). Secondly, 
and important if to be confident in the above studies, was the utilization of the so-called 
face-validity. This was done by an exposition of the whole survey, and its constituting 
constructs, to three industry experts. This included an investigation into their assignment 
of meaning to the construct, looking for potential differences between the expert assigned 
meanings and the intended meanings. No significant differences were identified. Finally 
the data collection in this study was achieved by means of survey-guided interviews, and 
not through paper- or web-based survey, but by telephone interviews. This made an 
additional service available to the inquired responders, in that whenever a given question, 
or some part of it, was not clear enough the interviewer was able to provide clarification. 
This may have been the single most important measure for eliminating 
misinterpretations; however, taken together the three utilized validity securing measures 
(validation by previous studies, face-validation, and interview information) suggest that 
the construct validity should be satisfactory. 
 
The next question is that of representational validity, which in this case closely relates to 
generalizibility. This study focused on the success factors for the readiness of a sales 
force in the Swedish pharmaceutical industry, with specific focus on product launches 
aimed at general practitioners. The investigation focused on a one-decade time-interval, 
where all product launches between 1995 and 2005 were addressed. This research 
succeeded in collecting data about a majority of the addressed instances of product 
launches and their associated sales force readiness. Clear and unambiguous patterns of 
product launch success vs. lack of such success were obtained from the data collected. It 
is therefore reasonable to conclude here that the results generated by this result effort are 
valid for the addressed instances: sales force readiness for new product launches aimed at 
general practitioners in the Swedish pharmaceutical industry, conducted between the 
years 1995 and 2005. The more interesting and difficult question here is whether the 
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results obtained here may be valid or generalized for related domains yet outside the 
defined scope investigated here. In general, caution is suggested here against any 
uncritical generalizations outside the present scope. However, it is suggested that the 
findings here may well be assumed for the same industrial and operational domain, in 
most of North European markets – e.g. Nordic markets, Benelux, UK, Ireland and 
Germany – and for the post-2005 year period up to now. The reason for this is that this 
industry and the mentioned markets show a great amount of homogeneity, and that the 
Swedish pharmaceutical industry was ahead of the mentioned markets in terms of its 
evolution with regard to the sales representatives’ access to the General Practitioners 
(Dannacher and Stahl 2005) and that the global emerging environment for 
pharmaceutical sales forces around the world follows this trend (Dutton and Reece 1996; 
Rhee 2009). This evolution seems to have stagnated in Sweden but is still ongoing in the 
Northern European markets. While it is assumed that other markets in Europe, such as 
Eastern and Southern Europe, as well as the North and South American markets differ 
more significantly in their structure and process of sales operations aimed at General 
Practitioners, it is reasonable to assume that several of the findings obtained in this study 
may be less relevant for these later markets.  
 
Reliability is described in section 2.6, where the validation process for the PLS modeling 
is described as performed with leave-one-out cross-validation technique (jack-knifing) in 
all cases. The results of the validation are presented in Figure 12 and are considered to be 
very good.  
 
Relevance of this study has been justified extensively in Chapter 1, Introduction, and will 
not be repeated here. However, in summary the key justification here is that on the one 
hand, managers face significant challenges in situations when sales force must be 
managed to successfully launch a new pharmaceutical product and, on the other hand, 
there is little available empirically-based scientific knowledge to guide such product 
launch sales forces, and there exists no such knowledge for the Swedish pharmaceutical 
industry. Taken together, this creates an urgency of unmet knowledge need, where 
managerial mistakes give rise to significant losses of potential sales revenue at a time 
when the industry needs them more than ever. 
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3. LITERATURE REVIEW 
 
The three investigated fields of research are Sales Force Management (and Selling), 
Product Launch and Pharmaceutical Industry. From these main fields, a set of overlaps 
were identified as important for this research; Sales Force Management during Product 
Launch, Sales Force Management within the Pharmaceutical Industry and Product 
Launch within the Pharmaceutical Industry (graphically presented in Figure 3). Many of 
the findings discovered in these overlaps during the literature review are integrated in 
Chapter 1, Introduction.  
 
The sections below will provide a summary overview of the relevant literature, presented 
according to four identified sales force management themes. In addition, this text 
analyzes, in detail, the key publications which include the most important constructs and 
form the scientific base for the formulation of the Preliminary Model and the Research 
Model. The literature review process is described in more detail in Chapter 2, Research 
Approach. 
 
An overall conclusion is that the three investigated fields of research; Sales Force 
Management (and Selling), Product Launch and Pharmaceutical Industry and their areas 
of overlap form a group of heterogeneous publications. However, from the most relevant 
findings within these research areas, a pattern, or a number of main themes could be 
identified. These themes were; 1) Sales Force Management Control; 2) Internal and 
External Sales Force Collaboration; 3) Sales Force Accountability and Decision Making; 
and, 4) Complexity of the Sales Environment. The formulated Preliminary Model and the 
developed Research Model are based on and structured very similarly to these 
overarching themes. Further, as described in Chapter 2, Research Approach, six key 
scientific models were identified and selected from the literature to be included as the 
scientific base when the Preliminary Model were formulated. Further, these six models 
and their publications include the key constructs and definitions which serve as the 
foundation for the definition of Sales Force Readiness during New Product Launch. 
These publications will be explored in more detail later on.  
 
The text below opens with a presentation of the identified main sales force management 
themes. The key scientific publications are then explored in more detail and the text ends 
with a conclusion based on the full literature review.  
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3.1. Identified Sales Force Management Themes 
 
The findings from the literature review are presented here as an overview, following the 
four main sales force management themes that emerged from the research areas 
investigated. The most extensive area in the literature, Sales Force Management Control 
is presented first, followed by the themes Internal and External Sales Force 
Collaboration; Sales Force Accountability and Decision Making; and Complexity of the 
Sales Environment.  
 
3.1.1. Sales Force Management Control 
 
Sales force management control is an important cornerstone within the literature field of 
sales force management. In the literature, the terms sales management control and 
marketing and sales management control are often used synonymously. It could be 
concluded that there are several gaps in the present literature and empirical research and 
that knowledge is very limited concerning the effect of management control on sales 
managers’ attitude, behavior, and performance (Baldauf et al. 2005). Further, it is pointed 
out that one challenge for management will be to decide how much control should be 
applied and the extent to which it should focus on behavior and (or) outcomes (Baldauf et 
al. 2005).  
 
Some of the literature on sales force management within the pharmaceutical industry 
does cover management control issues. For example, some older results in the area of 
management control and performance within the pharmaceutical industry concluded that 
higher performing pharmaceutical salesmen have three predictable characteristics in 
relation to lower performing salesmen: 1) perceive high clarity of the management 
control system; 2) perceive high personal influence and control over established job 
goals; and, 3) perceive that job rewards are based on performance (Futrell et al. 1976). 
Furthermore, it has been investigated in which way changes in the pharmaceutical 
industry and the reorganization of the UK’s national health service have led management 
to re-evaluate the balance between control and autonomy in managing sales 
representatives’ work (Lloyd and Newell 2001). The key findings are that management’s 
desire to empower and upskill the representatives were undermined by the use of forms 
of control which reduced autonomy and routinized the work process.  
 
One of the questions asked in the literature about the general field of sales force 
management control is what should drive the choice of control strategy. Considering the 
sales force management elements of environment, organization and individual 
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(salesperson), the empirical evidence does not point in any strong direction to any 
predictors of an appropriate type of management control according to Baldauf et al. 
(2005), who further argue that there appears to be an emerging view that management 
control in sales and marketing consists of a combination of different control dimensions 
rather than a fixed set of control categories or types. The “combination view” of control 
dimensions is present in the work of, for example, Cravens et al. (2004) and Jaworski et 
al. (1993). Jaworski (1993) identifies four alternative combinations or "systems" of 
control. The first is a traditional bureaucratic management control system with primary 
emphasis on formal controls; the second, a clan system with primary emphasis on 
informal controls; the third, a low control system, and the fourth, a high control system 
(Jaworski et al. 1993). Others support this notion, for example, there has been a 
conclusion that salesperson supervision, evaluation and compensation decisions should 
be seen as a continuum ranging from behavior to outcome control and that movement in 
one direction or another entails a compensatory process (Oliver and Anderson 1995).  
 
In the overview of sales management control by Baldauf et al. (2005), two selected 
theoretical foundations have been identified as pathways for following the research 
development. The first foundation and conceptualization is the one developed by 
Anderson and Oliver (1987), where behavior-based sales management control is 
characterized by “high levels of supervisor monitoring, direction and intervention in 
activities, and subjective and more complex methods of evaluating performance, typically 
centered on the salesperson’s job inputs” (Anderson and Oliver 1987). The definition 
here of behavior-based sales management control is “an organization’s set of procedures 
for monitoring, directing, evaluating, and compensating its employees” (Anderson and 
Oliver 1987). This theoretical foundation is drawn from the economic, organizational 
behavior and psychology theoretical approaches. The second selected conceptualization 
is Jaworski’s (1988) formal and informal control theoretical foundation (Jaworski 1988). 
The resulting research propositions from this conceptualization are rooted to a great 
extent in the management and accounting disciplines and are concerned with the 
antecedents (e.g. environment) and consequences (e.g. individual effects) of formal and 
informal control. Unlike Oliver and Anderson (1987), Jaworski (1988) defines control as 
“attempts by managers and other stakeholders within the SBU (strategic business unit) to 
influence the behavior and activities of marketing personnel to achieve desired 
outcomes” (Jaworski 1988). Formal control is comprised of output and process, and 
formal control is a written, management-initiated mechanism. Informal control includes 
social, cultural, and self-control, and is an unwritten, worker-initiated mechanism. Given 
these two control conceptualizations in sales and marketing, it has been pointed out that 
Anderson and Oliver (1987) focus on the consequences of their formal control construct, 
whereas Jaworski (1988) relates the use of formal and informal controls to antecedents 
and consequences. It is concluded that, without this being explicitly addressed, their 
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contributions correspond well with the Walker et al.(1979) important core sales 
management paradigm (Walker et al. 1979). Within that paradigm, management control 
is placed under supervision and motivation and identifies control as an important part of 
the responsibilities of sales force management.  
 
The two theoretical foundations by Anderson and Oliver (1987) and Jaworski (1988) 
respectively led to different research streams, which have brought different insights and 
learning to the broad field of sales management control. These two research streams are 
followed separately in the next two sections.  
 
Based on the Anderson and Oliver (1987) theoretical foundation 
 
Following the research stream, categorized as using the Anderson and Oliver (1987) 
control philosophy and using either Anderson and Oliver (1987), Oliver and Anderson 
(1994), Babakus et al. (1996), Cravens et al. (1993) and/or own scale as control 
measures, several studies of interest can be identified (Anderson and Oliver 1987; 
Babakus et al. 1996; Cravens et al. 1993; Oliver and Anderson 1994). In chronological 
order, the first example is Cravens et al. (1993), in which the readers are first reminded 
that it is important to note that compensation control should not be confused with the far 
more comprehensive concept of management control. Their results suggested that the use 
of heavy incentive pay plans as the core for sales force control systems could be a risky 
strategy and should be combined with other control mechanisms (Cravens et al. 1993). It 
has also been identified that industrial field sales people could encounter ethical conflicts 
when dealing with customers and others as often as on a daily basis (Robertson and 
Anderson 1993). The research by Robertson and Anderson (1993) aims to determine the 
effect of the firm’s control systems and dimensions of work task environment upon 
ethical judgments made by the sales people. The findings indicate that the firm's sales 
force control system does have an impact on the ethical reaction patterns of its 
salespeople and that more ethical responses are seen in behavior-control systems.  
 
Oliver and Anderson (1994) empirically test a set of propositions about how control 
system perceptions influence salespeople (Oliver and Anderson 1994). They found that 
the perception of behavior control appeared to be related to greater affect and acceptance 
among salespeople than did outcome control. The results further indicated that the 
commitment of the salespeople was greater in a behavior-controlled system. The reasons 
given are reduced stress as a result of a more formalized system, which is perceived by 
the sales representatives to be more innovative and supportive. Interestingly, in this case, 
more formal is not seen to mean more bureaucratic. In another empirical investigation in 
Australia, a model examines the sales management control system, sales territory design, 
sales force behavior and outcome performance, and sales organization effectiveness 
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(Babakus et al. 1996). This investigation found that higher sales force behavioral 
performance gives higher outcome performance and sales organization effectiveness. 
Moreover, they found that more behavior-based sales management led to higher sales 
behavioral performance and greater satisfaction with the territory design. The conclusion 
drawn was that well-designed sales forces with high performance led to effectiveness and 
that field sales managers are very important if effectiveness is to be achieved.  
 
Similar to the research examples above being based on Anderson and Oliver’s (1987) 
theoretical foundation; Krafft (1999) looks into a set of hypotheses from agency theory, 
transaction cost analysis and Ouchi’s theoretical framework for the environmental, 
company, and salesperson characteristics, on the design of sales force control systems 
(Krafft 1999; Ouchi 1979). The conclusion is that to reduce uncertainty among the sales 
representatives, the sales manager extends the product line or territory to give the sales 
representative a wider scope of products and customers to select from. Also, it is 
perceived that coaching reduces uncertainty. Furthermore, the results showed that 
environmental and company factors are more important than the characteristics of the 
sales representatives when designing control systems. Another empirical investigation 
aiming to examine the relationship between sales force management practices and 
performance has been made by Slater and Olson (2000). Using the distinction between 
constructs of the four product and market strategy approaches; prospectors, analyzers, 
defenders and reactor, the role of marketing in the implementation of business strategy 
has been examined (Slater and Olson 2000). The core findings related to sales force were 
that prospectors, analyzers, and differential defenders perform better when employing an 
internal sales force, while low-cost defenders should contract an external sales force. 
Moreover, it was found that moderate supervisory control should be utilized by 
prospectors and analyzers. Low supervisory control should be the choice for low-cost 
defenders and differentiated defenders should utilize high supervisory control. As far as 
control systems are concerned, an outcome-based control system is preferred for the 
prospector and low cost defender, a mix control system for analyzers and behavior-based 
for the differentiated defender. 
 
The literature argues the need for non-US based sales force research to prescribe better 
local recommendations and to validate earlier research in a more global business setting 
(Baldauf et al. 2001a; Baldauf et al. 2001b). Baldauf et al. (2001a) investigates sales 
organizations from the UK and Austria and finds that behavioral-based control on 
behavioral performance was only valid for the Austrian population, showing that cultural 
differences are a fact within sales force strategy elements. They suggest that it may be a 
possible failure to align strategy and structure when implementing business strategy 
through sales force operations. Their line of arguments is based on finding a weak link 
between some of the key elements of companies’ strategic orientation and salespeople 
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performance and effectiveness. In the area of effectiveness, they found that salespeople 
who achieve their targets are very important for effective sales organizations and that 
territory design may be important for outcome performance but not for effectiveness. In 
the second investigation, Baldauf et al. (2001b) point out the value of behavioral control; 
however they conclude that the research area is incomplete in order to draw any final 
recommendations. They summarize that much research evidence supports the importance 
of motivated salespeople, but also that there is a lack of knowledge about the impact of 
behavioral control on motivation. Others drawing the conclusion of cultural differences 
are Rouzies and Macquin (2002), who state that there exist differences across borders and 
that personnel sales governance structure needs to be reassessed per market or cultural 
background. This concerns how managers conduct monitoring, directing, evaluation and 
compensation.   
 
During the more recent years, research based on Anderson and Oliver’s (1987) 
theoretical foundations is exemplified by investigations such as Menguc and Barker 
(2003) where it is concluded that a mix of both financial and non-financial incentives in 
the sales force is preferable (Menguc and Barker 2003). This was found during an 
investigation of the performance effect of outcome-based incentives on sales 
organizations. Another research that further extends the geographic scientific base on 
salesperson performance and effectiveness is Piercy et al. (2004) who have conducted an 
investigation in developing countries. They examine the impact of management control in 
combination with incentive pay and territory design on salespersons’ performance and 
the unit’s effectiveness (Piercy et al. 2004). They find differences between the countries, 
and conclude that it is a concern that managers sometimes have over-reliance on 
incentive pay for the sales force. Furthermore, their findings did not indicate that 
behavior control, percentage incentive pay and territory design satisfaction cause any 
changes in the performance and effectiveness.  
 
Based on the Jaworski (1988) theoretical foundation 
 
The second path or theoretical foundation of research identified by Baldauf et al. (2005) 
with regard to sales management control research was the one developed by Jaworski 
(1988). There are several examples of research using Jaworski (1988) and/or Jaworski 
and MacInnis (1989) as control measures (Jaworski 1988; Jaworski and MacInnis 1989). 
Some interesting examples are presented in chronological order below. Jaworski and 
MacInnis (1989) continue the work towards a more complete framework and investigate 
the role of task characteristics when developing control systems and how these systems 
affect marketing managers. The findings showed strong positive relationships between 
procedural knowledge and process controls and performance documentation and output 
controls. Further, self-controls are associated with reduced dysfunctional behavior and 
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output and process controls are associated with less information asymmetry. In a study 
about supervisory feedback, Jaworski and Kohl (1991) conclude that sales managers 
should provide positive feedback instead of negative feedback (Jaworski and Kohl 1991). 
Positive feedback about behavior seems to be good as information about clarifying 
expectations for outputs and behaviors. On the other hand, negative feedback does not 
seem to be as motivating for salespeople as positive feedback and the impact on 
performance seems to be less with negative feedback. However, the authors suggest that 
negative feedback does not lower salespeople’s satisfaction with supervisors. Lusch and 
Jaworski (1991) have conducted an investigation into management control, stress and 
performance of managers (Lusch and Jaworski 1991). They found that control systems 
played a role in affecting performance but that they do not directly affect it. However, it 
is concluded that a direct link to performance could be made in other situations, but this 
might be offset by various psychological (stress and nervousness) and behavioral 
(dysfunctional behavior) responses. To develop a control combination framework and 
empirically test the types of control combinations in marketing operations, Jaworski et al. 
(1993) have conducted a study (Jaworski et al. 1993). In this study they also set out to 
find variables that predict the use of these control systems. They argued that organization 
size and task complexity appear to be good predictors of which control system is used. 
With increased size, bureaucratic control systems are more likely. Also, the authors 
suggest that earlier literature associated tighter controls with profitability, but argues that 
this is not the case.   
 
For capability control, it was found that sales managers are likely to increase 
salespeople's motivation and enjoy a more productive relationship with them, as well as 
improve their selling (Challagalla and Shervani 1996). It was further found that 
supervisors should be careful when using activity control, even if it is useful under 
certain circumstances. This is because salespeople may view monitoring and reinforcing 
routine activities as redundant. The study by Challagalla and Shervani (1996) focuses on 
practical and theoretical issues regarding the impact of supervisory controls on individual 
salespeople, such as on capability control and activity control. Activity control was not 
found to be as effective as capability control in reducing ambiguity and enhancing 
satisfaction with the supervisor. A well-balanced mix is preferred between the managers’ 
time spent on improving skills versus detailed activity specification. In the study made by 
Lusch, Boyt and Schuler (1996), it was shown that social controls were important in 
building company culture, and that they may have the effect of increased support from 
the employees (Lusch et al. 1996). It was found that increased social control increased 
socialization; however, a company can not translate social controls into higher employee 
socialization. The authors argued that this was a neglected area and that more research is 
needed as it might provide valuable benefits for managers and well as scholars.   
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An investigation examines two different theories of marketing control systems; 
traditional and contingency (Ramaswami 1996). It was found that the traditional 
perspective gained more support than the contingency perspective. This conclusion was 
drawn when using dysfunctional behavior as the focal negative response. Tasks and 
supervision were examined where tasks are defined as performance documentation and 
procedural knowledge and supervision defined as the degree to which employees 
perceive that they are allowed to participate and that supervisors are both knowledgeable, 
and considerate about their performance. 
 
Again, activity and capability control have been investigated by Challagalla and Shervani 
(1997). In this study, they suggest that it is important for the effectiveness of the 
organization that activity control ensure that employees focus on activities that are 
identified as key for long-term success (Challagalla and Shervani 1997). They present a 
measurement model that is argued to have several theoretical, substantive, and 
methodological implications for future research on control. It claims to provide a set of 
measures that capture the nine facets of output and behavior control. The study also 
provides evidence for both activity control and capability control.  
 
In an attempt to investigate distribution channels in terms of the coordination processes 
that govern the relationship between export manufacturers and their foreign-based 
distributors, Bello and Gilliland (1997) found that control and flexibility are associated 
with export channel performance in terms of meeting economic goals, achieving high 
levels of selling performance, and establishing effective marketing strategies for the 
foreign market (Bello and Gilliland 1997). Also, it was found that process control had no 
performance effect. It was concluded that it is the manufacturers’ emphasis on output-
based monitoring rather than on process controls that accounts for the performance 
benefits of a firm's involvement with its foreign partner. Moreover, influencing a  
distributor's specific selling and marketing behavior will not contribute directly to 
channel performance outcomes.  
 
In regards to the question whether output-based or process-based controls help reduce the 
harmful impact of formalization on salespeople’s attitudes, support was found that 
formalization leads to negative attitudes among salespersons (Agarwal 1999). However, 
Agarwal (1999) found that the use of output-based control reduces the negative impact of 
formalization on role ambiguity and organizational commitment, but not on role conflict. 
For process-based control, the findings showed that it is not helpful in reducing the 
negative impact of formalization for any of three outcomes - role ambiguity, 
organizational commitment and role conflict. Bonner, Ruekert, and Walker (2002) 
conduct a study about control with teams dealing with new product development projects 
(Bonner et al. 2002). The findings indicate that the creative potential of a cross-functional 
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new product development team is likely to be better realized if less control, or more 
flexibility, is given by upper management. The team should decide their own procedures 
and processes, with only a more strategic directive and less intervention from upper 
management.  
 
As far as gender differences are concerned, the generalization of Jaworski’s framework 
has been tested  (Ramaswami 2002). The results indicate that there is no difference 
between how control systems are perceived by men or women, nor in their responses to 
controls. In a gender neutral cross-industry investigation,  it was further found that the 
most favorable salesperson consequences were with high control combination, while low 
control is linked to the least favorable consequences (Cravens et al. 2004).  It was also 
found that salespeople under a more visible control system (high control) perform better, 
are more satisfied, and display lower role stress when compared to salespeople working 
under bureaucratic, clan, and low control combinations. Cravens et al. (2004) examine 
the conceptualization of the high, bureaucratic clan and low management control 
combinations as another perspective to behavior-based management control (Cravens et 
al. 2004).  
 
In specific findings to new product launch and sales force within this second path or 
theoretical foundation based on Jaworski (1988), it was found that behavior and outcome 
controls have differential effects on sales force performance in selling a new product; 
while the implications of behavior control (lack of discretion and flexibility) are resented 
by the sales force, outcome control is positively related to salespeople’s selling 
performance (Hultink and Atuahene-Gima 2000). This study examines the effect of new 
product adoption by the sales force on selling performance, and the potential supervisory 
and market factors that moderate this linkage. The constructs and model from this 
investigation are found to be key for this research and will be used when formulating the 
Preliminary Model in a later chapter. The publication and model will be discussed in 
more detail below. In another study focused on trust, in which trust is defined as the 
salesperson’s belief that the sales managers genuinely care and are concerned for his or 
her welfare in the process of new product selling (Atuahene-Gima and Li 2006), it is 
argued to be the first study where the relationship between formal control mechanisms 
and supervisee trust in new product selling are tested. The investigation concerns young 
and inexperienced salespeople in China. The conceptual model is related to parts of the 
broader model by Atuahene-Gima (1997). A set of hypotheses was formulated and tested 
empirically on 250 high-technology firms in China. The key findings show that the use of 
process control rather than output control helps in building trust with the young Chinese 
salespeople during new product launch.   
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3.1.2. Internal and External Sales Force Collaboration 
 
In the literature, it is argued that both internal and external collaboration for sales 
organizations are of increasing importance (Ingram 2004). As with the theme of sales 
force management control, it can be concluded that there are gaps in the literature and 
that further research is needed. Ingram (2004) has developed a set of sub-categories 
within the theme of collaboration and provides some thoughts about the opportunities for 
further research. Others support these identified sub-categories of collaboration 
(Corcoran et al. 1995; Schwepker Jr 2003). The first sub-category is the need for more 
collaboration between the internal functions such as sales, marketing and other functional 
units. The identified research opportunities in this subcategory explore the impact of joint 
goal-setting, inter-functional teams, common rewards and how the salespeople’s roles 
might be changed to better coordinate activities. The second sub-category is also directed 
internally and deals with the needs to shift from having sales management direct their 
sales force and instead having them move towards a more collaborative approach. The 
direction is to have sales managers collaborate with their salespeople without relying on 
authority. For this to take place, sales managers need to build trust as well as ensure that 
the salespeople take leadership for self-managing when required. The area for closing the 
research gap would be to expand the Leader-Member Exchange (LMX) research to 
determine where the manager and salesperson need a stronger relationship. Furthermore, 
it is important to investigate how managers could develop, and Ingram (2004) suggests 
further expansion of Behavioral Self-Management (BSM) within sales management 
research. The issue around the need to be more customer-oriented in selling is identified 
as the third sub-category. The managerial response suggested should be to expand and 
train the salespeople towards more customer-oriented behavior, handling conflicts and 
service recovery as well as to build on trust-based relationship selling. The opportunities 
for research in this area are suggested in the following areas: evaluating the effectiveness 
of service recovery and conflict resolution efforts; investigating how to promote 
customer-orientation in the organization and expanding customer oriented research 
around aspects such as definitions, concepts and measures. Interaction with customers 
should be added to this last sub-category.  
 
Internal collaboration has been investigated within the pharmaceutical companies’ sales 
force. One example is a study based on the socioanalytic theory, where a model is tested 
on a US pharmaceutical company in order to examine the relationship between lone wolf 
tendencies, task performance, contextual performance, job satisfaction, and turnover 
intensions (Mulki et al. 2007). Sales people with lone wolf tendencies dedicate very little 
time and energy to developing interpersonal relationships: they like to work alone and 
believe others are less capable and effective. The sample of pharmaceutical salespeople 
showed that about one-third of the respondents had moderate to high levels of lone wolf 
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tendencies. A lone wolf’s unwillingness to become a team player leads to lower 
contextual performance as represented by the dimensions of helping, courtesy, and 
sportsmanship and is harmful to the organization in a number of ways. Task performance 
is subsequently reduced. Also, some research from sales force automation (SFA) 
literature was found to be related to investigations in the pharmaceutical industry. Engle 
and Barnes’ (2000) study showed that the use of sales force automation technology 
contributes to more effective sales operations and higher volumes (Engle and Barnes 
2000). The two most dominant factors contributing to higher sales performance were 
“active sales tool” and “administration and external information exchange”, which 
suggested, based on the authors’ analysis, that sales performance will increase when 
usage of a sales force automation system directly involves customers. They concluded 
that it may be possible for information technology to create value in terms of productivity 
without improving profits due to productivity being channeled to fewer or non-profitable 
activities. There are also lessons to be learned from Dong-Gil and Dennis (2004) research 
within this area. They relate to the lack of benefit of using a SFA in Big Pharma for an 
experienced sales representative compared to an average one, and the possibility that a 
more experienced sales representative could be more reluctant to change (Dong-Gil and 
Dennis 2004).  
 
External collaboration with customers is of utmost importance as the sales staff serve as 
the company’s personal link to the customers and the sales representative is often 
regarded as the company for many of its customers while at the same time bringing back 
much-needed information from the customer (Kotler 2000). Within the pharmaceutical 
industry, research discusses and investigates the sales force topic of collaboration during 
launch. As an example of how it is related to external collaboration with, or sales aimed 
at, customers and in the form of tactical execution that focuses on a launch situation; a 
model for repeat purchase environment has been developed and investigated with 
pharmaceutical firms as research subjects (Lilien et al. 1981). The investigation concerns 
a physician specialty being detailed (sold) an ethical drug. The model is focused on the 
situation when word-of-mouth in effect is present and is then tested with a few cases 
which give a fairly good performance of the model within the scope. Another 
investigation of a pharmaceutical product launch, defined as a disruptive innovation, 
concluded that the product was extensively used, because of the buildup of market 
awareness before the launch (Sandberg 2002). Also, the same basic targeting actions (e.g. 
symposiums and congresses) could be used to arouse interest, primarily in the customer 
groups referred to as innovators and early adopters. The study was conducted in the form 
of a case study and the author illustrated proactiveness through this case study. Firms that 
develop and launch disruptive innovations, i.e. innovations that create their own market, 
face challenges when proactively preparing the market. The author used proactiveness as 
a concept with the definition of proactivness being the firm’s ability to create 
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opportunities or the ability to recognize or anticipate and act on opportunities (or 
dangers) when they present themselves. Moreover, innovations are referred to as 
something that is invented for the first time and is a commercial success, while disruptive 
innovations are innovations that involve significant new technologies, require a 
considerable change in consumption patterns and are perceived as offering substantially 
enhanced benefits. 
 
There is also literature that investigates the external collaboration, or sales situation, with 
customers within the pharmaceutical industry; however, this is not focused on the launch 
phase. For example, Mizik and Jacobson (2004) prove that, for three drugs investigated, 
the effect of detailing (sales call) had a positive statistically significant effect on 
prescriptions (Mizik and Jacobson 2004). This is also proven by Manchanda and 
Chintagunta (2004) and Gonul et al. (2001) in other studies (Gonul et al. 2001; 
Manchanda and Chintagijnta 2004). In another research on the subject of sales call 
elasticity, it was concluded with a model for sales response that sales call elasticity is 
negative when no samples or handouts are given during a sales call (Parsons and Abeele 
1981). That samples have a positive and significant effect on prescriptions in detailing is 
also found by Gonul et al. (2001).  
  
3.1.3. Sales Force Accountability and Decision Making 
 
Sales force accountability and decision making is of interest when managing the sales 
force, especially during new product launch, as company management has no guarantee 
of sales force commitment (Atuahene-Gima 1997).  
 
Sales Force Accountability 
 
Motivation of the sales force could also be included in the broad spectrum of 
accountability. Ingram (2004) identified and defined three subcategories in the area of 
accountability and suggests areas of further research. Of the three accountability issues 
identified, the first was the justification of sales as an important marketing 
communications tool. For managers to appreciate this, salespeople should be a part of 
both designing and delivering relevant sales messages. The identified opportunity for 
further research included determining the sales presentation variables such as content, 
sequence, style, amount of two-way interaction and methods for addressing questions and 
objections. Also included are exploring presentation strategies and accurately identifying 
reasons for sales presentation success and failure as well as investigating how a sales 
manager can assist the salesperson in doing this. The second subcategory under 
accountability refers to the demand from customers to be faced with trustworthy and 
professional salespeople. The managerial response suggested is to ensure that the ethical 
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and legal framework is understood by the salespeople. This also includes understanding 
variations in culture and global market conditions. The identified areas for research 
opportunities involve how buyers and salespeople differ or agree on unethical behavior, 
how goal-setting impacts ethical or unethical behavior in addition to the opportunity to 
study the interactions between ethical climate, control systems, goal-setting as well as 
how management’s role should be in communicating ethical climate. The third 
subcategory identified is the increasing efficiency and effectiveness of sales operations in 
which the managerial implication is to find and implement less expensive methods, more 
effective sales organizational structures and to develop new evaluation procedures 
including metrics. Ingram (2004) refers to research opportunities in the examination of 
hybrid coverage models for sales where the integration of personal selling is mixed with 
other customer contacts. Moreover, suggested research opportunities would be to model 
sales force decisions such as sales force size, workload, allocations and geographical or 
territory design as well as measure customer value and return on CRM. Some of the areas 
suggested as further research have been touched upon by research identified above 
(Dong-Gil and Dennis 2004; Engle and Barnes 2000).  
 
For a sales force launching a new product it was found that salespeople selling new 
products had a higher level of education and experience, lower customer role ambiguity, 
and a positive attitude towards the potential for new products (Atuahene-Gima and 
Micheal 1998). However, the findings indicated that it would be wrong to assume a 
simple direct relationship between a salesperson's effort and his or her satisfaction and 
performance in new product selling, which again shows that accountability cannot be 
taken for granted within a sales force. The findings of Atuahene-Gima and Micheal 
(1998), were made in an investigation of the potential moderators of the link between 
effort in new product selling and satisfaction and performance.  
 
Within pharmaceutical sales force research, the literature includes suggestions for the 
characteristics of a good pharmaceutical sales representative, including criteria such as 
the ability to close sales, the degree of service orientation, knowledge of the company, its 
products and its customers, personal appearance, gender, age, as well as ability to learn 
and think analytically, which all are recommended when hiring, training and managing 
the pharmaceutical sales force (Parsons and Abeele 1981; Tengilimoglu et al. 2004). 
Further, it is concluded that the characteristics of a good pharmaceutical sales 
representative are being warm (empathic), easy going (socially oriented) and cooperative 
(approval seeking), which was argued to be in line with earlier research (Sager and Ferris 
1986). Sager and Ferris (1986) also propose in this study a two-facet process for hiring 
pharmaceutical sales representatives. In other pharmaceutical industry research, a study 
investigated job-performance and job-related behavior of pharmaceutical sales 
representatives with the aim of finding the impact of task-specific behaviors as opposed 
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to adaptive behavior on sales performance (Blackshear and Plank 1994). Blackshear and 
Plank (1994) found that both managers and salespeople reported that task-specific 
behavior was important to performance, whereas adaptive behavior had a weaker impact. 
However, the authors argue that the evidence calls for a re-evaluation of adaptive 
behavior to sales effectiveness. Giacobbe et al. (2006) conducts a research that 
investigates the relationship between adaptive selling behavior and selling performance, 
where a multi-division health-care product company (including pharmaceuticals) 
represented one of two subgroups (Giacobbe et al. 2006). The findings from Giacobbe et 
al. (2006) strongly indicate that adaptive selling behaviors are positively associated with 
the performance of salespeople and that the sales situation moderates the strength of the 
relationship. Furthermore, with concepts and theory from organizational literature, Futrell 
et al. (1983) have developed a model about salespersons’ motivational behaviour (Futrell 
et al. 1983). Parts of the model are tested on a US pharmaceutical company and a hospital 
supply company. The findings reveal that the relationship between effort and 
performance is surprisingly low, although statistically significant. Further, the low 
performance-satisfaction correlations imply that salespeople who are rated as high 
performers do not necessarily enjoy high levels of satisfaction. In addition, they found 
that the links between five job satisfaction facets and the propensity to leave the job have 
a clear inverse relationship between satisfaction to and propensity to leave. 
 
Sales Force and Decision Making 
 
The selling job has changed and evolved over time and some literature has linked the 
different stages of evolution to the impact of key sales management decision areas 
(Wotruba 1991). Wotruba (1991) identifies five stages in the evolution of selling and lists 
the related literature and its development in chronological order. An important 
contribution is the summaries concluded by Wotruba (1991) on how these evolutionary 
stages impact key sales management decision areas. The five areas identified to be 
impacted are organizational design, recruiting and selection, training, compensation and 
control, and performance evaluation. The evolutionary stages are defined as the Provider 
Stage, in which selling is limited to accepting orders for supplier’s available offerings, 
the Persuader Stage, which involves attempting to convince any and all market members 
to buy, the Prospector Stage, in which selling includes seeking selected buyers who are 
perceived to have a need for the available offerings, the Problem-Solver Stage, in which 
the selling involves obtaining the participation of the buyers in identifying their problems 
and translating them into needs, and the Procreator Stage, in which selling is defined as 
creating uniquely tailored solutions to buyers problems or needs by means of active 
buyer-seller collaboration. According to Wotruba (1991), these stages of evolution are 
cumulative, and are defined as a growing and enlarging selling job, where the previous 
stage does not dismiss, but rather includes the preceding stages of necessary capabilities. 
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Furthermore, the author argues that the result of this is that the selling strategy expands in 
complexity and that this is made necessary by the growing intensity of competition and 
the increasing sophistication of buyers. It is also argued that the intensity of competition 
and sophistication of buyers differs from market to market and it is even stated that “the 
practice of selling may not be at the same stage at a given time in all industries, or in all 
companies in the same industry or even in all components of the total sales organization 
within one company”. To still be effective, each additional step imposes greater costs as 
well as the need for more time and talent. This implies that in the move towards the later 
stages, more attention has to be paid to efficiency, because as the firm’s selling focus 
evolves from stage to stage; policies and procedures for managing the personal selling 
function will also change. A very important note by the author is that an advanced step is 
not necessarily associated with greater success, but it might be necessary based on the 
market dynamics of competitors and buyer sophistication as argued above.  
 
As for most companies, making marketing decisions is important for pharmaceutical 
companies and the support for these decisions is discussed in the literature, for example, 
in terms of Marketing Decision Support System (MDSS), diagnostics for new products 
and the product launch process. Further, research on the tactical execution that focuses on 
a launch situation provides examples of contributions to this. With the great uncertainty 
in the marketplace when the launch strategy for a pharmaceutical product is formulated, it 
is suggested that the marketing department will be better off taking a more “holistic” 
view. To be more specific, a Marketing Decision Support System (MDSS) is proposed 
for building the launch strategy (Rao 2000b). The usage of the MDSS within the 
pharmaceutical industry is further explored in other research, but with focus on pricing 
(Rao 2000a). The model from this investigation includes various pricing-related decision-
making processes while capturing the interrelated dynamics of all key players with the 
aim of providing knowledge of a new product’s potential performance over time as a 
basis for resource allocation in marketing and sales. Furthermore, within an investigation, 
a more streamlined marketing approach is described to market new pharmaceutical 
products more efficiently (Rao 2002). The author continues to refer to the “holistic” view 
explored in earlier research and the approach is based on a more systematic use of 
marketing research. This approach is argued to lead to benefits in the sales force, such as 
more optimized sales force sizing, structure and alignment. The proposed market-driven 
approach enlarges traditional methods, referred to as historically generated prescriptions 
and analogue product comparison. The enlarged approach would include customer view-
points, customer profiles and present and future customer practices.  
 
 Diagnostics for new products in areas such as early estimate of long-run market share 
and the breakdown of total sales due to marketing activities, word-of-mouth and repeat 
sales, are provided in a model developed by Hahn et al. (1994) (Hahn et al. 1994). The 
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model was tested with 21 ethical drugs in seven different product classes to calibrate a 
four-segment trial-repeat model. The model is developed to model sales of a frequently 
purchased product early in its life cycle. Furthermore, the model covers four customer 
segments in the market. In addition, the effectiveness of the marketing efforts for the 
product to be introduced, word-of-mouth communication and buyers’ trial experience 
could be analyzed with the model. The situation is described as when a new product is 
launched into an established product class, consumers become aware of the product 
through the marketing efforts or through word-of-mouth. It is assumed that these two 
sources of indirect product experience lead to trial. In the model, the number of new 
prescriptions is used as a measure for sales. It is concluded that the most important 
activities for pharmaceutical sales are sales force activities and advertising in medical 
journals, which makes the authors use total expenditure for detailing and advertising as 
the measure of the firms’ marketing activities. One of the findings suggested that 
activities on trial are mainly related to product quality attributes. In addition, the authors 
found that word-of-mouth was associated with product class characteristics and market 
competitiveness. It was also found that the repeat purchase was related to product quality 
attributes and market characteristics such as size, growth, competitiveness and 
familiarity.    
 
Concerning product launch process support, a model to guide the product launch process 
for pharmaceutical companies launching their products is proposed with the objective of 
constructing a valid and user-friendly new product launch strategy (NPLS) model in 
which marketers can eliminate risk or reduce specific types of risk associated with a 
successful new pharmaceutical product strategy (Trim and Pan 2005). It should be seen 
as a decision-foundation on which to build a brand positioning strategy that will result in 
a successful positioning within the industry. Three key strategic decisions have been 
identified to precede the product launch. These three decisions concern: (a) product 
strategy; (b) market strategy; and, (c) firm’s strategy. A second key component of the 
proposed model is the pharmaceutical industry factors. The suggestion of Popper and 
Nason (1994), who argue for the specificity of the pharmaceutical industry, which 
governs its strategies and operations, is followed. The third and final component of the 
proposed model is the tactical product launch decisions. These are adapted from a set of 
references but with no clear specification of the specific origins of each factor. This 
includes four areas: (i) decisions regarding the product, including branding and 
assortment; (ii) decisions regarding the prices, including level and strategy; (iii) decisions 
regarding the promotion, including expenditure and instruments; and, (iv) decisions 
regarding the distribution, including channels and expenditure. The model is then 
validated, where the validation consists of two interviews with two product managers 
within one pharmaceutical company, and a focus group with product managers and sales 
managers, within the same pharmaceutical company. It is stated that on the whole, the 
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interviewers and the focus group participants find the proposed model to be valid. Two 
limitations of the proposed model are given. First, the assumption that there is a one-way 
relationship between the strategic and the tactical decisions in a product launch process; 
rather, there may be an interaction between these. The second limitation is the lack of a 
feedback loop for evaluation of the conducted launch. 
 
In research investigating whether launch strategy decisions lead to changes being made 
by companies when introducing and adding a new product to the sales force, it has been 
concluded that significant changes are made to the sales management mix (Wotruba and 
Rochford 1995). As a conclusion, the investigation summarized that adjustments to 
quotas are the most frequent changes, while organizational structure is changed least. The 
investigation focuses on changes which take place within a company and provides no 
guidance as to what would contribute positively or negatively during launch. However, 
another investigation found that a larger extent of changes made by the firm within the 
controllable sales force management mix led to more successful launches (Rochford and 
Wotruba 1996). In this study it was found that quotas, compensation and 
supervision/motivation brought about the most changes in these successful firms.   
 
Sales force sizing and structure issues have been investigated in order to support resource 
allocation decisions. One investigation  analyzes the problem of designing the structure 
of multi-product sales forces within pharmaceutical companies, with a generalized angle 
on an environment where purchase decisions are made on a straight rebuy or modified 
rebuy situation (Rangaswamy et al. 1990). Rangaswamy et al. (1990) present a 
mathematical programming model with the aim of helping firms design the structure of 
the multi-product sales force. The authors also refer to how some implementations of the 
applied model have led to improved decision making, results and insights, from which 
they suggest two important lessons resulting from applying the model to these few cases. 
The first is that companies with mature product lines who are not achieving their annual 
profit goals will frequently view the sales force as a cost item. The second lesson is that 
merely applying the model might not be beneficial from a humane and sales force morale 
stand-point, as it may recommend substantial downsizing ultimately impacting many 
people in order to optimize profit, and companies are recommended to examine sales 
force implications before major changes are made. 
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3.1.4. Complexity of the Sales Environment 
 
As far as the theme complexity of the sales environment is concerned, even if it is not 
recognized as being unique to sales, the literature argues that as the sales organization has 
most contact activities with customers, this puts them in the first-line for dealing with 
rapid changes and the increased pressure to perform to higher standards (Ingram 2004).  
 
Much of the literature describing the complexity of the sales environment in general, and 
for new product launch and pharmaceutical sales forces in particular, is presented in 
Chapter 1, Introduction.  However, within the area, some general categories are identified 
and gaps in the literature for further research can be highlighted. 
 
The first category includes the increasing expectations from customers which are argued 
as being fueled by buyer dominance, slow-growth economics and increasing competition 
(Ingram 2004). In this category, some research opportunities have been highlighted. First, 
a recommendation to scientifically and more explicitly define the customer centric firm 
has been made, followed by the recommendation to define the role of the sales 
organization in a customer-centric firm and to examine the impact this would have on 
sales organizations and individuals’ performance and effectiveness. The second category 
highlights the issue of change and how it occurs more frequently. Examples such as rapid 
advancing of sales technology, new product development, and accelerating product life 
cycle were put forward (Ingram 2004). Proposed managerial responses to these issues are 
to put sales in a more strategic position for the company and to move towards a learning 
organization with more initial and ongoing training. Identified research opportunities in 
this category are to work on the conceptualization and measurement of the sales strategy 
construct, specifying optimal process for information handling. Also, examining CRM 
and how it can be used as a strategic business capability for both the firm and the sales 
organization were put forward as other important areas. The third identified area is how 
the buying center interaction is becoming more complex, and the influencers of purchase 
decisions are increasing (Ingram 2004). The managerial response should be to develop 
sales strategies and tactics suited for different buying centers, and to ensure that 
salespeople can be able to analyze lines of power and influence. For further research in 
this category, a suggestion for research that determines how effectiveness differs from 
group or individual was proposed. The fourth category in this theme addresses the issue 
of sales organizations becoming more global and the fact that the customers are 
becoming more diversified (Ingram 2004). The research opportunities here would be in 
the area of the identification of sales people adaptiveness to multi-cultural customer 
types. Also, the selection and training methods for evaluation and education of 
intercultural competence are of interest together with how to handle distance 
communication and related supporting technology.   
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During launch, complexity is added to the environment depending on the new product’s 
level of innovation. The area of innovativeness is another area of the research literature 
where information about new product launch and sales has been found. For example, it 
has been found that the relation between product innovativeness and product performance 
is U-shaped, concluding that an innovative product has significant impact on new product 
performance, but most interestingly, also giving non-innovative revisions and cost 
improvements a significant relationship to product performance as well (Kleinschmidt 
and Cooper 1991). Innovativeness is not alone in adding complexity to the new product 
launch; rather there exist a whole range of criteria. This is for example illustrated by a 
developed model which consists of three sets of variables; launch strategy, market 
characteristics, and new product performance (Hultink and Robben 1995). The model is 
build on earlier literature based on Montaya-Weiss and Calantone (1994) meta-analysis 
of determinants of new product performance and studies within the same area (Choffray 
and Lilien 1986; Green et al. 1995; Hultink et al. 1997; Hultink and Robben 1995; 
Montoya-Weiss and Calantone 1994). The conclusion is made that earlier work relied on 
industrial and high-tech products. This research aimed to expand the scope with samples 
from consumer and industrial products cross-industry. The results concluded for both 
consumer and industrial products, that the impact of launch strategy was greater for 
market acceptance than for product performance. Furthermore, and in line with previous 
studies, market acceptance and product performance are driven by multiple factors, e.g. 
the product’s innovativeness, branding and breadth of assortment. The overall results 
suggest that to achieve successful new product performance, important factors are an 
innovative product, a broad range of complementing products, early timing, capitalizing 
on existing brand names, specific penetration objectives per market, pricing and 
competitive awareness.   
 
The complexity of pharmaceutical sales force operations is described in more detail in 
section 1.6, The Pharmaceutical Sales Force Operations and Life Cycle Challenges, 
where it is concluded that the pharmaceutical sales force operations are increasingly 
encountering challenges in the market place in the form of stricter regulations and 
restrictions, a trend which has been observed in most countries around the world (Dutton 
and Reece 1996; Smith et al. 2002). Other literature highlights and adds to this 
complexity from a slightly different angle. For example, the issue of over-detailing of 
sales force leading to diminishing return at individual physician level in certain product 
categories is true (Manchanda and Chintagijnta 2004). Also it was found that excessive 
detailing or samples are counterproductive, suggesting an inverted–U shape for these 
activities (Gonul et al. 2001). Moreover, other  literature suggests the same issue of 
diminishing return on over-detailing and other sales force activities, and proposes 
increased effectiveness by building better long-term relations with physicians (Elling et 
 85 
 
al. 2002). These findings include improved segmentation, providing better information, 
and redefining the sales manager’s role as well as including concepts such as life-time 
value of physicians’ prescribing behavior. With all these suggestions driving cost 
upwards at a time when cost efficiency and savings are sought, it is further concluded, 
from the resource-based view, from an examination of the sustained competitive 
advantage in the U.S. pharmaceutical industry, that sales force expenditures have a direct 
impact on sustained competitive advantage (Yeoh and Roth 1999). Also, they found that 
sales force expenditure positively and indirectly affects approval success of NCE (New 
Compound Entity). Yeoh and Roth (1999) concluded that in the pharmaceutical industry, 
sustained competitive advantage is dependent on: (1) sales and technological strength; 
and, (2) having a unique, superior product with a differentiated advantage in the market.  
 
3.2. The Key Constructs and Models 
 
In this section, the most relevant constructs and models used in the formulation process 
of the Preliminary Model and the Research Model will be presented. These will be 
reviewed and presented in greater detail than the other publications reviewed, based on 
their importance for this research’s model formulation process. In addition to the review 
within this section, the models will be further described and presented in Appendix 1. 
These six publications also include the different constructs and definitions which are the 
main foundation for the definition of Sales Force Readiness during New Product Launch. 
 
The first three identified key scientific contributions are developed by Atuahene-Gima 
(1997), Hultink and Atuahene-Gima (2000) and Micheal et al. (2003). These three 
publications include concepts and constructs within the scholarly area of new product 
adoption. The other three identified scientific contributions are developed by Baldauf and 
Cravens (1999), Piercy et al. (1999) and Piercy et al. (1997) and are derived from the 
scholarly research area of sales organizational effectiveness.  
 
3.2.1. New Product Adoption  
 
The most comprehensive constructs and model are found within the research stream 
about the broader concept of new product adoption in the sales force (Atuahene-Gima 
1997). The constructs and model were developed by Atuahene-Gima (1997). Atuahene-
Gima (1997) attempts to fill the argued gap in the literature regarding which factors affect 
sales force adoption of new products. The conceptual comprehensive model (see 
Appendix 1) was built describing the factors and outcomes of new product adoption by 
the sales force and propositions and managerial implication of the model were suggested. 
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The model and propositions were not empirically tested in this publication. Some 
examples from case studies are used to highlight managerial importance, stating that 
changes in both sales force organization and management practices might be necessary 
during launch. Also, it was argued that there may be sales force resistance to management 
changes and that other changes might lead to dysfunctional behavior among the sales 
force. It is of importance that the sales force be treated as internal customers and that the 
sales representatives must “buy” the new product in order to achieve success in new 
product selling. New product adoption by the sales force is defined as “the interaction 
between the degree to which they accept and internalize the goals of a new product (i.e. 
commitment) and the extent to which they work smart and hard (i.e. effort) to achieve 
these goals”. The construct is built on the two dimensions, commitment and effort, and is 
based on the assumption that the sales force is an internal customer. This definition is in 
line with the innovation adoption literature. By developing this model, Atuahene-Gima 
(1997) forms a good foundation in this area of the literature for further development and 
empirical testing. Atuahene-Gima (1997) builds the concepts, model and propositions 
from a broad range of sales force management and innovation literature, e.g. Cravens et 
al. (1993), House and Mitchell (1974), Jaworski and MacInnis (1989), Mathieu and Zajac 
(1990), Meyer and Allen (1991), Oliver and Anderson (1994) and Ouchi (1979) (Cravens 
et al. 1993; House and Mitchell 1974; Jaworski and MacInnis 1989; Mathieu and Zajac 
1990; Meyer and Allen 1991; Oliver and Anderson 1994; Ouchi 1979). The formulation 
of propositions is well grounded in earlier research and an academic line of arguments. 
The propositions are formulated within the categories of salesperson characteristics, 
organizational factors, sales management support, sales control, product innovativeness 
and the outcome of new products by the sales force. The model takes into account the 
moderating of product innovativeness and market competition. It is argued that several 
factors may be moderators between new product adoption and dysfunctional behavior 
and outcome. Five propositions are formulated here. The author argues that this 
theoretical framework set-up will open up for empirical research in the field of the role of 
sales force in the new product process as the definitions are sufficiently broad to integrate 
selling of both products and services as well as a multiple level of analysis such as 
individual, sales team and the whole firm’s sales force. The publication is focused on the 
individual salesperson. Among the benefits of the model is the fact that it appears to be a 
relevant model and proposition for the conception and understanding of the sales force’s 
adoption of a new product. It is further theoretically grounded in an extensive literature 
review. The model includes and integrates interesting and relevant constructs about 
product innovativeness and intensity of market competition, which are typically 
eliminated in other models. One limitation is that, when written, the model is a theoretical 
construction and lacks any empirical experience and testing. Also the model is slightly 
too complex; and will probably need to be divided when tested. 
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Among the studies investigating a more specific area of the conceptualization of new 
product adoption in the sales force is the research done by Hultink and Atuahene-Gima 
(2000), in which they develop and modify the model proposed by Atuahene-Gima (1997) 
for empirical testing (Hultink and Atuahene-Gima 2000). This study examines the effect 
of new product adoption by sales force on selling performance, and the potential 
supervisory and market factors that moderate this linkage. They found that sales force 
adoption is positively related to selling performance. It is clearly acknowledged that 
earlier studies have found and suggested that the sales force is a major contributor to new 
product success, but they were conducted without any deeper investigation into the 
adoption of the new product by the new sales force. The model (see Appendix 1) and 
research also looked at supervisory factors such as sales controls, internal marketing of 
new product, training, trust, field attention and market volatility. They found that internal 
marketing and market volatility were positively related to new product success, defined 
as selling performance. Further, results reveal that behavior and outcome controls have 
differential effects on sales force performance when selling a new product; where the 
implications of behavior control (lack of discretion and flexibility) are presented by the 
sales force, outcome control is positively related to salespeople’s selling performance. 
Furthermore, the findings showed that training and field attention weakened the adoption-
performance linkage, with a possible explanation being culture differences in the country 
of the study, the Netherlands. They argue that based on the culture in the Netherlands, 
salespeople interpret these two variables as “micro-managing” and having the supervisor 
looking over their shoulders. Hultink and Atuahene-Gima (2000) adopt the Atuahene-
Gima (1997) definition of sales force new product adoption being the degree to which 
sales people accept and internalize the goals of the new product (i.e. commitment) and 
the extent to which they work hard and smart to achieve these goals (i.e. effort). The 
construct is two dimensional; commitment, which is attitude, including acceptance of the 
new product, emotional commitment to make it a success to fulfill self-interest objectives 
and effort being the salesperson’s force, energy, persistence and intensity of activities to 
reach the results. An important notion for the definition suggested by Atuahene-Gima 
(1997) being two dimensional is his argument that, although the two dimensions could 
have independent effects on selling performance, effort alone without commitment to its 
goal does not constitute adoption. The argument is built on the fact that effort without 
salesperson commitment could be misdirected at activities that lead to short-term sales 
but are non-favorable to the long-term success. The conclusion would be that a 
combination of the two dimensions would have greater impact on selling performance 
than each dimension alone. This is argued by Hultink and Atuahene-Gima (2000) to be 
further supported by innovation adoption literature. Eight hypotheses are formulated in 
the publication. These hypotheses are to some extent grounded in the literature. The data 
sample was high technology firms in the Netherlands. The choice of industry was based 
on the assumption that this industry would be more likely to have launched new products 
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recently. A pre-tested questionnaire was sent out to sales managers for distribution in the 
sales force. The instrument was developed and well tested. The final sample size was 97, 
which was a response rate of 23%.  
 
The research provides opportunities in terms of identifying many areas of research yet to 
be explored. One of the limitations identified, to some extent even by the authors, is the 
low relevance of the research results in terms of being cross-industry and conducted only 
in the Netherlands market. The study is of an exploratory character with few tested 
moderators. The relationships between the mediators are not verified, and the sample size 
is small. Moreover, the results are based on collected data from the perception of sales 
representatives only.  
 
A further addition to the investigations of a more specific area of the full 
conceptualization of new product adoption in the sales force is the research conducted by 
Micheal et al. (2003). Micheal et al. (2003) build their construct on similar concepts 
described about new product adoption in the sales force, but expand on the concepts of 
newness that the product has brought to either the firm or the market (Micheal et al. 
2003). The concepts are influenced by e.g. Kleinschmidt and Cooper (1991) and 
Rochford and Wotruba (1996) (Kleinschmidt and Cooper 1991; Rochford and Wotruba 
1996). The model (see Appendix 1) does not include the concept of measuring 
performance, which is acknowledged as a weakness by the authors. Also, the focus and 
research aim is different in terms of the investigation being into how firms adjust sales 
management strategy for new product launch. In other terms, they investigated the 
relationship between the type of newness of a new product and the sales force changes 
accompanying its launch by the sales force. Michael et al. (2003) concluded that the type 
of newness of a product does affect the incidence of changes made to the sales 
management strategy of the firm introducing the new product. In general, firms with not-
new-to-the-market but new-to-the firm products made more changes in sales strategy 
than did firms with new-to-the-market and new-to-the-firm products, with the exception 
of the strategy categories of supervision/motivation and compensation. It was considered 
interesting that the results showed that, in general, firms with the greatest degree of 
market newness do not make the most adjustments for products. The authors formulated 
and tested four hypotheses. These hypotheses were tested in two ways: 1) the incidence 
of sales management strategy changes by measuring the percent of firms making at least 
one change in each sales management strategy category and in aggregate; 2) 
measurement of the average number of changes made in each sales management strategy 
category and in aggregate. The sample population was 1,100 firms with 30 or more 
employees. The subjects were selected from a commercial source of Australian 
manufacturing firms. After the selection based on set criteria, 378 sales managers were 
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sent a pre-tested mail questionnaire. The response rate was 51%, resulting in 187 
questionnaires that could be categorized properly.  
 
The most relevant part of the Michael et al. (2003) publication is the model and how well 
grounded it is in earlier research. Benefits of the model are the inclusion of the six 
categories for sales management strategies with the addition of the three categories for 
product newness. Furthermore, the model builds perceptual-logical elimination of 
external factors. The limiting factors are first, that the research only indicates that things 
change and in which specific areas of sales management strategy this occurs. The missing 
pieces are the reasons for these changes being made, which ones are most important and 
most critical, and which of these changes is successful. This last issue is identified in the 
article and proposed as a recommendation for further research. Also, the market focus is 
in Australia and thirdly the subjects are cross-industry.   
 
The three publications discussed above included relevant models representing the main 
contribution to the formulation of the Preliminary Model, which is used in this research 
as a base for conducting case studies and expert interviews. They also provided important 
information to be used in both the formulation of the Research Model and for 
interpretations and recommendation of the results.  
 
3.2.2. Sales Organizational Effectiveness 
 
The concern here is new product launch, and as stated above, the constructs of the 
Preliminary Model and Research Model were chosen in preference to the construct 
developed within the new product adoption models. The reason for this was that the 
constructs in these models have been developed, tested and validated with learning about 
sales force strategy for new product launch as a main research goal, which fits well with 
the scope of this research. The following three scientific contributions within the research 
area of sales organizational effectiveness did however include very important constructs 
for the whole formulation process for the Preliminary Model and the Research Model.  
 
In the fourth key publication, identified within sales force effectiveness literature, Piercy 
et al. (1997) suggest that their model (see Appendix 1) is a summary view of the 
approaches shared by several studies in this research stream of sales organizational 
effectiveness (Piercy et al. 1997). The model proposes five categories of sales force 
operations that determine the sales organization’s effectiveness. The investigation shows 
that there are major differences between efficient and inefficient sales organizations. 
However, it is concluded that it is not easy to explain what determines these differences.  
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In the publication, some arguments are included to try to clarify how the construct of 
performance of salespeople is used in the effectiveness literature. The difference between 
“the effectiveness of the sales organization” and “the performance of salespeople” is 
explained in terms of effectiveness as the overall organizational outcome. Organizational 
effectiveness is usually measured as sales revenue, profit contribution, or the like. On the 
other hand, sales force performance is defined as the working behavior of salespeople and 
the results they achieve. High sales force performance is expected to contribute to the 
effectiveness of the sales organization. Other factors that may also influence overall 
effectiveness, outside the control of the salesperson, are factors such as competitive 
behavior, market potential, and market change. Piercy et al. (1997) argue, with support 
from earlier literature (Anderson and Oliver 1987; Challagalla and Shervani 1996; Oliver 
and Anderson 1994), that a salesperson’s behavior performance in such activities as 
planning sales calls and involvement in team-based selling may make a significant 
contribution to sales outcome performance and, in turn, sales organization effectiveness. 
It has also been found; with support from the literature (Babakus et al. 1996; Cravens et 
al. 1993; Cravens et al. 1992; Grant and Cravens 1996), that superior sales force behavior 
performance is directly related to superior outcome performance. 
 
The research by Piercy et al. (1997) collected data from 144 field sales managers in 
companies in the United Kingdom and the aim of the sampling plan was to include 
organizations in different environments, following an approach employed in other similar 
studies (Babakus et al. 1996; Cravens et al. 1993; Grant and Cravens 1996). The 
objective of the research was to find sales organizations with relatively high performance 
and to examine why differences exist. They formulated five more specific research 
questions to gain wider knowledge of the source of sales organizational effectiveness. 
The first question addressed the relationship between salesperson compensation (as a 
control mechanism) and sales organizational effectiveness. They found that the most 
effective sales organizations are those where salary is a high proportion of total 
compensation, but rarely comprises the total compensation package and that there is 
typically an incentive payment in the 5-25 per cent range while in less effective 
organizations the incentives element is lower. The second question addressed the 
salesperson characteristics associated with higher effectiveness and in this instance the 
result showed that the effective organizations are characterized by high salesperson 
motivation. Thirdly, for the question addressing the sales force performance that 
produces higher sales organization effectiveness, they found that high outcome 
performance stands out in terms of a characteristic of the highly effective sales 
organizations. Selling activity performance around sales presentation and technical 
knowledge are higher, but not significantly so, while non-selling activities, such as 
support, planning, adaptiveness, and teamwork are higher and significant. The fourth 
question addressed the sales management control practices that appear to be related to 
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higher effectiveness. Here the overall findings were that field sales managers spend 
significantly more effort on behavior-based control in effective organizations. The fifth 
question addressed the structural or organizational issues that provide a salesperson with 
the opportunity to achieve superior performance and higher sales organization 
effectiveness, where they concluded that organizational design is also an important driver 
for effectiveness in sales organizations. An interesting finding was that the units 
dedicated to the more effective group (better; sales volume, market share, profitability 
and customer satisfaction), were larger but they sold less per head from a smaller 
customer base, had lower new customer sales per cent and spent more time selling, and 
their selling costs ran substantially above the level of the other. Based on this, they 
concluded that if the real achievements in effectiveness are to be found, conventional 
metrics such as call rates and expense ratio, are not simply lacking insight, they may be 
positively misleading.  
 
Some of the identified benefits with the model developed by Piercy et al. (1997) are the 
proposed five categories for sales force organization efficiency and also the identified 
interrelations between these categories and sales organization effectiveness. The items in 
the model were developed and tested in earlier research (Cravens et al. 1993) and are 
grounded in the literature area of outcome and behavior performance in selling (Anderson 
and Oliver 1987; Oliver and Anderson 1994). The research has only been conducted in 
the United Kingdom market. The survey and the subjects of the research are cross 
industry as well as multi-type sales forces (generalists, product-market specialists and 
product-customer specialists), making it less relevant for the pharmaceutical industry 
targeted in this research. Also, the measurement of the sales organization is based on 
closing a deal, which is not possible to the same extent in the pharmaceutical industry. 
 
In the fifth publication, also identified within the area of sales force efficiency, Baldauf 
and Cravens (1999) define and examine sales organization effectiveness and hypothesize 
relationships between constructs, which they argue are potentially useful in explaining 
differences in effectiveness (Baldauf and Cravens 1999). Both salesperson and sales 
organization constructs are included in their model (see Appendix 1). They define sales 
organization effectiveness as a summary of organizational outcomes (e.g. sales, volume, 
market share, profit contribution, or customer satisfaction) to which the salesperson is a 
partial contributor (Churchill et al. 1997). The research is focused on field sales unit level 
instead of the entire sales organization, with respondents being field sales managers 
responsible for direct supervision of assigned salespeople.  
 
The study was conducted in Austria and the research methodology and employed 
research instrument were adopted for this market. An eight-page questionnaire was used 
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and responses were obtained from 159 sales managers in 79 companies giving a response 
rate of 39%.  
 
Baldauf and Cravens (1999) have developed five main hypotheses. Their work is based 
on earlier research (Beswick and Cravens 1977; LaForge and Cravens 1985; Ryans and 
Weinberg 1987). The first hypothesis suggests that the greater the extent of monitoring, 
directing, evaluating, and rewarding activities by field sales managers, the higher the 
level of sales unit effectiveness. They received mixed support for this hypothesis. There 
was stronger support on directing activities which gave significance over all four 
effectiveness variables. The second hypothesis, stating that field sales managers who are 
more satisfied with their unit’s sales territory designs will display relatively high sales 
unit effectiveness compared to managers who are less satisfied with the design, found 
strong support in the results. The third hypothesis was divided into four parts, being that 
the greater the extent that a sales organization’s salespeople have the following 
characteristics; intrinsic motivation; recognition motivation; sales support orientation; 
customer orientation, the higher the effectiveness of the sales unit will be. Intrinsic 
motivation and recognition motivation were found to be significant for all effectiveness 
measures. Sales support orientation was perceived to be significant in effectiveness 
measures 1, 2 and 4 and customer orientation only in effectiveness measures 2 and 4.  
The fourth hypothesis formulated as; higher levels of sales unit effectiveness will be 
found in organizations where salespeople display relatively high performance for the 
following aspects of behavioral performance: Technical knowledge; Adaptive selling; 
Teamwork; Sales presentation; Sales planning; Sales support, was found to have overall 
strong support for all aspects, with the exception of technical support and sales support. 
The fifth hypothesis, that higher levels of sales unit effectiveness will be found in 
organizations whose salespeople display relatively high outcome performance, gained 
strong support in the results. They concluded that the role of sales managers in many 
organizations is shifting away from command and control management toward a 
coaching style of management. Also, this study validates and reinforces previous studies 
with similar constructs. The study was conducted cross-industry and does not take into 
consideration the product’s position in the lifecycle. Furthermore, the study does not 
seem to address interrelations between the determinants.  
 
In the sixth key publication, and the third identified in the sales force effectiveness 
literature, Piercy et al. (1999) evaluates the determinants of sales organization 
effectiveness with the purpose of examining important relationships between sales 
management control, sales territory design, sales force performance and sales 
organization effectiveness (Piercy et al. 1999). In the article, the authors elaborate on the 
differences and similarities of sales organization effectiveness and sales force 
performance. According to their line of argument, the performance of sales 
 93 
 
representatives contributes to, but does not completely determine, sales organization 
effectiveness. The view is that salespersons performance should be restricted to factors 
under the control of sales representatives, whereas sales organization effectiveness 
assessments are overall results determined by many situational factors including sales 
representative performance. Piercy et al. (1999) refers to earlier research with empirical 
support to justify the suggestion that organizational effectiveness and salesperson 
performance are related but conceptually different constructs (Beswick and Cravens 
1977; Cravens et al. 1972; LaForge and Cravens 1985; Ryans and Weinberg 1979; Ryans 
and Weinberg 1987). Their findings support that the variations in sales organization 
effectiveness are explained by changes in the environmental factors (e.g. competition) 
and organizational factors (e.g. management control systems, advertising spending and 
brand image) as well as by salesperson factors, which are broader and include salesperson 
performance. 
 
The study was conducted among sales organizations in the United Kingdom. The data 
was collected using a postal questionnaire. The questionnaire used was adapted from 
instrument used in previous research (Babakus et al. 1996; Cravens et al. 1993; Grant and 
Cravens 1996). From the sent questionnaires 144 responses from 62 different sales forces 
were received (approx 25% response rate). 
 
The empirical research data collected showed that, overall, effective sales organizations 
are those that are both well-designed and have high performance sales forces. The 
research validates and reinforces previous studies with similar constructs. It also suggests 
that cultural differences may be determinative. Seven specific hypotheses were 
formulated and tested in the research. The first one argued that the higher the level of 
sales force behavioral performance, the higher the levels of sales force outcome 
performance, and received strong support in the results. High, positive correlations 
between outcome performance and the various components of behavioral performance 
were found. The second hypothesis suggested a positive association of the fact that the 
higher the levels of sales force outcome performance, the higher the level of sales 
organization effectiveness. The third argued that the greater the extent of behavior-based 
sales management control, the higher the level of salesperson behavioral performance. 
This third hypothesis received substantial support, with a few exceptions. However, the 
authors concluded that the evidence was convincingly strong for support of the 
hypothesis overall. The fourth suggested that, the greater the extent of behavior-based 
sales management control, the higher the level of satisfaction with the sales territory 
design, and the results showed support for the directing and evaluating components of 
sales management control, but not for the monitoring and rewarding components. The 
fifth hypothesis, i.e. the greater the extent of satisfaction with sales territory design, the 
higher level of sales organization effectiveness, did receive strong support. The sixth 
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suggested that the greater the extent of satisfaction with sales territory design, the higher 
the levels of sales force behavioral performance, also received strong support. The 
seventh and final hypothesis, i.e. that the greater the extent of satisfaction with sales 
territory design, the higher the level of sales outcome performance, received strong 
support in a significant correlation.  
 
The model (see Appendix 1) developed by Piercy et al. (1999) is valuable as it identifies 
many important aspects of the sales management factors. However, the model does not 
address the individual characteristics of the sales person as do the other models. The 
empirical research has been conducted as a cross-industry survey and covers the United 
Kingdom market. Furthermore, the product’s position in the lifecycle has not been taken 
into consideration.  
 
3.7. Conclusion 
 
Based on the review of Sales Force Management (including Selling), Product Launch, 
and Pharmaceutical Industry literature, it can be concluded that these areas are 
developing as research domains but that there exists limited research related to sales force 
management within the pharmaceutical industry and that it is almost non-existent for the 
Swedish market, which is the focus of this research. Even if the conclusion is that the 
research focus selected here – sales force readiness during new product launch in the 
pharmaceutical industry in Sweden – is as such unresearched, there are still interesting 
findings in the literature on which this research has been built.  
 
A key lesson learned is that there are strong indications that evidence, or at least rational 
discourse, does exist for issues when sales force management research is compared. To 
be able to better compare the outcome of research, the studied subjects should be 
homogenous in terms of the sales forces’ need for internal capabilities and know-how as 
well as to what extent their customers operations are conducted (Wotruba 1991). 
 
The broader area of the literature on the full discipline of Selling and Sales Force 
Management has increased substantially in the last decade and it has started to mature as 
a field (Baldauf et al. 2005; Dinu and Tachiciu 2009; Dong-Gil and Dennis 2004; 
McBane et al. 2003; Moncrief et al. 2000). It has also been concluded that even if there is 
a rapid increase in the number of publications, most of the research areas within selling 
and sales management are still in their infancy (Ingram 2004). There have been several 
efforts at writing overviews of the field of sales force management and selling. The 
overview publications have approached the field from somewhat different directions 
(Baldauf et al. 2005; Ingram 2004; Wotruba 1991). For example, Baldauf et al. (2005) are 
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making an effort to synthesize various sales management control research initiatives to 
guide the development of an agenda for further research. Of the articles identified by 
Baldauf et al. (2005) in the field of sales force management control, including empirical 
work, over half of the research knowledge came from data gathered in the United States. 
However, it was concluded that empirical studies have also been conducted in Europe 
(Austria, Germany, Greece, the Netherlands, and the United Kingdom), Australia, and 
Asia (China, India, and Malaysia). In another overview, Ingram (2004) makes an effort to 
identify critical issues in selling and sales management and attempts to illustrate how 
progressive sales organizations are responding to these issues and also presents related 
research opportunities. Ingram’s (2004) article and themes are very well grounded in a 
broad range of sales force management literature. Further, Wotruba (1991) has conducted 
an inductive analysis of how selling jobs change and evolve based on available literature. 
There have also been studies within the selling and sales management literature that 
examine this research fields’ productivity concerning publications as well as which 
authors and institutions that are most represented. They conclude that the field is growing 
and the importance of selling and sales management as a sub-discipline of marketing has 
increased substantially (Bush and Grant 1991; Bush and Grant 1994; Moncrief et al. 
2000; Swan et al. 1991). In addition, there is literature that has worked to index and 
classify the selling and sales management discipline (McBane et al. 2003).  
  
Much of the literature describing both the sales environment and new product launch for 
pharmaceutical sales forces is presented in Chapter 1, Introduction.  However, the main 
themes indentified and presented above, match well to the defined Preliminary Model 
and Research Model. The themes were; Sales Force Management Control; Internal and 
External Sales Force Collaboration; Sales Force Accountability and Decision Making; 
and Complexity of the Sales Environment (Baldauf et al. 2005; Ingram 2004; Wotruba 
1991), and these formed the structure for the literature review presentation, together with 
the six identified key scientific contributions which were presented in more detail. The 
overview of sales force management control summarizes an overview of two research 
paths in the sales management literature (Baldauf et al. 2005) which are of great 
importance for this research and are to a major extent visible in the Research Model. 
Here, the basic constructs have been developed by Oliver and Anderson (1987) and 
Jaworski (1988), but control within these constructs is defined differently. Under this 
framework of control, the relevant literature on sales forces management control for new 
product launch and in the pharmaceutical industry is added to make the focus more 
relevant. The other three main themes, also visible in the Research Model, were described 
as 1) collaboration, both internal and external to the sales organization, is necessary for 
survival and success; 2) the need for sales executives, sales managers, and salespeople to 
be held more accountable for their actions, decisions and outcomes; and, 3) sales 
environment is becoming more complex (Ingram 2004). When reviewing these main 
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themes, the literature concluded that it seems to be hard for the academic efforts to keep 
the research up to speed in the changing environment. It further implicitly argues for 
more micro studies of isolated situations, market dynamics, or conditions. This isolated 
focus seems to gain more specific learning and avoids for example the risk of cultural 
implications on the applied theories (Ingram 2004).   
 
Concerning the launch process literature, little detail is revealed of the new product 
launch process in relation to sales force, pharmaceuticals, or the geographical scope of 
Sweden. This limited literature base is also true for the area of pharmaceutical industry 
research, within the defined focus of this research. When reviewing the literature on the 
management of sales forces during new product launch with focus on pharmaceutical 
products, it was found that the topic was present in the literature but that it was very 
limited and had no collective focus. Examples and relevant literature directed towards 
sales force management and also marketing during launch within the pharmaceutical 
industry are spread in focus in terms of both what is investigated and how the research is 
conducted, i.e. no research or discourse stream could be clearly identified. The area was 
found to not follow any specific research stream related to the pharmaceutical industry 
and sales force, but could rather be divided into two separate groups. The first group is 
research with the intent to guide managers in the pharmaceutical industry, while the 
second group includes research that builds on already existing various research streams 
within the general sales management literature but where the pharmaceutical business is 
applied as a subject for investigation with the aim of drawing a generalized conclusion. 
The models and concepts developed and empirically tested are not sufficiently detailed in 
the research to form any sales force management or sales force readiness conclusions for 
the here assumed scope. However, two overall conclusions can be drawn from this 
literature review namely: 1) a new product launch process is of great value for any 
company, and the findings in this research might feed well into the marketing and sales 
domain of further exploration and research of the full new product process; 2) marketing 
and sales force execution, often referred to as a critical contributor in driving the success 
of new products, is confirmed as very important.  
 
The reviewed literature for the management of sales force during new product launch, not 
specific to the pharmaceutical industry, was found to have high relevance for this 
research. Primarily, the area of new product adoption in the sales force stood out as 
important, together with the area of sales force efficiency, and these areas contributed 
with six key scientific contributions. Another research stream in the literature, which 
added value, included some of the investigations from the new product development 
(NPD) literature. This research stream has some specific sales force or marketing-related 
studies: however, most are very brief and the conclusions are not specific enough to 
provide complete understanding of sales force management and launch. 
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The key scientific contributions, which have laid the foundation for formulating the 
Research Model and for defining Sales Force Readiness during New Product Launch, are 
found, as stated above, in the sales force management literature’s area of new product 
adoption and sales force efficiency. In addition to their interesting scientific findings, the 
six  models developed in these publications (Atuahene-Gima 1997; Baldauf and Cravens 
1999; Hultink and Atuahene-Gima 2000; Micheal et al. 2003; Piercy et al. 1999; Piercy et 
al. 1997) formed the scientific base in the formulation and synthesis of the Preliminary 
Model or generic model for sales force readiness during new product launch. As a final 
conclusion it can be stated that the literature in the area of the academic fields reviewed 
here, i.e. Sales Force Management (including Selling), Product Launch, and 
Pharmaceutical Industry, which has increased in quality and importance, the here 
assumed research is so far unresearched and its results should contribute with interesting 
and relevant learning to the existing literature.  
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4. DEVELOPMENT OF THE RESEARCH MODEL  
 
This chapter opens with a presentation of the Preliminary Model, which was derived from 
the relevant models identified during the literature review. Next, the outcome of the case 
studies and the expert interviews will be summarized, followed by the construction of the 
Research Model, comprising an adaptation of the Preliminary Model with the results of 
the case studies, expert interviews and findings in the literature. The chapter ends with a 
walkthrough of the Research Model and its variables.      
 
4.1. The Preliminary Model 
 
As described in the Research Approach chapter, the Preliminary Model has been derived 
and formulated from earlier scientific work. The model is developed as a generic model 
for sales force readiness during new product launch. The purpose of the Preliminary 
Model is to make sure that concept and constructs are grounded in the literature and also 
to form a broad base of variables for the identification, via qualitative research, of 
potential key success factors (variables in the later defined Research Model), which are 
relevant within the scope of this research. The detailed formulation process of the 
Preliminary Model is described in Appendix 2 and shown in a graphical representation in 
Figure 5.     
 
The formulated Preliminary Model is defined in three stages. The first stage, 
Circumstance, includes the two categories type of new product and market dynamics. The 
type of new product is understood here either as a new product type to the world and 
hence for the company, or that the product type is not new to the world but new to the 
company or that the product is only a revision or update of a product currently within the 
company (Micheal et al. 2003). The market dynamics are understood here as the nature 
of the market environment for the product at the time it was introduced (Hultink and 
Atuahene-Gima 2000).  
  
The second stage, Sales Force Factors, includes the six categories: sales force new 
product adoption, sales force behavior control, sales force outcome control, supervisory 
context, sales force organization design and salesperson characteristics. The categories 
are described as follows: Sales force new product adoption is defined as the 
commitment and effort the sales representatives put into the new product, emotionally, in 
interaction with other sales representatives and in the planning and execution phase 
(Hultink and Atuahene-Gima 2000). Sales force behavior control focuses on how the 
sales forces followed procedures and the evaluation of how they were held accountable 
for their actions (Hultink and Atuahene-Gima 2000). Sales force outcome control is 
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described as to what level performance goals were evaluated, weight towards tangible 
rewards and how the follow-up on these goals was handled (Hultink and Atuahene-Gima 
2000). Supervisory context includes the level of internal marketing around the sales 
force understanding of the background and rationale of the product, trust in supervisors 
and intra-company relationships, training received and the field attention that they were 
given (Hultink and Atuahene-Gima 2000). Sales force organization design is described 
as the way in which the sales force was organized, e.g. geographic, assigned towards 
customer type, in teams, etc (Micheal et al. 2003). Salesperson characteristics described 
the salesperson’s experience, ability to learn, solve problems and his/her preference for 
career success (Atuahene-Gima 1997).  
 
The third stage, Effect, is described by the category performance in selling a new 
product, which constitutes the extent to which the product has been successful in terms 
of market share, volume, uptake in the market, exceeding set targets, achievement of 
sales managers’ objectives and profit generation of old products (Hultink and Atuahene-
Gima 2000).  
 
 
 
Figure 5: Preliminary Model 
Generic model for sales force readiness during new product launch.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The variables and items identified in the Preliminary Model will be further explored in 
section 4.4, Construction of Research Model, in relation to the outcome of conducted 
Sales force New Product Adoption 
Type of new product 
Sales Force Factors
Circumstance
Sales force behavior control  
Sales force Outcome Control 
Supervisory Context 
Sales force Organization Design 
Sales-person Characteristics 
Market dynamics 
Performance in 
selling a new 
product 
Effect 
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case studies and expert interviews, both in terms of how they apply to a final Research 
Model and their base in the literature.  
 
The stages, categories, variables and related items of the Preliminary Model are presented 
in Table 7, together with its primary sources in the literature. 
 
 
Table 7: Details of the Preliminary Model  
The Preliminary Model (generic model for sales force readiness during new product 
launch) with its stages, categories, variables, items and primary source within the 
literature.  
 
 
Stage  Category/Variable Items Primary Source 
Circumstance    
 Type of new 
product 
• new-to-the-market and new-to-the-firm 
• not-new-to-the-market but new-to-the-
firm 
• not-new-to-the-market and revisions-to-
the-firm 
 
Micheal et al 
(2003) 
 
 Market Dynamics the nature of the market environment for this 
new product at the time it was introduced 
1. Stable – unstable 
2. Certain – uncertain 
3. Changes slowly – changes rapidly 
4. Predictable – unpredictable  
 
Erik Jan 
HULTNIK, 
Kwaku 
ATUAHENE-
GIMA. (2000). 
Sales Force  
Factors 
   
 Sales-force new 
product adoption 
a.      commitment 
 i.      Sales Rep emotionally attached to the 
success of this new product  
 
ii.      Achieving objectives for this new 
products has a great deal of personal 
meaning to the Sales Rep 
 
iii.      Sales Rep discusses this new product 
with other salespeople  
 
iv.      Sales Rep feel a strong sense of duty 
to ensure the success of this new product 
 
v.      Sales Rep would be willing to make 
further investment of my time and energy to 
support this new product 
 
b.      effort (formative scale) 
 
i.      Compared to other products you have 
sold, how much effort did the Sales Rep 
Erik Jan 
HULTNIK, 
Kwaku 
ATUAHENE-
GIMA. (2000). 
 101 
 
devote to this new product in: 
1. Prospecting for customers 
2. Planning sales calls 
3. Collecting market information 
4. Using market information 
5. Building customer relationships  
 
 Sales-force 
behavior control 
a.    Sales people are held accountable 
for their actions in selling the new product, 
regardless of results they achieve 
 
b.      Sales Rep’s supervisor monitors the 
extent to which salespeople follow 
established procedures pertaining to the new 
product 
 
c.       Sales Reps’ supervisors evaluates the 
procedures salespeople use to accomplish the 
task of selling this new product 
 
d.      Sales Rep’s pay increases and other 
tangible rewards depend on: 
 
d-i.      How well I follow laid down 
procedures pertaining to this new product 
 
d-ii.      My knowledge of specific 
procedures and practices in selling this new 
product 
Erik Jan 
HULTNIK, 
Kwaku 
ATUAHENE-
GIMA. (2000). 
 Sales-force outcome 
control 
a.       Performance evaluations of 
salespeople on this new product place 
primary weight on results 
 
b.      If Sales Rep’s performance goals for 
this new product were not met, the Sales Rep 
would be required to explain why 
 
c.       Sales Rep’s pay increases and other 
tangible rewards depend on: 
 
c-i.      How Sales Rep’s performance 
compares with the goals for this new product 
 
c-ii.      The degree to which Sales Rep have 
achieved the goals for this new product 
 
c-iii.      The degree to which Sales Rep have 
achieved specified outputs regardless of 
whether sales procedures were      
followed or not 
 
Erik Jan 
HULTNIK, 
Kwaku 
ATUAHENE-
GIMA. (2000). 
 Supervisory context a.     Internal Marketing 
 
i.      Sales Rep’s supervisory made sure 
every salesperson knew the incentives for 
Erik Jan 
HULTNIK, 
Kwaku 
ATUAHENE-
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selling this product 
 
ii.      Sales Rep’s supervisory explained the 
rationale for the introduction of this product 
 
iii.      Sales Rep’s supervisory explained the 
research behind the development of this new 
product 
 
iv.      Sales Rep’s supervisory explained 
how this new product fits in the company’s 
strategic objectives 
 
b.      Trust  
 
i.      Sales Rep’s supervisory and I have a 
sharing relationship. Sales Reps can freely 
share ideas and feelings about the work. 
 
ii.      Sales Rep can freely talk to his/her 
supervisor about difficulties they have at 
work and know that he or she will want to 
listen. 
 
iii.      Sales Rep’s supervisor and Sales Rep 
have made a considerable emotional 
investments in our working relationship 
 
c.       Training 
 
i.      Sales Rep received substantial training 
before assumed responsibility for selling this 
new product 
 
ii.      Sales Rep have spent a significant 
amount of time in training for this new 
product 
 
iii.      training program for this new product 
is first class 
 
d.      Field Attention  
 
i.      Sales Rep’s supervisor spends time 
with me in the field 
 
ii.      Sales Rep’s supervisor makes joint 
sales calls with me 
 
iii.      Sales Rep’s supervisor observes my 
performance in the field 
 
GIMA. (2000). 
 Sales force 
organization design 
a.       Geographic (are territories assigned 
geographically?) 
 
b.      Customer types (are customer types 
Micheal et al 
(2003) 
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assigned independent of or dependent on 
geography) 
 
 
c.       National Accounts 
 
d.      Independent Agents or Representatives 
 
e.       Product Groups 
 
f. Selling Teams 
 
 Sales-person 
characteristics 
a.       learning orientation of the salesperson 
 
b.       performance orientation of the 
salesperson 
 
c.      problem-solver: (intuitive vs. 
systematic) 
 
d.       career success of the salesperson 
 
e.      salesperson’s experience  
 
Atuahene-Gima 
(1997) 
Effect    
 PERFORMANCE 
in Selling a new 
product 
a.       to what extent have you been 
successful in 
 
i.      gaining significant market share for this 
new product? 
 
ii.      Generating high level sales volume for 
this new product? 
 
iii.      Quickly generating sales for this new 
product? 
 
iv. Exceeding sales targets set for this new 
product? 
          
v.      Assisting sales manager in achieving 
the objectives for this new product? 
 
vi.     Profits/enabling sales of “old” 
products?  
 
Erik Jan 
HULTNIK, 
Kwaku 
ATUAHENE-
GIMA. (2000). 
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4.2. Case Studies 
 
This section presents the findings from six case studies of product launches in the 
Swedish pharmaceutical industry, while the next section presents the results from six 
expert interviews. The case study findings were, together with the set of expert interviews 
and findings in the literature, the foundation for the qualitative adaptation of the 
Preliminary Model (generic model for sales force readiness during new product launch) 
into the Research Model. 
 
The cases conducted for this research were real pharmaceutical product launches in 
Sweden. The information is collected from two to four people involved in each product 
launch. The interviewed group always included both sales management and sales 
personnel. The six products were launched by three different companies. The companies 
in which the launch took place are Big Pharma companies operating with a marketing and 
sales affiliate in Sweden. For further details of the case studies’ products and companies 
selection criteria and profiles, see section 2.4, Formulating the Research Model.   
  
When conducting the case studies, a discussion guide was used, which was based on the 
Preliminary Model. As the interviews were conducted either face-to-face or over the 
phone, explanations and definitions of each variable and item could be included to secure 
full understanding of its meaning. This better secured the results as to which variables 
should be selected as being the most important. The case study summaries do not include 
any discussions or analysis by the author, and are entirely the perceptions and 
experiences of the participating sales personnel. 
 
The following text presents a summary of two of the six case studies. The documentation 
of the remaining four case studies is found in Appendix 4. After the presentation of the 
two case studies, conclusions are drawn and a summary of the results from all the case 
studies is presented in terms of the most important outcomes from each study based upon 
their perceived key success factors (or variables from the Preliminary Model) for a 
successful launch. 
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4.2.1. Case Study 1 (of 6): The Launch of an Antibiotic 
 
Sales Management saw this launch of their new antibiotic as a battle of having to do 
“more than the competitors”. They were referring to the share of voice, i.e. number of 
calls or recollection of core messages among physicians compared to their competitors. 
The physician target group for the product is identified as general practitioners. In 
addition, a handful of key experts, referred to as “gurus” in the antibiotic field were also 
targeted. The reason for including these experts as an initial target group together with 
the general practitioners is that the new product had only a few recommendations from 
the different counties; but needed to have many counties’ recommendations to be 
successful. The process for getting a recommendation was de-centralized and in every 
major town, different experts influenced the local recommendation. The need to have the 
experts’ support in being considered as first-line treatment was very important if the 
messages were to be effectively delivered to the general practitioners. (Type of Product) 
The product is considered fairly new to the market as well as new to the company. 
However, the company has experience of the therapeutic area, so there is no need for a 
steep learning curve. (Market Dynamics) The product is launched into a very 
competitive market. The market is seen as stable, certain, predictable and with slow 
change. The team agreed that both the type of product and the market dynamics are 
influential for formulating a launch strategy.   
 
When the launch team agree on a marketing theme for launching the product as a first 
choice recommendation, the campaigns and marketing and sales material are developed 
around this theme. The developed theme and story resonate well in the sales force. The 
market, in which the product is being launched, had been identified as having a great 
need of supporting material in the field, e.g. such as books. This material enforces the 
theme of the sales discussions with the physicians and generates access to more sales 
meetings.  
 
(New Product Adoption) The most important factor for generating commitment in the 
sales force is to get the sales personnel emotionally attached to the success of the product. 
“You need the sales representative to emotionally believe in the product and its success in 
the market, as it will show in every conversation with a customer, and if not shown, the 
sales call might actually hurt more than it helps”. The sales force consists of fairly young 
and active people. They are considered “hungry to sell”, so there is no perception that 
generating effort is an issue. The team also agrees that even though this might have been 
seen as an issue, the emotional component still far exceeds in importance. The emotional 
commitment is seen as generating the necessary effort. Product discussions among sales 
representatives are not encouraged, as the management want to ensure that sales 
personnel “stays on the message”.  
 106 
 
 
The company’s aim is to have and keep on generating a team spirit and a strong sense of 
belonging to the company throughout the launch. This team spirit generating effort is 
continuously integrated in all aspects of internal communications and interactions. The 
continuous message about being better than the competitors is primarily driven by the 
sharing of market data and success stories in the field. The company wants to be 
perceived as having a flat organization with delegated decision making. However, in this 
context, control mechanisms in the sales force are also perceived as very important.  
 
(Sales-force behavior control) The individual sales representative’s actions, especially 
when launching a new product, are considered to be of great importance. They should 
clearly be aware that they are accountable for their actions, regardless of whether their 
results are achieved or not. Also, the sales manager monitors them to make sure that set 
procedures are followed as this is seen as important for a successful launch. (Sales force 
outcome control) Incentives are not seen as very important for driving new launch 
success for this launch. Instead, the launch teams are allowed to set up internal sales 
competitions to generate excitement in the sales force. When setting the goals for a sales 
representative, it is seen as very important to follow up and to make sure that the person 
does explain why those performance goals were not met, if that turns out to be the case.  
 
 (Supervisory context) Given the contradictory situation of, on the one hand, the 
company’s wish for a perceived flat organization and an open company culture with 
delegated decision making and, on the other hand, the close monitoring of the sales 
representative’s behavior and actions, it is very important for sales managers to build 
trust among their representatives. Building trust between the sales manager and sales 
representative is perceived to be of outmost importance, especially in dialogues and 
discussions around difficulties at work. The ability of a sales manager to carefully listen 
to the sales representative and instill confidence by encouraging free expression of 
difficulties is seen as very important. Further, it is seen as crucial to a successful launch, 
to ensure that sales personnel understand the rationale for launching the new product. 
This covered all angles - the rationale from the overall company perspective, as well as 
that of the customers, patients and other stakeholders. The only importance of training is 
that the sales representatives spend significant time on the new product’s literature. The 
team also agrees that quantity of training is more important than quality, because it 
generates the right language appropriate in the therapeutic area and around the customers. 
Much training is carried out, both within selling skills and product-specific education. 
The sales managers are also encouraged to develop their own adapted educational 
sessions. However, in general, compared to some of the other factors driving the 
successful launch, training is not seen as crucial. 
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The sales manager’s effort in observing in the field is seen as important, helping them to 
stay updated about market conditions as well as around the control mechanisms that they 
are asked to monitor. The sales managers frequently travel in the field with each 
representative.   
 
(Sales force organizational design) Each sales manager has seven to ten sales 
representatives in his/her team. The sales force is organized according to geographical 
areas. There are no indications or thoughts as to whether the organizational set-up would 
matter to the success of the launch or not. (Other) However, the number of sales 
representatives is seen as important. During the launch the team has a sense that there are 
sufficient sales representatives at hand that they do not need to worry about the size of 
their sales force too much. Furthermore, it is emphasized that the sales representatives 
carry several old products and are expected to sell these as well. Having the new product 
first in every sales call is seen as being essential to drive success.  
 
Desirable characteristics for a salesperson are being seen as a driven individual who 
adheres to procedures and having a general good appearance and manners. It is perceived 
as most important that he/she solves problems in a systematic way according to set 
guidelines. Experience and career success, whether in the past or in the future, are seen as 
less important. The freedom to venture outside procedures is not desirable from a sales 
management viewpoint and the sales representatives are closely monitored. Learning 
orientation is good but not necessary. It is enough to learn the overall therapeutic area and 
the agreed messages. It is clearly stated that positive relationship building with customers 
is always important. The company sees all people as performance-oriented. 
 
(Performance in Selling a New Product) Exceeding sales growth targets is the key 
measure for success. Other important measures are market share and share of voice. Sales 
management wants to always be on top of any research measuring share of voice during 
the launch. Also seen as important is the fulfillment of the objectives by the sales 
managers and the means by which sales representatives assist in the fulfillment of these. 
Profit is also measured.  
 
Retrospectively, everyone in the team concluded that it was a successful launch, based on 
the fact that the sales targets were exceeded and the objectives set for the sales 
representatives and sales managers were met in the majority of cases.  
 
 
  
 108 
 
4.2.2. Case Study 2 (of 6): The Launch of an Acid Reflux Medication 
 
This PPI or acid reflux medication is launched in an environment with a clear market 
leader, which is perceived as the best and was almost a medical revolution at the time of 
its launch. Also, the competing company is much stronger in resources and has 
established relations with customers and other stakeholders. Now, the team is trying to 
launch a very similar product that is not seen as new to the market, but rather a “me-too” 
product. (Type of Product) Conversely, for the launch team and its company, the 
product and therapeutic area are new. The type of newness is an important influencer in 
how the launch strategy is formulated. The team has primarily planned for a price 
strategy. Their market research shows clearly that a 20-25% price reduction at launch will 
be feasible if they are to successfully enter and compete in the current environment. 
However, the global corporation, to which this marketing and sales affiliate belongs, does 
not approve of such a price decrease in the local market, so the team has to rely heavily 
on marketing and sales force messaging to complement the 10% decrease in price that 
they have approval for. (Market Dynamics) The market environment is considered 
stable, certain, slow to change and fairly predictable. The market environment is not a 
huge concern, based on its simplicity of nature and straightforward competitor 
environment with only one main player. At the time of launch, the main competitor is 
prepared and ready. The competitor is doing everything they can to interfere with the 
launch, e.g. they stop the launch product brochure, with the result that the launch team 
initially loses momentum. This is not, as agreed by the team, a good opening. One of the 
more resource-intensive tactics is the inclusion of 25 sites for clinical testing around the 
country, which is followed up with extensive pre-launch and launch activities. The main 
target group is general practitioners and some key “gastroentologists”. A secondary target 
group is the rest of the “gastroentologists” as well as practicing surgeons.       
 
As the launch team is faced with a very competitive landscape, or more correctly, a very 
strong competitor, “team-spirit” is perceived as easy to build. However, building this 
team-spirit is also seen as one of the most important factors during launch. (New Product 
Adoption) The team point out the paramount importance of the sales representatives 
being emotionally attached to the success of the product and that they are willing to make 
further investments of time and energy. Effort is seen as important in the sense of 
thoroughly prospecting for customers and quickly building customer relations. As the 
team perceives that relations are built by investing extra time and energy with the 
customers, these factors of the discussion are also related to the commitment factor of 
their willingness to make further investments of time and energy. A lot of work is done 
by management to build up excitement and emotional attachment to the product in the 
sales force. There are off-site meetings and a larger kick-off meeting as well as some 
educational efforts. As much as possible is done in a collective group and in teams to 
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reinforce the “we-spirit”. This “we-spirit” leads to greater motivation that the team is able 
to do better than its competitor. Within this, the management encourages sales 
representatives to discuss the product with others. However, these discussions between 
sale representatives are not seen as a very important component for driving a successful 
launch.  
 
During the early launch, one mistake is made and needs to be corrected. The mistake is to 
initially promote a sales representative to product manager. The person’s experience of 
product management was not sufficient to build a compelling enough story in the tough 
competitive climate. This became a burden in the sales force, but once corrected, things 
improved quickly and the launch was back on track.  
 
With the competitor being so strong, the behavioral aspects become very important from 
the point of view of how the sales representatives act in the field. (Behavior Control) 
Sales management put much effort into spending as much time as possible in the field 
together with the sales representatives. The primary focus is to monitor and adjust the 
actions of the sales personnel. The sales representatives are held accountable for their 
actions, and sales management continues to do this for each sales representative, 
regardless of whether their sales results are positive or negative. There are hardly any 
formal procedures or guidelines set up within the company for the sales representatives to 
follow. These are primarily made up “on the go” as they are agreed upon by sales 
management in relation to how things develop in the field. Given this lack of processes 
and guidelines, there is no effort from sales management to either monitor or evaluate 
this.  
 
(Outcome Control) To reinforce the group and team spirit, incentives and performance 
evaluations of salespeople are set up accordingly. Sales are the highest valued and 
important measure. Performance evaluations are primarily based on these sales results. 
Also, an important factor in the follow-up of performance is to let failed results be 
explained. This is done in a group environment, mostly for learning and best practice 
sharing. Pay increase is not perceived as being connected in a positive way to 
performance evaluations. Most incentives are collective and rewarded in the form of a 
better choice of, for example, internal conference locations and levels of luxury. Since 
most incentives are team-based and fairly simple, management does not spend time 
making sure that every sales representative knows or understands exactly how they are 
set up, but just assumes that they understand.  
 
(Supervisory Context) The product and therapeutic area is new for the company, so 
emphasis is placed on internal marketing of several aspects. As the competing product is 
well-established in the market, a lot of effort from management is put into explaining the 
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rationale of introducing the new product from many angles, e.g. what it means for 
patients, physicians and payers. The research effort and strategy behind the product is not 
emphasized as the product was not developed within the company. To some degree, the 
company’s strategies are explained, but it is not seen as very important. The focus on 
team-spirit and collective incentives makes the sales management assume that trust will 
be easy to build. Even though it is seen as easy to build, it is also viewed as being very 
important, so all aspects of trust between the supervisor and sales representative are 
emphasized, (i.e. they are encouraged to freely share ideas and feelings about work, 
freely talk about difficulties while knowing the supervisor will listen, and make 
considerable emotional investments in the working relationship). Trust is seen to be well 
established throughout the launch. Training in the product is not really well-organized; it 
is communicated as being important, but it is seen as on-the-job learning as the sales 
representatives build up field experience in the therapeutic area. Instead of training, a lot 
of time is spent by management in the field, focusing on joint sales calls and observations 
of performance.  
   
(Sales force organizational design) The sales force is organized in geographical teams, 
with two sales representatives collaborating within that area. The only matter of 
importance in sales force organizational design, is the fact that there are sales teams of 
two sales representatives for the same geographical area, (i.e. they have to collaborate 
and share customers). (Other) The number of sales representatives is seen as important 
for ensuring that the number of sales calls is better than or in line with competitors. While 
sales management wants to have many sales representatives, the senior company 
management wants to minimize costs to generate a good profit. Therefore, how to 
optimize the number of sales representatives is under continuous discussion within the 
company. During the launch, a co-promotion agreement is made with another company. 
As a result of this agreement, additional sales representatives are added to better meet the 
share of voice of the competitor. The focus on the new product in the sales calls is seen as 
very important and as a consequence, the sales representatives only sell the new product.  
 
(Salesperson Characteristics) The background of the sales representatives in the sales 
force differs as people are moved from other products within the company into the new 
product. There are no established recruitment processes and the characteristics of the 
salesperson that are seen as important are their problem-solving techniques and their 
ability to learn fast. The preferred problem-solving approach for the sales representative 
is to be intuitive and adaptable to the situation. As quoted from one sales manager, “with 
sales representatives that learn fast as they go and solve problems based on their intuition, 
even the customer sees the engagement”.   
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(Performance in Selling a New Product) Exceeding the sales targets is the primary 
measure of launch success. Also, with collaborating teams and incentives built in the 
same way, success is also achieved when sales representatives, together with their 
manager, achieve their objectives (how the sales representative assists the sales manager 
in achieving the objectives for the new product). Secondary measures are volume uptake 
and profit, but these measures are not monitored frequently or with any great interest 
from the sales force or launch team.  
 
The launch is considered a success by the launch team members as sales targets were 
exceeded and sales managers’ and their team’s objectives were met.  
 
4.2.3. Conclusions and Results from the Case Studies 
 
The six case studies, where a summary of the first two is presented above and a summary 
of the remaining four is presented in Appendix 4, gave strong indications of what was 
perceived as driving the success of a product launch. During the interviews, each case 
study pointed out the most important variables in the Preliminary Model in relation to 
what had been a successful product launch in their case. All the launches covered in the 
case studies were perceived as successful by the launch teams. Even though some of the 
launch approaches did differ between case studies, it was mostly found that the same 
variables were of great (or greatest) importance for achieving a successful launch. In 
Table 8 below, the most important variables (perceived Key Success Factors) identified 
in the case studies are presented and reported in a consolidated format. In addition, all the 
case studies confirmed the assumption that after studying earlier launches, it will be 
possible to conduct new launches with a higher probability of success. The following is a 
reflection on the company to which the product belongs and how it might impact the 
sales force and launch success. Also, a short reflection as to whether the product’s 
success is driven by the sales force or the medical benefits of the product. The next step is 
to discuss and validate the case study findings, with a selected group of industry and 
academic experts. This is the topic of the next section.  
 
 
The product launch and the company launching the product  
 
The conclusion from the results of the case studies is that the investigated companies 
launching the product are all similar in their operations, which is further confirmed by 
both the interviewed sales people and the experts. The case studies are all of products 
belonging to Big Pharma companies. These companies are global companies with 
marketing and sales affiliates executing the product launches. Even though the companies 
do not operate identically and differences are detectable, the impact on this research is 
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considered minimal. The only clear patterns that could be identified, as also agreed by the 
experts as having some relation with regard to the company to which the product 
belonged, were within the category of Salesperson Characteristics and related to problem-
solving, as “intuitive” seemed to be preferred in Company B and “systematic” within the 
other two companies. The experts drew the conclusion that this could be related to 
whether or not the company has well-defined procedures for the sales force. In the 
product launches which had highlighted following procedures as being important for 
successful launch, there still seemed to be very little focus on measuring and rewarding 
on how these procedures were followed. However, accountability for the sales 
representatives’ actions seemed to be an important launch success factor cross-cases, 
whether or not procedures were established. 
 
 
The product launch and the culture   
 
It is acknowledged that earlier research has shown that the culture is of importance, such 
as in organization effectiveness research where it is suggested that cultural differences 
have an impact (Baldauf et al. 2001a; Piercy et al. 1999; Piercy et al. 2004; Rouzies and 
Macquin 2003). However, as the scope of this research includes launched products by the 
homogeneous base of sales and marketing affiliates of Big Pharma companies operating 
in Sweden, any minor differences in culture should not impact these research findings in 
a significant way. This is also confirmed by the case studies above, with conclusion that 
the investigated companies all have similar operations, processes and culture. The 
cultural aspects are further discussed in the limitations and further research section (6.2.1. 
Limitations).  
 
 
The product launch and the product’s medical benefit 
 
It is interesting to reflect upon the question whether the actual sale of a pharmaceutical 
product is driven by its medical benefits or by sales force activities. It is most likely to be 
a combination of the two. However the findings in the case studies and the literature 
clearly suggest that sales success is sales force driven to a greater extent than driven by 
medical benefit. As described earlier under the importance of the sales force, Lilien et al. 
(1981) and Hahn et al. (1994) argue that detailing (sales calls) from sales representatives 
aimed at physicians is one of the most important components in the marketing mix for a 
pharmaceutical company and that for the pharmaceutical companies, the sales force 
activity is the primary source of promotion (Lilien et al. 1981; Manchanda and 
Chintagijnta 2004; Mizik and Jacobson 2004; Tengilimoglu et al. 2004). The literature 
conclude that, for a given medical condition, several different drugs or treatment choices 
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are available and therefore pharmaceutical companies must invest heavily in marketing 
and sales (Datamonitor 2007b) and that streamlining marketing and sales processes can 
fundamentally alter a new pharmaceutical product sales profile with incremental revenue 
of $500 million to $1 billion within five years of sales (Rao 2002). Rangaswamy et al. 
(1990), put the selling of pharmaceutical products in the category of a repetitive buying 
environment, which is defined as usually having short purchase cycles and competitive 
interchangeable products available. The consequence is that sales representatives must 
attempt to maintain a constant presence at the doctors’ offices (Rangaswamy et al. 1990). 
It is therefore argued that calling on customers is vital for maintaining sales of the 
product and in many situations the relationship between the sales representative and the 
physician has a positive impact on sales (Rangaswamy et al. 1990). One practical 
example among many others is the launch of the product Zoloft, which was the third 
product to be launched in its category, with an almost identical medical profile to its 
competitors, yet won the position as market leader within a few years (Legernaes 2003). 
It should be mentioned that this was done without any price differences. All this suggests 
that an assumption to exclude the medical benefit from this research will give reliable 
results in terms of the key success factor for sales force readiness during launch, 
especially with the chosen focus of the physician group being General Practitioners.  
 
 
Table 8: Consolidated results from the Case Studies 
The most important variables (or perceived key success factors) for a successful new 
product launch identified in the six case studies 
 
 Case #1 
(Company A) 
Case #2 
(Company B) 
Case #3 
(Company B) 
Case #4 
(Company B) 
Case #5 
(Company A) 
Case # 6 
(Company C) 
Type of New 
Product 
New-to-Market 
and  
New-to-Company  
 
– influenced 
launch strategy 
formulation 
Not-New-to-
Market  
and  
New-to-
Company  
 
– influenced the 
launch strategy 
formulation 
Not-New-to- 
Market  
and  
New-to-
Company 
 
– influenced 
the launch 
strategy 
formulation 
Not-New-to- 
Market  
and  
New-to- 
Company  
 
– influenced the 
launch strategy 
formulation 
Not-New-to-
Market  
and  
Not-New-to-
Company  
 
- High influence 
on strategy 
formulation 
Not-New-to- 
Market  
and  
New-to-
Company  
 
– influenced 
the launch 
strategy 
formulation. 
Market 
Dynamics 
Stable 
Certain  
Predictable 
Slow change 
 
– Influenced 
launch strategy 
formulation  
Stable 
Certain  
Predictable 
Slow change  
 
– Low impact 
on launch 
strategy 
formulation  
Stable 
Certain 
Predictable 
To be rapid 
change  
 
– Influenced 
launch strategy 
formulation 
Stable 
Certain 
Predictable 
Slow change  
 
– Medium 
impact on 
launch strategy 
formulation 
Stable 
Certain 
Predictable 
Slow change  
 
– High impact 
on strategy 
formulation 
Stable 
Certain  
Predictable 
Slow change  
 
– Influenced 
launch strategy 
formulation 
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Sales Force 
New Product 
Adoption 
Commitment  
 
Emotionally 
attached   
Commitment  
 
Emotionally 
attached 
 
Willing to make 
further 
investment in 
time and energy 
 
Effort  
 
Prospecting for 
customers  
 
Building 
customer 
relations  
Commitment  
 
Emotionally 
attached  
  
Commitment  
 
Emotionally 
attached 
 
Formulate 
objectives with 
personal 
meaning 
 
Effort  
 
Prospecting for 
customers 
Commitment   
 
Emotionally 
attached 
 
Strong sense of 
duty to secure 
success 
Commitment  
 
Emotionally 
attached 
 
Effort 
 
Building 
customer 
relations   
Sales Force 
Behavior 
Control 
Held accountable 
for their actions 
  
Follow 
established 
procedures  
Held 
accountable for 
their actions 
Held 
accountable for 
their actions 
Held 
accountable for 
their actions 
Held 
accountable for 
their actions  
Held 
accountable for 
their actions 
 
Follow 
established 
procedures 
Sales Force 
Outcome 
Control 
Explain outcome 
of goal when not 
met 
Evaluations 
primary weight 
on results 
 
Explain 
outcome of goal 
when not met.  
Explain 
outcome of 
goal when not 
met 
 
Pay increase 
compared with 
achieved goals  
Explain 
outcome of goal 
when not met 
 
Pay increase 
compared with 
achieved goals 
Explain outcome 
of goal when not 
met 
Evaluations 
primary weight 
on results 
  
Explain 
outcome of 
goal when not 
met 
Supervisory 
Context  
 
Rationale for 
introduction 
 
Freely talk about 
difficulties  
 
Time on training.  
 
Sales managers 
observation in the 
field 
Rationale for 
introduction 
 
Freely sharing 
ideas and 
feelings,  
 
Freely talk 
about 
difficulties.  
 
Emotionally 
invest in 
relationship 
 
Time spent with 
sales rep in field 
 
Sales manager 
makes joint 
calls 
 
Sales manager’s 
observations in 
the field 
 
Knowledge of 
incentives 
  
Rationale for 
introduction 
 
Freely talk 
about 
difficulties 
 
Sales managers 
observations in 
the field 
 
Rationale for 
introduction 
 
Freely talk 
about 
difficulties 
 
Sales managers 
observations in 
the field 
 
Rationale for 
introduction 
 
Freely talk about 
difficulties 
 
Sales managers 
observations in 
the field.  
Rationale for 
introduction 
     
How new 
product fit 
with company 
strategy 
 
Freely talk 
about 
difficulties   
 
Sales Force 
Organization 
Design 
Not of importance Selling teams Not of 
importance 
Not of 
importance 
Not of 
importance 
Not of 
importance 
Salesperson 
Characteristic
s 
Problem-solver: 
“systematic”  
Learning 
orientation 
 
Problem-solver: 
“intuitive” 
Learning 
orientation  
 
Problem-
solver: 
“intuitive” 
Problem-solver: 
“intuitive” 
 
Performance 
orientation 
Problem-solver: 
“systematic” 
 
Performance 
orientation  
Problem-
solver: 
“systematic” 
Performance Exceed sales Exceed sales Exceed sales Exceed sales Exceed sales Exceed sales 
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in Selling a 
New Product 
targets 
  
Sales manager’s 
objectives 
targets  
 
Sales manager’s 
objectives 
targets 
 
Exceed Profit 
target.  
 
Sales 
manager’s 
objectives 
targets 
 
Exceed Profit 
target 
 
Sales manager’s 
objectives 
targets 
  
Sales manager’s 
objectives 
targets 
 
Other Order of product 
in sales call 
An optimal 
number of sales 
people 
 
Order of 
product in the 
sales call  
An optimal 
number of sales 
people 
  
Order of 
product in the 
sales call 
An optimal 
number of sales 
people 
  
Order of 
product in sales 
call (product 
sold alone) 
An optimal 
number of sales 
people 
 
Order of product 
in the sales call.  
An optimal 
number of 
salespeople 
 
Order of 
product in the 
sales call 
Result of 
Launch  
Successful  Successful Successful Successful Successful Successful 
 
 
4.3. Expert Interviews  
 
This section presents the important step of using expert interviews to support the analysis 
of the case study results and to adjust the Preliminary Model into the Research Model. 
The experts’ views of the most important variables (perceived key success factors) in the 
Preliminary Model were identified here. These interviews were also used to identify and 
validate the variables within the Research Model and build the data collection instrument. 
The experts were selected from both academic institutions and from the pharmaceutical 
industry, where the latter were considered to be industry experts with experience of 
formulating sales force strategies. The method and expert profiles are described in 
Chapter 2, Research Approach. 
 
A general analysis and observations from the experts regarding the case studies are 
presented below and a summary of the expert interviews is presented in Table 9. The 
results from the expert interviews related to each variable in the Preliminary Model are 
presented in Appendix 5. These results are based on the experts’ analysis of the six case 
studies and their own expertise around each variable in the Preliminary Model. In 
addition, some literature findings were discussed during the interviews. 
 
All the experts concluded that the case studies provided good insight into the perceived 
key success factors for a successful launch. Furthermore, all of them expressed that the 
pattern was clear in guiding the choice of the proposed key success factors (variables), 
for sales force readiness during new product launch, for inclusion in the Research Model.  
 
The cases’ spread among therapeutic areas and the selected companies was agreed to be 
good. Experts 1, 2, 3 and 5 raised and, in consensus, agreed with the conclusion that the 
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actual company to which the product belonged to seems to have very little relation to the 
perceived key success factors. The company to which the product belongs, its culture and 
established procedures or lack of the same, as well as the medical features of the product 
being launched, could probably in many areas have an impact on a launch, as briefly 
discussed in the sections above. However, to find the key factors for success in the sales 
force, all the experts concluded that this should be disregarded and an adapted Research 
Model based on the Preliminary Model should still be very accurate in guiding key 
success factors, as established in this research.  
 
The experts gave their full support to the research scope of sales force operations 
targeting physicians who were General Practitioners. Experts 3, 4, 5 and 6 all had a 
background of actively launching pharmaceutical products targeted at both specialists and 
general practitioners. These experts all concluded that it is most likely that there would be 
a difference in the set of success factors for launch if the product were launched towards 
specialists versus General Practitioners. Therefore, the scope defined was perceived as 
very positive by the experts and the agreed conclusion was that the final results would 
most likely be more accurate with the distinction between the sales force target groups, 
being the physicians’ specialty. Also, the experts agreed with the assumption that by 
studying earlier launches, it should be possible to conduct new launches with a greater 
probability of success. 
 
 
Table 9: Consolidated results from the Expert Interviews 
The most important variables (or perceived key success factors) for a successful new 
product launch identified in the six expert interviews  
 
 Expert 1 Expert 2 Expert 3 
 
Expert 4 
 
Expert 5 
 
Expert 6 
 
Type of New 
Product 
Inclusion in 
research model  
Inclusion in 
research model 
Inclusion in 
research model 
Inclusion in 
research model 
No 
recommendation 
for inclusion nor 
protest against 
inclusion 
Inclusion in 
research model 
Market 
Dynamics 
Inclusion of 
stable/unstable 
and slow/rapid 
 
Exclusion of 
certain/uncertain 
and 
predictable/unpre
dictable 
Inclusion of 
stable/unstable 
and slow/rapid 
 
Exclusion of 
certain/uncertai
n and 
predictable/unpr
edictable 
Inclusion of 
stable/unstable 
and slow/rapid 
 
Exclusion of 
certain/uncertai
n and 
predictable/unp
redictable 
Inclusion of all Inclusion of 
stable/unstable 
and slow/rapid 
 
Exclusion of 
certain/uncertain 
and 
predictable/unpr
edictable 
Inclusion of all 
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Sales Force 
New Product 
Adoption 
Commitment  
 
Emotionally 
attached   
Commitment  
 
Emotionally 
attached   
 
  
Commitment  
 
Emotionally 
attached  
Commitment  
 
Emotionally 
attached 
 
Objectives has a 
great deal of 
personal 
meaning 
 
Effort  
 
Prospecting for 
customers 
Commitment   
 
Emotionally 
attached  
Commitment  
 
Emotionally 
attached   
 
  
Sales Force 
Behavior 
Control 
Held accountable 
for their actions 
  
 
Held 
accountable for 
their actions 
 
Monitor 
established 
procedures 
 
Evaluates 
established 
procedures 
Held 
accountable for 
their actions 
 
Pay increase 
depended on 
how they 
follow any 
processes as 
well as their 
knowledge of 
these 
Held 
accountable for 
their actions 
 
Monitor 
established 
procedures 
 
Evaluates 
established 
procedures 
Held 
accountable for 
their actions  
Held 
accountable for 
their actions 
 
Sales Force 
Outcome 
Control 
Explain outcome 
of goal when not 
met 
 
Evaluations 
primary weight on 
results 
 
Explain 
outcome of goal 
when not met. 
 
Pay increase 
degree to 
achieved goals 
Explain 
outcome of 
goal when not 
met 
 
 
 
 
Explain 
outcome of goal 
when not met 
 
Evaluations 
primary weight 
on results 
 
Pay increase 
regardless 
procedures were 
followed or not 
 
Explain outcome 
of goal when not 
met 
 
Pay increase 
degree to 
achieved goals 
Explain 
outcome of 
goal when not 
met 
 
 
Supervisory 
Context  
 
Rationale for 
introduction 
 
Freely talk about 
difficulties  
 
Receive 
substantial 
training before 
assuming 
responsibility  
 
Sales manager’s 
observation in the 
field 
Rationale for 
introduction 
 
Freely talk 
about 
difficulties.  
 
 
Sales manager’s 
observation in 
the field  
Rationale for 
introduction 
 
How new 
product fits in 
with company 
strategy 
 
Sales 
manager’s 
observation in 
the field  
Rationale for 
introduction 
 
How new 
product fits in 
with company 
strategy 
 
Knowledge of 
incentives 
 
Freely talk 
about 
difficulties  
 
Sales manager’s 
observation in 
the field  
Rationale for 
introduction 
 
Freely talk about 
difficulties  
 
Sales manager’s 
observation in 
the field 
Rationale for 
introduction 
     
Freely talk 
about 
difficulties  
 
Sales 
manager’s 
observation in 
the field 
Sales Force 
Organization 
Design 
Not included in 
research model 
Not included in 
research model 
Not included in 
research model 
Not included in 
research model 
Not included in 
research model 
Not included 
in research 
model 
Salesperson 
Characteristic
s 
Problem-solving 
style 
 
Career success 
Problem-solving 
style 
 
Problem-
solving style 
 
Problem-
solving style 
 
Problem-solving 
style 
 
Problem-
solving style 
 
Performance 
in Selling a 
New Product 
Exceed sales 
targets 
  
Sales manager’s 
objectives 
Exceed sales 
targets 
  
Sales manager’s 
objectives  
Exceed sales 
targets 
  
Sales 
manager’s 
Exceed sales 
targets 
  
Sales manager’s 
objectives 
Exceed sales 
targets 
  
Sales manager’s 
objectives 
Exceed sales 
targets 
  
Sales 
manager’s 
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Exceed Profit 
target.  
 
objectives  
 
objectives 
Other An optimal 
number of sales 
people 
 
Product order in 
sales call 
 
 
An optimal 
number of sales 
people 
 
Product order in 
sales call (and 
promoted with 
other products)  
An optimal 
number of sales 
people 
 
Product order 
in sales call 
An optimal 
number of sales 
people 
 
Product order in 
sales call (and 
promoted with 
other products) 
An optimal 
number of sales 
people 
 
Product order in 
sales call (and 
promoted with 
other products) 
An optimal 
number of 
sales people 
 
Product order 
in sales call 
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4.4. Construction of the Research Model 
 
The following text presents the implications of the case studies, expert interviews and 
findings in the literature on the Preliminary Model, in terms of subtraction, additions and 
choice of variables or items to form the Research Model to be utilized here. All 
adaptations to the Preliminary Model were made with the objective of qualitatively 
formulating a Research Model that includes a set of proposed key success factors for 
sales force readiness during product launch in the Swedish pharmaceutical industry, for 
testing with quantitative empirical data collection and statistical analysis.   
 
The results and the findings from the six case studies and from the six expert interviews, 
summarized in earlier sections, led to several implications and adaptations to the 
Preliminary Model. Overall, the final Research Model was, like the Preliminary Model, 
found to be described in three stages, but with a much more limited set of variables. Stage 
one, Circumstances, aims to find any relations with relevant strategic background 
information for strategy formulation. Within stage two, Sales Force Factors, the identified 
key variables and items from the Preliminary Model were transferred into variables in the 
Research Model under the new name, Key Sales Force Factors. If a specific item within 
any variable in the Preliminary Model was identified as a standalone key success factor 
for launch success, it was transferred to represent a variable in the Research Model. In the 
third stage, Effect, the core items identified for measuring success were transferred in to 
the Research Model.  
 
The findings in the literature review were consulted regarding the items identified as 
proposed key success factors by the experts and case studies, in order to validate them in 
relation to earlier scientific results and lessons learnt. However, as concluded in the 
literature review chapter, the literature on sales force management and selling during the 
launch phase is limited, which makes it less conclusive, however some guidance is 
provided in most areas.    
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Circumstances 
 
The specific and detailed implication on the Preliminary Model for the Circumstances 
stage is described below.   
 
Type of Product 
 
The type of new product is understood here as whether the product type is new to the 
world and also for the company, or the product type is not new to the world but new to 
the company or that the product is only a revision of a product currently existing within 
the company. The conclusion from the case studies and expert interviews is that this 
variable is of interest when formulating a launch strategy. Based on the collected results 
and conclusions, the variable will be used in the Research Model, with the aim of finding 
how the type of newness of the launched product impacts the success of the launch. 
 
The variable, type of product, was transferred as derived from the literature into the 
Preliminary Model and will also be used in the Research Model. The variable was based 
on and derived from a variable in the literature by Michael et al (2003). Michael et al. 
(2003) measured product newness in a direct way based on a combination of two states of 
market newness and two states of company newness. In their questionnaire, two 
dichotomous questions were used to obtain this information from each respondent about 
the firm’s new product, and the answers were coded to place each new product into one 
of three groups (new-to-the-market & new-to-the-firm, not-new-to-the-market & new-to-
the-firm, not-new-to-the-market & revision-to-the-firm). These groups were also aligned 
with earlier research conducted by Kleinschmidt and Cooper (1991), where essentially 
the same groups or categories were used (Kleinschmidt and Cooper 1991). Kleinschmidt 
and Cooper (1991) found that product innovativeness does have a significant impact on 
new product performance. However, this relationship between innovativeness and 
product performance was found to be U-shaped, showing that even non-innovative 
products perform well.  
 
The recommendation gained from discussions with the experts as to how to measure this 
variable was followed. The recommendation meant that the information was collected 
directly according to one of the three groups: new-to-the-market & new-to-the-firm; not-
new-to-the-market & new-to-the-firm; not-new-to-the-market & revision-to-the-firm.  
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Market Dynamics 
 
The market dynamics part of the Preliminary Model is understood to be the nature of the 
market environment for the product at the time it was introduced, i.e. intensive or no 
competition, and/or major market dynamics or not.  
 
Going back to the literature, the original variable (Hultink and Atuahene-Gima 2000) was 
developed for market volatility and the degree of unpredictability of new product’s 
market condition. The commercialization of pharmaceutical products is very uncertain 
(Rao 2000b). Hultink and Atuahene-Gima (2000) argue that in a more volatile market, 
salespeople are less able to forecast customer preferences, new introductions, price 
changes, etc. Support for this can also be found in Achrol and Stern (1988), where they 
note that market unpredictability creates adaptation problems for market participants 
(Achrol and Stern 1988). Hultink and Atuahene-Gima (2000) use this argument to 
support their hypotheses that “the positive effect of sales force new product adoption on 
selling performance is weaker when market volatility is higher”. This hypothesis was not 
supported in their empirical data. However, Atuahene-Gima and Micheal (1998) found 
that “salespeople who perceived the market environment as intensely competitive derived 
greater satisfaction from their efforts in new product selling than those who perceived the 
environment as less competitive”. Hultink and Atuahene-Gima (2000) measured market 
variable volatility through four items in the instrument; “state your opinion of the nature 
of the market environment for this new product at the time it was introduced: 1) stable – 
unstable, 2) certain – uncertain, 3) changes slowly – changes rapidly, 4) predictable – 
unpredictable”. This aimed to reflect the salesperson’s perception of the degree of 
predictability of the market conditions. As the original variable was set up to measure 
product adoption, while the aim of this research is to find the relations between the new 
formulated variables and product launch success, a modification was made, based on the 
results of the case studies and expert interviews. 
 
Variables in the Preliminary Model were adjusted based on findings, to some extent from 
the case studies and to a greater extent from the expert interviews. It was identified that 
the market dynamics variable should exclude the two items “certain – uncertain” and 
“predictable – unpredictable” based on the agreement that they were less relevant. On the 
other hand, the two items “stable – unstable” and “changes slowly – changes rapidly” 
were retained, but broken down into two separate variables. The item “stable – unstable” 
was agreed by all experts to fairly well include the meaning of the two items “certain – 
uncertain” and “predictable – unpredictable”. The two new variables were named 
stability of market, and market change rate. In the instrument, based on the experts’ 
recommendation, these variables will be measured as binary, asking the respondent 
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which situation or state applied at time of launch: stable or unstable; changes slowly or 
changes rapidly.  
 
Sales Force Factors 
 
The adjustments made to the stage Sales Force Factors in the Preliminary Model to adapt 
it for the Research Model are described below. 
 
New Product Adoption 
 
In the Preliminary Model, the variable is derived from Hultink and Atuahene-Gima 
(2000), who have adopted the Atuahene-Gima (1997) definition of sales force new 
product adoption as being the degree to which sales people accept and internalize the 
goals of the new product (i.e. commitment) and the extent to which they work hard and 
smart to achieve these goals (i.e. effort). Commitment is an attitude (acceptance and 
emotional commitment to make it a success), while effort is defined as energy, force 
persistence and intensity of actions (Atuahene-Gima 1997).   
 
Atuahene-Gima (1997) based the Commitment variable and its items on the work of 
House and Mitchell (1974), Mathieu and Zajac (1990) and Meyer and Allen (1991) 
(House and Mitchell 1974; Mathieu and Zajac 1990; Meyer and Allen 1991). The 
variable commitment in Hultink and Atuahene-Gima (2000) was measured by five items. 
The case studies identified four items within commitment seen as key success factors. 
These were: “sales representatives emotionally attached to the success of this new 
product”; “sales representatives would be willing to make further investment on my time 
and energy to support this new product”; “achieving objectives for this new products has 
a great deal of personal meaning to the sales representative”; and, “sales representatives 
feel a strong sense of duty to ensure the success of this new product”.  
 
The item formulated as to whether a sales representative was emotionally attached to the 
success of this new product was identified as a key success factor in all case studies, 
while the other three only appeared once in a case study as an identified key success 
factor for successful launch. The item for the importance of whether the sales 
representative discusses this new product with other salespeople was not identified in any 
case study.  
 
In the literature, Hultink and Atuahene-Gima (2000) found that new product adoption 
(combination of effort and commitment) is positively related to performance in selling a 
new product in the sales force, and that commitment correlates to performance by itself. 
Atuahene-Gima (1999) suggests that it is of key importance that the sales force “buys” 
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the new product in order to sell it effectively and efficiently. Atuahene-Gima and Micheal 
(1998) found that salespeople with a positive attitude to the potential of new products 
strengthen customer relations.  
 
The consolidated expert view from the interviews supported and endorsed the main 
findings in the case studies. All experts highlighted the item; “sales representatives 
emotionally attached to the success of this new product”, as the most important key 
success factor.  
 
Based on the findings in the case studies and recommendations from expert interviews 
and literature, it was decided to include the item “sales representatives emotionally 
attached to the success of this new product” in the Research Model. The item was defined 
as a variable and named Emotional Attachment. The variable was, after discussions with 
the experts, decided to be measured as binary, yes or no, in the instrument, with the aim 
of finding out how it contributes positively to a successful new product launch. It was 
decided that the other items be excluded from the Research Model.  
 
The variable effort in Hultink and Atuahene-Gima (2000) was measured by five items. 
The case studies identified two items within effort as potential key success factors: 
“effort devoted to the new product in prospecting for customers” and “effort devoted for 
the new product in building customer relationships (compared to other products the sales 
representative has sold)”.   
 
The three other items in the variable effort: “effort devoted to the new product in 
planning sales calls”; “effort devoted to the new product in collecting market 
information”; and, “effort devoted to the new product for using market information 
(compared to other product the sales representative have sold)”, were not identified in 
any of the case studies, nor by the experts, as potential key success factors.  
 
As mentioned above, in the literature, Hultink and Atuahene-Gima (2000) found that new 
product adoption (combination of effort and commitment) is positively related to 
performance in selling a new product in the sales force. Atuahene-Gima (1997) suggests 
that a combination of commitment and effort yields greater impact on selling 
performance than the impact of each factor alone. However, he still acknowledges that 
the two dimensions of the adoption construct could have independent effects on selling 
performance.  
 
Even though it is important to acknowledge “effort” in the sales force, based on the 
findings in the case studies and discussions with the experts, there is not enough support 
to include the variable “effort” or any of its items in the Research Model as a key success 
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factor for sales force readiness during new product launch. The line of argument by 
Hultink and Atuahene-Gima (2000) that effort without commitment for a salesperson is 
not enough for effective performance in new product selling, could be true regarding 
adoption of the new product, but could be questioned as a key success factor for launch 
and is taken out as a variable in the Research Model. It is possible to argue that effort is 
always important, maybe equally important, when selling a product, whether it is old or 
new and independent of industry. 
 
The line of argument for excluding the variable “effort” and its items from the Research 
Model gains strong support in the conducted case studies and in the expert interviews. 
Also, although Hultink and Atuahene-Gima (2000) found that new product adoption is 
related to new product selling performance, further support for excluding “effort” as a 
key success factor is derived from the details in their results. They found that 
commitment correlates to performance while effort is unrelated to performance (Hultink 
and Atuahene-Gima 2000).   
 
Sales Control  
 
Sales control systems refer to systems in which managers can align the behavior and 
actions of the sales force, or individual sales representatives, with the organization’s 
objectives (Bello and Gilliland 1997; Jaworski 1988; Jaworski and MacInnis 1989).  
 
Two types of control systems are identified in the literature: formal and informal 
(Jaworski 1988; Ouchi 1979). The variable here is in line with the formal type. The 
formal control system in the literature is further divided into behavior-based control and 
outcome-based control.  
 
Behavior Control 
 
The extent to which managers emphasize procedures and activities in monitoring, 
evaluating and rewarding the salesperson is included in a behavior-based control system 
(Anderson and Oliver 1987; Jaworski 1988; Ouchi 1979).   
 
In the Preliminary Model, the variable is derived from Hultink and Atuahene-Gima 
(2000) and adopted from the Atuahene-Gima (1997) conceptual model. Hultink and 
Atuahene-Gima (2000) measured the variable with four items; however, five items were 
initially included. In the Preliminary Model all five items were kept to fully reflect the 
earlier conceptual model by Atuahene-Gima (1997).  
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In the case studies, the items that were identified as key success factors were: 
“salespeople are held accountable for their actions in selling the new product, regardless 
of results they achieve”; and “my supervisor monitors the extent to which salespeople 
follow established procedures pertained to the new product”. The former item was 
identified in all case studies, while the latter only in two. None of the three other items 
gained support in the case studies for being a potential key success factor. From the case 
studies, the excluded items were: “my supervisor evaluates the procedures salespeople 
use to accomplish the task of selling this new product”; “my pay increases and other 
tangible rewards depend on how well I follow established sales procedures pertained to 
this new product”; and, “my pay increases and other tangible rewards depend on my 
knowledge of specific procedures and practices in selling this new product”.  
 
Some evidence in the literature has been collected by empirical studies suggesting that  
behavioral control of the sales force is one of the most important factors for a successful 
launch of a new product (Ramaswami 1996). Although Hultink and Atuahene-Gima 
(2000) argue that if a salesperson is committed and willing to extend his/her effort in 
selling a new product, he or she requires flexibility and discretion, leading to the 
hypothesis that behavior control weakens the link to adoption and selling performance. 
This was not supported significantly in their results, but they do suggest an appropriate 
sign that the hypothesis is supported. However, the item identified in all the case studies 
as a key success factor was the one item: “salespeople are held accountable for their 
actions in selling the new product, regardless of the results they achieve”, which had been 
excluded from their measurement instrument by Hultink and Atuahene-Gima (2000). The 
conclusion of an appropriate sign in the research from Hultink and Atuahene-Gima 
(2000) might thus be disregarded, or at least questioned. This argument is based on the 
findings from the case studies, as it may have been the case that the most important item 
was taken out of their research, and the results of a signal for a weaken relationship to 
selling performance might have been neutralized or may even have rendered opposite 
results if the item had been included. Furthermore, Lloyd and Newell (2001) 
acknowledge that a common problem with control mechanisms is the development of 
control systems which are too rigid and which conflict with the need for discretion (Lloyd 
and Newell 2001). However, Piercy et al. (1997) found evidence that in more effective 
sales organizations, field sales managers spend significantly more effort on behavior-
based control, which suggests support for the importance, even though it is acknowledged 
that behavior control in this study was measured by slightly different items. Other 
literature has also found a strong relationship between sales force behavioral performance 
and outcome performance when examining the relationship of the control system with 
design, sales force performance, and organizational effectiveness (Babakus et al. 1996; 
Baldauf et al. 2001a; Baldauf et al. 2001b). Also, Blackshear et al. (1994) found that 
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pharmaceutical representatives’ behavior, in a US firm, does have a positive effect on 
sales performance (Blackshear and Plank 1994). 
 
As to the items connecting pay increase with following procedures and knowledge of 
those procedures, Piercy et al. (1997) found that in more effective organizations, 
rewarding is concerned predominately with feedback and rewards, which are often non-
financial for the quality of activities as well as results. Also, Cravens et al. (1993) found 
that incentive compensation played a limited role in sales force control systems. They 
also suggest the need for a proper blend between field sales management and 
compensation control. These results suggest support of the case study findings for not 
including these items.  
 
The expert interviews supported the notion that behavioral control of the sales force is 
one of the most important factors for a successful launch of a new product. Their 
consolidated view concluded the case study findings. There were some different opinions 
about inclusion of the other items in the Research Model; however, they all agreed that 
the most important item was to hold sales representatives accountable for their actions 
regardless of the results. 
 
Based on the findings in the case studies, recommendations from expert interviews and 
findings in the literature, the item “salespeople are held accountable for their actions in 
selling the new product, regardless of results they achieve” was defined as a variable in 
the Research Model and named Activity Accountability. It was decided, after discussions 
with the experts, that the variable be measured as binary, yes or no, in the instrument, 
with the aim of finding how it contributes positively to a successful new product launch. 
It was decided to exclude the other items from the Research Model.  
 
Outcome Control 
 
As described in the literature, an outcome-based control system is a subgroup of a formal 
control system (Jaworski 1988; Ouchi 1979). Outcome-based control pertains to the 
emphasis managers place on results when monitoring, evaluating and rewarding the sales 
force and is used to directly influence the performance objectives set for the sales 
representative (Hultink and Atuahene-Gima 2000). It provides incentives for the sales 
representative to take responsibility for results (Jaworski 1988; Ouchi 1979), but it also 
transfers risk to the sales representatives, especially in terms of environmental conditions 
over which they have little or no influence (Ramaswami 1996).  
 
In the Preliminary Model, the variable is derived from Hultink and Atuahene-Gima 
(2000) and adopted from the conceptual model by Atuahene-Gima (1997). Hultink and 
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Atuahene-Gima (2000) measured the variable with five items: “performance evaluations 
of salespeople on this new product place primary weight on results”; “if my performance 
goals for this new product were not met, I would be required to explain why”; “my pay 
increase and other tangible rewards depend on how my performance compares with the 
goals for this new product”; “my pay increase and other tangible rewards depend on the 
degree to which I have achieved the goals set for this product”; and, “my pay increase 
and other tangible rewards depend on the degree to which I have achieved specified 
outputs regardless of whether sales procedures were followed or not”.  
 
In the case studies, three items were identified as key success factors: “performance 
evaluations of salespeople on this new product place primary weight on results”; “if my 
performance goals for this new product were not met, I would be required to explain 
why”; and, “my pay increase and other tangible rewards depend on the degree to which I 
have achieved the goals set for this product”. The first and third items were identified in 
two case studies each, while the second was identified in all of the case studies.  
 
In the literature, Hultink and Atuahene-Gima (2000) support that selling performance is 
stronger when outcome-based control is greater. They argue that the sales representatives 
might find a greater sense of commitment and effort in achieving their results under 
outcome performance based on the greater autonomy and flexibility this might give them 
in the selling process (Hultink and Atuahene-Gima 2000). Also, it is suggested that 
explicit market penetration objectives are important if the firm is to achieve a successful 
product introduction (Hultink and Robben 1999)  
 
Piercy et al. (1997) and Baldauf et al. (2001a) found that in more effective sales 
organizations, sales managers both monitor and discuss performance evaluations with 
salespeople, which can be argued to support the item “if my performance goals for this 
new product were not met, I would be required to explain why” as a key success factor.      
 
Moreover, Piercy et al. (1997) found that the most effective sales organizations are those 
where salary is a high proportion of total compensation, but rarely makes up the total 
compensation package and where there is typically an incentive payment in the 5-25 per 
cent range. Menguc and Baker (2003) first argue that the earlier research is inconclusive 
if outcome-based incentive improves sales force performance, and then concluded that it 
is important with a mix of both financial and non-financial incentives in the sales force 
(Menguc and Barker 2003). Also, Piercy et al. (2004) are, based on their findings, 
providing a warning for over-reliance on incentive pay for achieving results in the sales 
force, and argue that it can have a negative impact (Piercy et al. 2004). Elling et al. 
(2002) conclude that bonus for the pharmaceutical sales representative in the United 
States is around 25 per cent. Between 5-25 per cent could be considered fairly low 
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incentive pay (Elling et al. 2002), so only 5-25 per cent of incentive rewards depending 
on achieved goals in effective organizations would suggest support of the case study 
results that the third item is not a key success factor. However, it should be 
acknowledged that sales bonuses implemented by more developed compensation tools 
might change the importance of this in the future (Turner et al. 2007) as well as the with 
use of new sales competitions with pharmaceutical sales forces (Murphy and Dacin 
2009), which was not found during the here conducted data collection.   
 
The expert interviews supported the notion of flexibility and autonomy in the selling 
process; however, the insights given were much more focused on the flexibility of 
continuous adjustments of outcome control measures such as sales and market share, as 
these usually deviate greatly from what had been expected before and during early 
launch. Measuring strictly on early set outcome control measures might generate a lack of 
motivation in the sales force based on these measures’ incorrectness instead of the 
intended motivation of giving more flexibility in the process.   
 
The experts concluded in consensus, and in line with the results from the case study 
findings, that the most important item for successful launch was, “if my performance 
goals for this new product were not met, I would be required to explain why”. This would 
give the sales representative together with management a formal process to continuously 
update objectives. Two experts agreed with the first item identified in the case studies, 
while two other experts agreed with the third. Also, only one expert found the evidence in 
the case studies to be sufficient for including any other item in the research model.  
 
Based on the findings in the case studies, recommendations from expert interviews and 
findings in the literature, the item, “if my performance goals for this new product were 
not met, I would be required to explain why”, was chosen for inclusion in the Research 
Model. The item was defined as a variable and named Explanation of Unachieved Sales 
Goals. It was decided, after discussions with the experts, to measure the variable as 
binary, yes or no, in the instrument with the aim of finding how it contributes positively 
to successful new product launch. It was decided to exclude the other items from the 
Research Model. 
 
Supervisory Context 
 
Supervisory Context refers to several supervisory behaviors which could be exercised in 
order to improve the sales representative’s performance when selling the new product 
(Hultink and Atuahene-Gima 2000; Rochford and Wotruba 1996; Rochford and Wotruba 
1993). Based on concepts and findings in the literature; internal marketing, trust, training, 
and field attention were included in the Preliminary Model.    
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Internal marketing 
 
The extent to which the sales management explains the background and rationale behind 
the new product to the sales representatives is referred to as internal marketing (Hultink 
and Atuahene-Gima 2000). In the Preliminary Model the variable” internal marketing“ is 
derived from Hultink and Atuahene-Gima (2000) and adopted from the Atuahene-Gima 
(1997) conceptual model. Hultink and Atuahene-Gima (2000) measured the variable with 
four items: “my supervisor made sure every salesperson knew the incentives for selling 
this product”; “my supervisor explained the rationale for the introduction of this 
product”; “my supervisor explained the research behind the development of this new 
product”; and, “my supervisor explained how this new product fits in the company’s 
strategic objectives”.  
 
In the case studies, three items were identified as key success factors: “my supervisor 
made sure every salesperson knew the incentives for selling this product”; “my 
supervisor explained the rationale for the introduction of this product”; and “my 
supervisor explained how this new product fits in the company’s strategic objectives”. 
The first and third were identified in one case study each, while the second was identified 
in all of the case studies. The item “my supervisor explained the research behind the 
development of this new product” was not identified in any of the case studies.  
 
Earlier research suggests that sales representatives need to be convinced of both the 
benefits and the strategic importance of the new product as well as the fact that internal 
marketing reduces ambiguities among the sales force in terms of procedures and 
objectives (Anderson and Robertson 1995). Moreover, Hultink and Atuahene-Gima 
(2000) gained strong support for their hypothesis that sales force new product adoption 
on selling performance is stronger when internal marketing is higher, and that internal 
marketing was significantly related to selling performance by itself. They argue that 
managers should focus significant resources and effort on internal marketing before 
sending sales representatives to the field.  
 
With the strong support found in the case studies for the item of having the supervisor 
explain the rationale for the introduction of this product, the experts agreed that this 
should be a variable in the Research Model. The variable was named Introduction 
Rationale of the Product. It was decided, after discussions with the experts, that the 
variable would be measured as binary, yes or no, in the instrument with the aim of 
finding out how it contributes positively to successful new product launch. 
 
The experts did not fully agree about including the item about the importance of sales 
managers explaining how this new product fits in the company’s strategic objectives. 
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Two experts argued that it should be included while the other four agreed that with the 
results from the case studies, that it was of less importance and definitely not a key 
success factor. It was decided to exclude this item as well as the other two.  
 
Trust  
 
Trust refers to how willing the sales representative is to rely on the sales manager and 
whether the sales representative has confidence in an exchange relationship.  
 
In the Preliminary Model the variable is derived from Hultink and Atuahene-Gima (2000) 
and adopted from the conceptual model by Atuahene-Gima (1997). Hultink and 
Atuahene-Gima (2000) measured the variable with five items: “my supervisor and I have 
a sharing relationship, we can freely share our ideas and feelings about the work I do”; “I 
can freely talk to my supervisor about difficulties I am having at work and know that he 
or she will want to listen”; “if I share my problems with my supervisor, I know he or she 
would respond constructively and caringly”; “we both feel a sense of loss if we could no 
longer work together”; and, “my supervisor and I have made considerable emotional 
investments in our working relationship”.  
 
In all the case studies the item “I can freely talk to my supervisor about difficulties I am 
having at work and know that he or she will want to listen” was identified as a key 
success factor. In addition, in one case study the two items; “my supervisor and I have a 
sharing relationship, we can freely share our ideas and feelings about the work I do” and 
“my supervisor and I have made considerable emotional investments in our working 
relationship”, were identified as a key success factors. No other items were identified in 
the case studies.  
 
Hultink and Atuahene-Gima (2000), argued, based on earlier research involving  
interpersonal trust, that trust leads to greater commitment to the relationship and 
increased cooperation. However, they did not find support for any positive effect on sales 
force adoption of a new product on selling performance being stronger when trust is 
greater. On the other hand, Atuahene-Gima and Li (2006) found that sales management 
process control has greater potential than output control in building a salesperson’s trust 
in new product selling. Also, Piercy et al. (1997) found that in more effective sales 
organizations, the field managers spend significantly more effort on coaching and 
communicating, which can be argued as a way to build trust. 
 
The experts did have different notions of the importance of the items about trust, and 
whether it could be classified as a key success factor. However, with strong indications 
from the case studies, the majority of them recommended inclusion of the one item; “I 
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can freely talk to my supervisor about difficulties I am having at work and know that he 
or she will want to listen”. 
 
Based on the case study results and experts’ recommendation, the item; “I can freely talk 
to my supervisor about difficulties I am having at work and know that he or she will want 
to listen”, was included in the Research Model as a variable. The variable was named 
Speak Freely with Manager and it was decided, after discussions with the experts, to 
measure it as binary, yes or no, in the instrument with the aim of finding how it 
contributes positively to successful new product launch. The other four items were not 
included in the Research Model.  
 
Training  
 
“Training” is defined as the understanding and guidance received by the sales 
representative on the product and process of selling before assuming responsibility for 
selling the new product (Hultink and Atuahene-Gima 2000). In the Preliminary Model, 
the variable is derived from Hultink and Atuahene-Gima (2000) and adopted from the 
Atuahene-Gima (1997) conceptual model. Hultink and Atuahene-Gima (2000) measured 
the variable with three items: “I have received substantial training before I assumed 
responsibility for selling this new product”; “I have spent a significant amount of time in 
training for this new product”; and, “our training program for this new product is first 
class”.  
 
Only one case study identified the time the sales representatives spent in training for the 
new product as a key success factor. The experts interviewed also revealed that training 
was not seen as being very important for a successful launch. This down-prioritization of 
training came in the light of the much greater perceived importance of the other variables 
and items. Only one expert assumed a position where the opinion of training was a 
potential key success factor.    
 
The case study and expert interview findings gain support in some of the literature.  
Hultink and Atuahene-Gima (2000) not only found that training weakened the adoption-
performance linkage but also that that results suggested that salespeople who are 
committed to selling the new product may perform poorly when they receive more 
training. Their explanation is based on potential perceived “micro-managing” of the sales 
representatives. Rackham (1998), observed that companies often train the sales force on 
new features, while they should secure good coaching where the customer problems can 
be solved by the product instead of only pushing the features (Rackham 1998). This is 
also confirmed in research, which applies to pharmaceutical companies (Giacobbe et al. 
2006; Lloyd and Newell 2001). Further support for dismissing training as a key success 
 132 
 
factor when launching a product is suggested in the research results by Piercy et al. 
(1997), in which they found that salesperson performance in the area of technical 
knowledge, which includes knowing the product’s functions and applications as well as 
design and specification of the company’s product or services, is not significantly higher 
in more effective sales organizations.   
 
However, the literature is mixed in the area of training as research has also been 
conducted which suggests that effective training is important for new skills in selling, for 
sales representatives to understand responsibilities as well as to provide an indication of 
management commitment to the new product (Anderson and Robertson 1995; Atuahene-
Gima 1997).  
 
Based on the case studies’ and expert interviews’ clear signal that training should not be 
perceived as a key success factor together with results obtained from earlier literatures, 
the variable training and its items were excluded from the Research Model.     
 
Field attention 
 
Field attention is defined as the extent to which managers attend to the needs and 
problems of salespeople through field contacts such as making joint calls and being 
accessible to them in the field (Oliver and Anderson 1994). In the Preliminary Model, the 
variable is derived from Hultink and Atuahene-Gima (2000) and adopted from the 
Atuahene-Gima (1997) conceptual model. Hultink and Atuahene-Gima (2000) measured 
the variable with three items: “my supervisor spends time with me in the field”; “my 
supervisor makes joint sales calls with me”; and, “my supervisor observes my 
performance in the field”.  
 
In the case studies, all three items were identified as key success factors. The third item, 
managers’ observation of performance in the field, was identified in five case studies, 
while the two other items were both identified in one and the same case study.   
 
The literature is mixed about the importance of field attention, both pointing out its 
importance while also suggesting weak relations to selling performance. For example, 
Hultink and Atuahene-Gima (2000) found in their research that field attention weakens 
the new product adoption on selling performance when supervisors’ field attention is 
greater. In fact, their results showed that salespeople may become less effective with 
more field attention. They explain this with cultural differences regarding the acceptance 
of a “don’t look over my shoulder” attitude. Other research findings suggest that travel 
with sales representatives is important to demonstrate recognition of special problems 
with the new product and for managers to gain firsthand knowledge of the situation, for 
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them to be able to provide quality feedback (Anderson and Robertson 1995). Piercy et al. 
(1997) found that in more effective sales organizations, sales managers do monitor and 
place more emphasis on observing the performance of salespeople. This is also further 
supported in other studies (Baldauf et al. 2001a; Baldauf et al. 2001b). Futrell et al. 
(1976) found that the pharmaceutical salesman’s supervisor must provide information to 
the employee to enable the employee to know what is expected and to bring clarity into 
how the supervisor makes his or her evaluation (Futrell et al. 1976), which suggests 
further importance of being close to the sales representatives in the field. 
 
The experts all agreed with the findings in the case studies that the item involving the 
supervisors’ observation of performance in the field is a key success factor.  
 
Based on the findings in the case studies, the expert interviews and the line of argument 
in the literature around the importance of field attention, the item, “my supervisor 
observes my performance in the field”, was included in the Research Model. The variable 
was named Sales Manager Observations in the Field, and was, after discussions with the 
experts, decided to be measured as, “no”, “medium” or “high”, in the instrument, with the 
aim of finding how it contributes positively to a successful new product launch. The other 
two items were not included in the Research Model.   
 
Sales force organizational design 
 
Sales force organizational design is referred to as the deployment of the sales force, and 
in the Preliminary Model the variable is derived from Micheal et al. (2003). Micheal et al. 
(2003) used seven items when they measured changes in sales force management strategy 
of new product introductions: geographic (assigned geographical territories); customer 
types; national accounts; independent agents or representatives; product groups; selling 
teams; and, other.  
 
The literature indicates both that there exists some support as to the importance as well as 
some questions as to the importance of sales organization design, even with the 
suggestion that changes of structure might be harmful when launching a new product 
(Baldauf and Cravens 1999; Micheal et al. 2003; Piercy et al. 1999). In their research, 
Micheal et al. (2003) did not gain support for their hypothesis that “change in the sales 
management strategy category of organizational structure, size, and deployment is most 
likely to occur with new products”. Further in their research, they argue that 
organizational change can be disruptive for the sales force when new territories are 
drawn, particularly in the area of customer relations. Piercy et al. (1999) and Baldauf and 
Cravens (1999) concluded that sales territory design has received little interest in earlier 
research, and in their research, they found that the greater the extent of satisfaction with 
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sales territory design, the higher level of sales organization effectiveness (Baldauf and 
Cravens 1999; Piercy et al. 1999). However, it was found that sales force design was not 
a predictor for effectiveness (Baldauf et al. 2001a). Also, empirical data has shown that 
even if a significant number of sales force management changes are made when 
launching a new product, organizational changes are made least often (Wotruba and 
Rochford 1995). However if an organizational change is to be made, it is usually related 
to organizations with salespeople specialized by customer or product group, not divided 
by geography (Wotruba and Rochford 1995). Another study showed that more changes in 
the sales management mix could lead to a more successful launch. However, 
organizational change had not taken place to any great extent within these successful 
cases (Rochford and Wotruba 1996). It is suggested that the sales force design for 
pharmaceutical products has been set up to serve the more valuable customers, 
commonly identified with methods assessing the amount of prescriptions generated 
historically or with analogue products (i.e. existing products with as many similarities to 
the new product as possible), and that this is somewhat out-of-date and needs extended 
analysis in order to fine-tune according to product and customer specifics (Rao 2000a; 
Rao 2002). 
 
In the case studies, one item only in one case study, “selling teams”, was identified as a 
key success factor for new product launch. The experts did not support any of the items 
as being a key success factor. However, in both the case studies and in the expert 
interviews, a related set of key success factors were identified, which was triggered 
during the interviews under the sales force organizational design topic. The set of key 
success factors was defined as: “optimal size of the sales force”; “the new product being 
promoted alone or with other products”; and, “sales order of the new product when 
promoted together with other products”. The literature confirms that the sales force 
structuring decision is related to the issues of sales force size and sales effort deployment 
and that is an important managerial concern (Lilien et al. 1981; Manchanda and 
Chintagijnta 2004; Rangaswamy et al. 1990). None of these related specific items were 
included in the Preliminary Model, however guiding support was found in the literature, 
as described below.  
 
The first factor, related to sales force organizational design and identified as a key 
success factor, was the question of size of sales forces and how this could be optimized. 
A main reason for this being such an important managerial question, according to the 
expert interviews, is the high impact on profit, as the sales force is one of the, or indeed 
the highest, cost elements for the company as a whole during launch. The cost of sales 
force as a managerial issue is also raised as an overall issue for companies and 
particularly for pharmaceutical companies in the literature (Baldauf and Cravens 1999; 
Blackshear and Plank 1994; Corcoran et al. 1995; Cravens 1995; Elling et al. 2002; 
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Kotler 2000; Manchanda and Chintagijnta 2004; Piercy et al. 1999; Rangaswamy et al. 
1990). Piercy et al. (1999) found that too many or too few salespeople where needed, will 
influence what salespeople do (behavioral performance) as well as the results they 
achieve (outcome performance). Situations like this could lead to extreme role conflict, 
which has been identified as a source of psychological stress linked to lower levels of 
salesperson satisfaction and performance (Churchill Jr et al. 1985; Piercy et al. 1997; 
Rangaswamy et al. 1990; Sager 1994). Piercy et al. (1997) found empirical evidence, in 
terms of sales unit size and staffing, that more effective sales organization managers see 
far less scope for improving performance by changing the number of salespeople, while 
in the less effective organizations the satisfaction with headcount is markedly less. 
Manchanda and Chintagijnta (2004) raise the issues around diminishing return on sales 
calls for the pharmaceutical representative to physicians, also referred to as “over-
detailing”. This is further supported in the literature (Elling et al. 2002). By “over-
detailing” they mean “more sales calls than optimal” and prove this as true in many 
categories by empirical testing. This suggests that the more effective sales organizations 
may be closer to being right-sized. Piercy et al. (1999) suggest that effectiveness cannot 
be increased by just adding further salespeople to sales units. Even though, as an 
interesting note, the number of pharmaceutical sales representatives doubled in the 
United States between 1995 and 2001 (Elling et al. 2002). Another interesting conclusion 
from Piercy et al. (1999) was that if a firm advocates a customer-oriented relationship, 
selling could very well inhibit the sales behavior desired, simply by there being too many 
customers assigned to each sales representative. 
 
The second factor, related to sales force organizational design and identified as a key 
success factor, was whether or not the new product was being promoted with other 
products. The experts strongly advise including a variable investigating the importance of 
promoting the new product alone or with other products. In the pharmaceutical sales 
forces, the practice has often been that more than one drug is sold during a sales call 
(Mizik and Jacobson 2004), but it is becoming more common that one or two products 
are the scope in the sales call (Elling et al. 2002; Manchanda and Chintagijnta 2004). 
This is also highlighted in the literature in terms of when a major new product is being 
launched, it might be beneficial to create a special sales force for that product, in order to 
give it necessary coverage as well as to ensure that the older products receive enough 
attention and focus (Rangaswamy et al. 1990). Rangaswamy (1990) gives an example of 
a pharmaceutical company splitting their one sales force into two when launching their 
new blockbuster. Further, selling multiple products might be a major constraint with 
limited access and time to spend with the physicians and a particular mix of products in a 
sales force (Rangaswamy et al. 1990). There is also cross-industry literature that suggests 
that a broad product assortment has a positive impact on new product performance 
(Hultink and Robben 1999).  
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The third factor, related to sales force organizational design and identified as a key 
success factor, was the sales order of the new product when the decision is made to sell 
multiple products with the same sales force. The experts strongly advised including a 
variable to investigate the importance of the order in which the product is sold in the sales 
calls, specifically whether it is first or not. Even if companies might see the benefits, (e.g. 
customer access with split sales forces), it might limit profitability (Rangaswamy et al. 
1990). The facts that sales force focus is one of the core decisions in most organizations 
and that a pharmaceutical sales force usually promotes between two and four medically 
sophisticated products (Rangaswamy et al. 1990), also highlight the importance of this 
success factor if the choice is to promote several products together with the new one 
within the same sales force.  
 
Based on the case studies and expert interviews’ clear signal about the items in the 
Preliminary Model for sales force organization design not being perceived as key success 
factors while at the same time receiving support in the results of some earlier literatures, 
the variable “sales force organization design,” and its items in the original format were 
excluded from the Research Model. However, based on the findings in the case studies 
and expert interviews and with strong support from the literature, three new variables 
were added to the Research Model.  
 
The first added variable was named Numbers of Sales Representatives. The 
recommendation from the experts, in order to investigate the optimal number of sales 
representatives, was to collect data in terms of how many sales representatives were used 
during launch. The limitation could be argued that the results will be very specific to the 
market investigated. However, it might also be argued that in a market with conditions 
similar to the one to be tested (General Practitioners in Sweden), other markets should be 
able to draw conclusions based on size of the population targeted with the product. 
Further, it could be debated as to whether this would be different per therapeutic area or 
product category even in the pharmaceutical market in Sweden. However, with a 
homogenous group such as the General Practitioners, being the target population here, it 
is argued that the same guidelines about sales force size could be directive for all 
therapeutic areas and product categories, aimed at this customer group.  
 
The second variable added was named Promoted with Other Products. This variable 
should investigate how a successful launch is positively impacted dependent on whether 
the product is sold alone or together with other products. The recommendation from the 
experts was to collect data binary, in terms of the new product being promoted alone or 
together with other products.   
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In the case of the product being sold together with other products, a third variable was 
added to the Research Model. This was named Product Order in Sales Call, and the 
experts recommended limiting the collection of data to asking whether the product was 
first or not first in the sales call.     
  
Salesperson Characteristics 
 
In the Atuahene-Gima (1997) article, a set of salesperson characteristic propositions are 
developed for the adoption of a new product in the sales force. Salesperson characteristics 
are described by Atuahene-Gima (1997) as the salesperson’s experience, ability to learn, 
solve problems, performance orientation, and his/her preference for career success.  
 
All case studies found problem-solving style to be a key success factor; however, both 
the intuitive and the systematic problem-solving style were identified. The intuitive 
problem-solving style was preferred in three case studies and systematic in the other 
three. Learning style and performance orientation were also identified as key success 
factors in two case studies each. The other items did not receive any support in the cases 
studies.  
 
The experts concluded that the salesperson characteristics: “learning orientation”; 
“performance orientation”; and, “preference for career success”, were too generic to have 
any impact on launching a new product versus selling an old product or be a key driver 
for new product success. These were seen as basic criteria for any salesperson’s success. 
The experts recommended not including any of these variables in the Research Model. In 
the literature, specific to pharmaceutical sales representatives’ characteristics, criteria 
such as the ability to close sales, the degree of service orientation, knowledge of the 
company and its products and its customers, personal appearance, gender, age, and ability 
to learn and think analytically are seen as reasonably important for increasing results of 
individual sales calls. However, these attributes are seen as a more qualitative dimension, 
which should be taken into account by managers when hiring and managing the sales 
force (Parsons and Abeele 1981; Tengilimoglu et al. 2004). Further, Sager and Ferris 
(1986) concluded that the characteristics of good pharmaceutical sales representatives 
include a person being warm (empathic), easy-going (socially oriented) and cooperative 
(approval seeking), which they argued to be in line with earlier research. These findings 
are considered to support the experts’ view of being too generic to be characteristics to be 
included as key factors for success sales force readiness during new product launch.  
 
Concerning “salesperson’s experience”, some discussions took place among the experts 
about its potential relevance as a key success factor. Based on the fact that none of the 
case studies identified it as a key success factor, it was recommended by the experts that 
 138 
 
it be excluded from the Research Model. Also, Atuahene-Gima and Micheal (1998) 
found that their hypothesis, “that salespersons with greater experience will derive greater 
satisfaction and performance from their efforts in new product selling than those with less 
experience”, was not only wrong but also supported a contrary hypothesis. Some 
literature found general relevance of experience for sales representative performance 
(Parsons and Abeele 1981; Tengilimoglu et al. 2004), but it could only be proven to be 
marginally significant in a more attitudinal empirical study with pharmaceutical sales 
representatives (Tengilimoglu et al. 2004). Further, there are also arguments in this 
literature stating that sales representatives with long experience may be less willing to 
adapt to new situations (Dong-Gil and Dennis 2004), which can be seen as the case when 
launching a new product.  
 
The greatest interest from the experts was generated around finding out how problem-
solving style positively influenced the success of a new product. Even though all experts 
thought, based on experience, that the systematic problem-solving style would be 
preferred over intuitive problem-solving, their recommendations were based on the case 
studies’ results and their notion of problem-solving style as being very important, and 
suggested having both the intuitive and the systematic style tested. 
 
In the literature of innovative behavior, there are arguments for two problem solving 
styles: systematic and intuitive (Jabri 1991; Scott and Bruce 1994).  
 
Systematic problem-solving style is defined as using rationality and logic, following a set 
of routines and habits within disciplinary boundaries. Some literature suggests that the 
systematic problem-solver is likely to generate conventional solutions (Jabri 1991; Scott 
and Bruce 1994). Atuahene-Gima (1997), argues that systematic problem-solving is less 
likely to lead to success in new product selling and, hence, is likely to have a greater 
propensity for dysfunctional behavior in selling.  Atuahene-Gima (1997) formulated the 
following proposition; “The greater the degree of systematic problem-solving style of the 
salesperson (a) the lower the adoption of new products and (b) the greater the 
dysfunctional behavior in selling”. This proposition was not tested empirically, which 
makes it hard to draw any conclusion of its correctness.   
 
Intuitive problem-solving style is defined as giving little attention to rules and 
disciplinary boundaries, with greater propensity to collect and process information from 
different sources, act on intuition and generate novel solutions to problems (Jabri 1991; 
Scott and Bruce 1994). Atuahene-Gima (1997) argues that selling new products entails 
greater uncertainty than selling existing products since it requires the use of novel 
solutions for customer problems. Atuahene-Gima (1997) formulated the following 
proposition; “The greater the degree of intuitive problem-solving style of the salesperson 
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(a) the greater the adoption of new products and (b) the lower the dysfunctional behavior 
in selling”. This proposition was not tested empirically, with the implication that it is not 
easy to draw any conclusion as to its correctness. As intuitive problem solving could be 
seen as more participative, research has found that pharmaceutical sales representatives in 
the United States had increased commitment when increased participative decision-
making occurred (Futrell et al. 1976), which might be seen as supportive. 
 
One argument is that the match between the problem-solving style and the task 
determines employee performance (Payne et al. 1990). Scott and Bruce (1994) found that 
a predicted positive relationship between intuitive problem-solving style and innovative 
behavior was not supported. Also, they found that systematic problem-solving style is 
negatively related to innovative behavior of employees. A non-innovative behavior in the 
sales force when launching a product was supported by the experts. The experts argued 
for support of a preferred systematic problem-solving style, and, in line with some of the 
case studies, that to succeed with a new product launch, it is desired to have non-
innovative behavior in the sales force, to secure that the core message is delivered in a 
consistent way and that problems which are taken care of in a systematic manner also 
reinforce a consistent core message.  
 
Based on the findings of the case studies, the expert interviews and the line of arguments 
of its potential impact in the literature, the “problem-solving characteristic” was included 
in the research model. The variable was named Problem Solution Approach, and it was, 
decided after discussions with the experts, that it would be measured as either “intuitive” 
or “systematic” in the instrument with the aim of finding how the different styles 
contribute positively to successful new product launch and which one is preferred. The 
other salesperson characteristics were not included in the Research Model.   
 
Performance in Selling a New Product 
 
The construct of “performance in selling a new product” is similar to the “sales 
organization effectiveness” and the “new product success” constructs. Sales organization 
effectiveness has been defined as a summary evaluation of overall organizational 
outcomes, which may refer to the entire sales organization or an organizational subset; 
such as region, district, territory or customer group (Churchill Jr et al. 1985). According 
to some literature, the most frequently used measures of sales organizational 
effectiveness and new product success are total sales volume, followed by market share 
and profit (Baldauf and Cravens 1999; Cooper and Kleinschmidt 2000; Hultink and 
Robben 1999; Piercy et al. 1999).  
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The variable in the Preliminary Model is derived from the research variable from Hultink 
and Atuahene-Gima (2000). The items belong to the “performance in selling a new 
product” category. Hultink and Atuahene-Gima (2000) build their items on the work of 
Sujan, Weitz and Kumar (1994) (Sujan et al. 1994). The variable has six items: (To what 
extent have you been successful in): “gaining significant market share for this new 
product”; “generating a high level of sales volume for this new product”; “quickly 
generating sales for this new product”; “exceeding sales targets set for this new product”; 
“assisting sales manager in achieving the objectives for this new product”; and, 
“exceeding profits and/or enabling sales of old products”. These measures seem to fit 
well with the overall literature of measuring sales force performance, but it is also 
acknowledged that there are many ways of measuring new product success, such as their 
impact on the firm; being seen as “great” technical success or advancement, etc. (Cooper 
and Kleinschmidt 2000; Hultink et al. 1999; Hultink and Robben 1995). It is suggested 
that there are over 75 different measures of new product performance in the literature 
(Griffin and Page 1993; Griffin and Page 1996). 
 
The conclusion from the case studies was that the item, “exceeding sales targets set for 
this new product”, was seen as the most important measure and was identified by all case 
studies, and that the item, “assisting sales manager in achieving the objectives for this 
new product”, was identified in five of the case studies, and was also seen as important 
for measuring new product success. In addition, “exceeding profit target for the new 
product” was identified in two case studies. The other items were not seen as important 
measures.  
 
The expert interviews concluded that exceeding the sales target and meeting the 
manager’s objectives were the two most important variables for measuring new product 
launch success. Exceeding profit target was also seen as important, however the experts 
highlighted that it is very difficult to use this measure in a correct way as the real profit 
numbers might not be known by any of the subjects interviewed. This is based on many 
factors identified, (e.g. a new pharmaceutical product is often a global product, produced 
to supply many markets), which makes it hard to estimate the exact numbers for matters 
like cost of goods, shipping etc, as this information may only be available to upper 
management or finance and not to persons at sales manager or even sales executive level. 
Collecting profit data was perceived as potentially misleading and the recommendation 
was to collect the data from the subjects in form of the two items exceeding sales target 
and meeting the managers’ objectives. However, to define launch success, this should be 
positive for the first two consecutive years in order to more accurately measure a 
successful launch.  
 
 141 
 
There was also a recommendation from the experts to validate these more subjective 
launch success measures with more objective third party data. Based on this, a decision 
was taken to increase the quality of the classification of a successful launch in this 
research. More objective market sales numbers and market shares from a third party 
database would be used as a “validation” of the more subjective items (“exceeding sales 
targets set for this new product” and “assisting sales managers in achieving the objectives 
for this new product”).    
 
By using third party sales and market share data as above, a launch that was classified 
successful, (i.e. as exceeding its set sales targets, as well as having the sales force 
successfully assisted the sales managers in achieving the objectives), could be validated 
by the relative increase in sales and market share during the first four years (or two to 
three years for later launches), using data from a different source.     
 
This variable in the Research Model, kept its original name Performance in selling a new 
product and was agreed to be measured with the items: “exceeding sales targets set for 
this new product (year 1 and year 2)”; “assisting sales managers in achieving the 
objectives for this new product (year 1 and year 2)”; and, to be classified as a successful 
launch, more objective third party sales numbers and market shares should show a clear 
growth trend over years one to four.   
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4.5. The Research Model  
 
This section presents the final Research Model and its variables as well as the operational 
questions and instrument used to investigate key success factors for sales force readiness 
during new product launch in the Swedish pharmaceutical industry. See Figure 6 for a 
graphical presentation of the Research Model. Based on the analysis of the conducted 
case studies, the expert interviews and findings in the literature, the Research Model was 
finalized and the operational data collection instrument developed. The data collection 
instrument can be found in Appendix 6. The final model and its variables have strong 
support in the six conducted case studies and the six conducted expert interviews as well 
as in the literature. The Research Model is divided into three stages. The first stage, 
circumstances, is intended to identify how the product’s newness, the stability of the 
market and the change rate of the market are related to launch success. The notion is that 
these factors are not controllable by sales management, but are useful and important 
insights for sales force strategy formulation. Stage two, key sales force factors, includes 
the key sales force variables to be investigated in terms of their importance to a 
successful new product launch. The notion of key sales force factors is that these sales 
force readiness elements involve methods and practices controllable by the sales 
manager, which is in line with the way sales force strategy elements are defined in the 
literature (Dubinsky and Barry 1982; Dubinsky and Hansen 1981; Micheal et al. 2003). 
The third stage, effect, includes the outcome of the launch in terms of being successful or 
not.   
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Figure 6: The Research Model 
The model used for investigating key success factors in sales force readiness during 
launch of pharmaceutical products in the Swedish market. 
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Circumstances 
 
 
Type of New Product: 
  
This variable investigates whether the type of newness of the launched product impacts 
the success of the launch. The three defined types are: (a) the product is not a new type of 
product to the market and a revision of a previous product for the company launching it 
(Old-Old); (b) the product is not a new type to the market while it is of a new type to the 
company launching it (Old-New); and (c) the product is a new type of product to the 
market and it is also new to the company launching it (New-New). This variable is shown 
under the stage “circumstances” in the Research Model. The variable is derived from a 
variable in the literature by Micheal et al (2003).  
 
This variable was made operational in the data collection instrument as:  
• At time of launch, was this product: 
a. not-new-to-the-market and revisions-to-the-firm? 
b. not-new-to-the-market but new-to-the-firm? 
c. new-to-the-market and new-to-the-firm? 
 
Stability of the Market 
  
This variable is shown under the stage “circumstances” in the Research Model. This 
variable aims to investigate whether a successful product launch is more favored by a 
stable market or by an unstable market. The variable is a derived item from the variable 
“market volatility” in the literature by Hultink and Autahene-Gima (2000).  
 
This variable was made operational in the data collection instrument as:  
• What was the nature of the market environment for this new product at the time it was 
introduced: stable or unstable?  
 
Market Change Rate 
 
This variable aims to investigate whether a successful product launch is more favored by 
a rapidly changing market, or the opposite, by a slowly changing market. This variable is 
shown under the stage “circumstances” in the Research Model. The variable is a derived 
item from the variable “market volatility” in the literature by Hultink and Autahene-Gima 
(2000).  
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This variable was made operational in the data collection instrument as:  
• What was the nature of the market environment for this new product at the time it was 
introduced: did it change slowly, or change rapidly? 
 
 
Key Sales Force Factors  
 
 
Emotional Attachment 
 
This variable aims to investigate the emotional attachment and commitment of the sales 
representatives for the success of the new product. This variable is shown under the stage 
“Key Sales Force Factors” in the Research Model. The variable is a derived item from the 
variable “new product adoption / commitment” from the literature by Hultink and 
Autahene-Gima (2000).  
 
This variable was made operational in the data collection instrument as:  
• During launch, did the sales representatives feel emotionally attached to the success 
of this new product? (Yes/No)  
 
Activity Accountability  
 
This variable aims to investigate whether or not the sales representatives were held 
accountable for their sales activities. This variable is shown under the stage “Key Sales 
Force Factors” in the Research Model. The variable is a derived item from the variable 
“Sales Controls / Behavior Control” from the literature by Hultink and Autahene-Gima 
(2000).  
 
This variable was made operational in the data collection instrument as:  
• During launch, were the salespeople held accountable for their actions in selling 
the new product, regardless of results they achieved? (Yes/No) 
 
Explanation of Unachieved Sales Goals 
 
This variable aims to investigate whether the sales representatives had to explain 
themselves to their manager(s) when they did not achieve their set performance goals. 
This variable is shown under the stage “Key Sales Force Factors” in the Research Model. 
The variable is a derived item from the variable “Sales Controls / Outcome Control” from 
the literature by Hultink and Autahene-Gima (2000).  
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This variable was made operational in the data collection instrument as:  
• During launch, if the sales representatives’ performance goals for this new 
product were not met, would the sales representatives be required to explain why? 
(Yes/No) 
 
Introduction Rationale of the Product 
 
This variable aims to investigate whether the sales representatives were provided with an 
explanation of the rationale for the introduction of the product. This variable is shown 
under the stage “Key Sales Force Factors” in the Research Model. The variable is a 
derived item from the variable “Supervisory Context / Internal marketing” from the 
literature by Hultink and Autahene-Gima (2000).  
 
This variable was made operational in the data collection instrument as:  
• Did the sales representatives’ supervisors explain the rationale for the introduction 
of this product? (Yes/No) 
 
Speak Freely with Managers 
 
This variable aims to investigate whether the sales representatives were able and also 
encouraged to speak freely with their managers regarding easy and also difficult issues in 
their work, in the knowledge that he or she would want to listen. This variable is shown 
under the stage “Key Sales Force Factors” in the Research Model. The variable is a 
derived item from the variable “Supervisory Context / Trust” from the literature by 
Hultink and Autahene-Gima (2000).  
 
This variable was made operational in the data collection instrument as:  
• During launch, the sales representatives could talk freely to their supervisor about 
difficulties they had at work and would know that he or she would want to listen? 
(Yes/No) 
 
Sales Manager Observations in the Field 
 
This variable aims to investigate to what extent the sales manager should, or should not, 
observe the sales representatives’ performance in the field in order to contribute to a 
successful product launch. This variable is shown under the stage “Key Sales Force 
Factors” in the Research Model. The variable is a derived item from the variable 
“Supervisory Context / Field Attention” from the literature by Hultink and Autahene-
Gima (2000).  
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This variable was made operational in the data collection instrument as:  
• During launch, to what extent did the sales representatives’ supervisor observe 
their performance in the field: no-monitoring; medium-monitoring; or high-
monitoring? 
 
Problem Solution Approach 
 
This variable aims to investigate the character of sales representatives for a successful 
product launch with focus on the approach that sales representatives utilize for problem 
solving in their sales situations. This variable is shown under the stage “Key Sales Force 
Factors” in the Research Model. The variable is a derived item from the propositions 
around “Sales-person characteristics / Problem-solving: intuitive and systematic” from 
the literature by Atuahene-Gima (1997).  
 
This variable was made operational in the data collection instrument as:  
• During launch, how did the sales representatives handle problem solving: intuitive 
or systematic?  
 
Numbers of Sales Representatives 
 
This variable aims to investigate the optimal number of sales representatives to be 
utilized by the sales force during a successful product launch. This variable is shown 
under the stage “Key Sales Force Factors” in the Research Model. The variable is derived 
from the conducted expert interviews and case studies with strong support from the 
literature (Churchill Jr et al. 1985; Piercy et al. 1997; Rangaswamy et al. 1990; Sager 
1994) and based on the variable “sales force organizational design” derived from Micheal 
et al. (2003). 
 
This variable was made operational in the data collection instrument as:  
• How many sales representatives did you utilize during the launch of this new 
product?       
 
Promoted with Other Products 
 
This variable aims to investigate whether the product launched on the market should be 
sold by the sales representatives together with other products or otherwise alone. This 
variable is shown under the stage “Key Sales Force Factors” in the Research Model. The 
variable is derived from the conducted expert interviews and case studies, with support in 
the literature (Rangaswamy et al. 1990) and is based on the variable “sales force 
organizational design” derived from Micheal et al. (2003).  
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This variable was made operational in the data collection instrument as:  
• Did the sales representatives sell the new product only or did they sell other 
products during the same sales call: “Alone” or “Together with other products”?   
 
Product Order in Sales Call 
 
This variable aims to investigate the order in which the product launched is sold during a 
sales representative’s sales call with the physician. The variable addresses those 
situations when a sales representative sells two or more pharmaceutical products during 
his or her sales call to the physician. The question is whether the launched product should 
be sold first in order to contribute to a successful launch, or if the launched product does 
not need to be sold first and the launch will still be successful. This variable is shown 
under the stage “Key Sales Force Factors” in the Research Model. The variable is derived 
from the conducted expert interviews and case studies, with support in the literature 
(Rangaswamy et al. 1990) and is based on the variable “sales force organizational 
design” derived from Micheal et al. (2003). 
 
This variable was made operational in the data collection instrument as:  
• During launch, was the new product sold first during the sales call?  (Yes or No) 
 
 
Effect 
 
 
Performance in selling a new product 
 
This variable aims to investigate if a launch was successful or not, in measure of 
performance outcome. This variable is shown under the stage “Effect” in the Research 
Model. The variable is partly based on and derived from items in the variable “Sales 
force outcome performance / performance in selling a new product” from the literature by 
Hultink and Autahene-Gima (2000). The data was to be collected from two sources for 
validation purposes; of which one, the data collection instrument, was considered more 
subjective and, the other, available third party sales and market share data, was 
considered more objective.  
 
This variable was made operational in the data collection instrument (subjective) with the 
following items:  
a) For launch year one, did you exceed sales targets set for this new product? (Yes or 
No) 
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b) For launch year two, did you exceed sales targets set for this new product? (Yes 
or No) 
c) For launch year one, did sales representatives assist sales managers in achieving 
the objectives for this new product? (Yes or No)  
d) For launch year two, did sales representatives assist sales managers in achieving 
the objectives for this new product? (Yes or No)  
 
Items where data was to be collected from a third party data source (objective):  
 
e)  Gaining significant market share for this new product: 
- Market share, year one  
- Market share, year two  
- Market share, year three  
- Market share, year four  
 
f) Generating a high level of sales volumes for this new product (quickly generating 
sales for this new product);  
- Sales, year one  
- Sales, year two 
- Sales, year three 
- Sales, year four 
 
 
The full data collection instrument can be found in Appendix 6. The instrument was 
tested on four sales managers and two of the experts from the expert interviews. Minor 
modifications were made to the formulation of the questions to secure better 
understanding of the concept, however as the interviews were conducted over the phone 
there was always an opportunity to explain concepts or questions.  
 
All items are derived from earlier research and are well grounded in the literature and 
from the empirical data collected in the course of the case studies and expert interviews. 
The scale has been modified and defined based on the interviewed experts’ 
recommendations in order to better suit the investigation pursued here.  
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5. RESULTS  
 
The Research Model was empirically tested on fifty product launches of pharmaceutical 
products in Sweden. This text presents the results from the statistical analysis together 
with discussions and recommendations arising from these scientific results.  
 
The overall aim of the research project was to guide the sales force readiness during new 
product launch. The assumption is that by studying earlier launches, it should be possible 
to conduct new launches with a higher probability of success. The result of the statistical 
analysis conducted on the data collected here gives a good indication of how, and to what 
degree the variables in the Research Model (or Key Success Factors) are of importance 
during launch.  
 
This chapter presents the actual results of the analysis of the empirical data collected for 
the Research Model. A brief description of the collected empirical data set is presented 
first, after which the identified patterns of the successful product launches are displayed 
and discussed. The third section presents the results from the validation of the model 
generated with PLS analysis. The fourth section presents the values that each variable 
from the model generated using the PLS analysis, together with an interpretation of their 
meaning; see Table 10 for an overview. The fifth section presents the pattern created by 
the values together and thereby provides a clear indication of the answer to the addressed 
research question; see also the related Table 11. This is followed by the conclusions that 
may be drawn from the results presented here and a section with discussions and 
managerial recommendation.  
 
5.1. Description of the Empirical Data Set 
 
The fifty products investigated were launched on the Swedish market by fifteen different 
companies. The product launches took place between the years 1995 and 2005. Of the 
investigated product launches, 66% were successful and 34% were not successful. Figure 
7 illustrates how the product launches are divided between the years and broken down 
into successful and not successful launches.  
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Figure 7: Investigated product launches  
Product launches divided per year with “successful launch” and “not successful launch” 
 
 
 
 
 
The Empirical Data Set and Missing Values 
 
For the key sales force factors or variables in the Research Model, only two had missing 
values in the full data set. For the variable “Promoted with Other Products” 32% of the 
data was missing, prompting a caution as to the results. Furthermore, the data set 
included thirteen launches where the product was identified as being sold together with 
another product during the sales call. Even here, a caution has been introduced to the 
results, as 15% values were missing and a limited number of investigated objects were 
identified in this situation. Figure 8 illustrates the results for missing values for the 
collected data set for each variable.  
 
 
Figure 8: Percent of collected data for each variable 
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The Empirical Data Set and Successful Launches  
 
With further investigation into the data set of the product launches that were identified as 
successful, the responses for each of the variables in the data set were seen to be divided 
up as follows:  
 
• Emotional Attachment: 94% responded that the sales representatives felt 
emotionally attached to the success of this new product 
• Activity Accountability: 79% responded that the salespeople were held 
accountable for their actions in selling the new product, regardless of the results 
they achieved  
• Explanation of Unachieved Sales Goals: 58% responded that if the sales 
representatives’ performance goals for this new product were not met, the sales 
representative was required to explain why  
• Introduction Rationale of the Product: 100% of the successful product launches 
responded that sales representatives’ supervisors did explain the rationale for the 
introduction of the product 
• Speak Freely with Managers: 88% responded that the sales representatives could 
freely talk to their supervisor about difficulties they had at work and knew that he 
or she would want to listen 
• Sales Manager Observations on the Field: 9 % responded that “no-monitoring” 
was done by the supervisors of the sales representatives’ performance in the field, 
while 52% responded “medium-monitoring” and 39% responded “high-
monitoring”.  
• Problem Solution Approach: 52% responded that they had an “Intuitive 
Approach” to problem solving, while 48% responded that they utilized a 
“Systematic Approach” 
• Numbers of Sales Representatives: The average number of sales representatives 
used in launching a product was thirteen (13,1), with a spread from 3 to 40. Figure 
8 shows the numbers of sales representatives that were utilized for the successful 
launches, within and outside the generated success range, as generated by the PLS 
analysis in section 5.2.2.   
• Promoted with Other Products: 49% of the products were sold alone and 21% 
sold together with other products, while 30% of the values were missing for the 
successful launches  
• Product Order in Sales Call: Among the successful products sold together with 
other products, 57% were sold first, and 14% not sold first, during the sales call, 
while 29% were missing values for the successful launches    
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• Type of New Product: 18% were product launches that were not a new type of 
product to the market and a revision of a previous product for the company 
launching it (Old-Old). 52% were product launches that were not a new type of 
product to the market while it is of a new type to the company launching it (Old-
New). 30 % were product launches that were a new type of product to the market 
and also new to the company launching it (New-New). 
• Stability of the Market: 67% of the product launches were faced with a stable 
market, while 33% faced an unstable market.  
• Market Change Rate: 61% of the product launches were launched into a slowly 
changing market, while 39% were launched in a rapidly changing market 
 
 
 
Figure 9: The number of sales representatives utilized for the successful launches  
The numbers of sales representatives that were utilized for the successful launches, 
within (9 to 12) and outside the, by PLS analysis generated, success range. 
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5.2. Identified Patterns of the Successful Product Launches 
 
As described in the Research Approach chapter, PLS (Partial Least Squares) analysis has 
been applied to the data set. From this analysis, a clear pattern for successful launch has 
been identified and will be discussed in this section.    
 
Successful Launch 
 
The analysis of the data collected via the questionnaire showed a clear difference 
between successful launches and not successful launches. The way in which successful 
launch has been defined in the data is described in Chapter 2, Research Approach. The 
items collected by the questionnaire for the variables “successful launch” could be seen 
as a more subjective measure, as someone “decides” whether the launch was successful 
or not. One way to add objectivity and verify whether the launch was successful or not, is 
to collect third-party sales and market share data (MIDAS-Database 2007b) and make an 
analysis of these data.  
 
The analysis of the more “objective” data, i.e. the sales and market share data, shows a 
clear match with the more “subjective” data.   
 
An analysis of the sales data is shown in Figure 10, where every data-point is an object, 
i.e. a launched pharmaceutical product. The two graphs show exactly the same model. In 
the left graph, a successful launch has been colored red and a not successful one blue as 
defined by the research instrument's "subjective" data collection, i.e. interview subjects’ 
perceived successful launch. In the right graph, the colors are blue, purple and red 
depending on whether the sales increase has been low, medium or high during the launch 
years. The data in the right graph comes from the research instrument's "objective" data 
collection, i.e. sales data from a third party database. Both graphs show that the 
successful launches are placed in the same area of the model, i.e. the graphs give the 
same clusters of successful (defined by a circle in the graphs) and not successful 
launches.  
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Figure 10: Sales data matched against successful and not successful launches 
Data are plotted with the exactly the same statistical model. 
 
 
Market share data analysis also clearly validates the more subjective results of successful 
and not successful launches. Figure 11 shows the market share increase in the same way 
as sales increase was shown in above analysis. In the left graph, a successful launch has 
been colored red and a not successful one blue. In the right graph, the colors are blue, 
purple and red depending on whether the market share increase has been low, medium or 
high during the launch years. Again, both graphs show the successful launches placed in 
the same area of the model, i.e. the graphs give the same clusters of successful (defined 
by circle in the graphs) and not successful launches. 
 
Figure 11: Market share data matched against successful and not successful 
launches 
Data are plotted with the exactly the same statistical model. 
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It can be concluded that the more subjective measure of “Successful launch” well 
matches the more objective measure (of sales and market share increase) of “Successful 
launch”. So, since the data clearly shows systematic differences between successful and 
not successful launches, the ability to handle this information in the right way should give 
important guidance on how to more quickly reach peak sales while utilizing available 
resources better in future launches in the form of key success factors. 
 
Validation 
 
While the PLS model gives a very good split between the “successful launches” and the 
“not successful launches”, it still has to be acknowledged that the received data is binary, 
i.e. 1 or 0. As reality is not this black and white, the two groups’ data has a spread. With 
cross validation, the group to which each specific launch belongs has a Root Mean 
Square Error of Prediction (RMSEP), being standard deviation over range, of 0,25. This 
can be considered to be very good. See Figure 12 for a graphical presentation. Further, it 
can be concluded that the group with “not successful launches” has a greater spread, 
which indicates that it is possible to “fail” a launch in many ways, while the more 
homogeneous group of “successful launches” indicates that there is a narrower span of 
ways of driving success.  
 
 
Figure 12: Successful Launch - Root Mean Square Error of Prediction (RMSEP)  
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5.3. The Realized Value of each Variable and its Interpretation 
 
This section opens with some methodological aspects, for easier comprehension of the 
results, followed by a presentation of the results of each variable. 
 
5.3.1. Value Interpretation Framework 
 
As described in chapter 2, Research Approach, this research does not utilize the 
traditional top-down, hypothesis-testing research approach, with regression analysis 
techniques and Structural Equation Modeling. Instead, the approach selected here was to 
utilize a so-called bottom-up pattern identifying research approach, employing the Partial 
Least Squares Analysis (PLS). The choice has been guided by e.g. Thomson (2004), Chin 
(1998) and Haenlein and Kaplan (2004). Examples of arguments specified in chapter 2 
for using this analysis are that the conducted test has predictive aspiration, where PLS is 
suggested to be more powerful than its current alternatives (Ryan et al. 1999). Also, PLS 
is more suitable for use when there is a relatively small data set to be analyzed (Brown 
and Mazzarol 2009) and the number of independent variables is relatively large 
(Garthwaite 1994). Also, PLS’ ability to positively handle multi-collinearity and 
independent variables with different weights (e.g. Ryan et al, 1991) supports this choice. 
Additional  advantages of the PLS approach, which are relevant for the present study, are 
that it puts minimal demands on measurement scales (Brown and Mazzarol 2009) and 
also that it handles random error variance fairly well (Garthwaite 1994). The Research 
Model, as described in Chapter 2, Research Approach, is validated with the jack-knifing 
technique, also referred to as the leave-one-out cross-validation technique. With this 
technique, over-estimation (noise) can be avoided and an accurate model be obtained.  
 
The interpretation of success for each variable or key success factor for sales force 
readiness during new product launch, is set within a range, known here as the success-
range. This means that in order to contribute to a successful product launch, the given 
variable must assume a value within the defined success-range. Further, within this 
success-range, an ideal-value has been defined, which is the mean-value for each variable 
within the success-range. A variable is defined as sensitive if the “success-range” is 0,2 
or less from the “ideal value”, i.e. that it offers a narrow tolerance-space for failing this 
variable to obtain a successful product launch. To give an analogy for illustration 
purposes; if the dependent variable is “to drive a car without collision”, and one of the 
independent variables is “the driving speed”, then we could say that, for example, in 
order “to drive without collision” we must drive at a speed between 50 – 70 km/h, while 
the ideal is 60 km/h in order to give the highest probability of reaching the targeted goal. 
In this case, the speed range given is the success-range while the ideal is the ideal-value.  
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5.3.2. Generated Values of the Variables 
 
The individual variables of the Research Model and their generated values are presented 
and discussed below and a summarized overview of the variables together with their 
respective range and ideal values is presented in Table 10. The results from the variables 
included as Key Sales Force Factors will be presented first, followed by the variables 
included under the category Circumstances.  
 
 
Key Sales Force Factors 
 
Emotional Attachment of the Sales Representatives 
  
For the variable Emotional Attachment held by the sales representatives for the product 
and its successful launch, this analysis generated a success-range between 0,6 and 1,5 for 
a successful product launch, while the ideal-value is 1,0; where the meaning of “1” was 
set to a full emotional commitment. 
 
Clearly, this shows that a positive emotional commitment held by the sales 
representatives during a product launch positively impacts the success of this launch. On 
the other hand, the values of the success-range show that this is not a very sensitive 
variable; hence a successful product launch may be generated even when only a partial 
emotional commitment has been achieved.  
 
Activity Accountability of Sales Representatives 
 
This variable investigates whether or not the sales representatives were held accountable 
for their sales activities. The performed analysis generated a success-range between 0,8 
and 1,0 for a successful product launch, while the ideal-value is 0,9; where the meaning 
of “1” was set to a full accountability. 
 
This result shows that Accountability of sales representatives contributes positively to a 
successful product launch. Unlike the previously presented variable, this is a very 
sensitive variable where the generated values show that high accountability will 
contribute to a successful product launch, and that if this is not achieved then the 
contribution of this success-driver will likely not contribute at all to a successful product 
launch.  
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Explanation of Unachieved Sales Goals 
 
This variable inquires whether or not the sales representatives had to explain themselves 
to their manager(s) when they did not achieve the set sales goals. The performed analysis 
generated a success-range between 0,6 and 0,8 for a successful product launch, while the 
ideal-value is 0,7; where the meaning of “1” was set.  
 
This variable’s mean-value is somewhat distant from to a full requirement for 
explanation, while at the same time being rather sensitive. This is interpreted as, on the 
one hand, asking the sales representatives to explain themselves when they do not reach 
their performance goals in contributing to a successful product launch; and on the other 
hand, that the sales representatives do not fully need to explain themselves when not 
reaching their sales goals.  
 
Introduction Rationale of the Product for the Sales Representatives 
 
This variable investigates whether the sales representatives were provided with an 
explanation of the rationale for the introduction of the product. The outcome of the 
analysis generated a success-range between 0,7 – 1,4, for a successful product launch, 
while the ideal-value is 1,0; where the meaning of “1” was set to a full explanation of the 
product rational.  
 
Clearly, the ideal-value shows that if the sales representatives are provided with a full 
explanation of the product rationality, this will contribute positively to a successful 
product launch. However, this variable is not very sensitive, as it provides a significant 
span of success-range, showing that even if not all sales representatives are provided with 
an explanation of the product rationality then the product launch may still be successful.  
 
Sales Representatives may Speak Freely with their Manager 
 
This variable addresses whether the sales representatives were able and also encouraged 
to speak freely with their managers, regarding easy and also difficult issues in their work. 
The outcome of the analysis generated a success-range between 0,8 – 1,2, for a successful 
product launch, while the ideal-value is 1,0, where the meaning of “1” was that the sales 
representatives could speak freely with their managers. 
 
These results show that if the sales representatives are provided the freedom to speak 
with their managers of any related work issues and that managers do listen, this will 
contribute positively to a successful product launch. Further, the success-range values 
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show that this variable is a crucial driver for a successful product launch, while at the 
same time providing some tolerance-space, about 20 % in each direction.  
 
Sales Manager Observations of Sales Representatives in the Field 
 
This variable investigates to what extent the sales manager should, or should not, monitor 
the sales representatives in their work in the field in order to contribute to a successful 
product launch. This variable could assume one of the following three values: “no-
monitoring”, “medium-monitoring”, and “high-monitoring”. The outcome of the analysis 
conducted here showed that the success-range for “no-monitoring” was between 0,0 – 0,1 
while its ideal-value was 0,0, where “1” accounted for a positive relation, (i.e. “no-
monitoring” contributes positively to a successful product launch).  
 
The results here show that the opposite value to “1” is the ideal, i.e. “0”, which is a 
negation of the relationship mentioned here. The results say thus that no “no-monitoring” 
relates positively to a successful product launch, or that no-monitoring is not good for a 
successful product launch. Further, the success-range values show that this variable is 
very sensitive.  
 
When focus is transferred to the second value of the sales manager’s monitoring of the 
sales representatives, the “medium-monitoring” value, the analysis shows a success-range 
between 0,4 – 0,6  while the ideal-value was 0,5, where “1” accounted for a positive 
relation. Interestingly enough, exactly the same results for the success-range and for the 
ideal-value were obtained for the third variable value, “high-monitoring”. This means 
that these two variable values, medium-monitoring and high-monitoring, are preferable to 
the variable value “no-monitoring”. They also show that medium-monitoring and high-
monitoring contribute positively to a successful product launch; (0,5 + 0,5 = 1,0) 
manifesting together a full positive relation with a successful launch. Further, the range-
values show that this is a very sensitive variable.  
 
Sales Representatives’ Problem Solution Approach 
 
This variable investigated the character of sales representatives for successful product 
launch in terms of the approach they utilized for problem-solving in their sales situations. 
This variable could assume two distinct values: Systematic Approach or Intuitive 
Approach. 
  
The results shows that the Systematic Approach received a success-range between 0,3 – 
0,6, with the ideal-value of 0,5, while the Intuitive Approach received a success-range 
between – 0,1 – 0,6, with the ideal-value of 0,3. In this case, “1” was a positive relation 
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between the particular value and the successful product launch. The results here show 
that a Systematic Problem-Solving Approach for sales representatives is preferable to an 
Intuitive Approach, if a successful product launch is to be achieved. On the other hand, 
this variable is not sensitive, offering a tolerance in failing to achieve its value and yet 
obtaining a successful product launch.  
 
Number of Sales Representatives  
 
The variable is the number of sales representatives utilized by the sales force during the 
product launch. The analysis performed here generated a success-range between 9,4 and 
12,3 sales representatives for a successful product launch, while the ideal-value is 10,8.  
  
This means that about ten to eleven sales representatives provide the highest probability 
for a successful product launch, with a margin of about ten percent up or down. It also 
shows that this variable is rather sensitive, and if, for example, a launch is performed with 
five sales representatives it will most likely contribute to reduced success, while a launch 
with more than eleven may imply decreased success or no additional success.  
  
Promoted with Other Products 
 
This variable investigates whether the product launched on the market should be sold by 
the sales representatives together with other products or otherwise alone. In this case, “1” 
signifies for the value “together” a positive relation to successful launch; similarly “1” 
signifies for the value “together with other products” a positive relation to successful 
launch. The results gives a success-range of 0,0 – 0,5 and an ideal-value of 0,2 for the 
value “together with other products”, while a success-range of -0,1 – 0,6 and an ideal-
value of 0,3 for the value “alone”. The numbers show that it is better to sell the launched 
product alone than together with other products if a successful product launch is to be 
achieved, but that it is not crucial.  
 
Product Order in Sales Call 
 
This variable aims to investigate the order in which the product launched is sold during a 
sales representative’s sales call with the physician. The variable addresses those 
situations when a sales representative sells two or more pharmaceutical products during 
his or her sales call to the physician. The question is whether the launched product should 
be sold first in order to contribute to a successful launch, or if it does not need to be sold 
first and yet can still contribute to a successful launch. In the present analysis, “1” 
signifies that the product is sold first. The success-range obtained is 1,1 – 1,3 while the 
ideal-value is 1,2. These numbers show that it is important to have the launched product 
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sold first. Assuming that the results obtained here may be regarded as valid with regard to 
the missing values in the data set, the implication is that in situations when a product is 
being launched in a manner whereby it should be sold together with other products, it is 
crucial for the success of the launch that the launched product is sold first during the sales 
representative’s sales call. 
 
 
Circumstance 
 
The next set of variables belongs under “Circumstances” in the Research Model. These 
elements of the Research Model aim to provide important circumstantial information of 
interest when formulating launch strategy, but are of the nature that sales management 
has little or no influence. 
 
The Newness of the Launched Product 
 
This variable investigates whether or not the type of newness of the launched product 
impacts the success of the launch. Newness was operationalized in terms of three values: 
(a) the product is not a new type of product to the market and is a revision of a previous 
product for the company launching it (Old-Old); (b) the product is not a new type to the 
market while it is of a new type to the company launching it (Old-New); and (c) the 
product is a new type of product to the market and it is also new to the company 
launching it (New-New). For each of the values, a positive relation with a successful 
product launch is signified by a “1”.  
 
The obtained results show that the Old-Old type of products had a success-range between 
0,1 – 0,2 and an ideal-value of 0,1; the Old-New type of products had a success-range 
between 0,2 – 1,0 with an ideal-value of 0,6; while the New-New type of products has a 
success-range between -0,1 – 0,6 with an ideal-value of 0,3. The Old-New type of 
products seems to be the best contributor or driver of a successful product launch of the 
three types being investigated, as it is closest to the value 1,0. On the other hand this 
situation is not particularly sensitive. Also, the New-New type of products contribute 
more to a successful product launch than do the Old-Old type of products, while still 
contributing less than the Old-New type of products. 
 
Given that the typical situation is that the team launching a product cannot determine or 
influence the newness of the product, an implication that can be perceived here is that a 
product launch team does not need to critically worry about the success of product launch 
with regards to the newness of the product launched. However, there is a fairly strong 
correlation between the Old-New type of product and the success of its launch. This is 
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not very sensitive, and thus not a particularly crucial driver for success. Some managerial 
implications will be discussed in a later section. 
 
Stability of the Market 
 
This variable investigates whether a successful product launch is more favored by a 
stable market or by an unstable market. This binary characterization – stable vs. unstable 
– of the market space of the launched product needs to have a “1” to denote a positive 
relationship. The results for the value unstable market showed a success-range between 
0,7 – 0,8 with an ideal value of 0,7 while the results for the stable market show a success-
range between 0,2 – 0,3 with an ideal value of 0,3. Clearly, the results show that a 
product launch in an unstable market space is more likely to generate success than a 
product launch in a stable market; this variable being very sensitive. The implications of 
this situation are challenging in so far as we can seldom choose whether the market the 
product will be launched in is stable or unstable; and that our ability to influence a market 
to change its condition is typically limited, however, some strategic considerations will 
be discussed in a later section. 
 
Market Change Rate 
 
This variable investigates whether successful product launch is more favored by a rapidly 
changing market or the opposite, by a slowly changing market. This binary 
characterization of the market of the launched product – slow vs. rapid – needs to have a 
“1” to signify a positive relationship. The results for the value rapid market change 
showed a success-range between 0,4 – 1,1 with an ideal value of 0,8 while the result for 
the slow market change showed a success-range between -0,1 – 0,6 with an ideal value of 
0,2. The results show that a product launch in a rapidly changing market is more likely to 
generate success than a product launch in a slowly changing market; this variable is not 
very sensitive. Also here, as with the two previous variables, the implication of this 
situation is challenging in so far as we can seldom choose whether our launch will take 
place in a market space that is changing slowly or rapidly; also our ability to influence the 
rate of change of a market is typically limited, however, some strategic considerations 
will be discussed in a later section. 
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Table 10: Results from Research Model data analysis, utilizing PLS  
 
Variables Min Ideal Max 
Key Success Sales Factors 
Emotional Attachment 0,6 1,0 1,5 
Activity Accountability 0,8 0,9 1,0 
Explanation of Unachieved Sales Goals  0,6 0,7 0,8 
Introduction Rationale of the Product  0,7 1,0 1,4 
Speak Freely with Managers 0,8 1,0 1,2 
Sales Manager Observations on the Field: Non 0,0 0,0 0,1 
Sales Manager Observations on the Field: Medium 0,4 0,5 0,6 
Sales Manager Observations on the Field: High 0,4 0,5 0,6 
Problem-Solving Approach: Intuitive -0,1 0,3 0,6 
Problem-Solving Approach: Systematic 0,3 0,5 0,6 
Numbers of Sales Representatives  9,4 10,8 12,3 
Promoted with Other Products: with other products 0,0 0,2 0,5 
Promoted with Other Products: alone -0,1 0,3 0,6 
Product Order in Sales Call 1,1 1,2 1,3 
Circumstances 
Type of New Product: Old-Old 0,1 0,1 0,2 
Type of New Product: Old-New 0,2 0,6 1,0 
Type of New Product: New-New -0,1 0,3 0,6 
Stability of the Market: Unstable 0,7 0,7 0,8 
Stability of the Market: Stable 0,2 0,3 0,3 
Market Change Rate: Fast 0,4 0,8 1,1 
Market Change Rate: Slow -0,1 0,2 0,6 
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5.4. The Total Pattern and its Interpretation 
 
Given the-above presented results of each of the variables investigated here, it is now 
possible to identify the overall emerging pattern of successful sales force readiness during 
launch of new pharmaceutical product aimed at General Practitioners in Sweden. See 
Table 11 for an overview. 
 
5.4.1. Five Important & Crucial Key Success Factors 
 
Five important & crucial key success factors for sales force readiness were identified for 
driving successful product launch. By “important” it is meant that each of these factors 
shows a strong positive influence on the success of a launch; while “crucial” denotes here 
that the absence of any of the five factors found may negatively influence the product 
launch success. In analytical terms, “crucial” is defined here as the variables from the 
PLS analysis showing both an ideal value close to a full positive relation to a successful 
launch and which were identified as being sensitive, i.e. offering a narrow tolerance-
space for failing this variable to obtain a successful product launch. The “cut-off” value 
for being “crucial” was selected, for the Key Sales Force Factors, as an “ideal value” 
close to equal or more (ideal value equal or more than 0,9) to a full positive relation 
towards a successful launch (1,0). 
These five key success factors or success drivers include: (i) establishing a high sales 
representative activity accountability; (ii) establishing a relation between the sales 
representatives and their sales managers where the sales representative can speak freely 
about any related issue; (iii) establishing medium- to high-intensive monitoring of the 
sales representatives’ sales behavior in the field; (iv) securing that the launched product is 
sold by the sales representatives as the first one, in the case when several products are 
sold (detailed) during the same sales call, and finally; and, (v) the sales force should be 
composed of a range between nine and thirteen sales representatives. 
 
5.4.2. Five Important Key Success Factors 
 
The analysis performed here has also uncovered five important key success factors of 
sales force readiness that drive successful product launch. By “important” it is here meant 
that each of these factors shows a positive influence on the success of a launch; however, 
unlike the five previously-discussed “important and crucial factors”, the absence of each 
of the five factors found here should not show any significantly negative impact on the 
product launch success. The definition “important” (but not crucial) is used for the 
variables that in the PLS analysis showed as having a more distant “ideal-value” to a full 
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positive relation towards a successful launch and/or not being sensitive, i.e. offering more 
tolerance-space for failing this variable to obtain a successful product launch. The “cut-
off” value for being “important” (but not crucial) was selected, for the Key Sales Force 
Factors as an “ideal value” being less close (less than 0,9) to a full positive relation to a 
successful launch (1,0) and/or a “success-range” being 20% or more distant from the 
“ideal value”.    
 
These five important (but not crucial) key success factors or success drivers include: (i) 
having established emotional attachment of sales representatives to the launched product; 
(ii) requiring that the sales representatives explain themselves when their sales objectives 
are not met; (iii) having explained the product rationality for the sales representatives; 
(iv) acquiring sales representatives that possess a systematic problem-solving capability 
rather than an intuitive one; and, (v) securing that the launched product is sold (detailed) 
by the sales representatives as a stand-alone product, rather than together with other 
products. 
 
5.4.3. The Ideal Market Conditions for a Successful Launch 
 
The analysis performed here has further uncovered the ideal market conditions for a 
successful product launch. These market conditions are constituted by two market 
characteristics which typically cannot be influenced in the sense that they can be selected 
freely. However, the information about these market conditions produces managers with 
the opportunity to adjust other strategic and operational aspects of the product launch so 
that a match between market conditions and strategic and operational set-up can be 
achieved. The results show that the ideal market for launch is unstable in its behavior and 
that the market changes rapidly. 
 
5.4.4. The Ideal Type of Product for a Successful Launch 
 
The present study has also identified the type of newness of the product to be launched, 
which is the most ideal type for a successful launch. The ideal product should be of a type 
which is not new to the market, however, which is of a new type for the firm launching it 
on the market. 
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Table 11: Key Success Factors 
Key success factors for sales force readiness during new product launch in the Swedish 
pharmaceutical industry.  
 
Key Success Factors for Sales Force Readiness during New Product Launch 
Five Important and Crucial Key Success Factors 
(i) Establishing a high sales representative activity accountability 
(ii) Establishing a relation between the sales representatives and their sales managers 
where the first-mentioned can speak freely about any related issue 
(iii) Establishing medium to high intensive monitoring of the sales representatives sales 
behavior in the field 
(iv) Securing that the launched product is sold by the sales representatives as the first 
one, in the case when several products are detailed during the same sales call 
(v) The sales force should be composed of a range between nine and thirteen sales 
representatives 
Five Important Key Success Factors 
(i) Having established emotional attachment of sales representatives toward the 
launched product  
(ii) Requiring that the sales representatives explain themselves when their sales 
objectives are not met 
(iii) Having explained the product rationality for the sales representatives 
(iv) Acquiring sales representatives that posses a systematic problem solving capability 
rather than intuitive 
(v) Securing that the launched product is detailed by the sales representatives as a 
stand-alone product, rather than together with other products 
Ideal Market Conditions 
 The results show that the ideal market for launch is unstable in its behavior and that 
the market changes rapidly 
The Ideal Type of Product for a Successful Launch 
 A product which is not new to the market, however, which is of a new type for the 
firm that launches it to the market 
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5.5. Conclusions of this Result 
 
This study has been fruitful in that it has been able to discriminate a set of key success 
factors of sales force readiness, that drive the success of new product launch. Further, the 
study has also succeeded in discriminating between four types of key success factors: the 
key success factors that are important & crucial for a successful launch, the key success 
factors that are important yet not necessarily crucial for a successful launch, thirdly the 
market conditions that are most ideal for a successful launch, and finally the type of 
newness of the product that is most suitable for launch. While the two first-mentioned 
factors can be more easily managed and influenced by the company launching the 
product, the latter two types of factor can typically not be influenced by the launching 
company; rather the company needs to adapt or prepare itself to the prevailing conditions. 
With both the set of case studies and the set of expert interviews supporting the notion 
that, even with significant industry changes, it should be possible to conduct new 
launches with a higher probability of success by studying earlier launches, these results 
should be of considerable interest for both practicing managers and academic scholars. 
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5.6. Discussion & Managerial Recommendations 
 
This section presents the discussions and managerial recommendations, based on the 
findings of this study. The managerial recommendation for each key success factor is also 
summarized in Table 12.  
 
 
Five Important & Crucial Key Success Factors 
 
(i) Establishing a high sales representative activity accountability 
 
Activity accountability is identified as an important & crucial key success factor for a 
successful launch. It shows that there is a need to keep sales representatives accountable 
for their sales activities to a greater extent than other measures. As identified earlier, one 
implication of this result is that careful planning and efforts should be put into securing 
that sales representatives are held accountable for their sales activities, in order to 
generate a successful product launch. A possible explanation for this high importance of 
activity control during new product launch could be that outcome measures, such as sales 
numbers and market share prognosis, are very uncertain and hard to predict when 
launching a new product versus selling older products which have been on the market for 
some time. As these launch outcome measures could be obsolete or misguiding very early 
in the launch, based on lack of information or “guesstimates” when setting forecasts, the 
sales representative might lose motivation as he/she would be chasing impossible or 
unrealistic objectives. One way to solve this would be to have more flexible outcome 
measures or update the measures very frequently. However, based on the results of this 
research, it is argued that the best solution is to put more emphasis on the activities, as 
this will keep the sales representatives focused on factors over which they have greater 
direct influence, even in an uncertain marketplace. This could also be argued to be even 
more important, as the ideal market for launch was found to be an unstable market with 
rapid change, in which it can be assumed that uncertainty will increase even more. 
 
The “activity accountability” factor belongs to the category behavior control, and on an 
overview basis, the result here is supported by earlier research that concludes that the 
behavior control category  is one of the most important factors for a successful launch of 
a new product (Ramaswami 1996). In the field of sales force effectiveness, Baldauf and 
Cravens (1999) suggest, based on their empirical findings, that the role of sales managers 
in many organizations is shifting away from command and control management toward 
coaching styles of management, which in some degree supports behavioral control over 
outcome control. Their finding concludes some support for behavioral-based sales 
management control strategies being associated with a higher level of sales unit 
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effectiveness. Also the characteristics of the pharmaceutical market, with its difficulties 
in measuring sales on a representative level, especially outside the US, might be part of 
the explanation as to why behavioral based-measures are to be preferred over outcome- 
based (Lloyd and Newell 2001). There are also a few earlier research efforts that have 
hypothesized the opposite, (i.e. behavior control weakens the relationship to successful 
launch), but have failed to support this hypothesis and also omitted activity accountability 
from their measurement instrument (Hultink and Atuahene-Gima 2000). In essence, the 
conducted research adds to the growing base of evidence that behavior-based sales 
management strategies are being adopted to a greater extent and that these strategies 
might provide a higher level of sales force effectiveness and readiness. It is however 
important to note that research has concluded that sales-managers competencies in 
behavior-based control is not well researched (Piercy et al. 2009), why this is an area for 
further research.    
 
When managers plan to secure that sales representatives are held accountable for their 
sales activities, a recommendation is to put some emphasis on the clarification and 
description of what is defined by the company as excellent sales activity behavior, using 
descriptive examples. This will particularly guide new sales representatives as to the right 
expectations as well as to a better understanding of any objectives set by managers in 
support of reinforcing activity accountability. Also, using balanced scorecard or a 
modified version thereof, with weight on activities, might be a wise addition in the 
management control system.  
 
(ii) Establishing a relation between the sales representatives and their sales managers 
where the sales representatives mentioned can speak freely about any related issue 
 
The results for the variable, Speak Freely with Managers, showed that if the sales 
representatives are provided with the freedom to speak with their managers about any 
related work issues and that managers do listen; this will contribute positively to a 
successful product launch.  
 
The original variable belongs to the subcategory trust in the literature under new product 
adoption. The support for this in the new product launch literature is not very strong, for 
example, Hultink and Atuahene-Gima (2000), argued, based on earlier research on 
interpersonal trust, that trust leads to greater commitment to the relationship and 
increased cooperation, but they did not find support for any positive effect that sales force 
adoption of a new product on selling performance being stronger when trust is greater. As 
this is highlighted in all case studies conducted in this research and is also identified as an 
important & crucial success factor in the analysis for a successful launch, it is 
recommended here that managers keep this high on the agenda, both during preparation 
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and during launch. The implication for managers that may be drawn from the results 
found here is that the planning and execution of a sales force management strategy for a 
new product launch, should include the sales representatives’ freedom to speak with their 
managers on any related work issue and making sure that managers are able to listen. 
This might be best achieved by training sales management in appropriate coaching 
techniques, following the findings of Piercy et al. (1997) that more effective sales 
organizations put more effort into coaching and communicating. Also, it is recommended 
that objectives supporting that behavior should be included in the sales managers’ 
objectives.   
 
(iii) Establishing medium- to high-intensive monitoring of the sales representatives 
sales behavior in the field 
 
The results from the variable which investigated to what extent the sales manager should, 
or should not, monitor the sales representatives in their work in the field in order to 
contribute to a successful product launch, found that managers should monitor the sales 
representatives in the field. However, the results further showed that both “medium-
monitoring” and “high-monitoring” contribute positively to a successful product launch, 
with no difference between their results.  
 
The literature has some mixed support for this, as discussed earlier when constructing the 
Research Model under field attention. However, there is research that suggests that travel 
with sales representatives is important for a new product success (Anderson and 
Robertson 1995; Atuahene-Gima 1997). This literature indicates the importance of co-
travel based on providing timely feedback and for managers to gain firsthand knowledge 
from the market.  
 
The managerial recommendations, based on the findings in this research and on the 
literature, are to include field travel for monitoring sales representatives as an important 
and crucial factor in the sales force strategy when launching a new product. With medium 
and high monitoring having equal importance for a successful product launch, the 
recommendation is to keep the field monitoring on a medium level. This approach has 
several purposes; on the one hand to secure enough observation time for the sales 
managers to gain firsthand knowledge of the market issues, and to be able to provide 
quality, timely and fair objective performance evaluations, and on the other hand, to 
optimize resource consumption and hopefully avoid any perceived “looking-over-my-
shoulder” perception in the sales force.  
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(iv) Securing that the launched product is sold by the sales representatives as the first 
one, in the case when several products are sold (detailed) during the same sales 
call 
 
The result showed that, even if the data collected on this topic had a smaller population, 
in situations when a product is launched and is planned to be sold together with other 
products, it is important and crucial for the success of the launch that the new product be 
sold first of all products during the sales representative’s sales call. The managerial 
recommendation is to always adopt a sales force strategy during launch with the new 
product being sold first in all sales calls. The only exceptions would be if the company 
possesses a very good segmentation model, in which individual customers could be 
identified on the basis that another order of products sold during the sales call would 
increase benefits for another product, while still bringing equal benefits to the new 
product as if it was sold first, even if the new product is put in a non-first position during 
the sales call. In addition, it has also been learned from the literature that the salesperson 
is likely to be more effective if the product lines are synergistic with one another, such as 
complementary product positioning or customers who need many different products from 
the product line (Rangaswamy et al. 1990). This might be very true among the General 
Practitioners, who cover a broad range of therapeutic areas.  
 
(v) The sales force should be composed of a range between nine and thirteen sales 
representatives 
 
The optimal numbers of sales representatives for a successful launch found in this 
research were between nine and thirteen. This number is of course valid for the project 
scope identified. In the collected data set, the average number of sales representatives 
used in launching a product was thirteen (13.1), with a spread from three to forty. For the 
successful launches, 40% of sales forces had above thirteen sales representatives, 36% 
below nine, and 24% within the identified success range. Figure 9 shows the numbers of 
sales representatives that were utilized for the successful launches, within and outside the 
generated success range. This indicates a slight overinvestment in sales force 
representatives, leading to a higher than necessary cost. These results suggest some 
confirmation of the issue raised by Manchanda and Chintagunta (2004) of the presence of 
over-detailing in the pharmaceutical industry. Recent trends have also shown that, even if 
this is not specific for product launch, that the numbers of representatives in the sales 
force are decreasing (Dutton and Reece 1996; Rangaswamy et al. 1990; Ruzicic and 
Danner 2007). Corporate down-sizing of sales forces in the pharmaceutical industry has 
been a trend for many years in the developed world, including Sweden. Piercy et al. 
(1997) refer, when in an era of substantial corporate downsizing, that “right-sizing” of the 
sales force is a highly significant issue for managers concerned about effectiveness. Their 
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findings suggest that “right-sizing” at sales unit level should be a priority in recovering 
from corporate re-structuring, if superior sales effectiveness is to be achieved (Piercy et 
al. 1997). Further they suggest that the more effective sales organizations may be closer 
to being right-sized. Their research also suggests that effectiveness cannot be increased 
by just adding further salespeople to sales units. 
 
The managerial recommendation is that significant effort should be put into allocation of 
right-sizing the sales force, and from the results of this research, a number of between 
nine and thirteen should be pursued when launching aimed at General Practitioners in 
Sweden. Having a sales force larger than thirteen suggests inefficiency and might lead to 
lost profit. Also, having a sales force smaller than nine might jeopardize a successful 
launch of the new product. This result could also be complemented with other literatures 
suggestions for mathematical models to optimize the sales calls resources (Agnetis et al. 
2010).   
 
The results from this study on the number of sales representatives are, as already stated, 
of course guiding and very specific for the new product launch target group, general 
practitioners, and the market investigated in this research. However, as discussed earlier, 
it might be assumed, if in another market with similar conditions, with the new product 
launch target group being the same, that sales force number might be assumed to be 
scaled in a linear manner in accordance with the size of the target group.  
 
 
Five Important Key Success Factors 
 
(i) Having established the emotional attachment of sales representatives toward the 
launched product 
 
The results showed that emotional attachment held by the sales representatives towards 
the new product during a product launch positively impacts a successful launch. The 
managerial recommendation is to plan and execute activities for generation of emotional 
attachment to the product in advance and during early launch for greater possibility of 
success during the new product launch. However, the results also showed that a 
successful product launch may be achieved even with only partial emotional attachment. 
One implication is that high investments focused on initiatives that attempt to achieve 
high emotional attachment may not be efficient from a resource point of view. Emotional 
attachment activities are typically somewhat subtle and may require great effort and thus 
significant resources. The case studies identified examples to generate high emotional 
attachment in the sales force to the new product as activities such as teambuilding 
activities where the aim was to have everyone comfortable with the arguments for 
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skeptical customers; investments in bringing the sales representatives to congresses for 
further development; interactions with both physicians and nurses to learn the importance 
of the product in practice; and having the launch team meet with patients to hear their 
stories.  
 
Emotional attachment belongs to the subcategory commitment under new product 
adoption in the literature (Hultink and Atuahene-Gima 2000). Hultink and Atuahene-
Gima (2000) found that commitment correlates positively to performance when selling a 
new product. Even though emotional attachment is an item under the commitment 
variable in Hultink and Atuahene-Gima (2000), this suggests that the results support 
earlier findings in the literature.   
 
(ii) Requiring that the sales representatives to explain themselves when their sales 
objectives are not met 
 
In this research, having the sales representatives explain their unachieved goals is an 
important key success factor for a successful product launch. However, tolerance was 
also identified for the fact that a successful product launch may be achieved without 
having all sales representatives onboard. One implication is that planning of a successful 
product launch should include the need for sales representatives to explain themselves, 
while the other related implication is that there is no need to over-invest in this effort. 
However, formally giving the sales representatives the opportunity to explain their 
performance achievements, especially when their objectives are not met, might increase 
their motivation to still work towards objectives or outcome goals that are becoming 
unrealistic on the basis of unpredictable or unknown market dynamics before or during 
launch, as they would know that even if they cannot achieve their goals, their work will 
be fairly evaluated based on their explanations. Lilien et al. (1981) argue, in support of 
above, that often too little data is available during launch of a pharmaceutical product, to 
make accurate sales forecasts.   
 
This suggests further support to and is complementary to the identified important and 
crucial key success factor, about accountability for activities, in terms of motivation 
being driven by factors within that the sales representative’s control. So, the combination 
of behavior control in the form of activities performed in the field, together with outcome 
control in the form of clear managerial guidance of giving the sales representatives the 
chance to explain any outcome measures and why these are not achieved, might increase 
the sales representatives’ ability to better influence their objectives in the unpredictable 
environment of a new launch environment, thus leading to higher motivation and 
commitment. Following this, the managerial recommendation is to include requirements 
for the sales representatives to explain performance in the control system, in form of a 
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formal process. It is recommended that this be communicated to the sales force as a 
means to give them ongoing influence on the adjustment of their performance objectives. 
 
(iii) Having explained the product rationality for the sales representatives 
 
The results of the key success factor for the variable if the sales representatives were 
provided an explanation of the rationale for the introduction of the product, clearly 
showed that if the sales representatives are provided with a full explanation of the product 
rationale, this will contribute positively to a successful product launch. Also, from the 
results it was concluded that even if not all sales representatives are given or understand 
the explanation of the product rationale, the product launch may still be successful.  
 
Even if the literature has not directly analyzed the item about explanation of product 
rationale, it can still be argued that, with the variable belonging to the category of internal 
marketing, its results are supported in earlier research. Earlier research suggests that 
internal marketing reduces ambiguities among the sales force in terms of procedures and 
objectives (Anderson and Robertson 1995). Further, Hultink and Atuahene-Gima (2000) 
gained strong support for internal marketing being nearly significantly related to selling 
performance.  
 
The managerial recommendations, to include in the strategic plan, are that the sales 
managers provide their sales representatives with a thorough explanation of the rationale 
for launching this product. The rationale should include how the new product fits into the 
market place for its customers (the physicians) and their customers (the patients) as well 
as for the company. This might preferably be implemented as a continuous agenda topic 
during pre-launch and launch meetings instead of a larger onetime event. Hultink and 
Atuahene-Gima (2000) argued that managers should focus significant resources and 
effort on internal marketing before sending sales representatives to the field. However, 
the results of this research identified that there should be no need to down-prioritize other 
factors in a situation with scarce resources in favor of explaining the rationale, as a 
certain lack of understanding should not jeopardize the launch. This indicates that over-
investments may not pay off, suggesting clear inclusion with moderate investments to 
achieve the best profit situation.   
 
(iv) Acquiring sales representatives that possesses a systematic problem solving 
capability rather than intuitive 
 
This variable in the research model investigated the character of sales representatives for 
a successful product launch in terms of the approach that they utilized for problem-
solving in their sales situations. This variable could assume two distinct values, a 
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systematic approach or an intuitive approach. The results found that a systematic 
problem-solving approach for sales representatives is preferable to an intuitive approach, 
if a successful product launch is to be achieved. On the other hand, the results also 
suggested the variable as not being sensitive, offering tolerance for failing to achieve a 
fully systematic problem-solving approach in the sales force and yet obtaining a 
successful product launch. 
 
As research by Scott and Bruce (1994) found that systematic problem-solving style is 
negatively related to innovative behavior of employees, it can be elaborated based on the 
results found in this research that during product launch a company might want to have a 
sales force with little innovative behavior in order to reach a greater possibility of 
success. Therefore, a managerial recommendation is to place a specific recruitment 
criterion on problem-solving approach in the recruitment process for the new product’s 
sales force in favor of sales representatives with a systematic problem-solving approach, 
and as discussed above, less innovative behavior might be a complementary criterion to 
include. Selecting and hiring salespeople is a difficult and important task for sales 
managers as it has long-range impact on sales district performance and the rate of 
salesperson turnover (Sager and Ferris 1986).   
 
An observation from the case studies was that all cases that identified a systematic 
problem-solving approach as preferred also had a much higher level of implemented 
procedures and processes related to behavior and outcome control. The opposite applied 
to the cases that identified intuitive problem-solving approach as preferable, and they 
instead had a low degree of established procedures and processes for behavior and 
outcome control. Based on this, the recommendation is extended to take into 
consideration that if the company’s defined processes for sales force control are 
developed and implemented to a high level, the stricter the above recruitment 
recommendation should be implemented.  
 
Based on discussions with the experts and sales management in the case studies, it was 
argued that with future developments in the pharmaceutical industry in terms of customer 
access issues, governmental and economic pressure, etc, the trend might shift towards a 
more flexible and intuitive problem-solving approach as it may be necessary to be more 
flexible and innovative in the sales force to penetrate with the message. This is also 
highlighted in the literature, where it is concluded that physicians are starting to ask 
questions about what patients think of the drug, how much they pay, whether they 
comply with treatment regime and recommendation lists etc. (Elling et al. 2002; 
Tengilimoglu et al. 2004). A suggestion for future research is to see if the preferred 
problem-solving approach changes over time and which market trends would drive those 
changes.   
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(v) Secure that the launched product is sold (detailed) by the sales representatives as a 
stand-alone product, rather than together with other products 
 
The variable in the model investigated whether the product launched should be sold by 
the sales representatives together with other products or alone. The result showed that it 
is better to sell the new product alone than together with other products if a successful 
launch is to be achieved. However, the results showed little difference between selling 
the product alone or selling it together with other products. It might be seen as somewhat 
contra-intuitive, as one can easily intuitively assume that a standalone promotion is 
always better than a combined. Clearly, this does not need to be the case based on the 
findings in the research. However, a reminder here is the results found in this study 
around another variable, being an important and crucial key success factor, which states 
that if a new product is sold together with other products it should be sold first to achieve 
a successful launch. Therefore, everything indicates that being first is more important 
than being alone.  
  
The managerial recommendation from these results may be twofold. In the cases when 
the costs of selling are crucial to the overall business and full product portfolio success, 
the alternative of promoting the launched product together with other products may be 
attractive. On the other hand, in a situation when the costs of selling are not as critical for 
the overall business and full product portfolio success, the alternative choice of selling 
the product alone should be considered as this option is more likely to contribute to a 
successful product launch than the former. Further, this choice may depend on how the 
sales force is organized before launching the product, as organizational change can be 
disruptive for the sales force (Micheal et al. 2003).  
 
 
Ideal Market Conditions 
 
The results show that the ideal market for launch success is both unstable in its behavior 
and in rapid change. The unstable variable was identified as the stronger driver.  
 
It can be assumed that in an unpredictable market, salespeople will face more challenges 
or be less able to predict customer adoption or preferences, price changes and other 
factors that will have impact on the results for a new product launch (Hultink and 
Atuahene-Gima 2000; Rao 2000a; Rao 2000b). Further, the implication of this situation 
is challenging in so far as that we can seldom choose whether the market for the launch is 
stable or unstable, combined with the fact that our ability to influence a market to change 
its condition is typically limited. Some literature suggests that customers in a more 
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volatile market would show more resistance to new products and that salespeople 
encounter ambiguities versus a nonvolatile market (Achrol and Stern 1988; Atuahene-
Gima 1997).  
 
However, the findings in this research that unstable state and rapid change in the market 
have a positive relation to product launch success are argued to be further supported in 
the literature. Even if the two variables researched in this study do not add up to a full 
analysis of market volatility or degree of unpredictability according to some previously 
conducted studies on new product adoption in the sales force, there are such clear results 
suggesting a positive relationship to launch success for both variables, that it can be 
assumed here to support current literature with the same findings. The findings are 
supported by the results found in Hultink and Atuahene-Gima 2000. They also found that 
market volatility is positively related to salespeople’s performance in selling a new 
product. They argue that salespeople may actually enjoy themselves and perform better 
when facing challenges in the environment. This argumentation is also supported in other 
research, where job satisfaction when selling new products is higher when the market 
volatility is greater (Atuahene-Gima and Micheal 1998). The research results can be 
further explained as when a product enters a market that is in rapid change and is 
unstable, customers’ behavior or their preferences might be easier to change or influence. 
 
This finding leads to several potential strategic considerations that can be drawn from 
these results. Firstly, as the sales force might encounter difficulties around targeting and 
segmentation of customers, while managers would still be advised to work with all key 
success factors, extra emphasis should be put on the key success factor “activity 
accountability”, as it might be much easier for the sales manager and sales representative 
to set common accepted objectives and expectations for activities. More loosely-defined 
or more flexible sales targets might motivate as they are harder to predict, while 
managers should avoid pushing for extensive customer or territory profiles, so as not to 
demotivate the sales force with more onerous tasks.    
 
When the ideal market conditions for launch are applicable, even if probability for 
success is increased when launching in an unstable market with rapid change, managers 
are recommended to use more caution in the forecasting and budget process. The 
preferred strategy would be to pursue a more defensive approach. However, an important 
implication in adopting a defensive forecasting strategy is the requirement of clear 
communication to any production and supply chain processes, in order to prepare them 
for a more flexible supply situation, handling any unexpected increase in forecasted sales. 
In a situation when the market situation is less ideal for launching a new product, being a 
stable market with slow change, with assumed better availability of reliable market and 
customer data, more accuracy could be assumed in the forecast and budget.  
 179 
 
When launching in a less ideal market, which is thus likely to reduce the probability of 
success, other available actions should be taken to balance this negative driver. It 
becomes even more important to secure extra resources for all the key success factors that 
have been identified in this research.  
 
The recommendation for companies that are not launching, but facing entering 
competitors, is to be extra prepared when unstable and rapid change is the defined market 
state at time of the competitor’s product introduction. More actions and contra messaging 
might be necessary.  
 
 
The Ideal Type of Product for a Successful Launch  
 
The results from this research suggest that the ideal type of product for a successful 
launch is when a product type is “not-new-to-the-market but new-to-the-firm” launching 
it. In response to the question why this type of product is the best driver for a successful 
launch, a possible explanation is that when a firm is new to a product, there is a greater 
sense of urgency and understanding that knowledge needs to be acquired and the old way 
of working should be questioned to a greater extent. The results from some findings in 
the new product development literature support this explanation by highlighting that 
when this occurs, launch activities receive better resources and focus (Calantone and 
Cooper 1981; Hultink et al. 1999). The same explanation might apply to the product type 
“new-to-the-market and new-to-the-firm”, however, in this case it can be argued that the 
external factors are different in terms of the market data and information available, 
benchmarking opportunities and perhaps most important, that the customer will not have 
the knowledge to adopt the new product as quickly as if the behavior and product 
category is already understood. For the “not-new-to-the-market and not-new-to-the-firm” 
product type, the arguments would be that by having already established behaviors and 
processes both in the market and within the sales force, some assumptions might be 
wrongly used by sales management in terms that “business as usual” would apply best to 
the new product. This issue was also raised within some of the case studies, where it was 
seen as an important issue that new messages for the new product cannot be adapted and 
implemented as easily in the sales force if the pre-notion of “we already know this” 
exists, leading to the outcome that messages might not be optimal for the new product, 
but instead support old behaviors from customers where change is wanted and needed to 
drive success for the new product. 
 
Previous research brings some further support to the findings and argumentation within 
this research. Michael et al. (2003) concluded that the implication on their results for 
firms launching new products suggest that all elements of current sales management 
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strategy should be scrutinized for potential beneficial changes. This was based on the 
overview results that nearly two-thirds of their respondent firms made some kind of 
change in sales management strategy to accompany the new product introduction. 
Micheal et al. 2003 did not measure or relate any of the changes to whether the product 
was successful or not, neither did this research capture the amount of changes, however 
both researches together indicate that “not-new-to-the-market but new-to-the-firm” has 
most changes when formulating strategy as well as likelihood of succeeding when 
launching a new product.  
 
It is recommended, based on the above line of argument, that managers make sure that a 
deliberately increased focus and effort are applied to the strategy formulation process and 
the identified key success factors when the product type is “not-new-to-the-market and 
not-new-to-the company”, compared to the other two type of new products.  
 
 
Table 12: Overview of managerial recommendation 
 
Key Success Factor for 
New Product Launch 
Managerial Recommendation 
Five Important and Crucial Key Success Factor
(i) Establishing a high sales 
representative activity 
accountability 
 
- careful planning and efforts put into securing that 
sales representatives are held accountable for their 
sales activities 
- clarification and description of what is defined by 
the company as excellent sales activity behavior, 
using descriptive examples 
- using balanced score card, weights towards 
activities  
(ii) Establishing a relation 
between the sales 
representatives and their 
sales managers where the 
sales representatives can 
speak freely about any 
related issue 
- planning and execution of a sales strategy for a new 
product launch should include the sales 
representatives’ freedom to speak with their 
managers about any related work issue as well as 
ensuring managers are able to listen 
- training and preparing sales management in 
appropriate coaching techniques  
- including behavior support objectives around open 
communication in the sales managers’ objectives 
(iii) Establishing medium- 
to high-intensive 
monitoring of the sales 
representatives’ sales 
behavior in the field 
- optimizing resource consumption by adopting 
medium monitoring effort, which might also avoid 
any perceived “looking-over-my-shoulder” 
mentality  
- securing enough observation time for the sales 
managers to gain firsthand knowledge of the market 
issues and to be able to provide quality, timely and 
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fair objective performance evaluations 
(iv) Securing that the 
launched product is sold 
first by the sales 
representatives, in the case 
when several products are 
detailed during the same 
sales call 
- always adopting a sales strategy during launch 
whereby the new product is sold first in all sales 
calls 
(v) The sales force should 
be composed of a range 
between nine and thirteen 
sales representatives 
- significant effort should be put into allocation of the 
right-sizing of the sales force. The results here 
suggest a number between nine and thirteen sales 
representatives  
- having a larger size sales force than thirteen 
suggests inefficiency and might lead to lost profit 
- having a smaller size sales force than nine might 
jeopardize a successful launch    
 
(results apply to the new product launch target 
group and market investigated here) 
 
Five Important Key Success Factors
(i) Having established 
emotional commitment of 
sales representatives toward 
the launched product 
- plan and execute activities for emotional 
commitment, however, efficient investment is 
recommended 
 
(ii) Require the sales 
representatives to explain 
themselves when their sales 
objectives are not met 
- include in the control system, but do not over-invest 
in this effort 
- implement sales representatives to explain 
themselves as a formal process 
- communicate process as a means for sales 
representatives and management to have 
opportunities for ongoing objectives adjustments 
(iii) Having explained the 
product rationale for the 
sales representatives 
- include a thorough explanation by managers of the 
rationale for launching this product to sales 
representatives in the strategic plan 
- the rationale should include how the new product 
fits in the market place, for its customers and their 
customers as well as for the company  
- implement continuously during pre-launch and 
launch  
- clear inclusion in launch plans but with moderate 
investments to gain best profit situation 
(iv) acquiring sales 
representatives that 
possesses a systematic 
problem solving capability 
- place a specific recruitment criterion for sales 
representatives with a systematic problem-solving 
approach in the recruitment process  
- emphasize the recruitment criterion to a higher 
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rather than intuitive degree if the company’s defined processes for sales 
force control are developed and implemented to a 
high level 
(v) secure that the launched 
product is detailed by the 
sales representatives as a 
stand-alone product, rather 
than together with other 
products 
- when the costs of selling are not as critical for the 
overall business and full product portfolio success, 
selling the product alone should be considered as it 
increases likelihood for success 
- when the cost of selling is critical to overall 
business and full product portfolio success, the 
alternative of promoting the new product together 
with other products may be more attractive 
- also, include consideration around  how the sales 
force is organized before launching the product, as 
organizational changes might be disruptive for the 
sales force  
Launch Circumstances 
Ideal Market Conditions - the ideal market for launch success is unstable in its 
behavior and in rapid change  
- extra emphasis on the key success factor; activity 
accountability 
- more flexibility in sales targets for the sales force 
- avoid pushing for extensive customer or territory 
profiles 
- use more caution in the forecasting and budget 
process 
- prepare for a more flexible supply situation 
- for companies facing competing entry; consider 
more actions and contra- messaging 
- when the market conditions are not ideal, more 
accuracy in forecasts may be assumed 
- when the market conditions are not ideal, secure 
extra resources for all the key success factors 
Ideal Type of Product - the ideal type of product for a successful launch is 
when a product type is “not-new-to-the-market but 
new-to-the-firm”  
- make sure that a deliberately increased focus and 
effort are spent on the strategy formulation process 
when the product type is “not-new-to-the-market 
and not-new-to-the company”, compared to the 
other two type of new products 
 
 
 
 
 
 183 
 
6. SUMMARY AND CONCLUSIONS 
 
The overall aim of this research initiative was to provide guidance for sales force 
readiness during a new product launch. The research set out to answer the research 
question: What are the Key Success Factors for Sales Force Readiness during the 
Launch of a New Pharmaceutical Product on the Swedish Market? The overall 
conclusion is that this focused research area had not previously been researched and that 
the initiative did successfully answer the research question.  
 
The text below first provides a summary and conclusion for this research initiative, which 
is followed by the identified possibilities for further research.    
 
6.1. Research Summary and Conclusions 
 
The recent year’s changes and increased challenges to which the pharmaceutical industry, 
and especially the Big Pharma companies, is currently exposed, highlight the increased 
need for successful launches of new products. These challenges are many and appear in 
all parts of a pharmaceutical product’s life cycle. However, it is concluded that the launch 
phase is of particular importance for a product’s chance of quickly reaching peak sales 
and receiving return on investments for the company’s research efforts. Further, with the 
increased challenges in other parts of the life cycle, there is less, if any time available to 
re-launch a product without losing too much in potential sales. With detailing (sales calls) 
by sales representatives aimed at physicians being one of the most important components 
in the marketing mix for a pharmaceutical company, the sales force with its utilization 
and management is, together with the launch of new products, another key challenge for 
the pharmaceutical companies. The challenges for the sales force are for example 
increased cost, diminishing return on over-detailing and increased imposed regulations. 
This research dealt with a combination of the two key challenges; new product launch 
and sales force management, forming the defined area of “Sales force Readiness during 
New Product Launch”. “Sales force Readiness during New Product Launch” is broadly 
understood as the degree to which a sales force is prepared, able or willing to support a 
new product in order to generate a successful launch. In short, “Sales Force Readiness 
during New Product Launch” refers to a set of properties of the product to be introduced 
into a market place, the properties of such a market, the properties of the sales force 
conducting such an introduction, and then the outcome of such a product launch. 
 
The research was conducted in two parts; the first with a qualitative focus and the second 
with a quantitative focus. In the first, qualitative part of the research, the literature within 
the areas of Sales Force Management (including Selling), Product Launch and the 
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Pharmaceutical Industry was reviewed. The literature revealed little knowledge of the 
specific empirical situation investigated in this research; however six relevant models 
were found and utilized for formulating a Preliminary Model. These six key models 
formed the foundation of the theory and were derived from the literature area of new 
product adoption and sales force efficiency (Atuahene-Gima 1997; Baldauf and Cravens 
1999; Hultink and Atuahene-Gima 2000; Micheal et al. 2003; Piercy et al. 1999; Piercy et 
al. 1997). This Preliminary Model was transformed into a Research Model adapted for 
the focus and scope of this investigation. The scope was defined as: Industry 
(pharmaceutical) & Geographical (Sweden), Life Cycle Stage (new product launch), 
Pharmaceutical Products (ethical prescription drugs) & Customers (physicians). This 
transformation was guided by six case studies, six expert interviews and findings in the 
literature. The Research Model included a set of variables to be tested quantitatively with 
empirical data.  
 
The second research part, with a more quantitative focus, included the formulation of the 
data collection instrument, identification of subjects for investigation, data collection, 
statistical analysis and interpretation of the results. The research utilized a bottom-up 
pattern identifying research approach, employing the Partial Least Squares analysis (PLS) 
guided by e.g. Thomson (2004), Chin (1998) and Haenlein and Kaplan (2004). The test 
had a predictive aspiration, where PLS was considered more powerful than its current 
alternatives (Ryan et al. 1999). This analysis supplied knowledge in order to successfully 
answer the research question by identifying a set of key success factors for sales force 
readiness during new product launch. 
 
In the interpretation of the results, the identified key success factors have also 
successfully discriminated between four different types of key success factors: the key 
success factors that are important & crucial for a successful launch, the key success 
factors that are important, yet not necessarily crucial for a successful launch; the market 
conditions that are most ideal for a successful launch, and finally the type of newness of 
the product that is most suitable for launch. While the two first-mentioned key success 
factors can be more easily managed and influenced by the company launching the 
product, the latter two types of factors can typically not be influenced by the launching 
company; instead the company needs to adapt itself to the prevailing conditions.  
 
The important & crucial key success factor were: (i) establishing a high sales 
representative activity accountability; (ii) establishing a relation between the sales 
representatives and their sales managers where the sales representative can speak freely 
about any related issue; (iii) establishing medium- to high-intensive monitoring of the 
sales representatives’ sales behavior in the field; (iv) securing that the launched product is 
sold first by the sales representatives, in the case of several products being sold (detailed) 
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during the same sales call; and, finally (v) the sales force should be composed of a range 
between nine and thirteen sales representatives (note that this fifth factors is being very 
specific to the scope of this research). 
 
The important, yet not necessarily crucial, key success factors were: (i) having 
established emotional attachment of sales representatives toward the launched product; 
(ii) requiring that the sales representatives explain themselves when their sales objectives 
are not met; (iii) explaining the product rationale for the sales representatives; (iv) 
acquiring sales representatives who possess a systematic problem-solving capability 
rather than an intuitive one; and, (v) securing that the launched product is sold (detailed) 
by the sales representatives as a stand-alone product, rather than together with other 
products. 
 
Further, the ideal market for launch is unstable in its behavior and the market is changing 
rapidly. The ideal product should be of a type which is not new to the market, but of a 
new type for the firm launching it on the market. 
 
The results and their interpretation were also presented in terms of managerial 
implications and recommendations.  
 
The target groups for this research were defined as two types of professionals: 
researchers and practitioners. The first being the scholars studying and researching the 
area of product launch and sales force, while the second target group could be divided 
into the staff members, primarily managers of companies formulating and implementing 
sales force strategies, and business advisors such as consultants. This research has been 
found to contribute to both the academic scholars and to managers.  
 
This research’s main contribution to academic Scholars can be summarized in four 
important areas: 
 
The two developed models, the Preliminary Model and the Research Model.  
 
The Preliminary Model can be used for further research to either investigate 
generalization over industries or validate the result within the pharmaceutical industry, 
primarily in other geographical markets. The Research Model with its identified factors 
(with the methodological aspect of being built with triangulation of case studies, expert 
interviews and literature, which adds to the “real life” validation of the model) can be 
suggested to be applied directly (i.e. instead of building a new model with the 
Preliminary Model as base) for the validation or confirmation of the results in the same 
industry in other geographical markets. 
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The utilization of the Partial Least Square analysis 
 
With this research, a main contribution is the answer to the requests in the literature from 
several authors to more commonly apply Partial Least Square analysis to various social 
science disciplines (Cassel and Hackl 2000; Ryan et al. 1999), and also directly to 
marketing science (Graber et al. 2002). Further, conventional top-down hypotheses 
formulations and testing would be very cumbersome and undirected as there exists very 
little pre-knowledge regarding the investigated empirical domain. Indeed, in the present 
research, the results that have been received would most probably not have been obtained 
by means of conventional top-down research approach.  
 
The results 
 
As the generations of the results are done through the combination of literature review, 
case studies, qualitative interviews and quantitative empirical collection, the results 
provide a fairly unique dimension and validated learning to the collective scholarly 
knowledge within the area. Further, it is argued that with this research´s scope 
(geographical borders - giving similar regulatory, legal and governmental conditions; 
industry - adopting similar entry and exit barriers, risks and dynamics; and a homogenous 
group of research subjects - here manifested by pharmaceutical products aimed at the 
same homogenous customer group, defined as General Practitioners), the right level of 
limitations to the scope has been applied in order to identify interesting and relevant 
results. This gives the third main contribution, where the results and conclusions can be 
used as comparators and references in future investigations, analysis and discourse.  
 
Suggestions for further research  
 
Fourthly, the base and suggestions for further research laid out within this research 
constitute an outline for a serious and important research program to be explored and 
researched. 
 
This research’s main contribution to Practitioners (managers) can be summarized in 
three important areas, emerging out of the results: 
 
Focus attention on the most important factors for the sales force during launch 
 
As the literature presents many possible factors (variables) for a sales force that influence 
the outcome of a launch, these results will help guide Managers to focus attention on the 
elements that contribute most positively to a successful product launch among the factors 
investigated here.  
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Better prioritize resources 
 
With the sales force being a resource-consuming part (e.g. Kotler 2000; Piercy et al. 
1999; Piercy et al. 1997; Baldauf and Cravens 1999; Lilien et al. 1981; Dannacher and 
Stahl 2005; Elling et al. 2002) during the launch for a pharmaceutical company, the 
results here will help guide managers to better prioritize their available resources to the 
activities that contribute to the highest predictability of a successful launch. One example 
is the resources allocated to a sales manager’s monitoring in the field. The research 
results suggest that medium and high monitoring of the sales representative behavior in 
the field has contributed equally positively to a successful product launch. This clearly 
suggests that a high monitoring by the sales managers in the field, being very resource 
consuming, is not well-spent resources compared to keep the monitoring to a medium 
level.   
 
Guide the implementation of Sales Force Readiness  
 
The managerial recommendation presented in this research gives managers advice on 
how to practically implement sales force readiness, which is suggested to lead to a higher 
probability of success.   
 
 
In addition, this research should also be able to add value for companies with products 
already in the market where competitors are due to enter as these companies could benefit 
from better-informed defense strategies, both in terms of the company’s own actions 
around the key success factors and predicting what the competitor is going to do.  
 
In general, this research suggests being cautions with any uncritical generalizations 
outside the present scope. However, it is suggested that the findings here may well be 
assumed for the same industrial and operational domain and for the post-2005 year period 
to date, primarily for the North European markets. The reason for this is that this industry 
and markets show a great amount of homogeneity, and that the Swedish pharmaceutical 
industry lies ahead of the other markets in terms of its evolution with regard to the sales 
representatives’ access to the General Practitioners (Dannacher and Stahl 2005) and that 
the global emerging environment for pharmaceutical sales forces around the world is 
following this trend (Dutton and Reece 1996).  
 
It is the author’s aspiration that the results will add knowledge to future research 
colleagues’ endeavors, but first and foremost that the results, and their recommendations, 
will be helpful for managers in their future strategy formulation and implementation of 
sales force readiness during new product launch.    
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6.2. Limitations & Further Research  
 
This section first includes a discussion concerning some limitations and general areas for 
further research. This is followed by the presentation of a more structured proposed set of 
areas that may deserve further research attention. Limitations described here should be 
seen as an addition to the specified possible limitations of the Preliminary Model and 
formulation of the Research Model presented earlier in this text (Chapter 2, section 2.3.1 
and 2.4.1) 
 
Limitations and further research discussions 
 
One aim of this research is to provide managers, who are planning and executing the 
sales force operations during launch, with a set of key success factors that should make 
them better prepared and give them a higher probability of success for an upcoming 
product launch. It is the author’s belief that this has been achieved. However, at the same 
time it is acknowledged that there are many other aspects that might influence the success 
of a launch.  
 
As the scope of this research concerns the sales force operations during a new product 
launch, one important aspect among many of the identified sales force factors is that the 
factors are assumed to lead to a successful sales call (detailing), being the interaction 
between the sales representative and its primary customer (here the physician classified 
as a general practitioner), which in turn should generate an uptake in sales and by that be 
classified as a successful launch. The sales call is generally the most effective tool that is 
available for the sales force, hence the central driver of how the sales force contributes to 
the success. However, there are several stakeholders, both internal and external, that 
might influence the overall success of a new product launch.  
 
 
The internal stakeholders could include the marketing department, the medical 
department or any other department conducting market activities (as described in section 
1.6.). Here it should be added the possible tools (e.g. advertising and advisory boards) 
and channels (e.g. e-marketing) that could be utilized by the various departments to 
influence the success of a launch. Looking into the future, e-marketing is predicted to 
have a higher influence, with increases in both opportunities and risks for the business 
(Davis 2010; Jambulingam and Sharma 2010) and it is a very important area for further 
research to define the impact on sales force operations. Also, one important influencer is 
the R&D organization’s success in having conducted a trustworthy development of the 
product during the new product development phase (NPD) and also how they succeeded 
in making it appreciated among important key opinion leaders (Meffert 2009). The 
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importance of cross-functional work to achieve a successful product launch is also found 
in recent literature (Smith 2010).    
 
Continuing with the external stakeholder (as described in section 1.6.), it is important to 
expand the knowledge base on how these stakeholders influence a successful launch and 
to what degree. External stakeholders could be nurses, patients, relatives, pharmacies, etc. 
Payers, whether it is insurance companies, governments, finance departments in hospitals 
or patients, are gaining in importance concerning the uptake of a new pharmaceutical 
product (Ruzicic and Danner 2007). This is why it is also encouraged to find how these 
stakeholders influence sales force and launch. Also payers as a stakeholder have been 
identified as important in the pre-launch phase (Smith 2010).     
 
In addition to the importance of the different stakeholders comes the question of the 
impact of company culture, working climate and processes, as well as the medical benefit 
of the product (earlier discussed in section 4.2.3. Conclusions and Results from the Case 
Studies). As this research is conducted in a country-specific setting, it is assumed that the 
differences in cross-company cultures are insignificant to the results presented here. 
However, concerning cultural differences of country boarders is definitely an interesting 
addition to the model for further research conducted in several countries. Further, in this 
research the sales force factors are to a great extent separated from the emotional and 
motivational aspects of the customers. Some of these aspects are inherent in the model 
through the qualitative phase by the experience of the interviewed subjects, but only less 
so in the quantitative phase. Related to this is the impact of the external environment in 
terms of the product’s brand (built by the marketing department through other channels), 
the company’s reputation, social responsibility engagements, etc. Therefore, for the 
future, it is encouraged to consider how this could be implemented in the model or how 
this could be investigated to complement the results found in this research. In this aspect, 
identified interesting areas that could be related towards the models and concepts 
addressed here, would be the concept of relationship management (RM), which has 
successfully been researched through the years (Grönroos 1994; Gummesson 1997).  
 
Hence, concerning the Research Model, it will be interesting to further develop the 
current Model with the attempt to identify additional driving factors and moderating 
factors that would influence a successful launch.  
 
Another aspect that has been argued in this text is the cost for having a sales force and 
especially a field-based sales force. As outsourcing of sales forces has started to interest 
many companies (Rapp 2009), it might be of interest to also consider this approach for 
further research to find how different aspects of the launch and the sales force differ 
between the two alternatives.    
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It is hard to draw any final conclusion whether the results in this research are specific to 
the pharmaceutical industry or if it could be generalized to other industries. The literature 
argues that different industries and markets are governed by different conditions, for 
example, regulatory, economic, cultural and social etc. (McGahan 2004; Porter 1995; 
Porter 1987; Churchill Jr et al. 1985), and this has also been suggested to apply for the 
pharmaceutical industry (Dutton and Reece 1996). In regards to the key topic here (the 
sales force), a very important difference between the pharmaceutical industry and most 
other industries is the sales process and in particular the close of the sales, which is 
manifested by the fact that a sales representative does not close the sale. The sale is 
typically made in the pharmacy or by a hospital, making the sales representatives’ key 
role to deliver messages and provide information to their primary customers (the 
physicians), to educate customers about the product’s therapeutic value, side effects, 
dosage (based on clinical studies), and deliver samples to promote the company’s 
products (Dong-Gil and Dennis 2004; Lloyd and Newell 2001; Mizik and Jacobson 2004; 
Parsons and Abeele 1981; Rangaswamy et al. 1990). The sales connection is only made 
when a physician meets a suitable patient and writes a prescription, which the patient 
takes to the pharmacy to be dispensed (Datamonitor 2007b; Dong-Gil and Dennis 2004; 
Lloyd and Newell 2001).  
 
Hence, in industries with similar dynamics, a generalization of the results could more 
likely be made. However, since underlying sales processes and dynamics are also likely 
to be similar cross-industry, it might be found that the results are applicable over industry 
borders. These are possible topics for further research, as it should be fairly easy to 
investigate by applying the Preliminary Model to other industries. Preferably this would 
then be done using very similar methodology, i.e. utilizing case studies and interviews to 
first identify the most important factors and then quantitatively test an adopted model 
through PLS analysis. It would give a very good empirical base to compare the Key 
Success Factors across industries. This might also identify best practices over industry 
borders. 
 
Propositions for Further Research 
  
The discussion above concerning identified limitations and general encouragement for 
further research ideas, are followed here by a presentation of five more structured domain 
areas of potential further research, which cover the perceived most relevant part of the 
above discussions. See Figure 13 for an overview of the domain areas. The further 
research suggested here may be understood as representing two principal directions, an 
introspective and an extrospective. The introspective direction refers here to further 
development of details of the research scope as addressed in the present study. The 
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extrospective direction, on the other hand, refers to a broadening of the scope as 
addressed in the presented study.  
 
 
Figure 13: Five domains areas of potential further research  
 
 
 
 
Introspective Research Directions 
 
The research focus of this study is to identify the key success factors for sales force 
readiness, for pharmaceutical products launches in Sweden. This is the first empirically 
driven study of its kind. This uniqueness represents both opportunities and risks in 
relation to the research results presented here. As no similar studies exist that can be 
compared with the research results, the question of validity becomes a central issue. 
Therefore, one central proposal for the further research-agenda is to conduct either 
similar or partly-similar studies, which can be compared to the present one, and thus 
assess the validity of the research results presented. Ideally, such a similar study would be 
conducted with an independently collected data set and data analysis capabilities. 
 
The second area of research proposed here, indeed perhaps the most central area, is to 
address the type of constructs employed in this research to characterize the subject. The 
key question is whether there are enough constructs to do justice to the complexity of 
sales force readiness when launching a pharmaceutical product on the Swedish market. 
The present position is that the research results presented here, with the key success 
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factors identified, give a fair approximation of the real-life situation faced by sales 
directors when launching their pharmaceutical products. However, other research 
directions and the author’s own professional experience suggest that there may be other 
characteristics which would be useful for the description of the phenomenon addressed 
here. Examples of this could be a richer characterization of the market conditions or 
circumstances when the product is to be launched. One such category is “the position of 
the target group targeted by the launched product”, here the physicians versus the product 
to be launched. Another area is a further understanding of the characteristics of the sales 
representatives making up the sales force of the launched product, in relation to identified 
key success factors. 
  
Extrospective Research Directions 
 
In this section, a set of further research directions are discussed with the aim of 
broadening the research scope as assumed in this study. These cover five dimensions of 
the researched phenomenon, which are: (i) the geographical scope; (ii) the operational 
scope; (iii) the product lifecycle scope, (iv) the industry scope; and, (v) the target group 
scope. 
 
Geographical Extensions  
 
Starting with the Geographical scope, this study addresses the Swedish pharmaceutical 
market only. As discussed above, this was an intentional choice, as the Swedish market is 
assumed to have evolved ahead of other markets, particularly with regard to the 
regulations for the sales representatives’ access to their various customers: for example, 
physicians or local governmental officers. The understanding here is that the remaining 
Nordic markets will soon be governed by similar regulatory conditions, followed by other 
north European markets. Therefore, a proposed research topic is to replicate a similar 
study for the mentioned markets, and to identify the similarities and the differences, 
which could then be related to differences in the local market conditions. This would 
advance the insight into both the generic features and the market-specific features of sales 
force readiness for a pharmaceutical product launch. Again, this procedure could be 
replicated for more distant markets, such as Southern and Eastern Europe, and the North 
American market.  
 
Operational Extensions 
 
The next area of concern with regard to further research, addresses the operational 
aspects of a pharmaceutical product launch in Sweden. While the research presented here 
clearly focuses on sales force readiness as the determinant of a successful product launch, 
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other operational aspects of an organization (or a collaboration of several organizations) 
clearly have an impact on the outcome of a pharmaceutical product launch. Therefore, 
questions of interest for further research would be how to configure not only sales force 
readiness, but also marketing strategy and medical strategy, all aimed at enabling a 
successful launch of a pharmaceutical product. Such research would need to understand 
the mentioned operational areas in themselves and then proceed with an understanding of 
the aggregations of these areas, i.e. how their interaction together could best reach the 
desired success.  
 
Product Lifecycle Extensions 
 
Product lifecycle refers here to the various stages or phases of a product, from 
development through pre-launch preparation, launch, growth, maturity and then to its 
decline and sometimes withdrawal from the market (see Appendix 8 for further 
discussion and definition of the product lifecycle). These product lifecycle phases are the 
domain of this proposal for further research. While the research presented here addressed 
the key success factors for sales force readiness during the launch of a pharmaceutical 
product in the Swedish market, there is both an intellectual and a professional interest in 
finding out which success factors govern sales force strategy during the rest of the 
product lifecycle. 
 
Target Group Extensions 
 
The focus of the present study has been sales force readiness where its sales 
representatives target General Practitioners. However, there are clearly other relevant 
target groups to be addressed. Firstly, when part of the sales force targets the General 
Practitioners, other target groups are often addressed simultaneously, such as Key 
Opinion Leaders (typically leading medical professors) who influence the regular General 
Practitioners, the local governmental officers that allocate and balance resources for and 
between various medical diseases and treatments within a specific geographical region 
such as a county; the Heads of Health Centers who are responsible for distribution of 
resources and budgeting health center resources. The question for further research would 
be what kind of sales strategy should be devised for the sales representatives and 
professionals whose tasks are to address the other target groups as defined here. This 
could be researched in two ways. Firstly, what strategy should such a complementary 
sales force assume, to reach success? Secondly, what overall sales force strategy should 
be assumed for all the sales forces, addressing the various target groups, in order to 
secure a successful pharmaceutical launch? Should it be the same sales force or separate 
ones?  
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Industry Extensions 
 
The final area of further research, as mentioned here, addresses the industrial context. 
While this study focuses on the conditions in the pharmaceutical industry, several other 
industries may also be interested in knowledge and guidance for sales force readiness 
during successful product launch. As the study presented here may be regarded as having 
a business-to-professionals scope, where sales representatives address professionals 
within a heath care context, other industries manifest a similar structural set-up. 
Examples of this may be the Information Technology Industry, where companies 
launching new hardware and software products target IT-managers. Other professionals 
could include lawyers, facility brokers etc. Further research could investigate the key 
success factors of sales force readiness when launching products, such as software, and 
then compare the identified key success factors with those identified here for similarities 
and differences, and for how the present study could be further developed with lessons 
learned from other industries. 
 
Summary of Further Research Proposals 
 
The discussion above presents five domains which may deserve attention for further 
research initiatives with regard to the present study. These domains include the 
geographical extensions, the operational extensions, the product lifecycle extensions, the 
target group extensions and the industry extensions. Each domain offers three or more 
sub-domains to be explored – e.g. product lifecycle offers the pre-launch, growth, 
maturity, and decline phases. If the five main domains proposed here are combined with 
their constituting sub-domains, we will receive at least fifteen sub-domains for further 
research. Clearly, this may constitute an outline for a serious and important research 
program to be explored and researched.  
 
  
 195 
 
REFERENCES  
 
 
Achrol, Ravi S. and Louis W. Stern (1988), "Environmental Determinants of Decision-
Making Uncertainty in Marketing Channels," Journal of Marketing Research (JMR), 25 
(1), 36-50. 
 
Agarwal, Sanjeev (1999), "Impact of Job Formalization and Administrative Controls on 
Attitudes of Industrial Salespersons," Industrial Marketing Management, 28 (4), 359-68. 
 
Agnetis, Alessandro, Enza Messina, and Marco Pranzo (2010), "Call planning in 
European pharmaceutical sales force management," in IMA Journal of Management 
Mathematics Vol. 21. 
 
Anderson, Erin and Richard L. Oliver (1987), "Perspectives on Behavior-Based Versus 
Outcome-Based Salesforce Control Systems," Journal of Marketing, 51 (4), 76-88. 
 
Anderson, Erin and Thomas S. Robertson (1995), "Inducing multiline salespeople to 
adopt house brands," Journal of Marketing, 59 (2), 16. 
 
Atuahene-Gima, Kwaku (1997), "Adoption of New Products By the Sales Force: The 
Construct, Research Propositions and Managerial Implications," Journal of Product 
Innovation Management, 14 (6), 498-514. 
 
Atuahene-Gima, Kwaku and Haiyang Li (2006), "The Effects of Formal Controls on 
Supervisee Trust in the Manager in New Product Selling: Evidence from Young and 
Inexperienced Salespeople in China," Journal of Product Innovation Management, 23 (4), 
342-58. 
 
Atuahene-Gima, Kwaku and Kamel Micheal (1998), "A contingency analysis of the 
impact of salesperson's effort on satisfaction and performance in selling new products," 
European Journal of Marketing, 32 (9/10), 904-21. 
 
Babakus, Emin, David W. Cravens, Ken Grant, Thomas N. Ingram, and Raymond W. 
LaForge (1996), "Investigating the relationships among sales, management control, sales 
territory design, salesperson performance, and sales organization effectiveness," 
International Journal of Research in Marketing, 13 (4), 345-63. 
 
Baldauf, Artur and David W. Cravens (1999), "Improving the Effectiveness of Field 
Sales Organizations," Industrial Marketing Management, 28 (1), 63-72. 
 
Baldauf, Artur, David W. Cravens, and Nigel F. Piercy (2001a), "Examining Business 
Strategy, Sales Management, and Salesperson Antecedents of Sales Organization 
Effectiveness," Journal of Personal Selling & Sales Management, 21 (2), 109. 
 
 196 
 
---- (2001b), "Examining the consequences of sales management control strategies in 
European field sales organizations," International Marketing Review, 18 (5), 474. 
 
---- (2005), "SALES MANAGEMENT CONTROL RESEARCH--SYNTHESIS AND 
AN AGENDA FOR FUTURE RESEARCH," Journal of Personal Selling & Sales 
Management, 25 (1), 7-26. 
 
Ballance, Robert, Janos Pogany, and Helmut Forstner (1992), The world's pharmaceutical 
industries: An international perspective on innovation, competition and policy: Aldershot, 
U.K.: 
Elgar; distributed in the U.S. by Ashgate, Brookfield, Vt. 
 
Behrman, Douglas N. and William D. Perreault Jr (1982), "Measuring the Performance 
of Industrial Salespersons," in Journal of Business Research Vol. 10. 
 
Bello, Daniel C. and David I. Gilliland (1997), "The Effect of Output Controls, Process 
Controls, and Flexibility on Export Channel Performance," Journal of Marketing, 61 (1), 
22-38. 
 
Beswick, Charles A. and David W. Cravens (1977), "A Multistage Decision Model for 
Salesforce Management," Journal of Marketing Research (JMR), 14 (2), 135-44. 
 
Blackshear, Thomas and Richard E. Plank (1994), "THE IMPACT OF ADAPTIVE 
SELLING ON SALES EFFECTIVENESS WITHIN THE PARMACEUTICAL 
INDUSTRY," Journal of Marketing Theory & Practice, 2 (3), 106. 
 
Bonner, Joseph M., Robert W. Ruekert, and Orville C. Walker (2002), "Upper 
management control of new product development projects and project performance," 
Journal of Product Innovation Management, 19 (3), 233-45. 
 
Brown, Robert and Timothy Mazzarol (2009), "The importance of institutional image to 
student satisfaction and loyalty within higher education," in Higher Education Vol. 58. 
 
Bush, Alan J. and E. Stephen Grant (1991), "An Analysis of Leading Contributors to the 
Sales Force Research Literature, 1980 Through 1990," Journal of Personal Selling & 
Sales Management, 11 (3), 47. 
 
Bush, Man J. and K. Stephen Grant (1994), "Analyzing the Content of Marketing 
Journals to Assess Trends in Sales Force Research: 1980-1992," Journal of Personal 
Selling & Sales Management, 14 (3), 57-68. 
 
Calantone, Roger and Robert G. Cooper (1981), "NEW PRODUCT SCENARIOS: 
PROSPECTS FOR SUCCESS," Journal of Marketing, 45 (2), 48-60. 
 
 197 
 
Calantone, Roger J., Jeffrey B. Schmidt, and X. Michael Song (1996), "Controllable 
factors of new product success: A cross-national comparison," Marketing Science, 15 (4), 
341. 
 
Cassel, Claes M. and Peter Hackl (2000), "On measurement of intangible assets: a study 
of robustness of partial least squares," in Total Quality Management Vol. 11: Carfax 
Publishing Company. 
 
Challagalla, Goutam N. and Tasadduq A. Shervani (1996), "Dimensions and Types of 
Supervisory Control: Effects on Salesperson Performance and Satisfaction," Journal of 
Marketing, 60 (1), 89-105. 
 
---- (1997), "A Measurement Model of the Dimensions and Types of Output and 
Behavior Control: An Empirical Test in a Salesforce Context," Journal of Business 
Research, 39 (3), 159-72. 
 
Chin, W. W. Ed. (1998), The partial least squares approach to structural equation 
modelling. In G. A. Marcoulides (Ed.), Modern methods for business research (pp. 295-
336). Mahwah: Lawrence Erlbaum Associates. 
 
Choffray, Jean Marie and Gary L. Lilien (1986), "A Decision-Support System for 
Evaluating Sales Prospects and Launch Strategies for New Products," Industrial 
Marketing Management, 15 (1), 75-85. 
 
Churchill, Gilbert A., Jr. , Neil M. Ford, and Orville C. Walker, Jr. (1997), Sales Force 
Management (5th ed.). Chicago, IL: Irwin. 
 
Churchill Jr, Gilbert A., Neil M. Ford, Steven W. Hartley, and Orville C. Walker Jr 
(1985), "The Determinants of Salesperson Performance: A Meta-Analysis," Journal of 
Marketing Research (JMR), 22 (2), 103-18. 
 
CMR (2005), "Centre of Medicine Research, 2005 Report," CMR International, a 
Thomson Reuters business. 
 
Cooper, R. G. (1979), "THE DIMENSIONS OF INDUSTRIAL NEW PRODUCT 
SUCCESS AND FAILURE," Journal of Marketing, 43 (3), 93-103. 
 
Cooper, Robert (1998), "Benchmarking new product performance: Results of the best 
practices study," European Management Journal, 16 (1), 1. 
 
Cooper, Robert G. (1980), "Project NewProd: Factors in New Product Success," 
European Journal of Marketing, 14 (5/6), 277. 
 
---- (2000), "WINNING WITH NEW PRODUCTS: DOING IT RIGHT," Ivey Business 
Journal, 64 (6), 54. 
 
 198 
 
Cooper, Robert G. and Elko J. Kleinschmidt (2000), "New Product Performance: What 
Distinguishes the Star Products," Australian Journal of Management, 25 (1), 17. 
 
Corcoran, K. J., L. K.  Peterson, D. B.  Baitch, and M. F.   Barrett (1995), High 
Performance Sales Organizations: Irwin Professional Publishing, Chicago. 
 
Cravens, David W. (1995), "The Changing Role of the Sales Force," Marketing 
Management, 4 (2), 48-57. 
 
Cravens, David W., Thomas N. Ingram, Raymond W. LaForge, and Clifford E. Young 
(1993), "Behavior-based and outcome-based salesforce control systems," Journal of 
Marketing, 57 (4), 47. 
 
---- (1992), "Hallmarks of effective sales organizations," Marketing Management, 1 (1), 
56-66. 
 
Cravens, David W., Felicia G. Lassk, George S. Low, Greg W. Marshall, and William C. 
Moncrief (2004), "Formal and informal management control combinations in sales 
organizations: The impact on salesperson consequences," in Journal of Business Research 
Vol. 57. 
 
Cravens, David W., Robert B. Woodruff, and Joe C. Stamper (1972), "An Analytical 
Approach for Evaluating Sales Territory Performance," Journal of Marketing, 36 (1), 31-
37. 
 
Dannacher, Frank and Tommy Stahl (2005), "Improving Sales Force Effectiveness - a 
New Challenge in Sweden," in PharmaIndustry Vol. June 2005. 
 
Datamonitor (2007a), "Pfizer: timley response to industry challenges." March 2007 ed.: 
Datamonitor, MarketWatch: Pharmaceuticals. 
 
---- (2007b), "Pharmaceuticals Industry Profile: Sweden," in Pharmaceuticals Industry 
Profile: Sweden: Datamonitor Plc. 
 
Davies, Iain A. , Lynette J. Ryals, and Sue Holt (2010), "Relationship management: A 
sales role, or state of mind? An investigation of functions and attitudes across a business-
to-business sales force," Industrial Marketing Management (39), 1049-62. 
 
Davis, Joel J. (2010), "The challenge of Google Sidewiki for pharmaceutical marketers," 
in Journal of Medical Marketing Vol. 10. 
 
di Benedetto, C. Anthony (1999), "Identifying the Key Success Factors in New Product 
Launch," Journal of Product Innovation Management, 16 (6), 530-44. 
 
 199 
 
Dimasi, Joseph A. and Henry G. Grabowski (1995), "R&D costs, innovative output and 
firm size in the pharmaceutical industry," International Journal of the Economics of 
Business, 2 (2), 201. 
 
Dinu, Vasile and Laurentiu Tachiciu (2009), "Selling with Entrepreneurial Spirit: The 
Sales-Entrepreneur," Amfiteatru Economic, 11 (25), 21-28. 
 
Dong-Gil, Ko and Alan R. Dennis (2004), "SALES FORCE AUTOMATION AND 
SALES PERFORMANCE: DO EXPERIENCE AND EXPERTISE MATTER?," Journal 
of Personal Selling & Sales Management, 24 (4), 311-22. 
 
Dubinsky, Alan J. and Thomas E. Barry (1982), "A Survey of Sales Management 
Practices," Industrial Marketing Management, 11 (2), 133-41. 
 
Dubinsky, Alan J. and Richard W. Hansen (1981), "The Sales Force Management Audit," 
California Management Review, 24 (2), 86-95. 
 
Dutton, James E. and Michelle A. Reece (1996), "The Impact of Current Trends in 
Health Care on the Pharmaceutical Sales Force of the Future," Journal Of Pharmaceutical 
Marketing & Management, 10 (4), 237 - 49. 
 
EIU (2005), "Healthcare & Pharmaceuticals Forecast World," in Healthcare & 
Pharmaceuticals Forecast World: EIU: Economist Intelligence Unit. 
 
Elling, Martin, Chris Simon, and Chas McKhann (2002), "Making more of pharma's sales 
force," McKinsey Quarterly (3), 86-95. 
 
Engle, Robert L. and Michael L. Barnes (2000), "Sales force automation usage, 
effectiveness, and cost-benefit in Germany, England and the United States," Journal of 
Business & Industrial Marketing, 15 (4/5), 216. 
 
Froud, Julie, Colin Haslam, Sukhdev Johal, Karel Williams, and Robert Willis (1998), 
"British pharmaceuticals: a cautionary tale," Economy and society, 27 (4), 554-84. 
 
FTC (2002), "Federal Trade Commission, July FTC Study: Generic Drug Entry Prior to 
Patent Expiration." 
 
Futrell, Charles M., John E. Swan, and John T. Todd (1976), "Job Performance Related 
to Management Control Systems for Pharmaceutical Salesmen," Journal of Marketing 
Research (JMR), 13 (1), 25-33. 
 
Futrell, Charles, A. Parasuraman, and Jeffrey Sager (1983), "Sales Force Evaluation with 
Expectancy Theory," Industrial Marketing Management, 12 (2), 125-29. 
 
Garthwaite, Paul H. (1994), "An Interpretation of Partial Least Squares," Journal of the 
American Statistical Association, 89 (425), 122-27. 
 200 
 
 
Geladi, Paul and Bruce R. Kowalski (1986), "Partial least-squares regression: a tutorial," 
Analytica Chimica Acta, 185, 1-17. 
 
Giacobbe, Ralph W., Donald W. Jackson Jr, Lawrence A. Crosby, and Claudia M. 
Bridges (2006), "A CONTINGENCY APPROACH TO ADAPTIVE SELLING 
BEHAVIOR AND SALES PERFORMANCE: SELLING SITUATIONS AND 
SALESPERSON CHARACTERISTICS," Journal of Personal Selling & Sales 
Management, 26 (2), 115-42. 
 
Gilbert, J.P., P. Henske, and S. Singh (2003), "Rebuilding Big Pharma's Business 
Model," In Vivo, the Business and Medicine Report, Windhover Information Inc., Vol 
21, No. 10. November 2003. 
 
Gonul, Fusun F., Franklin Carter, Elina Petrova, and Kannan Srinivasan (2001), 
"Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior," 
Journal of Marketing, 65 (3), 79-90. 
 
Graber, Stéphane, Sandor Czellar, and Jean-Emile Denis (2002), "Using Partial Least 
Squares Regression in Marketing Research," University of Geneva. 
 
Grant, Ken and David W. Cravens (1996), "Examining Sales Force Performance in 
Organizations that Use Behavior-Based Sales Management Processes," Industrial 
Marketing Management, 25 (5), 361-71. 
 
Green, Donna H., Donald W. Barclay, and Adrian B. Ryans (1995), "Entry strategy and 
long-term performance: Conceptualization and empirical examination," Journal of 
Marketing, 59 (4), 1. 
 
Griffin, Abbie and Albert L. Page (1993), "An Interim Report on Measuring Product 
Development Success and Failure," Journal of Product Innovation Management, 10 (4), 
291-308. 
 
---- (1996), "PDMA Success Measurement Project: Recommended Measures for Product 
Development Success and Failure," Journal of Product Innovation Management, 13 (6), 
478-96. 
 
Grönroos, Christian (1994), "From Marketing Mix to Relationship Marketing: Towards a 
Paradigm Shift in Marketing," Management Decision, 32 (2), 4-20. 
 
Guiltinan, Joseph P. (1999), "Launch Strategy, Launch Tactics, and Demand Outcomes," 
Journal of Product Innovation Management, 16 (6), 509-29. 
 
Gummesson, Evert (1997), "Relationship marketing as a paradigm shift: Some 
conclusions from the 30R approach," Management Decision, 35 (3/4), 267. 
 
 201 
 
Haenlein, Michael and Andreas M. Kaplan (2004), "A Beginner's Guide to Partial Least 
Squares Analysis," Understanding Statistics, 3 (4), 283-97. 
 
Hahn, Minhi, Sehoon Park, Lakshman Krishnamurthi, and Andris A. Zoltners (1994), 
"ANALYSIS OF NEW PRODUCT DIFFUSION USING A FOUR-SEGMENT TRIAL-
REPEAT MODEL," Marketing Science, 13 (3), 224-47. 
 
Hernandez-Maestro, Rosa M., Pablo A. MuÃ±oz-Gallego, and Libia Santos-Requejo 
(2009), "Small-Business Owners' Knowledge and Rural Tourism Establishment 
Performance in Spain," in Journal of Travel Research Vol. 48. 
 
Hise, Richard T. and Edward L. Reid (1994), "Improving the Performance of the 
Industrial Sales Force in the 1990s," Industrial Marketing Management, 23 (4), 273-79. 
 
House, R.J. and T.R. Mitchell (1974), "Path-goal theory of leadership," Journal of 
Contemporary Business, 3, 81-97. 
 
Hultink, Erik Jan and Kwaku Atuahene-Gima (2000), "The effect of sales force adoption 
on new product selling performance," Journal of Product Innovation Management, 17 (6), 
435-50. 
 
Hultink, Erik Jan, Abbie Griffin, Susan Hart, and Henry S. J. Robben (1997), "Industrial 
New Product Launch Strategies and Product Development Performance," Journal of 
Product Innovation Management, 14 (4), 243-57. 
 
Hultink, Erik Jan, Susan J. Hart, Henry S. J. Robben, and Abbie J. Griffin (1999), "New 
consumer product launch: strategies and performance," Journal of Strategic Marketing, 7 
(3), 153-74. 
 
Hultink, Erik Jan and Henry S. J. Robben (1999), "Launch Strategy and New Product 
Performance: An Empirical Examination in The Netherlands," Journal of Product 
Innovation Management, 16 (6), 545-56. 
 
---- (1995), "Measuring New Product Success: The Difference that Time Perspective 
Makes," Journal of Product Innovation Management, 12 (5), 392-405. 
 
IMS (2008), "Generic Analogue Analysis Report, January 2008." 
 
---- (2006), "Generics Market Prognosis Report." 
 
---- (2007), "Market Insights Report, October 2007," IMS Health. 
 
Ingram, Thomas N. (2004), "FUTURE THEMES IN SALES AND SALES 
MANAGEMENT: COMPLEXITY, COLLABORATION, AND ACCOUNTABILITY," 
Journal of Marketing Theory & Practice, 12 (4), 18-28. 
 
 202 
 
Jabri, M. M. (1991), "The development of conceptually independent subscales in the 
measurement of modes of problem," Educational & Psychological Measurement, 51 (4), 
975. 
 
Jambulingam, Thani and Rajneesh Sharma (2010), "Estimating the value of internet 
marketing in the US pharmaceutical industry," in Journal of Medical Marketing Vol. 10. 
 
Jaworski, Bernard J. (1988), "Toward a Theory of Marketing Control: Environmental 
Context, Control Types, and Consequences," Journal of Marketing, 52 (3), 23-39. 
 
Jaworski, Bernard J. and Ajay K. Kohl (1991), "Supervisory Feedback: Alternative Types 
and Their Impact on Salespeople's Performance and Satisfaction," in Journal of 
Marketing Research (JMR) Vol. 28: American Marketing Association. 
 
Jaworski, Bernard J. and Deborah J. MacInnis (1989), "Marketing Jobs and Management 
Controls: Toward a Framework," Journal of Marketing Research (JMR), 26 (4), 406-19. 
 
Jaworski, Bernard J., Vlasis Stathakopoulos, and H. Shanker Krishnan (1993), "Control 
Combinations in Marketing: Conceptual Framework and Empirical Evidence," in Journal 
of Marketing Vol. 57: American Marketing Association. 
 
Kleinschmidt, E. J. and R. G. Cooper (1991), "The Impact of Product Innovativeness on 
Performance," Journal of Product Innovation Management, 8 (4), 240-51. 
 
Kolassa, E.M. (1997), Elements of Pharmaceutical Pricing The Pharmaceutical Products 
Press, NY. 
 
Kotler, Philip (2000), Marketing Management, The millennium edition. : Prentice-Hall, 
NY. 
 
Krafft, Manfred (1999), "An Empirical Investigation of the Antecedents of Sales Force 
Control Systems," Journal of Marketing, 63 (3), 120-34. 
 
LaForge, Raymond W. and David W. Cravens (1985), "EMPIRICAL AND 
JUDGMENT-BASED SALES-FORCE DECISION MODELS: A COMPARATIVE 
ANALYSIS," Decision Sciences, 16 (2), 177-95. 
 
Legernaes, Kjell (2003), "Zoloft - från nolll till markandsledare på sju år," in Pharma 
Industy Vol. 2. 
 
Lilien, Gary L., Ambar G. Rao, and Shlomo Kalish (1981), "BAYESIAN ESTIMATION 
AND CONTROL OF DETAILING EFFORT IN A REPEAT PURCHASE DIFFUSION 
ENVIRONMENT," Management Science, 27 (5), 493-506. 
 
 203 
 
Lloyd, Caroline and Helen Newell (2001), "Capture and transfer: improving the 
performance of the pharmaceutical sales rep," International Journal of Human Resource 
Management, 12 (3), 464-83. 
 
Lusch, Robert F., Thomas Boyt, and Drue Schuler (1996), "Employees as Customers: 
The Role of Social Controls and Employee Socialization in Developing Patronage," in 
Journal of Business Research Vol. 35. 
 
Lusch, Robert F. and Bernard J. Jaworski (1991), "Management Controls, Role Stress, 
and Retail Store Manager Performance," in Journal of Retailing Vol. 67: Elsevier Science 
Publishing Company, Inc. 
 
Manchanda, Puneet and Pradeep K. Chintagijnta (2004), "Responsiveness of Physician 
Prescription Behavior to Salesforce Effort: An Individual Level Analysis," Marketing 
Letters, 15 (2/3), 129-45. 
 
Mathieu, J. E. and D. M. Zajac (1990), "A review and meta-analysis of the antecedents, 
correlates, and consequences of organizational," Psychological Bulletin, 108 (2), 171. 
 
McBane, Donald A., Ellen Bolman Pullins, and David A. Reid (2003), "SalesLitDB: A 
CLASSIFICATION SYSTEM AND INDEX OF THE SALES-RELATED 
LITERATURE," Journal of Personal Selling & Sales Management, 23 (2), 115-23. 
 
McGahan, Anita M. (2004), "HOW INDUSTRIES CHANGE," Harvard Business 
Review, 82 (10), 86-94. 
 
Meffert, Jeffrey J. (2009), "Key opinion leaders: where they come from and how that 
affects the drugs you prescribe," in Dermatologic Therapy Vol. 22: Wiley-Blackwell. 
 
Menguc, Bulent and A. Tansu Barker (2003), "THE PERFORMANCE EFFECTS OF 
OUTCOME-BASED INCENTIVE PAY PLANS ON SALES ORGANIZATIONS: A 
CONTEXTUAL ANALYSIS," in Journal of Personal Selling & Sales Management Vol. 
23: M.E. Sharpe Inc. 
 
Meyer, John P. and Natalie J. Allen (1991), "A THREE-COMPONENT 
CONCEPTUALIZATION OF ORGANIZATIONAL COMMITMENT," Human 
Resource Management Review, 1 (1), 61. 
 
Micheal, Kamel, Linda Rochford, and Thomas R. Wotruba (2003), "How New Product 
Introductions Affect Sales Management Strategy: The Impact of Type of 
â€œNewnessâ€ of the New Product," Journal of Product Innovation Management, 20 
(4), 270-83. 
 
MIDAS-Database (2007a), "IMS MIDAS Global Database - Ethical pharmaceuticals 
2007 3Q MAT data." 
 
 204 
 
---- (2007b), "IMS MIDAS Global Database - Ethical pharmaceuticals: market share and 
sales data 1995-2007." 
 
Mizik, Natalie and Robert Jacobson (2004), "Are Physicians "Easy Marks"? Quantifying 
the Effects of Detailing and Sampling on New Prescriptions," Management Science, 50 
(12), 1704-15. 
 
Moncrief, William C., Greg W. Marshall, Courtney Watkins, and C. David Shepherd 
(2000), "Tracking Academic Research in Selling and Sales Management: Authors, 
Authorships, Academic Institutions, and Journals," Journal of Personal Selling & Sales 
Management, 20 (2), 99-108. 
 
Montoya-Weiss, Mitzi M. and Roger Calantone (1994), "Determinants of New Product 
Performance: A Review and Meta-Analysis," Journal of Product Innovation 
Management, 11 (5), 397-417. 
 
Moriarty, Rowland T. and Thomas J. Kosnik (1989), "High-tech marketing - concepts, 
continuity, and change," Sloan management review, 30 (4), 7-18. 
 
Mulki, Jay Prakash, Fernando Jaramillo, and Greg W. Marshall (2007), "LONE WOLF 
TENDENCIES AND SALESPERSON PERFORMANCE," Journal of Personal Selling 
& Sales Management, 27 (1), 25-38. 
 
Murphy, William H. and Peter A. Dacin (2009), "Sales contest research: Business and 
individual difference factors affecting intentions to pursue contest goals," Industrial 
Marketing Management, 38 (1), 109-18. 
 
Oliver, Richard L. and Erin Anderson (1995), "Behavior- and Outcome-Based Sales 
Control Systems: Evidence and Consequences of Pure-Form and Hybrid Governance," in 
Journal of Personal Selling & Sales Management Vol. 15: M.E. Sharpe Inc. 
 
---- (1994), "An empirical test of the consequences of behavior-and outcome-based sales 
control systems," Journal of Marketing, 58 (4), 53. 
 
Ouchi, William G. (1979), "A CONCEPTUAL FRAMEWORK FOR THE DESIGN OF 
ORGANIZATIONAL CONTROL MECHANISMS," Management Science, 25 (9), 833-
48. 
 
Parsons, Leonard Jon and Piet Vanden Abeele (1981), "Analysis of Sales Call 
Effectiveness," Journal of Marketing Research (JMR), 18 (1), 107-13. 
 
Pathak, D.S., A. Escovitz, and S. Kucukarslan (1992), Promotion of Pharmaceutical: 
Issues, Trends, Options: Pharmaceutical Products Press, NY. 
 
 205 
 
Payne, Roy L., Dawn Lane, and Muayyad Jabri (1990), "A Two-Dimensional Person-
Environment Fit Analysis of the Performance, Effort and Satisfaction of Research 
Scientists," British Journal of Management, 1 (1), 45. 
 
PhARMA (2005), "Tuffs CSDD Approved NCE Database." 
 
Pharmaceutical-Executive-Europe (2006). 
 
PhRMA (2001), "Based on Data from PhRMA Annual Survey and Standard & Poor’s 
Compustat, a Division of McGraw-Hill. ." 
 
---- (2003), "PhRMA 2003 Annual Report." 
 
---- (1995), "PhRMA, Data from from Center for the Study of Drug Development, Tuffs 
University." 
 
---- (2005), "Tuffs CSDD Approved NCE Database." 
 
Piercy, Nigel F., David W. Cravens, and Nikala Lane (2009), "Sales management control 
level and competencies: Antecedents and consequences," Industrial Marketing 
Management, 38 (4), 459-67. 
 
Piercy, Nigel F., David W. Cravens, and Neil A. Morgan (1999), "Relationships between 
Sales Management Control, Territory Design, Salesforce Performance and Sales 
Organization Effectiveness," British Journal of Management, 10 (2), 95-111. 
 
---- (1997), "Sources of effectiveness in the business-to-business sales organization," 
Journal of Marketing Practice: Applied Marketing Science, 3 (1), 45 - 71. 
 
Piercy, Nigel F., George S. Low, and David W. Cravens (2004), "Examining the 
effectiveness of sales management control practices in developing countries," Journal of 
World Business, 39 (3), 255-67. 
 
Popper, Kathleen M. LaFrancis and Robert W. Nason (1994), "The Drug Lag: A 20-Year 
Analysis of Six Country Markets," Journal of Public Policy & Marketing, 13 (2), 290-99. 
 
Porter, Michael E. (1995), CompetitiveAdvantage, Creating and Sustaining Superior 
Performance: The Free Press, NY. 
 
---- (1987), "From competitive advantage to corporate strategy," Harvard Business 
Review, 65 (3), 43-59. 
 
Rackham, Neil (1998), "From Experience: Why Bad Things Happen to Good New 
Products," Journal of Product Innovation Management, 15 (3), 201-07. 
 
 206 
 
Ramaswami, Sridhar N. (2002), "INFLUENCE OF CONTROL SYSTEMS ON 
OPPORTUNISTIC BEHAVIORS OF SALESPEOPLE: A TEST OF GENDER 
DIFFERENCES," in Journal of Personal Selling & Sales Management Vol. 22: M.E. 
Sharpe Inc. 
 
---- (1996), "Marketing Controls and Dysfunctional Employee Behaviors: A Test of 
Traditional and Contingency Theory Postulates," Journal of Marketing, 60 (2), 105-20. 
 
Rangaswamy, Arvind, Prabhak Ant Sinha, and Andris Zoltners (1990), "AN 
INTEGRATION MODEL-BASED APPROACH FOR SALES FORCE 
STRUCTURING," Marketing Science, 9 (4), 279. 
 
Rao, Sanjay K. (2000a), "A Marketing Decision Support System For Pricing New 
Pharmaceutical Products," Marketing Research, 12 (4), 21-29. 
 
---- (2000b), "Marketing Decision Support Systems for Strategy Building," Marketing 
Health Services, 20 (2), 14-18. 
 
---- (2002), "Pharmaceutical Marketing in a New Age. (cover story)," Marketing Health 
Services, 22 (1), 6-12. 
 
Rapp, Adam (2009), "Outsourcing the sales process: Hiring a mercenary sales force," in 
Industrial Marketing Management Vol. 38. 
 
Rhee, James (2009), "The Influence of the Pharmaceutical Industry on Healthcare 
Practitioners' Prescribing Habits," in Internet Journal of Academic Physician Assistants 
Vol. 7: Internet Scientific Publications LLC. 
 
Robertson, Diana C. and Erin Anderson (1993), "CONTROL SYSTEM AND TASK 
ENVIRONMENT EFFECTS ON ETHICAL JUDGMENT: AN EXPLORATORY 
STUDY OF INDUSTRIAL SALESPEOPLE," in Organization Science Vol. 4: 
INFORMS: Institute for Operations Research. 
 
Rochford, Linda and Thomas R. Wotruba (1996), "The Impact of Sales Management 
Changes on New Product Success," Journal of the Academy of Marketing Science, 24 
(3), 263. 
 
---- (1993), "New Product Development under Changing Economic Conditions: THE 
ROLE OF THE SALESFORCE," Journal of Business & Industrial Marketing, 8 (3), 4-
12. 
 
Rod, Michel, Nicholas J.  Ashill, and Janet Carruthers (2007), "Pharmaceutical marketing 
return-on-investment: a European perspective," International Journal of Pharmceutical 
and Healthcare Marketing, 1 (2), 174-89. 
 
 207 
 
Rouzies, Dominique and Anne Macquin (2003), "AN EXPLORATORY 
INVESTIGATION OF THE IMPACT OF CULTURE ON SALES FORCE 
MANAGEMENT CONTROL SYSTEMS IN EUROPE," Journal of Personal Selling & 
Sales Management, 23 (1), 61-72. 
 
Ruzicic, Aleksandar and Stephan Danner (2007), "Marketing Masterclass: Salesforce 
effectiveness: Is the pharmaceutical industry going in the right direction?," in Journal of 
Medical Marketing Vol. 7: Palgrave Macmillan Ltd. 
 
Ryan, Michael J., Robert Rayner, and Andy Morrison (1999), "Diagnosing Customer 
Loyalty Drivers," Marketing Research, 11 (2), 19-26. 
 
Ryans, Adrian B. and Charles B. Weinberg (1979), "Territory Sales Response," in 
Journal of Marketing Research (JMR) Vol. 16: American Marketing Association. 
 
---- (1987), "Territory Sales Response Models: Stability Over Time," in Journal of 
Marketing Research (JMR) Vol. 24: American Marketing Association. 
 
Sager, Jeffrey K. (1994), "A Structural Model Depicting Salespeople's Job Stress," 
Journal of the Academy of Marketing Science, 22 (1), 74-84. 
 
Sager, Jeffrey K. and Gerald R. Ferris (1986), "Personality and Salesforce Selection in 
the Pharmaceutical Industry," Industrial Marketing Management, 15 (4), 319-24. 
 
Sandberg, Birgitta (2002), "Creating the market for disruptive innovation: Market 
proactiveness at the launch stage," Journal of Targeting, Measurement & Analysis for 
Marketing, 11 (2), 184. 
 
Schwepker Jr, Charles H. (2003), "CUSTOMER-ORIENTED SELLING: A REVIEW, 
EXTENSION, AND DIRECTIONS FOR FUTURE RESEARCH," Journal of Personal 
Selling & Sales Management, 23 (2), 151-71. 
 
Scott, Susanne G. and Reginald A. Bruce (1994), "DETERMINANTS OF 
INNOVATIVE BEHAVIOR: A PATH MODEL OF INDIVIDUAL INNOVATION IN 
THE WORKPLACE," Academy of Management Journal, 37 (3), 580-607. 
 
Shane, Scott (1994a), "Cultural Values and the Championing Process," Entrepreneurship: 
Theory & Practice, 18 (4), 25-41. 
 
---- (1994b), "THE EFFECT OF NATIONAL CULTURE ON THE CHOICE 
BETWEEN LICENSING AND DIRECT FOREIGN INVESTMENT," Strategic 
Management Journal, 15 (8), 627-42. 
 
Slater, Stanley F. and Eric M. Olson (2000), "STRATEGY TYPE AND 
PERFORMANCE: THE INFLUENCE OF SALES FORCE MANAGEMENT," in 
Strategic Management Journal Vol. 21: John Wiley & Sons, Inc. / Business. 
 208 
 
 
Smith, Brian D. (2010), "Chartered Institute of Marketing Medical Marking Group 
launch excellence conference," in Journal of Medical Marketing. 3 ed. Vol. 10: Palgrave 
Macmillan Ltd. 
 
Smith, M. (1991), Pharmaceutical Marketing. Strategy and Cases. : Pharmaceutical 
Product Press, NY. 
 
Smith, M., E.M. Kolassa, G. Perkins, and B. Siecker (2002), Pharmaceutical Marketing. 
Principles, Environment, and Practices: Pharmaceutical Products Press, NY. 
 
Song, X. Michael, Mitzi M. Montoya-Weiss, and Jeffrey B. Schmidt (1997), "The Role 
of Marketing in Developing Successful New Products in South Korea and Taiwan," 
Journal of International Marketing, 5 (3), 47-69. 
 
Song, X. Michael and Mark E. Parry (1997), "The Determinants of Japanese New 
Product Successes," Journal of Marketing Research (JMR), 34 (1), 64-76. 
 
---- (1994), "The Dimensions of Industrial New Product Success and Failure in State 
Enterprises in the People's Republic of China," Journal of Product Innovation 
Management, 11 (2), 105-18. 
 
Srivastava, Rajendra K., Tasadduq A. Shervani, and Liam Fahey (1999), "Marketing, 
Business Processes, and Shareholder Value: An Organizationally Embedded View of 
Marketing Activities and the Discipline of Marketing," Journal of Marketing, 63 (4), 168-
79. 
 
Stockholm-TT (2008), "Merck dolde fakta om dödlig medicin," in Svenska Dagbladet. 
Stockholm. 
 
Sujan, Harish, Barton A. Weitz, and Nirmalya Kumar (1994), "Learning Orientation, 
Working Smart, and Effective Selling," Journal of Marketing, 58 (3), 39. 
 
Swan, John E., Thomas L. Powers, and Patrick M. Sobczak (1991), "Utilization of Sales 
Management Knowledge and Identification of Contributors: An Analysis of JPSSM 
1980-1990," in Journal of Personal Selling & Sales Management Vol. 11: M.E. Sharpe 
Inc. 
 
Tengilimoglu, Dilaver, Sezer Korkmaz, Fevzi Akinci, and Amy L. Parsons (2004), 
"Managerial Implications of Medical Sales Representative Perceptions of Job Duties, Job 
Qualifications, and Other Performance-Related Issues," Health Marketing Quarterly, 22 
(2), 3-26. 
 
Thomaselli, Rich (2005), "Big Pharma could take big hit as patents expire," Advertising 
Age, 76 (42), 8-8. 
 
 209 
 
Thompson, B (2004), "Exploratory and Confirmatory Factor Analysis: Understanding 
Concepts and Applications.." Washington, DC: American Psychological Association. 
 
Trim, Peter and Hao Pan (2005), "A new product launch strategy (NPLS) model for 
pharmaceutical companies," 17 (4), 325 - 39. 
 
Turner, Roger, Christophe Lasserre, and Pascal Beauchet (2007), "Marketing Metrics: 
Innovation in field force bonuses: Enhancing motivation through a structured process-
based approach," in Journal of Medical Marketing Vol. 7: Palgrave Macmillan Ltd. 
 
Walker, Jr, Orville C., Gilbert A. Churchill Jr, and Neil M. Ford (1979), "Where Do We 
Go From Here: Selected Conceptual and Empirical Issues Concerning the Motivation and 
Performance of Industrial Salesforce" in Gerald Albaum and Gilbert A. Churchill, Jr., 
eds., Critical Issues in Sales Management: State-of-the-Art and Future Reserach Needs 
Eugene, OR: University of Oregon. 
 
Wotruba, Thomas R. (1991), "The Evolution of Personal Selling," Journal of Personal 
Selling & Sales Management, 11 (3), 1. 
 
Wotruba, Thomas R. and Linda Rochford (1995), "The Impact of New Product 
Introductions on Sales Management Strategy," Journal of Personal Selling & Sales 
Management, 15 (1), 35-51. 
 
www.merck.com (2004), "Merck Announces Voluntary Worldwide Withdrawal of 
VIOXX®," (accessed April 23, 15:30, 2008), [available at 
http://www.merck.com/newsroom/vioxx/]. 
 
Yeoh, Poh-Lin (1994), "Speed to Global Markets: An Empirical Prediction of New 
Product Success in the Ethical Pharmaceutical Industry," European Journal of Marketing, 
28 (11), 29-49. 
 
Yeoh, Poh-Lin and Kendall Roth (1999), "An Empirical Analysis of Sustained 
Advantage in the U.S. Pharmaceutical Industry: Impact of Firm Resources and 
Capabilities " Strategic Management Journal (20), 637-53. 
 
Yin, Robert K. (1984), Case Study Research: Design and Methods. Newbury Park, 
California: Sage Publications. 
 
Zoltners, A. A., P. Sinha, and G.A Zoltners (2001), The Complete Guide to accelerating 
sales force performance: Amacom. 
 
 
 
 210 
 
APPENDICES  
 
Appendix 1: Models Derived from Reviewed Literature  
 
This appendix presents the models found in literature, forming a foundation for 
formulating the Preliminary Model, also referred to as the generic model for sales force 
readiness during new product launch. The six models identified as relevant in literature 
were divided into two groups; “Models for Sales force Strategy for New-Product-
Launch” and “Models for Sales force Strategy disregarding the product-lifecycle”.  
 
A1.1. Models for Sales force Strategy for New-Product-Launch 
 
The identified models in this group are derived directly from the publications of 
Atuahene-Gima (1997), Hultnik et al. (2000) and Micheal et al. (2003). The models are 
broken down in more detail below.  
 
Derived Model #1 
 
The first model is developed by Atuahene-Gima (1997),  and is labeled here as “Model 
#1, The Adoption of New Products by the Sales Force”. This model is built upon a set of 
propositions derived and developed from earlier literature and research findings. The 
model is explained in the flow of; Sales Person Characteristics => New Product 
Adoption & Selling Behavior + Market Competition => Outcome.  
The following is a slightly simplified overview of constructs and a graphical 
representation of the model (see Figure 14).  
• Sales Person Characteristics: Goal orientation; Problem-solving style; Career 
success; Sales experience 
• Organizational Factors: Firm commitment to innovation; Failure management; 
Speed of product innovation; Conflict in new product development process. 
• Sales Control Systems: Behavior control; Output control  
• Sales Management Support: Internal marketing of new product; Feedback from sales 
manager; Training 
• Sales Person Role Ambiguity 
• Product Innovativeness 
• New Product Adoption (Commitment x Effort) 
• Dysfunctional Behavior in Selling New Product 
• Intensity of Market Competition 
• OUTCOMES: Sales Performance; Job Satisfaction; Customer Satisfaction 
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Figure 14: Model #1, The Adoption of New Products by the Sales Force 
 
 
 
 
Derived Model #2 
 
The second model used here is from Hultnik et al (2000). In this research, the model has 
been labeled; “Model #2, Effect of Sales force Adoption on New Product Selling”. The 
variables and items in the model are defined as below and a graphical representation of 
the model is found in Figure 15.  
 
• Performance in Selling a New Product: To what extent have you been successful in 
gaining significant market share for this new product; generating a high level of sales 
volume for this new product; quickly generating sales for this new product; exceeding 
sales targets set for this new product; assisting the sales manager in achieving the 
objectives for this new product 
• New Product Adoption 
o Commitment: I feel emotionally attached to the success of this new product; 
achieving objectives for this new product has a great deal of personal meaning 
to me; I enjoy discussing this new product with other salespeople; I feel strong 
sense of duty to ensure the success for this new product; I would be willing to 
make further investments of my time and energy to support this new product. 
o Effort: compared to other products you have sold, how you much effort did 
you devote to this new product when prospecting for customers; planning 
sales calls; collecting market information; using market information; building 
customer relationships. 
• Sales Controls 
o Behavior based control: salespeople are held accountable for their actions in 
selling the new product, regardless of the results they achieve; my supervisor 
monitors the extent to which salespeople follow established procedures 
pertaining to the new product; my supervisor evaluates the procedures 
salespeople use to accomplish the task of selling this new product; my pay 
increases and other tangible rewards are dependent on how well I follow 
established sales procedures pertaining to this new product, my knowledge of 
specific procedures and practices in selling this new product. 
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o Outcome Control: performance evaluations of salespeople on this new 
product place primary weight on results; if my performance goals for this new 
product were not met, I would be required to explain why. My pay increases 
and other tangible rewards depend on how my performance compares with the 
goals for this new product; the degree to which I have achieved the goals set 
for this product; the degree to which I have achieved specified outputs 
regardless of whether sales procedures were followed or not. 
• Supervisory Context: 
o Internal Marketing: my supervisor made sure every salesperson knew the 
incentives for selling this product; my supervisor explained the rationale for 
the introduction of this product; my supervisor explained the research behind 
the development of this new product; my supervisor explained how this new 
product fits in the company’s strategic objectives. 
o Trust: my supervisor and I have a sharing relationship; we can freely share 
our ideas and feelings about the work I do; I can freely talk to my supervisor 
about difficulties I am having at work and know that he or she will want to 
listen; if I shared my problems with my supervisor I know he or she would 
respond constructively and caringly; we would both feel a sense of loss if we 
could no longer work together; my supervisor and I have made considerable 
emotional investments in our working relationship. 
o Training: I received substantial training before I assumed responsibility for 
selling this new product; I have spent a significant amount of time in training 
for this new product; our training program for this new product is first class. 
o Field attention: my supervisor spends time with me in the field; my supervisor 
makes joint calls with me; my supervisor observes my performance in the 
field. 
• Market Volatility: Indicate your opinion of the nature of the market environment 
for this new product at the time it was introduced: stable – unstable, certain – 
uncertain, changes slowly – changes rapidly, predictable – unpredictable 
• Covariates: 
o Selling experience: number of years the salesperson has been in a sales 
function 
o Main target market: consumer market vs. industrial market 
o Level of education: less than bachelor degree, bachelor’s degree, master’s 
degree, more than master’s degree 
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Figure 15: Model #2, Effect of Sales force Adoption on New Product Selling 
 
 
 
Derived Model #3 
 
The third and final model in this group is the model identified and adapted by Micheal et 
al (2003) from earlier literature, labeled here; “Model #3, Product Newness and Sales 
Management Strategy”. The variables and items in the model are defined below and a 
graphical representation of the model is found in Figure 16.  
 
• Type of Product Newness: New-to-the-market and new-to-the-firm; Not new to the 
market and new to the firm; and Not new to the market and revisions to the firm. 
• Organization: assigned geographic territory; realigned territories; customer types, 
national accounts; independent agents/representatives; product groups; selling teams; 
hired new sales force for new products, added to existing sales force. 
• Training: written training material for the new products; product training classes for 
the new products; training through supervisory visits related to new products; selling 
skill training for the new products; customer profiling and buying behavior training 
for new products; training videos related to new products, training thought videos.  
• Supervision, Motivation & Performance Evaluation: weekly/monthly meeting with 
salespeople & field managers; supervisors accompanying salespeople in their call 
routes; call reports; formal performance evaluations; periodic morale surveys of 
salespeople; promotional opportunities and career planning programs; opportunities 
to earn pre-requisites. 
• Quotas & Goals: sales quotas for all products; gross margin or other profit-oriented 
quotas for all products; activity gross; sales quotas for each product; sales quotas by 
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customer type; management by objectives; gross margin for each product; expense 
quotas; gross merging by customer type; sales estimates hand-in. 
• Compensation & Incentives: salary; commission on sales for all products; bonus for 
individual performance; bonus for group performance; commission on total gross 
margin; sales contests; incentive pay for points earned; separate commission on sales 
for individual products; incentive pay for activities performed; separate commission 
for gross margin; guaranteed draw or non guaranteed draw. 
• Sales Support: sales literature; catalogues; print media advertising; demonstrations; 
plant tours; promotional items; direct mail advertising; introductory pricing discounts; 
specially trained representatives; video programs; computer-aided purchasing systems 
for customers; special packaging; telemarketing assistance; trade shows; industrial 
stores. 
 
 
Figure 16: Model #3, Product Newness and Sales Management Strategy 
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A1.2. Models for Sales force Strategy Disregarding the Product Lifecycle 
 
The identified models in this second group are derived directly from the publications of 
Piercy et al (1997), Baldauf et al (1999) and Piercy et al (1999). These models are 
included in the sales management research stream for sales force effectiveness. The 
models are broken down in more detail below. 
 
Derived Model #4 
 
The first model in this group, and the fourth model identified in literature, is developed 
by Piercy et al. (1997) and is, labeled in this research; “Model #4, Model for Sales Force 
Effectiveness in B2B organizations”. The variables and items in the model are listed 
below and a graphical representation of the model is found in Figure 17.  
 
• Characteristics of Successful Salespeople: Measured by a 10-point scale where 1 = 
Not at All and 10 = To a great Extent, in response to the question “Please indicate the 
extent to which your salespeople…”. 
o Motivation: obtain a sense of accomplishment; feel a sense of personal growth 
and development in their work; receive high respect from supervisors; receive 
high respect from fellow workers; have a sense of being creative and 
imaginative in their work; get a feeling of loyal association with the company; 
feel a sense of being innovative in the work. 
o Customer Orientation: focus on satisfying customer needs; customize selling 
approaches to individual accounts; possess expert selling skills; possess 
extensive product/service knowledge; study customer needs to guide selling 
strategy. 
o Team Orientation: are willing to accept direction from you; co-operate as part 
of sales team; accept your authority; welcome review of their performance. 
o Sales Support Orientation: spend substantial time planning sales calls; 
perform non-selling activities effectively; perform sales support activities. 
• Sales Management Control: Measured by a 10-point scale where 1 = Not At All and 
10 = To A Great Extent, in response to the question “To What extent do you…? 
o Monitoring: Spend time with salespeople in the field; make joint calls with 
salespeople; regularly review call reports from salespeople; monitor the day-
to-day activities of salespeople; observe the performance of salespeople in the 
field; pay attention to the extent to which salespeople travel; closely watch 
salespeople’s expense accounts, pay attention to the credit terms that 
salespeople quote to customers. 
o Directing: encourage salespeople to increase their sales results by rewarding 
them for their achievements; actively participate in training salespeople on the 
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job; regularly spend time coaching salespeople; discuss performance 
evaluations with salespeople; help salespeople develop their potential.  
o Evaluating: evaluate the number of sales calls made by salespeople; evaluate 
the profit contribution achieved by each salesperson; evaluate the sales results 
of each salesperson; evaluate the quality of sales presentations made by 
salespeople; evaluate the professional development of salespeople. 
o Rewarding: provide performance feedback to salespeople; compensate 
salespeople based on the quality of their sales activities; use incentive 
compensation as a major means for motivating salespeople; make incentive 
compensation judgments based on the sales results achieved by salespeople; 
reward salespeople based on their results; use non-financial incentives to 
reward salespeople for their achievements; compensate salespeople based on 
the quality of their sales activities.   
• Sales Organization Design: Satisfaction with sales territory design was measured by 
a 7-point scale where 1 = Very Dissatisfied and 7 = Very Satisfied, in response to the 
question “My level of satisfaction with…? 
o Sales Territory Satisfaction: including unit size; scope for improving 
performance by changing number of salespeople; etc.  
• Sales Performance: Measured by a 7-point scale where 1 = Needs improvement and 
7 = Outstanding, in response to the question What is “your judgement about how the 
salespeople in your unit are performing”) 
o Outcome Performance: producing a high market share for your company; 
making sales of those products with the highest profit margin; generating a 
good level of £ sales; quickly generating sales of new company product 
services; identifying and selling to major accounts; producing sales or blanket 
contracts with long-term profitability; exceeding all sales targets and 
objectives during the year.  
o Selling Performance: (Sales presentation:) listening attentively in order to 
identify and understand the real concerns of customers; convincing customers 
that they understand their unique problems and concerns; using established 
contacts to develop new customers; communicating their sales presentations 
clearly and concisely; working out solutions to a customer’s questions and 
objections. (Technical Knowledge:) knowing the design and specification of 
the company’s product/services; knowing the applications and functions of the 
company’s products & services; keeping abreast of your company’s 
production and technical developments.  
o Non-Selling Performance: (Adaptiveness:) experimenting with different sales 
approaches; being flexible in selling approaches used; adapting selling 
approaches from one customer to another; varying sales style from situation to 
situation. (Teamwork:) generating considerable sales volume from team sales 
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(sales made jointly by two or more salespeople); building strong working 
relationships with other people in our company; working very closely with 
non-sales employees to handle post-sales problems and service; coordinating 
very closely with other company employees to handle post-sales problems and 
service; discussing selling strategies with people from various departments. 
(Sales planning:) planning each sales call; planning sales strategies for each 
customer; planning coverage of assigned territory/customer responsibility; 
planning daily activities. (Sales support:) providing after-sale service; 
checking on product delivery; handling customer complaints; following up on 
product use; troubleshooting application problems; analyzing product use 
experience to identify new product/service ideas. 
• Sales organization effectiveness 
o In order to identify high and low effectiveness in the sales unit, the multiple of 
measures of effectiveness relative to competitors and relative to objectives 
were combined into a single effectiveness index, and scores on this were used 
to divide respondents into three groups.  
 
 
Figure 17: Model #4, Model for Sales Force Effectiveness in B2B organizations 
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Derived Model #5 
 
The second model in this group, and the fifth model identified in the literature, is 
developed by Baldauf et al (1999), and aims to show which factors determine the 
effectiveness of a sales organization. In this research, the model is labeled “Model # 5, 
Model for Sales Organization Effectiveness- A”. The variables and items in the model are 
defined below and a graphical representation of the model is found in Figure 18.  
 
• Sales Management Control Strategy (based on Anderson and Oliver (1987), 
measured on a 10-point scale ranging from “to a great extent” to “not at all”): 
Monitoring, Directing, Evaluating, Rewarding 
• Sales Territory Design (based on Babakus et al. (1996), measured on a 7-point scale 
ranging from “very satisfied” to “not at all satisfied”) 
• Sales Person Characteristics (based on Cravens et al. (1993) and Oliver and 
Anderson (1994), measured on a 10-point scale ranging from “to a great extent” to 
“not at all”): Intrinsic motivation (three items); Recognition motivation (two items); 
sales support orientation (two items); customer orientation (two items).  
• Sales Force Performance (based on Behrman and Perreault Jr (1982), measured on a 
7-point scale, from “outstanding” to “needs improvement” (Behrman and Perreault Jr 
1982)) 
o Behavior Performance: Technical knowledge (three items); Adaptive selling 
(four items); Teamwork (five items); Sales presentation (five items); Sales 
planning (four items); Sales support (six items). 
o Outcome Performance: high market share; selling high-profit margin 
products; generating high dollar sales; selling new products/services; 
identifying and selling to major accounts, developing sales with long-term 
profitability, and exceeding all sales targets and objects.  
• Sales Organization Effectiveness (based on Cravens et al. (1993), measured on a 5-
point scale, from “much worse” to “much better”) 
o Effectiveness 1, 2 and 3: Sales unit objectives and market share compared 
with major competitor (four items); profitability (two items); customer 
satisfaction (two items). 
o Effectiveness 4: (New scale with six items, ranging from “needs 
improvement” to “outstanding”): sales manager’s evaluation of average sales 
per salesperson; selling expenses; obtaining new customers; salesperson 
turnover; use of computer technology; and retaining existing customers.   
 
 
  
 219 
 
Figure 18: Model #5, Model for Sales Organization Effectiveness - A 
 
 
 
 
Derived Model  #6 
 
The third and final identified model in this group, and the sixth model identified in 
literature, is developed by Piercy et al (1999), and is, labeled “Model # 6, Model for Sales 
Organization Effectiveness - B” in this research. The variables and items in the model are 
defined below and a graphical representation of the model is found in Figure 19.  
 
• Behavior-based Sales Management Control: (Based on Cravens et al. (1993), 
measured on a 10-point scale, from “to a great extent” to “not at all”) 
o Monitoring (To what extent do you): spend time with salespeople in the field; 
make joint calls with salespeople; regularly review call reports from 
salespeople; monitor the day-to-day activities of salespeople; observe the 
performance of salespeople in the field; pay attention to the extent to which 
salespeople travel; closely watch salespeople expense accounts; pay attention 
to the credit terms that salespeople quote customers. 
o Directing (To what extent do you): encourage salespeople to increase their 
sales results by rewarding them for their achievements; actively participate in 
training salespeople on the job; regularly spend time coaching salespeople; 
discuss performance evaluation with salespeople; help salespeople develop 
their potential. 
o Evaluating (To what extent do you): evaluate the number of sales calls made 
by salespeople; evaluate the profit contribution achieved by each salesperson; 
evaluate the sales results of each sales person; evaluate the quality of sales 
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presentations made by salespeople; evaluate the professional development of 
salespeople. 
o Rewarding (To what extent do you): provide performance feedback to 
salespeople on a regular basis; compensate salespeople based on the quality of 
their sales activities; use incentive compensation as the major means for 
motivating salespeople; make incentive compensation judgments based on the 
sales results achieved by salespeople; reward salespeople based on their sales 
results; use non-financial incentives to reward salespeople for their 
achievements; compensate salespeople based on the quality of their sales 
activities. 
• Satisfaction with Sales Organization Design: (New Scale, measured on a 7-point 
scale from “very satisfied” to “not at all”) My level of satisfaction with: the number 
of accounts in my territories; the number of large accounts in my territories; the 
number of calls made in my territories; the amount of travel required in my territories; 
the market potential in my territories; the number of territories in my sales unit; the 
assignment of salespeople to my territories; the equivalence in workload across 
territories; the overall design of my territories.  
• Sales Organization Effectiveness: (Based on Cravens et al. (1993), measured on a 5-
point scale, from “much worse” to “much better”): Sales volume compared with your 
major competitor (past 24 months); market share compared to your major competitor 
(past 24 months); profitability compared to your major competitor (past 24 months); 
customer satisfaction compared to your major competitor (past 24 months); sales 
volume compared to sales unit objectives; market share compared to sales unit 
objectives; profitability compared to sales unit objectives; customer satisfaction 
compared to sales unit objectives.  
• Sales Force Performance: (Based on e.g. Behrman and Perreault Jr (1982); Cravens 
et al. (1993), measured on a 7-point scale, from “outstanding” to “needs 
improvement”): 
o Outcome Performance: (How well are the salespeople in your unit 
performing:) producing a high market share for your company; making sales 
of those products with the highest profit margins; generating a high level of 
£ sales; quickly generating sales of new company products/services; 
identifying and selling to major accounts; producing sales or blanket contracts 
with long-term profitability; exceeding all sales targets and objectives during 
the year.  
o Technical Knowledge: (How well are the salespeople in your unit 
performing:) knowing the design and specifications of company 
products/services; knowing the applications and functions of company 
products/services; keeping abreast of your company’s production and 
technological developments.  
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o Adaptive selling: (How well are the salespeople in your unit performing:) 
experimenting with different sales approaches; being flexible in the selling 
approaches used; adapting selling approaches from one customer to another; 
varying sales style from situation to situation. 
o Teamwork: (How well are the salespeople in your unit performing:) 
generating considerable sales volume from team sales (sales made jointly by 
two or more salespeople); building strong working relationships with other 
people in our company; working very closely with non-sales employees to 
close sales; coordinating very closely with other company employees; 
handling post-sales problems and services; discussing selling strategies with 
people from various departments. 
o Sales Presentation: (How well are the salespeople in your unit performing:) 
listening attentively in order to identify and understand the real concerns of 
customers; convincing customers that they understand their unique problems 
and concerns; using established contacts to develop new customers; 
communicating their sales presentations clearly and concisely; working out 
solutions to a customer’s questions and objections. 
o Sales Planning: (How well are the salespeople in your unit performing:) 
planning each sales call; planning sales strategies for each customer; planning 
coverage of assigned territory/customer responsibility; planning daily 
activities. 
o Sales Support: (How well are the salespeople in your unit performing:) 
providing after-sales service; checking on product delivery; handling customer 
complaints; following up product use; troubleshooting application problems; 
analyzing product use experiences to identify new product/service ideas. 
 
Figure 19: Model #6, Model for Sales Organization Effectiveness - B 
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Appendix 2: Formulation and Synthesis of the Preliminary Model  
 
The development of the Preliminary Model, also referred to as the generic model for 
sales force readiness during new product launch, is presented in this section. This model 
will serve as the basis for identification of key success factors during launch in the 
Swedish pharmaceutical industry in a set of case studies and expert interviews. 
 
Key models derived from the review of literature and presented in detail in Appendix 1, 
will be synthesized with the aim of identifying one generic model, including a broad 
range of concepts and constructs, preferably proven empirically. This generic model will 
be used to identify key success factors from the case studies and expert interviews 
considered when formulating the Research Model assumed here for further empirical and 
statistical testing on pharmaceutical product launches in Sweden. To further clarify this, 
the Preliminary Model does not necessarily aim to cover all aspects, but the ones found to 
be most relevant will be included, in part or in full. Further, some constructs will be 
simplified in order to best synthesize the identified models. 
 
All models derived from literature are grounded in the sales force management area of 
the literature, but different focuses and research streams have taken the concepts and 
constructs in somewhat different directions. However, similarities and overlaps of 
constructs may be identified. The first group mainly belongs to the area and research 
stream of new product adoption of the sales force, while the other group belongs to the 
research stream of sales force effectiveness.   
 
The first group included constructs from literature in the sales force management 
discipline in terms of sales force adoption, sales force performance and the new product 
launch discipline. This group has been named “Models for Sales force Strategy for New-
Product-Launch”. Three models have been identified as relevant and current; Atuahene-
Gima (1997); Hultink and Atuahene-Gima (2000); Micheal et al. (2003). These models 
are basically built on the same constructs and definitions, with the theoretical Atuahene-
Gima (1997) as a base concept, with Hultink and Atuahene-Gima (2000) as a more 
operationalized adjusted model and Micheal et al. (2003) with a stronger focus on 
product newness. The Preliminary Model has most heavily adopted these constructs, as 
the focus of this research is sales force new product adoption during new product launch 
with the link to performance. By adopting this approach, the aim is to give the 
Preliminary Model the preference of tested variables and items within the sales force 
during the launch phase.  
 
The second group includes models found in literature in the discipline of sales force 
management in terms of sales force effectiveness, where no regard to product life-cycle 
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stage is considered. This group was named “Models for Sales force Strategy disregarding 
the product-lifecycle”. The three models identified are all part of the same research 
stream, based on the same concepts and definitions within sales force effectiveness. All 
three models were complementary with minor differences. The models are derived from 
Piercy et al. (1997), Baldauf and Cravens (1999), and Piercy et al. (1999). Even though 
the Preliminary Model has largely adopted constructs from the models in group 1, it is 
well complemented with input from the constructs of the models in group 2.  
 
The models were first compared and synthesized within each group, creating two 
synthesized models, which were then merged into one generic model.  
 
A2.1. Synthesizes of Models for Sales force Strategy for New-
Product-Launch 
 
Synthesis took place in three steps: 1) identification of similarities and overlaps; 2) 
alignment and merger of constructs; and, 3) synthesis into one model. An overview of 
model comparison for this group showed that the three models constituting components 
did overlap to some extent. This synthesis is summarized below.  
 
The first step, identifying similarities and overlaps, is summarized and presented in 
graphical form in Figure 20. Model #2 is an adaptation and operationalization of the 
theoretical Model #1. Model #1 is more extensive, while model #2 is much more specific 
in measures and has a supporting empirical outcome. Model #3 is also based on related 
literature as is Model #1, however as a different focus is assumed, some measures and 
definitions differ. The second step, which aligns and merges the three models’ constructs, 
is summarized in Figure 21.  
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Figure 20: Model similarities and overlaps in Group 1 
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Figure 21: Model alignment and merger of constructs for Group 1 
 
 
The third step, where the models are synthesized into one model, Synthesis-Model for 
Sales force Strategy for New-Product-Launch, is presented in graphical form in Figure 22 
and summarized below. 
 
The constructs and definitions are not exactly the same in Model #2 and Model #1. 
However, the two models are based on the same literature. Model #2 has its theoretical 
foundation in Model #1 and both are conceptualized in relation to the salesperson’s 
performance and outcome, which is not the case with Model #3. 
 
Type of New Product: Model #1 includes newness and measures it as product 
innovativeness. The construct examines the lack of synergy between the new product, 
current operations of the firm, and the salesperson’s current knowledge. Model #3 on the 
other hand measures two states of market newness and two states of newness to the firm. 
The newness concept is not included in Model #2.  As Model #1 did not test the concept 
empirically, the choice was to include the Model #3 construct for newness in the 
Preliminary Model.     
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Market dynamics includes “intensity of competition” from Model #1 and market 
volatility from Model #2. Model #3 lacks this construct. The definition and construct in 
Model #2 is broader and could be argued to include the concept from Model #1. The 
choice is therefore to include the construct from Model #2. 
 
Sales Force Management Factors: Model #1 and Model #2 include roughly the same 
constructs for the sales management factors, with the exceptions of “dysfunctional 
behavior in selling new products”, “sales person role ambiguity” and “organizational 
factors”, which are present only in Model #1. The construct in Models #3 is fairly well 
covered in that of Model #1 and Model #2.  
The concepts of “dysfunctional behavior in selling new products” and “sales person role 
ambiguity” from Model #1 are excluded based on the argument that these concepts, when 
synthesizing the models, are well covered under similar concepts in Model #2. Also, 
“organizational factors”, from Model #1, is disregarded, based on the argument that this 
construct, as defined, cannot be influenced by sales management when formulating their 
strategies for product introduction. However, it is acknowledged that these factors might 
have an impact on sales force management in general, yet on a higher, company-wide, 
level. Based on these rationales the choice here is to bring forward the variables and 
items from Model #2 with the addition of salesperson characteristics in Model #1 and 
sales force design in Model #3.  
 
Sales Force New Product Adoption: Only Model #1 and Model #2 include this concept; 
Model #2 has more well developed measures than Model #1, so the choice is to bring 
forward the construct from Model #2.  
 
Outcomes: Model #2 does not include job satisfaction and customer satisfaction, but they 
are included in Model #1. Model #3 does not include any outcome measures, even though 
they are acknowledged as important future possible extensions to that model. The 
construct in Model #2 has been tested with empirical data for new product launch, which 
is not the case with Model #1. Based on this, the decision was taken to remove the two 
variables “job satisfaction” and “customer satisfaction”, to measure new product 
performance outcome. The final choice became the construct of performance in selling a 
new product from Model #2.  
 
 
 
.  
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Figure 22: Synthesized Model for Sales force Strategy for New-Product-Launch 
 
 
 
 
 
A2.2. Synthesizes of Models for Sales Force Strategy Disregarding 
Lifecycle  
 
The overview of model comparison for the second group showed that the three models 
constituting components overlapped very strongly, as is visualized in Figure 23. The 
three models within this group are very similar with regard to their constituting 
components and constructs, as they are all based on the same literature, being constructs 
mainly derived from Cravens et al. (1993), Anderson and Oliver (1987) and Oliver and 
Anderson (1994). Model #6 (Piercy et al. 1999) excludes the component “Salesperson 
Characteristics”. This implies that these models reinforce each other and that Model #4 
(Piercy et al 1997) and # 5 (Baldauf et al1999) are the most comprehensive. Based on 
this, the models were synthesized into one model as summarized in Figure 24.  
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Figure 23: A comparison; Models for Sales force Strategy disregarding lifecycle 
 
 
Figure 24: Synthesized Model for Sales force Strategy disregarding lifecycle 
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A2.3. Formulation of the Preliminary Model  
 
The two synthesized models, “synthesized model for sales force strategy for new-
product-launch” and “synthesized model for sales force strategy disregarding the product 
lifecycle” were further unified in to one model to form the Preliminary Model, as 
described in this section.  
 
The overview comparison of the two synthesized models shows similarities between the 
two models (presented graphically in Figure 25). The “synthesized model for sales force 
strategy for new-product-launch”, from now referred to as “synthesized model for new-
product-launch” adds the newness aspect. The “synthesized model for sales force strategy 
disregarding the product lifecycle”, from now referred to as “synthesized model 
disregarding product life-cycle”, adds the sales force effectiveness aspect. The “intensity 
of market competition/market volatility” is present in both models as it is also inherent in 
the definition of sales organization effectiveness. The two models are related around the 
middle section, “sales force factors” and “outcome”.  
 
The first step of merging the models into one resulted in the model presented in Figure 26 
below, however a further merger of concepts was needed to practically fit the here 
assumed research. This first step of merging the synthesized models indicates a five-stage 
model. However, an analysis of the content of each step, based on the models from which 
they are derived, shows that further adoption to the model can be performed within each 
category as described below.  
 
Type of new product: This construct is derived from “synthesized model for new-product-
launch” and is not a developed construct in the “synthesized model disregarding the 
product lifecycle”. The identified variables and definitions for product newness from the 
former synthesized model will be used in the Preliminary Model.    
 
Market dynamics (intensity of market competition/market volatility): This includes 
concepts from both of the synthesized models, as it is related to sales organizational 
effectiveness in the “synthesized model disregarding the product lifecycle”, where 
environment aspects are included in its definition. There is strong support to retain this in 
the Preliminary Model. The choice was to include the construct from Model #2 in the 
Preliminary Model, as it was found in some research that during the new product process, 
the product’s competitive advantage (concept from “synthesized model disregarding the 
product lifecycle”) had a significant and negative effect (Song and Parry 1997). 
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Figure 25: Comparison of the two synthesized models 
 
 
 
 
Figure 26: First step of merger of the synthesized models  
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Sales-force management control, sales force organizational design, sales-person 
characteristics and sales force new product adoption; there are many similarities and 
overlaps between the synthesized models, but the constructs and definitions differ.  
 
Sales force management control is very similar in concept in the different models, 
however, the items used to measure the variables are somewhat differently formulated. 
Both constructs are linked back to the literature on the subject of behavior-based and 
outcome-based control systems (Anderson and Oliver, 1987). For the purpose of this 
research, the variables in “synthesized model for new-product launch” will be used in the 
Preliminary Model, as this construct has been adopted and tested according to the new 
product launch phase, which is the primary focus in the here assumed research. 
 
For sales force organizational design, the concepts between the two models differ in 
terms of what was measured. The “synthesized model disregarding product life-cycle” 
measured satisfaction within the sales force, regarding territory market potential, travel 
within territory, etc. The “synthesized model for new-product-launch” measured changes 
in organizational structure and deployment as well as the construct of new product 
launch. Based on this, the latter model’s construct will be used in the Preliminary Model.  
 
Sales person characteristics include different constructs between the two models. The 
“synthesized model for product-launch” uses the variables goal orientation, problem-
solving style, career success and sales experience. The “synthesized model disregarding 
life-cycle”, uses the variables monitoring, directing, evaluating and rewarding. Again, as 
the former model takes in new product launch as a basis for its constructs, these variables 
will be used in the Preliminary Model. However, the concepts of monitoring, directing, 
evaluating and rewarding within the “synthesized model disregarding life-cycle”, overlap 
with the construct of commitment and effort, together forming sales force new product 
adoption within the “synthesized model for new-product-launch”. The conclusion of 
adding product adoption from the “synthesized model for new-product-launch” to the 
Preliminary Model, also assumes that the concept of sales person characteristics from the 
“synthesized model disregarding life-cycle” is to a great extent included in the 
Preliminary Model.  
 
Performance in selling a new product (outcome performance) and sales organization 
effectiveness are two related concepts. The effectiveness and outcome performance 
constructs in “synthesized model disregarding product life-cycle” and the construct of 
performance in selling a new product in the “synthesized model for new-product-launch” 
are partly derived from the same literature (Oliver and Anderson, 1994) and the 
constructs are to some extent similar. Piercy et al. (1997) elaborates on the difference 
between the effectiveness of the sales organization and the performance of its 
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salespeople. According to them, the effectiveness describes the overall organizational 
outcome, and while high sales force performance is expected to contribute to the 
effectiveness of the sales organization, other factors may also influence overall 
effectiveness. These other factors may be outside the control of the salesperson (such as 
competitive behavior and market potential). Also, Piercy et al. (1997) found that high 
outcome performance is clearly an outstanding characteristic of the most effective sales 
organizations. They argue that salesperson behavior performance makes a significant 
contribution to sales outcome performance and in turn sales organization effectiveness 
(Piercy et al. 1997). They further argue that there is not a determined causal link between 
performance and effectiveness, however, the existence of a strong relationship does 
suggest a possible causal link. Based on the relations of the concepts of performance in 
selling a new product (outcome performance) and sales organization effectiveness, the 
proven direct link, and as effectiveness, is also determined by other factors outside the 
control of the sales force, the argument is made that the Preliminary Model could merge 
these concepts (or exclude effectiveness) in order to measure outcome of new product 
performance. Therefore, in the Preliminary Model , the preference for variables and items 
will be given to the “synthesized model for new-product-launch”, denote performance in 
selling a new product. 
 
This leads to the second step of merging the two synthesized models, which concludes 
the final Preliminary Model or generic model for sales force readiness during new 
product launch (see Figure 5, Chapter 4). This proposed generic model for sales force 
readiness during new product launch is described in three stages: 1) Circumstance; 2) 
Sales Force Factors; and, 3) Effect.  
 
Overall, the proposed merged model presents a set of variables and extensive 
interrelations that determine a very broad range of sales force management situations. As 
the concern here is on new product launch, the interrelations between the mediating 
variables are ignored in this model synthesis as they may be assumed to be general. 
Further, the final variables and items in each category were chosen in favor of the 
construct developed for the group “Synthesized model for Sales force Strategy for New-
Product-Launch”. The reason for this was that the constructs within these models had 
been developed, tested and validated with learning about sales force strategy for new 
product launch as a main research goal.  
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Appendix 3: Data Collection Instrument for Case Studies and 
Expert Interviews 
 
 
INTERVIEW GUIDE 
Empirical Data Collection for Case Studies & Topic Experts 
 
Key Success Factors for Sales Force Readiness during New Product Launch: 
“A study of Product Launches in the Swedish Pharmaceutical Industry” 
 
 
Introduction 
 
  
Sales Manager, Sales Representative or Expert information 
 
Name (to be disclosed):  
Title:  
Job description:  
Experience of Sales Management:  
Experience of New Product Launches:  
Years in industry:  
Company/other organization: (Current & Previous):  
 
Background to be given:  
 
Sales Force: The following questions concern management of sales force readiness 
during the product launch. Please answer the questions with the assumptions and 
conditions given at the actual time of launch for the product. Please also give examples if 
possible. There will be time at the end to reflect over differences from this product launch 
to today’s environment.   
 
Expert: The following questions concern management of sales force readiness during the 
product launch. We will go through some important variables. Please point out the most 
important variables, and explain why these are picked. Please also give examples if 
possible. Assume a market environment up until around 2006. There will be some time at 
the end to reflect over differences of product launches from 1995 and to today’s 
environment.   
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Variables 
 
** 
A product can have the following status (as set out below).  
Sales Force: At the time of launch, how would you perceive the conditions for this 
product were, choosing between the following?  
Expert: Could you elaborate on the consequences for each category when launching a 
product?  
 
1. Type of Product: 
• new-to-the-market and new-to-the-firm 
• not-new-to-the-market but new-to-the-firm 
• not-new-to-the-market and revisions-to-the-firm  
 
** 
A product can be launched in different market conditions (see below).  
Sales Force: At time of launch, how would you perceive the market condition for this 
product? 
Expert: Could you elaborate around the consequences for each when launching a 
product? 
 
1. Market Dynamics 
a. the nature of the market environment for this new product at the time it was 
introduced 
i. Stable – unstable 
ii. Certain – uncertain 
iii. Changes slowly – changes rapidly 
iv. Predictable – unpredictable 
 
** 
Sales Force: During  the time of the launch, how was the New Product Adoption from 
the sales force? (Ask about each variable) 
Expert: For the below items, please point out which are the most important variables, and 
why. Please also give examples if possible. Assume a market environment up until 2006. 
 
 
2.  New Product Adoption 
a. commitment 
i. Sales Rep emotionally attached to the success of this new product 
ii. Achieving objectives for this new products has a great deal  of personal 
meaning to the Sales Rep 
iii. Sales Rep discusses this new product with other salespeople this item is 
not as good as the others 
iv. Sales Rep feels a strong sense of duty to ensuring the success of this new 
product 
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v. Sales Rep would be willing to make further investments of his/her time 
and energy to support this new product 
 
b. effort  
i. Compared to other products you have sold, how much effort did the 
Sales Rep devote to this new product in: 
1. Prospecting for customers  
2. Planning sales calls 
3. Collecting market information 
4. Using market information 
5. Building customer relationships 
 
Sales Force: ask about the most important variable(s) for a successful launch, with 
examples 
 
** 
Sales Force: During the launch, how was sales forces behavior influenced? (Ask about 
each variable) 
Expert: Point out the most important variable(s), and explain why. Please also give 
examples if possible. Assume a market environment up until 2006. 
 
3. Behavior Control  
a. Salespeople are held accountable for their actions in selling the new product, 
regardless of results they achieve 
b. Sales Rep’s supervisor monitors the extent to which salespeople follow 
established procedures pertaining to the new product 
c. Sales Reps’ supervisors evaluate the procedures salespeople use to accomplish 
the task of selling this new product 
d. Sales Rep’s pay increases and other tangible rewards depend on: 
i. How well I follow established procedures pertaining to this new 
product 
ii. My knowledge of specific procedures and practices in selling this new 
product 
 
Sales Force: ask about the variable(s) which were most important for a successful launch 
and ask for examples 
 
** 
Sales Force: During the launch, how were the sales force’s outcome measured? (Ask 
about each variable) 
Expert: Point out the most important variables, and why. Please also give examples if 
possible. Assume a market environment up until 2006. 
 
4. Outcome Control  
a. Performance evaluations of salespeople on this new products place primary 
weight on results 
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b. If Sales Rep’s performance goals for this new product were not met, the Sales 
Rep would be required to explain why 
c. Sales Rep’s pay increases and other tangible rewards depend on: 
i. How Sales Rep’s performance compares with the goals for this new 
product 
ii. The degree to which Sales Reps have achieved the goals for this new 
product 
iii. The degree to which Sales Reps have achieved specified outputs 
regardless of whether sales procedures were followed or not 
 
Sales Force: ask about  variable(s) which was/were the most important for a successful 
launch and ask for examples 
 
 
** 
Sales Force: During launch, how was this product supervised in the sales force? (Ask 
about each variable) 
Expert: Point out the most important variables, and why. Please also give examples if 
possible. Assume a market environment up until 2006. 
 
5. Supervisory Context 
a. Internal Marketing 
i. Sales Rep’s supervisor made sure every salesperson knew the 
incentives for selling this product 
ii. Sales Rep’s supervisor explained the rationale for the introduction of 
this product 
iii. Sales Rep’s supervisor explained the research behind the development 
of this new product 
iv. Sales Rep’s supervisor explained how this new product fits into the 
company’s strategic objectives 
 
b. Trust  
i. Sales Rep’s supervisor and I have a sharing relationship. Sales Reps 
can freely share ideas and feelings about the work. 
ii. Sales Rep can freely talk to my supervisor about difficulties they have 
at work and know that he or she will want to listen. 
iii. Sales Rep’s supervisor and Sales Rep have made considerable 
emotional investments in our working relationship 
 
c. Training 
i. Sales Reps received substantial training before assuming responsibility 
for selling this new product 
ii. Sales Reps have spent a significant amount of time in training for this 
new product 
iii. training program for this new product is first class 
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d. Field Attention  
i. Sales Rep’s supervisor spends time with me in the field 
ii. Sales Rep’s supervisor makes joint sales calls with me 
iii. Sales Rep’s supervisor observes my performance in the field 
 
Sales Force: ask about the variable(s) which was/were most important for a successful 
launch and ask for examples 
 
** 
Sales Force: During launch, how was the sales force organization set up? (Ask about 
each variable) 
Expert: Point out the most important variables, and why. Please also give examples if 
possible. Assume a market environment up until 2006. 
 
6. Organization 
a. Geographic (are territories assigned geographically?) 
b. Customer types (are customer types assigned independently of geography?) 
c. National Accounts 
d. Independent Agents or Representatives 
e. Product Groups 
f. Selling Teams 
 
Sales Force: ask about the variable(s) which was/were the most important for a 
successful launch and ask for examples 
 
** 
Sales Force: During launch, what were the sales person’s characteristics? (Ask about 
each variable) 
Expert: Point out the most important variable(s) and why they are important. Please also 
give examples if possible. Assume a market environment up until 2006. 
 
7. Sales Person Characteristics 
a. learning orientation of the salesperson 
b. problem-solver: (intuitive vs. systematic) 
c. career success of the salesperson 
d. salesperson’s experience (no. of years, within ATC or outside) 
 
Sales Force: ask about the variable(s) which was/were the most important for a 
successful launch and ask for examples 
 
** 
Sales Force: How was the overall Performance when launching this product? (Ask about 
each variable) 
Expert: Point out the most important variables, and why. Please also give examples if 
possible. Assume a market environment up until 2006. 
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8. PERFORMANCE in Selling a new product 
 
a. to what extent have you been successful in 
i. Gaining significant market share for this new product? 
ii. Generating high level sales volume for this new product? 
iii. Quickly generating sales for this new product? 
iv. Exceeding sales targets set for this new product? 
v. Assisting sales manager in achieving the objectives for this new 
product 
vi. Profits/enabling sales of “old” products?? 
 
Sales Force: ask about the variable(s) which was/were most important for a successful 
launch and ask for examples 
 
** 
10. Sales Force & Experts: Which of the above variables or “categories of variables” 
would you, assuming a historical view, suggest to be most important for a successful 
launch? 
 
Why, give examples/rationale 
 
** 
11. Sales Force & Experts: Which of the above variables or “categories of variables” 
would you, in today’s and future environment, suggest as the most important for a 
successful launch? 
 
Why, give examples/rationale?  
 
** 
12. Experts: Of the variables chosen above, how should these be measured in a Research 
Model? (Open discussions depending on chosen variables above) 
 
** 
GUIDE APPENDIX 1: Preliminary Model – for use in discussions with experts 
GUIDE APPENDIX 2: Table of summary results from Case Studies – for use in 
discussions with experts 
 
**end** 
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Appendix 4: Case Study Results: Product Launches in Sweden  
 
The cases conducted in this research were actual pharmaceutical product launches in 
Sweden. The information has been collected from two to four people involved in each 
product launch. The interviewed group always included sales management and sales 
personnel. The six products were launched by three different companies. The case study 
summaries do not include discussions or analysis by the author, but consist entirely of the 
perceptions and experiences of the participating personnel.  
 
The first two case studies are presented in Chapter 4, section 4.2. Documentation of the 
four remaining case studies follows below.  
 
Case Study 3 (of 6): The Launch of an Oral Contraceptive  
 
At the time of its entry on the market, this type of product was not new in the market 
place and other competitors were on their way. The main competitor had built a very 
good feminine platform for messaging, so the obvious place for the team to position the 
product was already taken. Instead, the company created a campaign built on “balance”, 
as the product did not include as much estrogen as the main competitors’ product. This 
therapeutic area was surrounded by intense marketing spending. (Type of Product) The 
company was new to this area, so substantial resources were needed. The fact that the 
company had to enter this new therapeutic area, which was much more resource-intensive 
than those it was accustomed to, did influence how the strategy was formulated.  
 
(Market Dynamics) The market was considered to be stable, certain and predictable. 
However new products soon to enter the market made the team think that changes would 
need to be made rapidly. This particularly influenced the allocation of resources to a 
strategy with fast uptake of market share. The perception was that the sales of these 
products were mainly driven by word-of-mouth among young women, i.e. this was 
something girls talked about and if a product worked well for one, her friends would go 
and ask for the same. The political environment and pricing were not major issues at the 
time of launch. The competition was very tough and most players invested heavily in 
marketing, including sales force resources. The first few months of the launch, the main 
targets were the experts, followed by heavy marketing and sales activities the most 
frequent prescribers. It was important to have acceptance and good relations with the 
experts, as too many negative statements from experts could have a considerable impact 
on sales uptake.   
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(New Product Adoption) During the launch, the team was certain that, to succeed in the 
environment, they needed sales representatives who were emotionally attached to the 
product. This emotional attachment was the most important driving force in establishing 
commitment in the sales force. The launch team had a clear view and strategy of how to 
build an emotional attachment to the product. Physicians, nurses and patients were all 
frequently invited to the company for presentations and lectures about how the product 
was perceived by them. The aim was to clearly describe the value of the product for the 
patients and how it had improved their lives. Effort, together with other commitment 
factors such as further investment in time etc, would develop if the sales representatives 
had the right emotional commitment. Very little effort was put into market and customer 
research before launching, and planning before the sales calls was minimal. In light of 
this, sales management did not push or think it was important for the sales representatives 
to do so either.  
 
(Behavior Control) The company had not set up any established procedures and 
guidelines, nor was it viewed as important for any members of the marketing and sales 
organization to follow or be evaluated on processes. This meant sales management did 
not pay attention to procedures, nor were there any benefits or incentives related to it. 
What was seen as important, however, was that the sales representatives be held 
accountable for their actions when selling this new product. The goal was to build sales 
representatives with a strong emotional attachment to the product and to control their 
actions in the field.  
 
(Outcome Control) The sales representatives’ pay increase and incentive bonuses 
depended on how they achieved the goals for the new product. The sales representatives’ 
goals were related to results, but not primarily, as their actions and behavior were 
weighted in equally. To reinforce the importance of the decided criteria for performance 
evaluation, pay increase and incentives, a routine was set up. If the sales representatives 
did not meet their performance goals, they were to report directly why this had happened 
and how they would deal with it. (Supervisory Context) Also, this was continuously 
emphasized in the field and practically handled with very active sales management. Sales 
management spent many resources and much time observing performance in the field. 
Sales managers traveled together with the sales reps to monitor behavior and actions and 
followed up customer reports carefully. This was a way of improving behavior and the 
question “what if” was often used by sales management to trigger even better behavior. 
Information was transparent among sales management and frequent communication to all 
sales representatives occurred in order to share as much as possible in an effort to 
enhance performance. The sales managers were seen as role models. Also, the sales 
managers made every effort to explain and make sure that everyone clearly understood 
and knew how the incentives were set up. Further, it was important for sales 
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representatives to feel confident that the sales manager would listen carefully when 
difficulties did arise. Rationale behind the launch of the product was important. The sales 
representatives needed to understand why the company needed a successful launch with 
just this new product and to understand the impact at different customer levels, i.e. 
physicians and patients. Little focus was put on formal training. It was up to the 
representatives to make sure they had full understanding of the product. With such tight 
observation in the field, sales management thought that this should take care of itself. 
This was also concluded not to have caused any problems during launch and was not 
perceived as important.  
 
(Sales force organizational design) The sales force was organized according to 
geographic area, with six representatives per sales manager. The distribution of sales 
representatives was based on population distribution, which meant that sales personnel in 
less populated areas had larger geographical territories, while some sales personnel were 
dedicated only to one larger city. The organizational set-up was not seen as important at 
all for the launch success, as long as sufficient coverage of customers existed. The entire 
sales force operated with two to three fewer sales representatives than they would have 
wished for; however, as profit was important, there was an attempt from management to 
maximize this number. (Sales Person Characteristics) The sales team had much 
experience of general sales skills, but not in the area of this kind of product or within the 
therapeutic area. With no real process orientation or documentation describing guidelines 
and with training being the individual’s responsibility, learning orientation was seen as 
important. Also, it was positive that there was flexibility in handling problems, so 
intuitive problem solving was preferred. The team was largely made up of women, but 
considering the product category, gender was not seen as anything that mattered during 
launch. (Other) All sales representatives carried two products, the new one and an older, 
much more established product. The established product was not related to the same 
therapeutic area. Having two products was not seen as a problem. However, it was seen 
as very important that the new product was sold first during the sales call.  
 
(Performance in Selling a New Product) Exceeding profit target and sales targets were 
perceived as the most important measure of success. Also, the company had new 
products in the pipeline, which were soon to be launched within the same therapeutic area 
so relationship-building with key customers was seen as essential for future launches 
included in the sales manager’s objectives. This made it important for the sales 
representative to assist sales mangers in reaching their objectives. Other performance 
measured was market share gain, which was measured every quarter. In the first year 
profit was met, but not the set sales budget. The explanation for this was the time needed 
to build up relations with the experts did not generate direct prescriptions or sales as 
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quickly as the team had hoped for. In the second year, profit, sales and objectives were 
met and the launch was seen as a success.  
 
Case Study 4 (of 6): The Launch of an Antidepressant  
 
When this new anti-depressant for a major depressive disorder was launched, the product 
had a new mechanism of action and a different dosing scheme compared with the 
products currently on the market. However, early enthusiasm about the product was not 
great. Prior to the launch, the team received comments from senior management, such as 
“This is a me-too product and does not look as good as the competitors’ out there” and, 
“None of the differentiating factors seem to be very good or important”. This initial 
product perception from the marketing and sales directors made the planning for this 
launch difficult.  
 
To make matters even worse for the launch team, the company did not have a great deal 
of experience of the anti-depressant market other than from some of the more out-dated 
therapies.  
Despite its differences and novelties, the product was not seen as new to the market and 
the company had only limited and obsolete experience in the therapeutic area, yet the 
launch team had to consider it new for the company. (Type of Product). This influenced 
the way in which the launch team approached the strategy for the product introduction. It 
had primary influence on how they went about setting up the sales and marketing 
organization. The plan was to hire a very experienced product manager, sales manager 
and sales force. However, with competition in the market for good staff, the company 
was only able to recruit a few experienced sales reps as the best ones in the field already 
had good jobs with the competitors. For the role of product manager, the decision was 
made to transfer someone internally. The choice fell on one of the upcoming product 
managers whom had shown great interest, motivation and action orientation in previous 
jobs. To prepare her for the launch, she was trained by physicians in the clinics about the 
product, the disease, and treatments. This also set the scene for future relationship 
building for the sales force, as she made initial contacts and gained an understanding of 
the experts in the field, referred to as key opinion leaders. As the launch approached, the 
leading sales manager was also transferred from another internal product. The sales 
manager had plenty of sales management experience but not any specific experience of 
the anti-depressant market.  
 
The anti-depressant market was a fairly large market and it had a very satisfactory growth 
curve at the time of launch. About two to three years before the launch of the product a 
new treatment paradigm had penetrated the market. Up until then, only specialists, 
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psychiatrists, had been treating the disease and in an environment which had been 
characterized by close supervision of the patient under treatment. The treatments that had 
been available before had several side effects and an increased risk for suicide. With the 
new pharmaceutical options in the market, these issues became less important. This 
change in risk opened up treatment on a general practitioner level, as it was now 
perceived safer and simpler to prescribe those pharmaceuticals. The need for close 
supervision during treatment was no longer a crucial factor. The first of the new 
treatments launched quickly won a good market share, but close upon this came a 
competitor, who gained enormous growth with both specialists and general practitioners. 
These two successful products were the main competitors at the time of launch. (Market 
Dynamics.) By launch, however, the market dynamics had stabilized and were 
considered stable, fairly certain (and predictable) and major changes were not expected to 
come rapidly. The market dynamics were playing a medium role in the strategy 
formulation, mainly from the perspective of how competitors already acted in the market.   
 
Based on the fact that psychiatrists and general practitioners were the product’s target 
segments, the team identified an order of sales towards the target groups whereby they 
would first win over the specialists, the psychiatrists, and then quickly move on to reach 
the broad general practitioner segment. This was also the approach taken by the team. As 
the product launch approached, the product manager began to feel that the differentiating 
factors might be turned into an advantage and a marketing story was formed. The product 
manager and the leading sales manager were preparing to launch the product with main 
messages highlighting how the product worked differently in the body followed by very 
carefully crafted guidelines for communicating the dosing scheme, which was seen as a 
downside in the general practitioner segment but a upside in the psychiatrists’ segment. 
The launch teams perceived that their most important task during the initial planning and 
launch phase was to build commitment to the product. (New Product Adoption.) On the 
sales representative level, the emotional attachment to the product was seen as critical for 
success with this new product. Also, they felt the need to formulate objectives with a 
great deal of personal meaning to the sales representative. With commitment being very 
important, effort was also focused on extensive preparation for prospecting for the right 
customers. To create the emotional attachment, the marketing and sales team took the 
time to interact with physicians and nurses to find out the practical importance of these 
kinds of products. However, the activity that gave the most emotional impact was the fact 
that the team was meeting patients to hear their stories, and learn how these therapies had 
enormously affected their lives, re-establishing them from a situation with no hope or 
wish to continue living. To build in objectives with personal meaning to the sales 
representatives, they were measured on number of sales calls and market share together 
with success stories collected from physicians’ and nurses’ about  patients on the product 
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to be shared among the team members. This was aimed to bridge the emotional 
attachment and the personal objectives.  
 
There were not many established procedures or guidelines to be followed by the sales 
force or the sales management. (Behavior Control.) Following pre-set procedures was 
not seen to be very important, so there was no sales management monitoring of such. At 
one point, at a higher company management level, there was an initiative to establish 
strict procedures for the sales force, however this initiative did not reach the sales force in 
any practical way during launch. On the other hand, it was seen as important that sales 
representatives’ actions were appropriate in the field. There were considered to be 
informal directives on how to act as a sales representative, and all sales representatives 
were held accountable for their actions, regardless of whether the number of sales calls or 
market share were reached. The performance evaluations were not mainly weighted 
towards tangible results, such as sales calls and market share, but instead included more 
subjective measures, such as their actions in the field. (Outcome Control). The 
evaluation measures, which were in practice the same as their goals, had a direct impact 
on pay increase and bonuses. A significant factor that was seen as important was to 
follow up on any area of the performance goals that was not met. This was followed 
strictly by sales management and sales representatives were obliged to explain why they 
had not reached their goals.  
 
With limited enthusiasm and doubt from company management about the value and 
competitiveness of the product in the market, it was seen as extra important to have a 
very strong rationale for the team launching this product. (Supervisory Context.)The 
rationale was mainly built from an external perspective in a way similar to the way in 
which the emotional attachment was built. This was done by creating lectures for the 
whole launch team, where physicians spoke about failure and switch rates with existing 
products in the market and the gap the new product could fill, and patients told about how 
their lives had changed radically for the better when they were prescribed a therapy that 
worked. This created a very strong rationale for introducing this product. Little effort was 
put to explaining the research behind the product, with the exception of the fact that the 
product came from the company’s own pipeline. Sales management assumed that 
everybody understood the set-up of incentives, so no effort was put into ensuring 
everyone had full understanding. During launch, the team did not talk about or explain 
any match with company strategic objectives. The team felt that trust between sales 
management and sales representatives became strong during the activities to build up 
emotional attachment to the product and with the activities to build a strong rationale for 
product introduction. The important part of driving launch success was that the sales 
representatives could talk freely about difficulties and that the sales managers would 
really want to listen. As a result of this open communication, issues that could have 
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become serious could be taken care of early. Emotional investments in the working 
relationships and sharing ideas were seen as less important. Further, based on the way in 
which performance evaluations were set up, sales management spent much time 
observing the sales representatives’ performance in the field. This was seen to be very 
important for success of the launch t. Dedication to actual training was small, as it was 
not seen as important for launch success.  
 
The sales force was divided into territories based on geographic spread, which in turn 
were based on how national healthcare was organized in terms of budgets and 
prescription guidelines. (Sales force organizational design). The way in which the sales 
force organization was set up was not seen by the team as making any difference for 
launch success or not.  
 
The sales force was recruited from both outside and inside the company and all 
salespeople had different backgrounds and experience. (Sales Person Characteristics). 
The sales representatives were chosen mainly based on previous success in terms of sales. 
A background in the depression therapeutic area was preferable, but this was hard to find 
in the competitive climate. The most important attribute, which was also looked for 
during recruitment, was the ability to solve problems in an individual self-decisive way. 
Performance orientation was seen as given and acknowledged as important.   The team 
had a strong preference towards intuitive problem solving being important for launch 
success, mainly because the lack of guiding procedures in the sales force operations.  
 
The sales force sold one product only, and this was seen as very important. Based on the 
fact the product was sold alone, there was no need to discuss which product should be 
sold first. However, the team highlighted the importance of having the new product first 
in the sales call with the quote  from a sales manager “We once discussed co-promotion, 
and that would have been OK as long as they also had the product first in the call”. 
(Other) Senior management measured the success of the product during launch in terms 
of profit for the company, referred to as “bottom line” as the prognosis was not set high. 
For the launch team this had implications on resources, and especially on the number of 
sales representatives available. (Performance in Selling a New Product). The launch 
team on the other hand did measure success on sales growth and market share growth, 
referred to as “top line”. For a few years after launch success, the company’s 
management started to follow the same success measures as the launch team as it had 
quickly become a very important growth driver for the company. In addition to exceeding 
profit target to satisfy senior management and exceeding sales target to drive growth for 
the launch team; reaching all objectives based on sales management performance goals 
and the sales representatives’ performance goals, were seen as very important aspects for 
measuring success. The team concluded that the launch was a great success, especially in 
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relation to the expectations communicated by senior management prior to launch. All 
criteria for a successful launch were met, with the exception of for some specific 
performance goals for individual sales representatives with very minor overall impact 
 
Case Study 5 (of 6): The Launch of a Painkiller (Analgesic) 
 
The launch of this analgesic, more commonly referred to as a painkiller, was somewhat 
similar to a launch of a ”me-too” product in the marketplace. However, some features 
related to the substance made it possible to produce a compelling marketing story and 
gain a fairly good interest around the product in the sales force selling the product. The 
target group was General Practitioners and a few key opinion leaders in the field.  
 
As with a “me-too product”, the product was neither new to the company nor especially 
new to the market (Type of Product). The team was in agreement that the perceived 
“newness” of the product greatly influenced their approach to sales force strategy 
formulation both from an external and an internal perspective.  
 
The market into which this new product was introduced was seen as stable, certain 
(predictable), as well subject to slow change. (Market Dynamics).  
 
All involved parties concluded that adjusting strategy to the type of newness and the 
expected market dynamics was important and that it was likely to have a high impact on 
the selling performance.   
 
Due to the fact that the product was perceived as a “me-too-product”, the sales force’s 
commitment to adoption was a concern when planning the launch. The team’s pre-launch 
discussions included issues such as, whether it would be easier to gain commitment in the 
sales force since most of the sales personnel were already familiar with similar 
compounds, or if it would be more difficult because of already established sales 
arguments and relations, which would have to be altered for the new launch. During the 
actual launch, the sales force mostly consisted of younger, “hungry” salespeople. Also, 
the company in which the product was launched had a culture of fostering its sales 
personnel to perceive themselves as better than competitors. The culture and general 
training were also constructed to include commitment in selling new products. The 
launch team worked hard to produce the “news” argument and at the time of the launch 
the sales force accepted and perceived the product launch as bringing news to the 
customers. The driving force of commitment was identified as the emotional aspect, i.e. 
to make sure the sales representatives believed in and felt a connection to the product 
brand, its value as a therapy and its overall success. Sales representatives’ discussions 
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about the product were not seen to be important, rather the reverse due to the risk that 
they distort implementation of new messages. (New Product Adoption – commitment) 
 
The effort to sell the product was extensive, but as it originated from the culture within 
the company, it was similar to that with other products that had been launched or were 
already established in the sales representatives’ portfolio. The difference between the 
efforts for a new versus an older product was not seen as a very important issue if 
emotional commitment had been established. (Product Adoption – effort).  
 
In an effort to control the behavior and outcome (Behavior Control and Outcome 
Control), the sales force was kept very involved from the start in that they were shown 
sales numbers, market share and other market data as a means to push them to sell. It was 
also communicated to them that the company was the best in all aspects. This 
communication was a part of reinforcing the culture. The sales force carried several older 
products in the company portfolio in addition to the new one. The majority of incentives 
were aimed towards the new product to ensure that it was focused. However, the 
incentives were not high in monetary terms, but were more of a means to increase 
internal competitiveness. Also the new product was detailed first in the sales call. 
Managerial issues were how to continue selling the other products with the addition of 
the new one and how much time should be dedicated to the new versus the older products 
to optimize overall sales while still securing a sufficiently fast uptake of the new? The 
team agreed that even though the incentives and sales competitions were directed towards 
the new product, the two main drivers for controlling outcome were to first always let the 
sales representative be accountable, i.e. the sales representative would always have to 
justify and explain any outcomes versus set goal, good and bad, but especially bad 
outcomes. Secondly it was agreed that it was important to follow procedures, but to be 
successful in outcome control the sales representative should continuously be forced to 
explain his/her actions in selling the new products, and as quoted by a manager “actions 
speaks louder than words”.        
 
Supervisors’ behavior and actions (Supervisory Context) were seen as important if the 
sales representatives were to achieve a successful launch. During launch, co-travel with 
the sales representatives became even more important. The sales managers increased their 
visit frequency, and spent at least one session a week in the field with each sales 
representative in their team. The purpose of this was not always to teach, as this 
competence should already be in place, but more to observe, as this was perceived to give 
a more robust platform for sales managers to continue the development of the whole team 
as well as later give feedback to any individual on behavior and actions.  
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One key objective when launching this product and in line with the company culture, was 
to build team spirit and the emphasis on “we”. The sales managers’ task was defined as 
providing support for the sales representatives and not acting as the boss pursuing a 
directive style. As a result of this, trust in the team, the manager and the company all 
became important for the sales representatives. The most important aspect of trust was 
the ability to openly discuss difficulties and that concerns raised were taken seriously by 
the managers.  The perception of the manager as more supportive than directive was very 
important, while in reality, the manager was supposed to operate with very tight 
directions to the sales representatives, especially if something seemed to be going wrong 
as discussed in outcome control above. 
 
Training is important, but as this was perceived as something of a me-too-product in the 
market place there were not really any new concepts in the area of product features for 
the sales representatives to be trained in as they were familiar with the area and previous 
products. The training was much more focused on messaging and building commitment. 
The team agreed that in any circumstances product training was of less importance than 
message training. To increase commitment and alignment and build team spirit, sales 
management was encouraged to develop their own training material. The team ranked 
training in the features of the product as the least important area of internal marketing.  
 
Continuing the discussion about what was perceived as most important for supervisors, 
the team agreed that the internal marketing was of very great importance. Even if most of 
the aspects of internal marketing were perceived as significant, the importance of 
explaining the rationale for introduction from all angles far exceeded the importance of 
any internal marketing about the research behind the product or understanding of how the 
incentives had been set up.   
 
The current geographic organizational structure was used during the launch, so no 
changes were made to accommodate the launch of this new product.  The geographic 
split among sales staff and resources was based on area population, which meant that 
some areas, such as the northern part of the country, were left without sales 
representation. The sales teams had one sales manager to whom 5-7 sales representatives 
reported. The team agreed that organizational set-up (Sales force organizational design) 
was not of any great importance for a successful launch. 
 
During the launch, the sales team comprised of both experienced and new sales 
representatives. Most of them had a common background, having been recruited directly 
from universities or other industries. Very few of them had any background in other 
pharmaceutical companies. Performance orientation was seen as important. However, as 
the product therapy was not new to the company, some had previous experience from 
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selling similar products before. The core characteristics that the company was looking for 
in sales representatives, both in general and for this new product, were people able to 
comply with given rules and generally possessing a polite manner. The sales personnel 
had little room to maneuver by themselves and were very tightly directed, both on 
behavior and actions. Most of the sales personnel followed designated procedures and 
guidelines and did not do much intuitive decision making on their own. This was seen as 
the most important characteristic of sales representatives compared to their learning 
orientation, their career success and their experience. (Sales Person Characteristics) 
 
As interviews and discussions around the launch continued, other topics perceived as 
very important or almost critical for success were raised. The team pointed out that an 
important concern before the launch was to optimize the share of voice. They perceived 
share of voice as an important driver for sales uptake. The team described share of voice 
as being both number of salespeople and number of meetings with physicians. The share 
of voice could also be measured in market research as “top of mind” when physicians 
were asked the number one product or top message in the category.  At the same time as 
wanting to maximize the share of voice, the team wanted to optimize the cost to meet set 
budgets and profit targets. Further, as the sales representatives carried several older 
products in their portfolio, the importance of placing the product as number one in the 
sales call was perceived as very important.   
 
In Performance in Selling a New Product, measures of success were monetary sales 
targets which should be exceeded and the objectives of sales managers and sales 
representatives. As sales managers’ objectives were directly passed down to the sales 
representatives’ objectives, the sales personnel’s success, or assistance in meeting the 
sales managers’ objectives was critical in measuring success. Other important measures 
were market share increase, profit, and share of voice, i.e. number of calls or recollection 
of core messages among physicians compared to competitors. The launch of this 
painkiller was considered a success, as sales targets where exceeded and objectives of 
sales management were met.  
   
Case Study 6 (of 6): The Launch of a Migraine Treatment 
 
This product was due to be launched into a market where the competitor had been 
established over a period of ten years. The launch team could see many challenges in 
meeting a product that had been so well established for so many years. The competing 
company had great relations with all levels of customers within the therapeutic area. 
Many of the key customers had participated in post-marketing studies with the competing 
product and knew well how to handle any side effects and complications. The experience 
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of the launch team was that, under these circumstances, the customer base would 
welcome new choices and additions to their treatment options. However, judging from 
market anecdotes and market research this did not seem to be the case. The team’s launch 
strategy was built on the improved effect of the product, and it had solid proof that it was 
based on sound data. They were however concerned as to whether this increase in effect 
would be enough to change behavior on a customer level. The product was also the first 
of its kind for the company, so the commercial organization was faced with something 
completely new. (Type of Product.) It had taken the company ten years to develop this 
product and the sales and marketing team were committed to using all the knowledge 
built up in the research department as an advantage when launching the product. (Market 
Dynamics.) The market had changed very slowly and was seen as stable and the future 
was certain and predictable, even though new competitors were on their way into the 
market. Both the type of product and the market dynamics had impact on the launch 
strategy formulation. 
 
The product’s target group was general practitioners together with neurologists in an 
open clinical setting. The launch strategy for this product was to shake the market with as 
much noise as possible with a message compelling enough for customers to question and 
change their habits with the competing product. This meant that resources were an 
important topic for the team. Once internal approval had been given, the launch team 
planned and executed two very expensive initiatives. These initiatives had to have several 
objectives to be able to provide the desired return on investment. The first initiative 
involved a series of post-marketing studies with a very broad range of participating 
customers. This would fulfill the objective of providing many customers with knowledge 
and experience of the new product at an early stage. The second initiative was based on 
the extensive product knowledge that had been built up in the research department during 
development. Early in the launch, a series of large scale educational seminars on the new 
product, its development and progress within the therapeutic were conducted. These 
educational seminars had multiple objectives. From a customer standpoint, the objective 
was to make as many of them as possible aware of the new product and how its benefits 
could provide the therapeutic area with a good new option. This would give the sales 
force a head start of product awareness. Internally, these educational seminars had several 
objectives. One of the bases of the idea was that the sales representatives participated in 
similar conditions to the customers. First this had the objective of providing the sales 
representatives with sufficient basic product training. Also, as the sales representatives’ 
emotional attachment to the product was seen as very important, the second objective was 
to use this forum to build upon it. The third objective was to give the sales representatives 
a very relaxed and natural opportunity to build important customer relations. 
 
 251 
 
With the aim of building emotional attachment to the new product, the sales organization 
conducted several teambuilding activities in order to make everyone comfortable with 
arguments for skeptical customers. Further, investments were made to bring the sales 
representatives to congresses to further develop that emotional attachment. Previously 
only product managers and medical personnel had attended congresses. Commitments, 
other than building a strong emotional attachment, were not seen to be very important. 
(New Product Adoption). There was no indication that the success of the product launch 
had anything to do with the link to personal objectives or whether the sales 
representatives had discussed the product among themselves or not. Also, the team did 
not think that extra commitment compared to any other product sold would be needed. 
Much effort was put into building customer relations with key customers. This was seen 
as very important, especially in the light of the strong relationships the competitor had 
built over time. Other than for key customers, it was seen as less important to 
prospecting, planning, collecting or use market information collections. 
   
The company had very strict procedures to be followed by the sales representatives. 
(Behavior Control). It was seen as very important that these procedures were followed. 
When traveling with a sales representative, the sales manager monitored the sales reps’ to 
make sure that procedures were adhered to at all times. The sales representatives were 
held accountable for their actions, regardless of whether they achieved their results or 
not. There was no monitoring in order to evaluate the procedures as such and pay 
increases were not dependent on how the sales representatives followed or knew the 
procedures. (Outcome Control). The company wanted growth and evaluations were 
primarily based on results. The most important outcome metric was sales achieved by 
each representative and this was an important performance goal for them. Performance 
evaluations also included the extent to which the sales representative followed 
procedures. Pay increase and other tangible rewards were single-handedly based on the 
criteria of meeting or exceeding sales numbers, so there was no real connection between 
performance goals and pay increase or anything else the sales representative might have 
accomplished outside regular procedures. If the performance goals were not reached, the 
company required that the sales representatives explain why and present plans for 
achieving the next round of goals.    
 
(Supervisory Context). Two matters of prime importance within internal marketing 
were that the rationale for the product was understood and that the company’s strategy 
with the new product was explained. This was achieved by including the sales 
representatives in the educational seminars and bringing them to congresses and by 
continuously presenting the sales growth contribution and effect and market share 
numbers of the new product for the company. As the sales numbers alone provided the 
incentives for the new product, the team did not think that any explanation of how they 
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were set up was needed. The research behind the product was not important other than for 
the fact that it provided a valuable tool for marketing and sales operations in specific 
launch activities. Sales management considered that it was important to be what they 
referred to as “being ahead of the game”. This meant picking up signals in the sales force 
at an early stage. As product training and field attention in the form of joint calls or 
spending too much time with the sales representative were seen as not being too 
important, the trust between the sales representatives and sales management to freely talk 
about issues would give the sales managers these early signals without their having to 
spend extensive time in the field. To make this work the managers really needed to listen 
every time the sales representative spoke to reinforce the perception of them always 
being willing to listen.  Sharing ideas and other emotional investments were not seen as 
very important.  
 
The sales force was set up according to geographic territories, with a number of sales 
representatives in each comparable to number of customers in that territory. (Sales force 
organizational design). As long as the coverage of customers was solid in terms of 
number of calls, the importance of the sales force organization design was not seen as 
significant for the success of the product. The number of sales representatives was 
important, but the team faced no staffing problems since the company’s strategy was 
growth and it was at the time less concerned with profit. (Other). The sales force did 
carry other products, but this product was always first in every call. It was seen as 
necessary to have the product sold first if no opportunity was to be lost.   
 
Based on the perceived importance of following processes, the criteria for problem 
solving were systematic and according to “the book”. (Sales Person Characteristics). 
The profile the company expected and which was provided by the salespeople was 
competitiveness and adherence to procedures. Background and experience were of less 
importance. The sales force was made up of a range of personnel, from those with 
extreme explorer background to nurses and PhD’s. The performance orientation was 
obvious; all the sales representatives as well as competitors were seen to possess this, so 
competitiveness was preferred instead.  
 
In the situation where growth was on the agenda, the criterion on which the company, the 
launch team and sales management measured overall launch success was exceeding sales 
targets. (Performance in Selling a New Product). All other metrics were of less 
importance; even if metrics such as market share, volume, etc were all met, nobody paid 
attention to them at the time. The launch was successful and the sales targets were 
exceeded with good margin. After a few years the product became number one in sales 
and volume for the therapeutic area, outperforming the already established competitor.   
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Appendix 5: Expert Interview Results: Product Launches in 
Sweden 
 
This Appendix presents the documentation of the expert interviews conducted to support 
analysis of the case study results, adapt the Preliminary Model to the Research Model and 
to identify and validate the variables within the model and build the data collection 
instrument. The expert results are based on the experts’ analysis of the six case studies 
and their own expertise about each variable in the Preliminary Model. Also, during the 
interviews, some literature findings were occasionally discussed. 
 
Overall the expert interviews were in line with the results from the case studies.  The 
expert interviews provided valuable insights and recommendations for formulating the 
Research Model. Also a major contribution of the results from these interviews enabled 
the narrowing down of the number of key success factors and pin-pointing those 
considered most important for driving a successful launch of a new product in the 
Swedish pharmaceutical industry. A summary overview of the results from the expert 
interviews can be found in Table 9. 
 
General Analysis of the Case Studies by the Experts 
 
All experts concluded that the case studies provided an excellent insight into the 
perceived key success factors for sales force readiness during a new product launch. 
Further, all expressed that the patterns were fairly clear in guiding the choice of key 
factors driving success of new product launch.  
 
The spread among therapeutic areas and companies was agreed to be good. Experts 1, 2, 
3 and 5 raised and, in consensus, concluded that which company the product belonged to 
seems to have very little relevance or importance to the perceived launch success factors. 
The only clear pattern these experts could identify as far as company relations were 
concerned was within the areas of Sales Person Characteristics and problem-solving. As 
the concept “intuitive” seemed to be preferred in Company B and “systematic” within the 
other two companies, these experts drew the conclusion that this seemed to be related to 
whether or not the company had well-defined procedures for the sales force. Two of the 
three product launches had highlighted that following procedures was important for 
successful launch. On the other hand, within these cases there seemed to be very little 
focus on measuring and rewarding if the procedures were followed, while accountability 
to actions seems to be a cross-case important launch success driver, whether or not 
procedures were established. The company owning the product, its culture and 
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established procedures or lack of them could probably in many areas have impact on a 
launch. However, when identifying the key drivers for success in the sales force, all of 
the experts concluded that even if this was disregarded, an adapted research model based 
on the generic model would still be very accurate in guiding key success factors, as set 
out in the research objectives.  
 
The experts all gave full support to the research scope of sales force operations towards 
physicians who were general practitioners. Experts 3, 4, 5 and 6 all had a background in 
launching pharmaceutical products aimed at specialists and general practitioners. These 
experts all concluded that it is not unlikely that the set of success drivers for launch might 
differ if the product was launched for specialists versus general practitioners and the 
scope was seen very positively and the final results would be likely to be more accurate 
with this distinction between the sales force target groups.   
 
Type of Product 
 
The experts, with the exception of expert 5, all concluded that the newness of a product 
could definitely have an important impact on the launch success. However, this is 
something on which commercial organizations, especially sales forces, have a minimum 
influence. The five experts highlighted this variable as something to be retained in the 
adapted research model as it might give important guidance as to environmental impact 
when sales management strategies are formulated. Expert 5 did not think it should be 
included in the adapted research model, as the perceived view was that it had no 
importance. However, if it were retained, no harm would be done to the model and the 
results might not be those expected, and new lessons might be learned. 
 
The recommendation when data was collected was to ask which of the three conditions 
were met at time of launch and to analyze that condition against successful launch with 
the aim of identifying any relations indicating preferable or ideal condition. Expert 3 
raised interest in analyzing relations between type of product and effort in training, but 
had a change of mind when realizing that gained experience in the case studies showed 
the standpoint of training in the sales force as not being such an important driver for 
launch success.   
 
Market Dynamics 
 
The experts all thought that market dynamics should be included in the model and that 
the arguments were the same as for the variable type of product, since these insights 
would give important guidance for formulating sales management strategies. However, 
experts 1, 2, 3 and 5 pointed out that the two important conditions during launch would 
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be the dynamics of stability (stable/unstable) and changing speed (slowly versus rapid). 
Their argument was that both the conditions of predictability (predictable/unpredictable) 
and certainty (certain/uncertain) were less valid at time of launch, as product launches in 
most cases would make the market both more uncertain and more unpredictable, which 
meant that these factors were of less importance as background when formulating a 
product launch strategy. Also, the conditions appeared to be less clearly defined. These 
experts suggested that the factors predictable and certainty be removed. They also 
pointed out support in the case studies for this.  
As far as stability is concerned it was concluded that it should be kept in the research 
model as the product launch itself was not perceived to impact the stability of the market 
to any great extent and it was considered to be important input for launch strategy 
formulation. The launch itself could possibly impact the condition of slow or rapid 
change; however it was seen as very important knowledge when formulating the strategy. 
The recommendation when collecting data was to ask which of the conditions applied at 
time of launch and then analyze the condition against successful launch to find out which 
condition increased possibilities for  a successful launch.  
 
New Product Adoption 
 
This was stated as an important variable by all the experts, who mostly agreed with the 
case studies. Regarding commitment, the experts were unanimous in their agreement that 
the item querying the sales representative’s emotional attachment to the success of the 
new product was the most important item. Experts 3 and 6 both argued, based on their 
experience, that if emotional attachment is achieved among the sales representatives for 
the new product the rest will follow, i.e. product significance, sense of duty and 
investments in time and energy. They also argued that this included the effort variable. 
Experts 3 and 6 concluded that the only item that should be included in the key success 
factor research model for new product adoption was the emotional attachment. This 
viewpoint was largely similar for experts 1, 2 and 5, however, with a difference of 
opinion regarding the commitment item, willingness to make further investments in time 
and energy and the effort variable. On the one hand, they thought that the item 
(investments in time and energy) and variable (effort) could be taken for granted merely 
based on emotional commitment, and if included in the model should be treated 
separately. On the other hand, they did not think the either the item (investments in time 
and energy) or variable (effort) were important enough for inclusion in the research 
model as a key success factor. Expert 4 gave support towards including the variable for 
achieving objectives as having a great deal of personal meaning for the salesperson, in 
the research model. Further, this expert also wanted to include the item in the variable 
effort, for prospecting for customers. All experts dismissed the item of discussion with 
other sales representatives as important. The recommendation when collecting data was 
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to ask whether the sales force did or did not support the chosen item (binary) to find out if 
this was a driver for successful launch.  
 
Behavior Control 
 
That behavioral control is an important factor for successful launch was agreed by all the 
experts. Four of them (2, 3, 4 and 5) stated that based on their opinion, this factor is one 
of the most, if not the most important factor for achieving a successful launch. All the 
experts agreed with the findings in the case studies that the item about holding sales 
representatives accountable for their actions regardless of results was of importance. 
They all recommended including this item as a key success factor.  On the other variables 
however, their opinions differed. Experts 2 and 4 suggested that the items that 
supervisors should monitor the extent to which the sales representatives follow 
established procedures and that supervisors should evaluate the procedures salespeople 
used were both important for new product success. Their arguments were that if this was 
not done, needed procedure changes would not be detected and identified early on which 
might jeopardize launch success. Further, these experts did not agree to any real 
importance of how this was connected to pay increase and other rewards. Experts 1 and 6 
thought that none of the items other than holding the sales representatives accountable for 
their actions regardless of results, were sufficiently important to be included in the 
research model. Expert 3 suggested that for new product launch success, process 
evaluations, i.e. monitoring sales representatives and evaluating the procedure itself, 
should be excluded from the research model. However, expert 3 suggested that it would 
be of interest to include in the model if the item, if the sales representatives’ pay 
increased and tangible rewards on how the sales representatives followed any processes 
as well as their knowledge of, would be of interest to include in the model. The argument 
was that then only little monitoring would be necessary as the sales representatives would 
have the incentives to follow set procedures which would benefit the new product launch. 
The expert did not think that this would be the case if it was not connected to pay 
increase and tangible rewards. The experts recommended, whichever item was chosen, to 
measure the items in terms of whether or not the sales force was controlled, or not,on that 
item (binary), during launch to find out if this was a driver for successful launch. 
 
Outcome Control 
 
Regarding the items within outcome control, the experts were mostly in line with the 
results of the case studies. All the experts highlighted the item concerning that if 
performance goals for the new product were not met, the sales representative should be 
required to explain why, as the most important item to include in the model. They based 
it both on their own experience and the results of the case studies. Experts 3 and 6 argued 
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that performance evaluation should primarily not be measured on results, dismissing the 
item indicating this. The argument made was that with sales representatives having to 
continuously explain their unachieved results, the sales representatives, together with 
management, would have a formal process to continuously update the objectives. In an 
uncertain environment, such as might be perceived at a time of launch, some flexibility is 
needed within the selling process, and set performance objectives tend to quickly become 
obsolete in a launch situation (Lilien et al. 1981), so primary emphasis on results will 
often be unfair or prove to be unachievable for the sales representatives, which in turn 
might lower motivation for selling the product.  Experts 2, 3 and 5 had similar thoughts 
around flexibility in objectives and sales force outcome measures, such as market share 
and sales, to ensure that the sales force objectives do not deviate too much from reality 
and from expectations before or during a very early in the launch.  
 
Experts 2 and 5 were in support of the item “pay increase and other tangible rewards 
depend on the degree to which I have achieved the goals set for this product”. They 
argued that it is an important factor for sales representatives to receive monetary rewards 
and that those rewards should be tied to the goals set for the new product. For the item 
“pay increase depends on how sales representative performance compares with the goals 
for this new products”, was not identified as a key success factor by either the case 
studies or the experts. Experts 2 and 5 express preference for the first item rather than 
comparative item. The other experts argued that none of these items should be included 
based on the case studies since the explanation of unachieved goals and flexibility of 
changing them, as discussed above, were more important during new product launch.   
 
Experts 1 and 4 supported the item “performance evaluations of salespeople on this new 
product place primary weight on results”. They argued the standpoint that sales 
representatives are usually driven by results and that the item should be included based 
on this argument.  
 
Expert 4 supported the item “pay increases and rewards depend on the degree to which 
sales representatives have achieved specified outputs regardless of whether sales 
procedures were followed or not”. This item did not find a great deal of support as a key 
success factor in the case studies, however expert 4 argued that following the stand-point 
of putting primary evaluation weight on results, payments and rewards should not be tied 
to whether or not procedures were followed. However, expert 4 did later open up for the 
possibility to include some part in the evaluation on procedures.    
 
The recommendation was to keep the selected variable or variables to a binary measure, 
that is, did the variable find support or not during the launch in order to investigate if this 
was a driver for successful launch.   
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Supervisory Context 
 
As far as internal marketing is concerned, the experts agreed with the clear and strong 
support for the item of having the supervisors explain the rationale for the introduction of 
the product and the recommendation from all the experts was to include this item in the 
research model.  
 
While there was a consensus about the variable of explaining the rationale for product 
introduction, there was not full agreement as to whether or not to include the item about 
the importance for sales managers to explain how this new product fits in the company’s 
strategic objectives, in the research model. Experts 3 and 4 argued that this was important 
and suggested inclusion in the research model. The other experts agreed with the findings 
from the case studies that showed this item to be less important as a key success factor. 
They clearly recommended not including this item as a key success factor.  
 
All experts were in consensus about not including the item; “my supervisor explained the 
research behind the development of this new product”, based on the findings in the case 
studies as well as their own experience.  
 
The item identified in only one case study, “my supervisor made sure every salesperson 
knew the incentives for selling this product”, gained some support from expert 4, 
however not to any great extent.     
 
Interestingly and in contrast to the main outcome of the case studies, the trust variable 
generally received little support from all experts. The item, “I can freely talk to my 
supervisor about difficulties I am having at work and know that he or she will want to 
listen”, which was identified in all case studies as a key success factor for new product 
launch, was also highly regarded as the same by the experts. However, with the exception 
of expert 3 who did not want to include the item in the research model, all other experts 
recognized the strong support this item had received in the case studies and 
recommended the inclusion of the item in the research model. For the other items, all 
experts recommended exclusion from the research model.   
 
Regarding the training variable, the majority of the experts agreed with the findings of 
the case studies, suggesting exclusion of the variable. All experts, with the exception of 
expert 1, considered training to be of less importance and not regarded as a key success 
factor for inclusion in the research model. The argument was based on the relatively 
weak importance in relation to the recommended key success factors, such as emotional 
attachment to the new product and explanation of the rationale for introduction of the 
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product. Expert 1 argued that product training was important, mainly based on the nature 
of the complexity of pharmaceutical products in comparison with other categories such as 
most consumer products. Expert 1 argued for inclusion of the item that sales 
representatives should receive substantial training before assuming responsibility for 
selling the new product. This specific item was not identified in any of the case studies as 
a key success factor, however one case study did identify the item for time on training.  
 
For the variable field attention, the experts were in line with the results of the case 
studies. In the case studies the item, managers’ observation of performance in the field, 
was identified in five case studies as a key success factor. Also, all the experts agreed 
with inclusion of this item in the research model. They had several arguments in addition 
to the results from the case studies, such as their own experience, the importance of being 
seen as a manager in the field, closeness to customers and market dynamics, etc.   
 
None of the experts suggested that the other two items about time spent and making joint 
sales calls should be considered for inclusion in the model. They did not dismiss these 
items as unimportant, but did not see them as sufficiently important to be included in the 
model as key success factor.  
 
As with the previous variable, the expert recommended measuring the variable or 
variables for supervisory context as binary, i.e. yes or no, in the instrument with the aim 
of finding out whether they contribute positively to a successful new product launch. 
 
Sales force organizational design 
 
In the category of sales force organizational design, the experts were also in line with the 
results of the case studies. There was only one case that identified any of the items as a 
key success factor for new product launch and that was that of forming selling teams. 
Even though, discussions took place with experts 2, 4, and 5 about the benefits of 
organizing the sales force based on customers versus geographical organization, they 
were all in favor of a customer-organized sales force and none of them suggested 
including this or any other item about organizational design in the research model. 
However, they all pointed out that, based on their experience, one of the most important 
issues in sales management and especially in the pharmaceutical industry was the number 
of sales representatives that should be included in the sales force during a new product 
launch. This was highlighted in five case studies. The experts agreed that share of voice 
was important, but the most correct and holistic questions would be – what is the optimal 
number of sales representatives? This issue was raised on the basis of the balance of 
rapidly achieving sales and market share versus keeping the profit (P&L – profit and loss) 
optimized. The experts commented that, particularly in Sweden where most 
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pharmaceutical companies are only marketing and sales franchises of larger corporations, 
the main cost is the sales force. All experts recommended including a variable for 
measuring the optimal number of sales representatives needed for a successful product 
launch. Further, experts 1, 2, 4, and 5 recommended investigating the optimal number of 
sales representatives by collecting data in terms of how many sales representatives were 
used during launch and based on that, analyzing the optimal number of sales 
representatives needed.    
 
Sales Person Characteristics 
 
Even though the items, learning orientation and performance orientation, were identified 
in two case studies each as key success factors, none of the experts gave these items 
support. Their rationale was based on the fact that these two items were seen as inherent 
in a sales force and were too generic to have any impact on launching a new product 
versus selling an old product or be a driver for new product success. Experts 4 and 5 
argued that this is a basic criterion for any salesperson and should not be considered a key 
success factor. The experts recommended not including any of these variables in the 
research model. Also, concerning the item, career success of the salespeople, only expert 
1 considered it a driver for sales representatives to work with a new product and hence a 
driver for success.  
  
All the case studies found that problem-solving style was a potential key success factor, 
and much attention was given to this by the experts. Based on the results found, all 
experts recommended inclusion of the item in the research model. The experts showed a 
great interest in finding out whether problem-solving style did positively influence the 
success of a new product and argued that it was definitely a key success factor. Also, they 
discussed the potential outcome in terms of which problem-solving approach would be 
preferred over the other. The intuitive problem-solving style was preferred in three case 
studies and the systematic style in three. All experts believed, based on their own 
experience, that systematic problem-solving would be preferable to intuitive problem-
solving. Experts 1, 3, 4 and 5 argued for support of a preferred systematic problem-
solving style and, in line with some of the case studies, that in order to succeed with a 
new product launch, it is desirable to have non-innovative behavior in the sales force, 
thus securing that the core message is delivered in a consistent way and that problems 
which are taken care of systematically also reinforce a consistent core message.  Also, 
based on the results of the case studies, both intuitive and systematic styles should be 
tested in order to find out which one is preferred. 
 
Concerning salesperson’s experience, experts 1 and 3 discussed its relevance as a key 
success factor, but based on the fact that none of the case studies identified this as a 
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potential key success factor, it was recommended that it be excluded from the research 
model.  
 
Performance in selling a new product 
 
The case studies identified exceeding sales targets set for this new product and assisting 
the sales manager in achieving the objectives for this new product as the preferred items 
for measuring performance in selling a new product. Also, all experts concluded that 
these two items were the most appropriate for  measuring new product launch success. 
 
Exceeding profit target for the new product was identified in two case studies, and also 
identified by all the experts as an important measure. However, when this was discussed 
in a little more depth, the experts, with the exception of Expert 2, thought this might be 
difficult to measure in a correct way. They based this notion on many factors which they 
could identify, such as the fact that the launched products are often a global product 
produced in a larger context; that information such as cost of goods, shipping, etc., is 
often only known by upper management or finance and that sales managers will most 
likely not have access to this information, even high up in the sales organization, so the 
real profit numbers might not be known. They raised concerns about collecting this data 
with the risk of obtaining misleading results. Expert 2 still wanted to use the item as a 
measure, based on the perceived profit from the sales managers, as they still have 
assigned budgets to compare against.   
 
Experts 2, 3 and 5 suggested collecting data over time to provide the best guidance of a 
successful launch.  To define launch success, the sales and objectives item should be 
positive for the first two consecutive years in order for the launch to be deemed 
successful. Also, they suggested using third party data to validate the more subjective 
answers about launch success coming from the items. The third party data should then be 
used as a more objective validation of the final criteria if a successful launch was 
achieved.    
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Other 
 
First, the number of sales representatives needed for an optimal sale force was 
recommended for inclusion in the research model based on the discussion in the section 
above under the sub-heading sales force organization design.  
 
Of the issues arising from the case studies, those related to product order in sales calls 
attracted much attention from all the experts. They all concluded that many 
pharmaceutical sales forces carry several products or a portfolio of products. They all 
believed that handling this properly is a key success factor for new product launch. These 
issues were not included in any of the items in the generic model for sales force readiness 
during new product launch. All experts wanted to have this concept included in the 
research model. Experts 2, 4 and 5 recommended splitting this issue up into variables; 
one of which investigated the impact on successful launch if the product is promoted with 
other products (alone or with other products), and one investigating any impact from the 
order in which the product is sold during the sales call. Experts 2, 4 and 5 recommended 
collecting this data under the two separate variables and have both included in the 
Research Model.   
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Appendix 6: Data Collection Instrument for Research Model  
 
 
Data Collection Instrument for Research Model 
 
1. Was this product launch to General Practitioners? [Yes; No] – if No, close interview 
2. Product name  
3. Generic substance name  
4. How many sales representatives did you have during the launch of this new product? 
[integer] 
5. During launch, did the sales representatives feel emotionally attached to the success 
of this new product? [Yes:=1; No:=0] 
6. During launch, were the salespeople held accountable for their actions in selling the 
new product, regardless of results they achieved? [Yes:=1; No:=0] 
7. During launch, if the sales representatives’ performance goals for this new product 
were not met, would the sales representatives be required to explain why? [Yes:=1; 
No:=0] 
8. Did the sales representatives’ supervisors explain the rationale for the introduction of 
this product? [Yes:=1; No:=0] 
9. During launch, the sales representatives could freely talk to their supervisor about 
difficulties they had at work and known that he or she would want to listen? [Yes:=1; 
No:=0] 
10. During launch, to what extent did the sales representatives’ supervisor observe 
performance in the field; no-monitoring, medium-monitoring, or high-monitoring? 
[high-monitoring:= 3; medium-monitoring:=2; no-monitoring:=1] 
11. During launch, how did the sales representatives handle problem solving; intuitive or 
systematic? [1:= intuitive; 2:= systematic] 
12. Successful Launch? (Yes:= 1; No:= 0) – not a question 
13. For launch year one, did you exceed sales targets set for this new product? [Yes:=1; 
No:=0] 
14. For launch year one, did sales representatives assist sales managers in achieving the 
objectives for this new product? [Yes:=1; No:=0] 
15. For launch year two, did you exceed sales targets set for this new product? [Yes:=1; 
No:=0] 
16. For launch year two, did sales representatives assist sales managers in achieving the 
objectives for this new product? [Yes:=1; No:=0] 
17. Did the sales representatives only sell the new product or did they sell other products 
during the same sales call? [Alone:=1; Together with other products:=2] 
18. During launch, was the new product sold first during the sales call?  (1:=Yes; 2:=No) 
19. At time of launch, was this product: 
- new-to-the-market and new-to-the-firm? (=3) 
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- not-new-to-the-market but new-to-the-firm? (=2) 
- not-new-to-the-market and revisions-to-the-firm? (=1) 
20. What was the nature of the market environment for this new product at the time it was 
introduced, stable (=1) or unstable (=2)? 
21. What was the nature of the market environment for this new product at the time it was 
introduced, did it change slowly (=1), or change rapidly (=2)? 
22. Market share year one [per mille] – not a question, data from third party database 
23. Sales year one [SEK] – not a question, data from third party data base 
24. Market share year two [per mille] – not a question, data from third party database 
25. Sales year two [SEK] – not a question, data from third party data base 
26. Market share year three [per mille] – not a question, data from third party database 
27. Sales year three [SEK] – not a question, data from third party data base 
28. Market share year four [per mille] – not a question, data from third party database 
29. Sales year four [SEK] – not a question, data from third party data base 
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Appendix 7: The Size and Value of the Pharmaceutical Industry  
 
In order to give readers not familiar with the pharmaceutical industry a better 
understanding of the industry’s size and value, this appendix provides a brief overview. 
The pharmaceutical industry is a truly global industry, in the sense that a developed 
product is typically launched across all the major markets, including North America, 
Europe, Asia, and South America (EIU 2005; Popper and Nason 1994). In 2007 the 
global pharmaceutical market had total sales of around $600 billion and the market had 
grown from around $400 billion in 2002 (MIDAS-Database 2007a). To highlight overall 
growth of this industry; looking back to 1990, the world market for ethical 
pharmaceutical products was valued at $147 billion and the top three companies in terms 
of global ethical sales were Merck, with $6,4 billion, Glaxo, with $5.4 billion and Bristol-
Myers Squibb with $4.9 billion (Yeoh 1994). In 2007, these companies are still on the top 
fifteen companies’ list; their respective sales are around $22 billion, $42 billion and $18 
billion, and the growth of these companies has mainly been driven by new product 
introductions and mergers. See Table 13 for the top fifteen biggest pharmaceutical 
companies 2006.    
 
While the US is the largest single market with total sales  of $293 billion in 2007 (growth 
6%), Europe comes as number two with sales of $162 billion, where the largest markets 
include the UK, Germany, France, Italy, and Spain. (MIDAS-Database 2007a) 
 
However, the growth rate trend of the last few years is declining. During the period from 
2002 to 2007 the global growth rate declined steadily from around 10% in 2002 to around 
6% 2007 (MIDAS-Database 2007a). The market in the United States has had an overall 
decline in growth rate from around 11,5% in 2002 to around 4,5% in 2007. For the 
European big five markets (UK, Germany, France, Italy and Spain) growth has declined 
from around 8,5% in 2002 to 5% in 2007. (MIDAS-Database 2007a) 
 
This study addresses the Swedish pharmaceutical market. The Swedish pharmaceutical 
market represents total sales of $3.7 billion in 2007 (Datamonitor 2007b). The annual 
growth rate (CAGR) between 2003-2007 was 3,4% (Datamonitor 2007b).  
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Table 13: Top fifteen biggest pharmaceutical companies 
 (MIDAS-Database 2007a)    
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Appendix 8: The Lifecycle of a Pharmaceutical Product  
 
Kotler (2000) suggests that the concept of a product having a life cycle makes four 
assertions: “1) products have a limited life, 2) product sales pass through distinct stages, 
each posing different challenges, opportunities, and problems to the seller, 3) profits rise 
and fall at different stages of the product life cycle. 4) products require different 
marketing, financial, manufacturing, purchasing, and human resource strategies in each 
stage of their life cycle” (Kotler 2000). 
 
This definition could be argued to also be applicable to a company developing and selling 
an ethical research-based pharmaceutical product, as: 1) the patent life usually defines 
and limits the life of the product as to when the company can generate substantial 
revenue from the product; 2) the product goes through distinct stages, such as when it is 
introduced, when it faces increased competition or when generic products enter the 
market; 3) the profits can rise and fall as with the example of the phases in point two; 
and, 4) the product needs different strategies, again once again when facing the examples 
of the phases in point two.  
 
To better clarify and adopt a managerial literature-based definition of an ethical research-
based pharmaceutical product’s life cycle, Kotler’s (2000) general lifecycle stages will be 
used as a base. They suggest that the lifecycle of a product in the market is usually 
defined in four stages, 1) Introduction, 2) Growth, 3) Maturity 4) Decline (Kotler 2000). 
To be able to better include and describe a more complete set of challenges and issues 
faced by a research-based pharmaceutical company and relevant to the justification and 
motivation of this research, the development of the product preceding the in-market 
lifecycle is added. The full life cycle of a drug may then be understood in terms of an 
additional stage, Research and Development.   
 
As a definition in this research, the full lifecycle for an ethical research-based 
pharmaceutical product consists of the five main stages or phases, Research & 
Development, Introduction (Launch), Growth, Maturity and Decline. Theses stages will 
be described below.   
 
Research & Development 
 
The Research and Development stage could also be further divided in the sub-stages 
Discovery, Clinical Development and Registration. The development of pharmaceutical 
products is to a great degree performed by pharmaceutical companies, with academia and 
government contributing less than 10% (Dimasi and Grabowski 1995). The 
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Pharmaceutical industry is the source of 93.3% of new drugs, while Academia or Non-
Profit account for 3.5% and Government for 3.2% (Dimasi and Grabowski 1995).  
 
As stated above, the first phase of Research and Development is the discovery phase, 
which could be 2-10 years long. During this phase, compounds are screened and tested 
for desired criteria (e.g. potency, efficacy, toxicity, bioavailability, scale up as well as a 
commercial assessment). If it is decided to take the compound further, it goes into 
clinical development. The clinical development program is divided in four phases, and 
starts with pre-clinical testing, where laboratory and animal testing is conducted. This 
phase is about 4 years in length. Phase I, Phase II and Phase III of the clinical 
development program follow the pre-clinical testing. During Phase I, around 20-80 
healthy volunteers are used to determine safety and dosage. This phase takes about 2 
years. Phase II includes 100-300 patient volunteers looking for efficacy (proof of 
concept) and side effects and the duration of this phase is about 2 years. Phase III is 
where the majority of subjects are tested. 3000 – 5000 patient volunteers are used to 
monitor adverse reactions to long-term use in phase III. This phase is timely and costly 
and takes about 4 years. As soon as the clinical development program is finalized, the 
potential new drug is moved into Registration. This phase could also be referred to as the 
Pre-Launch phase, and denotes all the activities that are conducted in order to prepare for 
the introduction of the product on the market. Examples of such activities are the medical 
approvals from authorities – e.g. the “Food and Drug Administration” in the USA or the 
“European Medicines Agency” – the manufacturing and supply planning and 
preparations, various market research activities, and so on.  
 
Introduction (Launch)  
 
The second stage of a product’s lifecycle is the Launch phase or Introduction of the 
product. The introduction or launch phase is defined as a period of slow growth at the 
product is introduced in the market (Kotler 2000). Profits are low or nonexistent in this 
stage because of the heavy expenses incurred by product introduction (Kotler 2000). In 
the pharmaceutical industry, this accounts for two stages: firstly, market inductor 
activities, such as delivering the product to the pharmacies, informing the physicians of 
its existence and basic characteristics, while the second stage is the initial marketing and 
sales operations that follow immediately after the market introduction. This stage may 
vary considerably in length, depending on the type of product: from one to three years for 
a conventional drug targeted at General Practitioners; two to five years for an advanced 
transplantation or oncology product. The two stages of the Launch phase are important, 
as the first stage, the physical market introduction of the product, is typically short and 
definitive. It is during the second stage, the initial marketing and sales operations, that the 
actual communicative and other tactical launch activities may be executed. 
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Growth and Maturity 
 
The third and fourth stages of the lifecycle are constituted by regular marketing and sales 
operations, which represent the typical activities performed by the various marketing, 
sales, medical, regulatory, and other types of resources of the company, in order to 
achieve sales goals. The growth stage is defined as a period of rapid market acceptance 
and substantial profit improvement (Kotler 2000). The maturity phase, on the other hand, 
is defined as a period of a slowdown in sales growth because the product has achieved 
acceptance by most potential buyers. Profits stabilize or decline because of increased 
competition (Kotler 2000). These phases, in terms of time, may account for some ten 
years on the market where the product is protected by its patent. During this phase the 
responsible managers execute various tactical marketing and sales moves, all with the 
aim of maximizing sales and optimizing costs. 
 
Decline 
 
The decline phase is defined as a period when sales show downward drift and profits 
erode (Kotler 2000). When a pharmaceutical ethical product’s patent has expired, various 
courses of action may occur. If the product has been successful in terms of sales, then one 
or more generic companies will launch their copies at a, usually radically, lower price, 
which in turn, typically causes the original company to exit its product. On the other 
hand, if the product has not been very successful in terms of sales, and is thus less 
attractive for generic companies, or if its production represents considerable difficulties 
and costs, then the product may enjoy continuous marketing and sales by the original 
company, as no generics enter the market with copies. This phase could also be referred 
to here as Patent Expiry. This phase includes two sub-phases or stages: the patent expiry 
stage, where various actions may be made by generics and original companies with 
regard to exit and entry of product, while the second stage is the post-patent stage, when a 
product is typically sold by the originator or by generics, and in some cases, by both. The 
time of these sub-stages varies among products as well as nations.  
 
The focus of the research presented here encompasses the launch phase, also referred to 
as the introduction stage. As described in Chapter 1, Introduction, the issues and 
challenges identified in each stage reinforces the importance of successful launch to 
quickly secure return on investments as well as to maximize sales and profit.  
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